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ABSTRACT 
Introduction and aims: Fenofibrate (FF) is the most widely used fibric acid 
derivative for managing mixed dyslipidaemia, characterised by elevated levels of 
cholesterol, triglycerides and low-density lipoprotein cholesterol and low levels of 
high-density lipoprotein cholesterol. It is linked with various adverse effects, 
notably FF-associated creatininaemia (or inferred nephrotoxicity), but also injury to 
liver and muscle cells. However, the mechanism and clinical significance of FF 
toxicity in these tissues remain unclear. Monitoring of kidney function is 
recommended in patients receiving FF therapy. However, due to limitations of 
measuring serum creatinine (a routinely used marker of kidney function), cystatin 
C, a low molecular weight protein has been proposed as a better marker of kidney 
function. The impact of FF on cystatin C clearance and its clinical utility for 
monitoring kidney function in patients receiving FF therapy have not been fully 
elucidated, a main aim of this study. The overall focus was to investigate the 
impact of FF on routine clinical biomarkers in patients with dyslipidaemia, evaluate 
the utility of cystatin C for monitoring kidney function in patients receiving FF 
therapy and investigate underlying mechanisms of FF toxicity to kidney and 
muscle cells. 
Methods: The impact of FF therapy on routine clinical biomarkers was examined 
in 19 adult (14 male, 5 female) patients with mixed dyslipidaemia, aged 34 – 70 
years. All the particpants were administered FF at 160 mg/day and clinical 
biomarkers including kidney function test, liver function tests, lipid profile, markers 
of inflammation and muscle damage, and thyroid function tests were measured at 
baseline and after 3, 6 and 12 months after starting treatment. The impact of FF 
therapy on serum cystatin C level and cystatin C-based estimates of glomerular 
filtration rate (eGFR) was compared with serum creatinine level and creatinine-
based eGFR. Furthermore, FF cytotoxicity was assessed in kidney (NRK52E and 
HEK293) and skeletal muscle (L6) cell lines using the MTS assay and the potential 
mechanisms investigated using the reactive oxygen species (ROS) assay and 
western blot analysis to determine changes in related apoptotic protein markers. 
Results: FF therapy reduced serum triglyceride concentrations and increased 
HDL cholesterol levels in patients with dyslipidaemia. A moderate increase in 
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serum creatinine, urea and cystatin C levels were observed after 3 months of 
treatment. These were accompanied by a decrease in eGFR using creatinine-
based and cystatin C-based equations. Interestingly, this effect was reversed even 
when treatment was continued (after 12 months). Fenofibrate therapy also 
reduced serum uric acid concentration via increased urinary excretion. Serum liver 
enzymes were also reduced, with a much greater impact on serum ALP and GGT. 
The impact on liver enzymes was greater in individuals with higher pre-treatment 
values. Cystatin C-based eGFRs were higher than creatinine-based eGFRs 
suggesting underestimation of kidney function by the creatinine-based equations. 
Data from in vitro studies showed a dose- and cell line-dependent anti-proliferation 
impact of fenofibrate on the kidney and skeletal muscle cell lines, associated with 
oxidative stress due to intracellular ROS accumulation. Results from the western 
blot analysis of apoptosis-related proteins (Bax and Bcl-2) and the NFκB and 
MAPK signalling pathways did not indicate apoptosis as a potential mechanism of 
FF toxicity. 
Conclusion: This study confirms the association of fenofibrate therapy with 
increased serum creatinine levels, which is shown to be partially reversible even 
with long-term fenofibrate administration. Fenofibrate therapy is also shown to 
reduce serum uric acid and liver function tests. The clinical significance of the 
impact of FF therapy on serum uric acid and liver function tests is unclear. This 
study also suggests that fenofibrate is safe when administered within the 
therapeutic range. However, increased doses may be toxic to kidney and muscle 
cells via a mechanism that involves increased intracellular oxidative stress. 
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Chapter 1 
Introduction and main aims 
1.1 DYSLIPIDAEMIA 
Dyslipidaemia is a major risk factor for cardiovascular disease (CVD), which 
represents an important cause of morbidity and mortality worldwide (Jameson et 
al., 2013). In 2012, an estimated 17.5 million people died from CVD, representing 
31% of all global deaths (Al-Mawali, 2015; WHO, 2015). In the UK, there are about 
seven million people living with CVD and over 160,000 deaths (more than a 
quarter of all deaths) each year (British Heart Foundation, 2015). Dyslipidaemia 
refers to a spectrum of lipid disorders which usually include excessive levels of 
cholesterol, triglyceride (TRIG) and low-density lipoprotein (LDL) cholesterol, and 
low levels of high-density lipoprotein (HDL) cholesterol (Williams, 2013). Increased 
level of LDL cholesterol is reported as primarily responsible for the development of 
atherosclerosis, as oxidised LDL cholesterol and monocytes penetrate the 
endothelium and combine to form cholesterol-rich macrophages, which drive the 
development of atherosclerotic plaques (Hansson, 2005). Hypertriglyceridaemia is 
often associated with low HDL cholesterol levels, diabetes, hypertension, obesity 
and excess alcohol consumption. Excessively high levels of TRIG have also been 
linked with the risk of CVD and pancreatitis (Williams, 2013). High levels of TRIG 
together with low levels of HDL cholesterol are considered as risk factors for 
coronary heart disease (CHD) (Di Angelantonio et al., 2009), and ischaemic stroke 
(O’Donnell et al., 2010). However, it is unclear whether hypertriglyceridaemia is an 
independent risk factor for CVD when adjusted for other cholesterol disorders such 
as low HDL cholesterol and comorbidities (Williams, 2013).  
Recent prospective studies have suggested that a high TRIG level in combination 
with a low HDL cholesterol level (also referred to as atherogenic dyslipidaemia) 
may be a clinical marker to identify adults at risk of atherosclerotic CVD (Rana et 
al., 2010; Abdel-Maksoud et al., 2012; Anderson et al., 2014; Verges, 2015). 
Management of dyslipidaemia using lifestyle changes and hypolipidaemic agents 
(e.g. statins, fibrates, ezetimibe and niacin) is a vital strategy for reducing the risks 
of CVD (Hendrani et al., 2016). While statins are the first choice hypolipidaemic 
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drugs for managing dyslipidaemia, statin therapy may be limited by the failure to 
reach non-HDL cholesterol goals and sometimes poses the problem of intolerance 
or poor response to statin monotherapy in certain patients, thereby indicating the 
use of another class of lipid-lowering drug (NICE, 2014). Management guidelines 
are based on risk assessments for CVD and treatment targets, which in turn rely 
on the type or classification of dyslipidaemia (Thompson, 2004).  
 
1.2 CLASSIFICATION OF DYSLIPIDAEMIA 
Classification of dyslipidaemia is aimed at providing the foundation for the clinical 
management of the prevalent group of risk factors for CVD and pancreatitis, 
although it is sometimes overlooked in the mistaken belief that causes, 
consequences and management of disturbances in the plasma lipid profile are 
similar in the vast majority of patients (Sullivan and Lewis, 2011). According to 
Sullivan and Lewis (2011), the correct identification of the pattern of lipoprotein 
disorders and their primary or secondary origin provides important information 
concerning the natural history and treatment options that will optimise patient 
outcome. Dyslipidaemia can be classified on the basis of lipid phenotype as 
hypercholesterolaemia (i.e. increased level of cholesterol), hypertriglyceridaemia 
(i.e. increased level of TRIG), or mixed hyperlipidaemia (i.e. increased levels of 
both cholesterol and TRIG), or on the basis of causative factors such as familial 
(primary) hyperlipidaemia or acquired (secondary) hyperlipidaemia (Thompson, 
2004; Verma, 2016). Each one of these phenotypes can result from dysfunctional 
mutations of dominantly expressed genes encoding receptors, enzymes or 
transfer proteins involved in lipoprotein metabolism, usually indicated by a familial 
pattern of inheritance (Thompson, 2004).  
 
1.2.1 Familial (or primary) hyperlipidaemia 
Familial or primary hyperlipidaemia is usually caused by a genetic defect, which 
may be monogenic (i.e. a single gene defect) or polygenic (multiple gene defects). 
The traditional framework for the classification of dyslipidaemia is dominated by 
the Fredrickson classification (Table 1.1) in which familial dyslipidaemia is 
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classified into five types on the basis of electrophoresis or ultracentrifugation 
pattern of lipoprotein abnormalities (Fredrickson and Lees, 1965; Nirosha et al., 
2014). This system of classification was an early development which recognised 
that the variation in plasma lipid levels were due to disturbances in lipoprotein 
metabolism and provided a nomenclature that abbreviated the description of the 
various patterns of lipoprotein accumulation that were relevant to clinical practice 
(Sullivan and Lewis, 2011). It was later adopted by the World Health Organisation 
(WHO) as a useful tool for the management of hyperlipidaemia. 
A major limitation of the Fredrickson classification is that it provides only limited 
prognostic information when used in isolation. Most Fredrickson types are 
heterogeneous because the patterns of the most commonly associated CVD are 
usually the product of gene-environment interactions in which the quantitative 
severity of LDL cholesterol and HDL cholesterol abnormalities is of major 
importance (Sullivan and Lewis, 2011). The Fredrickson classification also 
overlooked altered levels of HDL cholesterol, elevation of lipoprotein a (Lpa) and 
adverse changes in the composition of LDL cholesterol in hypertriglyceridaemia, 
commonly seen in practice when both cholesterol and TRIG levels are elevated 
due to an increase in LDL and VLDL concentration (Nirosha et al., 2014). It 
remains a popular system of classification, but is considered outdated by many 
(Jain et al., 2007). 
 
1.2.2 Acquired (or secondary) hyperlipidaemia 
Acquired hyperlipidaemia (or secondary dyslipoproteinaemias) is caused by 
underlying disorders and leads to alterations in plasma lipid and lipoprotein 
metabolism (Verma, 2016). Acquired hyperlipidaemias may mimic primary forms 
of the disease and can have similar consequences. They may result in an 
increased risk of premature atherosclerosis, pancreatitis and other complications 
of the chylomicronaemia syndrome. The most common causes of acquired 
hyperlipidaemia include diabetes mellitus, use of drugs e.g. diuretics, ꞵ-blockers 
and oestrogens, alcohol consumption, hypothyroidism, renal failure, nephrotic 
syndrome and some rare disorders and metabolic disorders (Nirosha et al., 2014). 
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Table 1.1 Fredrickson classification of dyslipidaemia 
Type Disorder Cause Elevated 
lipoprotein 
Type I Familial hyperchylomicronaemia 
or primary hyperlipoproteinaemia 
LPL deficiency or 
altered ApoC2 
Chylomicrons 
Type IIa Familial hypercholesterolaemia or 
Polygenic hypercholesterolaemia 
LDL receptor 
deficiency 
LDL 
Type IIb Familial combined hyperlipidaemia Decreased LDL 
receptors 
LDL and 
VLDL 
Type III Familial dysbetalipoproteinaemia Defect in ApoE2 
synthesis and 
increased Apo B 
IDL  
Type IV Familial hypertriglyceridaemia Increased VLDL 
production and 
decreased excretion 
VLDL 
Type V Endogenous hypertriglyceridaemia Increased VLDL 
production and 
decreased LPL 
Chylomicrons 
and VLDL 
Abbreviations: LDL, low density lipoprotein cholesterol; VLDL, very low density 
lipoprotein cholesterol; IDL; intermediate density lipoprotein cholesterol; LPL, lipoprotein 
lipase. 
 
1.3 MANAGEMENT OF DYSLIPIDAEMIA 
Management of dyslipidaemia is at the centre of strategies of preventing CVD 
(Thompson, 2004). In 1987 the National Institute of Health (NIH) established the 
National Cholesterol Education Program (NCEP) which was directed by the Adult 
Treatment Panel (ATP) with the aim of issuing information for health professionals 
and the general public concerning testing, evaluating, monitoring and treating 
dyslipidaemia. An important criterion of the ATP guidelines is the development of 
treatment goals for dyslipidaemia based on a patient’s risk of coronary CHD 
(NCEP, 2002; Verma, 2016). 
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1.3.1 Guidelines for managing dyslipidaemia 
Various organisations and agencies have issued recommendations for the 
management of dyslipidaemia with various commonalities and differences among 
them (Thompson, 2004; Jacobson et al., 2015). Most of the current guidelines 
reflect the results of five major statin trials that were published between 1994 and 
1998, which demonstrated a reduction in the risk of CHD and total mortality in men 
and women below and above the age of 65, respectively (LaRosa et al., 1999; 
Thompson, 2004).  
Guidelines for the management of dyslipidaemia in the United States are based on 
the reports of the NCEP. The third report of the NCEP (NCEP, 2002) reiterated the 
use of the LDL cholesterol value as the criterion for when to initiate treatment and 
as a therapeutic goal; the greater the risk of CHD, the lower the concentration of 
LDL cholesterol at which treatment is initiated and the lower the target value to be 
achieved (NCEP 2001). By these guidelines, patients with CHD, diabetes or 
multiple risk factors, as in metabolic syndrome, that confer a 10 year risk of CHD 
of > 20% over 10 years are considered as high risk (Thompson, 2004). The 
treatment strategies include the use of lipid lowering drugs, which is required by 
the majority of patients to achieve the LDL cholesterol goal of < 2.6 mmol/L and 
therapeutic lifestyle changes to achieve less stringent target values of < 4.1 
mmol/L and < 3.4 mmol/L recommended for those at low and moderate risk, 
respectively.  
The European guidelines rely on the executive summary of the Third Joint Task 
Force of the European and other society on cardiovascular disease prevention in 
clinical practice (constituted by representative of eight societies and by invited 
experts) (De Backer, 2003). The European guidelines differ fundamentally from 
the US and UK guidelines as it is focused on the prevention of fatal CVD rather 
than CHD events (De Backer, 2003). CVD risk assessment is based on the 
systematic coronary risk evaluation (SCORE) system, which defines high risk as ≥ 
5% chance of fatal CVD within 10 years (Reiner et al., 2011). The treatment goal 
is to reduce total cholesterol and LDL cholesterol in high risk subjects to values 
below 5 mmol/L and 3 mmol/L, respectively, unless they have clinical CVD, 
diabetes or serum total and LDL cholesterol concentrations, which are already 
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below these values, when the goals of treatment become < 4.5 mmol/L and 2.5 
mmol/L, respectively. Similar to the US guidelines, lifestyle changes is the initial 
step in the management of dyslipidaemia and drugs are added when treatment 
goals are not achieved within 3 months. There are no specific goals set for TRIG 
and HDL cholesterol but a TRIG value of > 1.7 mmol/L and HDL cholesterol < 1.0 
mmol/L (men) and 1.2 mmol/L (women) are regarded as markers of increased risk 
(Catapano et al., 2016). 
In the UK, guidelines for the management of dyslipidaemia are based on the joint 
recommendations of the British Cardiac and Hypertension Societies and the 
British Hyperlipidaemia and Diabetic Associations published in 1998. Unlike the 
European guidelines, which use the SCORE system for risk assessment, the 
absolute risk of CHD is estimated using the Framingham based criteria, which 
include HDL cholesterol as a variable (Thompson, 2004). The Framingham risk 
score is a gender-specific algorithm used to estimate the 10-year cardiovascular 
risk of an individual. It is based on data from the Framingham heart study carried 
out between 1971 – 1974 involving 2489 men and 2856 women 30 to 74 years 
old, which demonstrated that blood pressure, total cholesterol and LDL cholesterol 
effectively predict CHD risk, leading to the development of a coronary disease 
prediction algorithm using categorical variables, which allows physicians to predict 
multivariate CHD risk in patients without overt CHD (Wilson, et al., 1998; 
D’Agostino et al., 2008). Based on the Framingham criteria, the UK guidelines, 
prioritised treatment for persons with existing CHD or with an estimated risk of ≥ 
15% over the following 10 years, either at current age or if extrapolated to age 60. 
Therapeutic lifestyle changes are  recommended to persons with serum total 
cholesterol ≥ 5 mmol/L or LDL cholesterol ≥ 3 mmol/L with the aim of reduction to 
values < 5mmol/L and < 3 mmol/L, respectively (Hermansson and Kahan, 2017). 
More recent guidelines applicable in England and Wales as set out in the National 
Service Framework for CHD, recommend that patients with CHD or at high risk 
(defined as ≥ 30% per 10 years) should be treated with diet and statins, with the 
aim of reducing serum total cholesterol below 5 mmol/L or by 20 - 25%, whichever 
would result in the lowest level; equivalent figures for LDL cholesterol are below 3 
mmol/L or by 30% (Lloyd-Mostyn, 2000).  
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Although management guidelines tend to differ in different parts of the world in 
terms of methods of risk assessment and treatment targets, all the guidelines have 
a common goal of curbing risks of CVD, by reducing high levels of total 
cholesterol, LDL cholesterol and TRIG, whilst increasing low levels of HDL 
cholesterol in blood. All the guidelines also recognise the importance of 
therapeutic lifestyle changes as the initial step in the management of 
dyslipidaemia, especially in those with low to moderate risk of CVD, and the use of 
therapeutic drugs is considered only when treatment goals are not achieved 
(Varady and Jones, 2005; Catapano et al., 2016). The most commonly used 
options for the pharmacologic treatment of dyslipidaemia are statins, resins, 
fibrate, niacin, and their combinations. However, other possibilities in selected 
cases are available, such as the proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors and the newly approved selective inhibitor of microsomal TRIG 
transfer protein and antisense oligonucleotide drugs (Zodda et al., 2018). 
 
1.3.2 Therapeutic lifestyle changes 
Therapeutic lifestyle changes (TLC) are non-pharmacologic measures that are 
often tried as initial treatment for dyslipidaemia, especially in mild cases of 
hyperlipidaemia and in persons with mild to moderate risk of CHD. Lifestyle 
management includes diet modification, regular physical activity, smoking 
cessation and weight reduction (Thompson, 2004). The Third Report of the NCEP 
(ATP III) recommends TLC in place of drug therapy for patients who fall into an 
intermediate range of CHD risk (NCEP, 2001). This approach was based on the 
panel’s review of the evidence in 1999, which concluded that diet and exercise can 
have a beneficial effect on serum levels of total cholesterol, LDL cholesterol, HDL 
cholesterol and triglycerides (Kelly, 2010). Some reports have also suggested that 
many patients prefer non-drug therapies for many reasons including adverse 
effects of antilipid drugs, contraindications or allergic reactions to drugs, 
perceptions of adverse effects of drugs, or personal preference for natural or 
alternative therapy (Varady and Jones, 2005).  
TLC has shown effectiveness in lowering serum cholesterol levels, with the most 
notable benefits obtained from diet modifications and weight loss (Dalen and 
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Devries, 2014; Catapano et al., 2016). However, it is important to keep in mind 
that when dieting, cholesterol intake is reduced but at the same time, production of 
cholesterol (especially by the liver) increases (Cohen, 2008). The NCEP ATP III 
recommended that daily energy intake of total fat should be restricted to 25 – 35%, 
saturated fatty acids be reduced to less than 7% of daily energy intake and 
cholesterol intake should also be less than 200 mg daily (NCEP, 2001; Verma, 
2016). The intake of plant sterol esters and soluble fibre is advisable. It is 
estimated that a healthy diet can result in 10 – 15% reduction of cholesterol blood 
level. Evidence from several reports has shown that lifestyle interventions also 
influence the metabolism of HDL cholesterol and TRL remnants (Maeda et al., 
2003; Nicholls et al., 2006; Kodama et al., 2007; Wang et al., 2009). 
The effects of exercise on serum lipid levels have been studied extensively. 
Published data have shown that regular aerobic exercise increases HDL 
cholesterol levels by 1.9 to 2.5 mg/dL (0.05 - 0.06 mmol/L) (Kodama et al., 2007). 
Other effects include decreases in total cholesterol, LDL cholesterol, and 
triglyceride levels by an average of 3.9, 3.9, and 7.1 mg/dL (0.10, 0.10, and 0.08 
mmol/L), respectively (Kelly, 2010). HDL cholesterol level has also been shown to 
increase by an average of 9% (3.7 mg/dL or 0.10 mmol/L) in patients with CVD 
who exercise aerobically and therefore suggesting greater benefits in this high-risk 
group (Kelly et al., 2006; Wang and Xu, 2017). Although, the improvement in HDL 
cholesterol levels seem to be related more to the amount of activity than to the 
intensity of exercise or improvement of fitness (Kraus et al., 2002, Khoury, Evans 
and Ratchford, 2019), physical inactivity is shown to have profound negative 
effects on lipid metabolism, including increase in LDL cholesterol levels (Slentz et 
al., 2007; Lavie et al., 2019).  
Also, the combination of exercise and changes in diet (i.e. with a low-saturated fat 
diet or plus nutritional supplements) have shown additive, or at least synergistic 
effects in reducing LDL cholesterol and TRIG levels, while increasing HDL 
cholesterol levels (Kelly, 2010, Wang and Xu, 2017). In subjects with type 2 
diabetes mellitus, intensive lifestyle intervention (weight loss, diet, and increased 
physical activity) had beneficial effects on glycaemic control and cardiometabolic 
risk factors, including HDL cholesterol and TRIG (Ilanne-Parikka et al., 2008; Wing 
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et al., 2010), and in the longer term was associated with reduction in CVD risk 
(Uusitupa et al., 2009).  
Moderate alcohol consumption is reported to increase HDL cholesterol and 
apolipoprotein A-I and has been linked with a reduction in all cause mortality, 
however, over-consumption has been associated with a higher mortality rate 
(Criqui, 1996; Catapano et al., 2016). Restriction of alcohol is advised in patients 
with dyslipidaemia as it increases blood pressure and plasma TRIG levels and can 
precipitate acute pancreatitis in individuals with high TRIG levels (Sasakabe et al., 
2018). Smoking increases TRL remnants and decreases HDL cholesterol levels 
(Chelland et al., 2008), secondary to insulin resistance and hyperinsulinaemia 
(Facchini et al., 1992; Chapman et al., 2011); these effects are rapidly reversed on 
cessation (Maeda et al., 2003). Although lifestyle changes have been shown to be 
important in reducing risks of CVD, long-term adherence to this approach to 
treatment has been a major challenge, and therefore many of these patients 
require additional pharmacological intervention (Middleton et al., 2013). 
 
1.3.3 Pharmacological management of dyslipidaemia 
Although TLC is the method of choice for managing dyslipidaemia, lipid-lowering 
drugs are widely used to reduce high levels of cholesterol, LDL cholesterol and 
TRIG and to increase low levels of HDL cholesterol in patients with dyslipidaemia 
at risk of CVD. Pharmacological treatment of dyslipidaemia is usually tailored to 
correct as much of the total dyslipidaemia as possible without inducing drug-
related side effects. Recent studies have shown the use of lipid-lowering drugs as 
an effective way of controlling cardiovascular risk (Reklou et al., 2019). Drug 
therapy is often considered for people with high risk of CVD and those with known 
atherosclerosis. A collaborative approach to the use of medical therapies has been 
shown to improve patient compliance and quality of life (Fletcher et al., 2005). The 
primary target of lipid therapy is to reduce LDL cholesterol, which is the major 
atherogenic lipoprotein. It is expected that reduction of LDL cholesterol will reduce 
atherosclerosis and in turn reduce cardiovascular adverse events (Shattat, 2014). 
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Five major classes of hypolipidaemic drugs are commonly used in the 
management of dyslipidaemia, namely statins (3-Hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors), fibrates (fibric acid derivatives), bile acid 
sequestrants (anionic exchange resins), niacin (nicotinic acid derivatives) and 
Ezetimibe (selective cholesterol absorption inhibitor) (Pahan, 2006, Drexel, 2009). 
The choice of hypolipidaemic agent often depends on the type of dyslipidaemia; 
while statins are the first choice treatment for reducing high serum levels of 
cholesterol, fibrates are known to effectively reduce elevated levels of TRIG and 
LDL cholesterol and improve HDL cholesterol levels in patients with dyslipidaemia 
(Drexel, 2009). Other drugs such as Ezetimibe, colesevelam, torcetrapib, 
avasimibe, implitapide, and niacin are also being considered for the management 
of dyslipidaemia (Table 1.2). These drugs have been shown to reduce fatal and 
non-fatal cardiovascular abnormalities in the general population (Pahan, 2006, 
Drexel, 2009). 
 
Table 1.2 Choice of lipid-lowering drugs by treatment goal based on the 
recommendations of the American Diabetes Association   
Goal Drug of Choice 
Lower LDL Statin, second choice: Bile acid binding resin or fenofibrate 
Increase HDL Fibrate (or nicotinic acid, with careful monitoring) 
Lower triglycerides Fibrate (fenofibrate, gemfibrozil), high-dose statin (in 
hypertriglyceridaemic patients with elevated LDL cholesterol levels). 
Treat combined 
hyperlipidaemia 
High dose statin, second choice: statin + fibrate (fenofibrate, 
gemfibrozil), third choice: bile acid binding resin + fibrate 
(fenofibrate or gemfibrozil) or statin + nicotinic acid (with careful 
monitoring of glycaemic control) 
LDL, low-density lipoprotein; HDL, high-density lipoprotein 
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1.3.3.1 Statins (or HMG-CoA reductase inhibitors)  
Statins (3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) 
are the most widely used evidence-based drugs for managing dyslipidaemia, with 
LDL cholesterol as their main target (NICE, 2014). Members of this class of 
hypolipidaemic drugs include Lovastatin, Simvastatin, Pravastatin, Fluvastatin, 
Atorvastatin, Rosuvastatin and Pitavastatin (Asztalos et al., 2002, Ward et al., 
2019). These drugs are structural analogues of HMG-CoA reductase substrates 
and act through mechanisms that inhibit cholesterol biosynthesis (Raghow, 2017). 
The primary mechanism of action of statins is the selective and competitive 
inhibition of HMG-CoA reductase. HMG-CoA reductase is an enzyme that 
catalyses the conversion of HMG-CoA to mevalonic acid, a precursor of sterols, 
including cholesterol (Figure 1.1). By inhibiting HMG-CoA reductase, statins 
initially cause a reduction in liver cholesterol, but compensatory mechanisms 
induce greater expression of both HMG-CoA reductase and LDL receptors (Zodda 
et al., 2018). Hence, through an indirect mechanism, statins also reduce LDL 
cholesterol by increasing receptor–mediated absorption of LDL cholesterol. The 
increase in the number of these receptors also causes a decrease in very low 
density lipoprotein (VLDL)  cholesterol and intermediate density lipoprotein (IDL) 
cholesterol, which are LDL cholesterol precursors, and further contribute to 
lowering LDL cholesterol (Raghow, 2017). In particular, atorvastatin and 
rosuvastatin produce a marked decrease in plasma TRIG, as they remove larger 
amounts of VLDL particles rich in TRIG (Stender et al., 2005). 
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Figure 1.1 Mechanism of action of statins.  
Statins are competitive inhibitors of the enzyme HMG-CoA reductase. This is a critical 
enzyme in the production of mevalonate and inhibition consequently reduces its 
derivatives, cholesterol, steroids and isoprenoids. The diagram shows the pathway of 
cholesterol synthesis and the point at which statins interfere with the metabolism of HMG-
CoA (Mora et al., 2009). 
 
Overall, the effect of statins on the lipid profile is consistent between statins, with 
reductions in total cholesterol, LDL cholesterol and triglycerides and an increase in 
HDL cholesterol. Despite having the same mechanism of action and comparative 
effects on lipid profiles, statins can still be subdivided into two categories: Type I, 
fungal-derived statins (lovastatin, pravastatin, simvastatin) or type II, synthetically-
derived (fluvastatin, cerivastatin, atorvastatin, rosuvastatin and pitavastatin) 
(Istvan, 2003). Type I statins maintain close structural homology to mevastatin, the 
first statin to be developed, maintaining the lactone/open acid moiety in addition to 
the substituted decalin ring skeleton, while Type II are fully synthetic inhibitors of 
HMG-CoA reductase, developed to maintain the HMG-CoA-like lactone moiety for 
binding. The Type II statins are reported to exhibit highly varied pharmacokinetic 
Fombon, I.S. (2020) 
13 
 
properties, including differences in metabolism, excretion, half-lives, bioavailability, 
dosing times and lipophilicity (Istvan, 2003; McFarland et al., 2014). 
The LDL cholesterol reduction by statins is dose dependent and varies between 
the different statins (Weng et al., 2010). Statins are among the most studied 
hypolipidaemic drugs used in CVD prevention and its effect in larger populations 
and subgroups have been examined in various meta-analyses (Mills et al., 2008; 
Baigent et al., 2010; Fulcher et al., 2015). Evidence from a meta-analysis involving 
170,000 participants in 26 randomised controlled trials with statins, known as the 
cholesterol treatment trial (CTT), showed that high-dose statin treatment was 
associated with a highly significant reduction in major vascular events of 28% per 
1.0 mmol/L LDL-cholesterol reduction achieved, compared with usual dose statin 
therapy (Baigent et al., 2010). They reported a 10% proportional reduction in all-
cause mortality and 20% proportional reduction in coronary artery disease (CAD) 
death per 1.0 mmol/L (or 40 mg/dL) LDL cholesterol reduction were reported. Risk 
of major coronary event and risk of stroke were also reduced by 23% and 17% per 
1.0 mmol/L LDL cholesterol reduction, respectively (Baigent et al., 2010). Reports 
by Fulcher and Keech (2012) also showed a directly proportional relationship 
between the reduction in absolute LDL-cholesterol concentration and the reduction 
in major vascular events with statin therapy.  
Evidence from experimental and clinical studies further suggests that apart from 
their cholesterol-lowering effects, statins may also have some other beneficial 
effects (pleiotropic effects of statins), such as anti-inflammatory and antioxidant 
effects, which are potentially relevant for the prevention of CVD (Davignon, 2004; 
Zhou and Liao, 2010). The effect of statins in other clinical conditions including 
dementia (McGuinness et al., 2010), hepatic steatosis (Eslami et al., 2013), cancer 
(Emberson et al., 2012; Nielsen et al., 2012), venous thromboembolism (Li et al., 
2011), polycystic ovary syndrome (Raval et al., 2011) and Alzheimer’s disease 
(Gauthier and Massicotte, 2015) has also been evaluated, although the results 
remain controversial (Pederson, 2010; Schultz, Patten and Berlau, 2018).  
Statins are generally well tolerated with the most common adverse effects being 
transient gastrointestinal symptoms, headache and dizziness. These symptoms 
are common with higher doses of the medication. However, treatment with statins 
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has also been associated with liver and muscle toxicity, which may be mild or 
severe ranging from myalgia to rhabdomyolysis which affects 5 – 10% of patients 
administered statins (Pinal-Fernandez et al., 2018). Recent evidence indicates that 
statin therapy can cause either self-limited myotoxicity, presumably due to the 
direct effect of statins in the muscle, or autoimmune myopathy associated with 
autoantibodies targeting HMG-CoA reductase (Pinal-Fernandez et al., 2018; Ward 
et al., 2019). Direct myotoxicity is dose-dependent and is often complicated by 
concomitant treatment with drugs and substances such as cyclosporine, azole 
antifungins, grapefruit juice, erythromycin, and clarithromycin, which inhibit the 
cytochrome p450 3A4 pathway via which most statins are metabolised (Thompson 
et al., 2016). Direct myotoxicity is usually resolved after discontinuing statin 
treatment (Pinal-Fernandez et al., 2018). Statin-induced autoimmune myopathy 
has been reported in a very small number of patients (approximately 2 - 3 per 
100,000 patients treated each year) usually characterised by proximal muscle 
weakness, muscle-cell necrosis and presence of autoantibodies against HMG-
CoA reductase. This type of myopathy does not revert after stopping statin 
treatment (Mammen, 2016; Pinal-Fernandez et al., 2018).  
Other complications of statins include the risk of developing diabetes mellitus 
which is estimated to occur in about 10 – 20 per 10,000 patients treated per year, 
although the pathogenesis is unknown (Shattat et al., 2014; Pinal-Fernandez et 
al., 2018). Statin therapy is also associated with an increase in serum liver 
enzymes, although serious liver injury due to statin treatment is a rare occurrence, 
and is thought to increase when statin is administered in combination with other 
drugs such as fibrates. 
 
1.3.3.2 Fibrates (or Fibric acid derivatives) 
Fibrates or fibric acid derivatives are lipid-lowering drugs that have been used in 
clinical practice for many decades (Katsiki et al., 2013). Members of this class of 
drugs include clofibrate, ciprofibrate, bezafibrate, fenofibrate and gemfibrozil. They 
are recommended for lowering TRIG and raising HDL cholesterol levels. 
Therefore, patients with diabetes and/or metabolic syndrome that are frequently 
characterised by increased TRIG and decreased HDL cholesterol levels, are those 
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more likely to benefit from fibrate treatment (Farnier, 2008; Katsiki et al., 2013). 
The lipid-modulating action of fibrates is mediated by their capacity to mimic the 
structure and biological functions of free fatty acids; in this way fibrates bind to the 
nuclear transcription factor, peroxisome proliferator-activated receptors (PPARs), 
members of the subfamily of nuclear hormone receptors (Chapman, 2003; 
Goldenberg et al., 2008). The PPARs become activated by ligand binding and 
migrate from the cytoplasm of the cell to the nucleus, where they form 
heterodimers with retinoic acid X receptor, RXR (Figure 1.2). The PPAR-RXR 
heterodimer subsequently recognises and binds to specific response elements for 
PPARs in the regulatory regions of a spectrum of target genes termed PPAR 
response elements (PPREs) leading to activation or repression of the expression 
of such genes (Staels, et al., 1998, Chapman, 2003; Goldenberg et al., 2008).  
The PPARs represent a family of three nuclear receptor isoforms, namely PPARα, 
PPARγ and PPARδ/β, which are encoded by different genes (Boitier et al., 2003). 
These receptors also play important roles in the regulation of glucose and lipid 
homeostasis as well as in cell proliferation, differentiation and inflammatory 
responses (Lamers et al., 2012). Fibrates bind to PPARα, which is predominantly 
expressed in the liver, kidney, heart and skeletal muscle; all of these tissues 
depend in large part on free fatty acids as a source of energy (Chapman, 2003; 
Fazio and Linton, 2004). The major genes implicated in the PPARα-mediated 
action of fibrates are listed in Table 1.3. The mechanism of action of fibrates on 
lipid metabolism can be divided into five groups, including induction of lipoprotein 
lipolysis, induction of hepatic fatty acid uptake which causes a reduction in hepatic 
triglyceride production, increased removal of LDL particles, reduction in neutral 
lipid and increase in HDL cholesterol production and stimulation of reverse 
cholesterol transport (RCT) (Staels et al., 1998). 
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Figure 1.2 Mechanism of action of fibrates.  
Fibrates are rapidly converted by tissue and plasma esterases into their active metabolite 
(fibric acid) before they enter the cell. Fibric acid binds to the PPARα and forms a 
heterodimer complex with retinoid X receptor (RXR). This complex then binds to specific 
peroxisome proliferator response elements (PPREs) to activate target gene transcription 
(Koltai, 2015). 
 
Fibrate treatment induces an increase in lipoprotein lipase (LPL) activity and 
inhibition of apolipoprotein C3 (apo C-III) expression (a strong inhibitor of LPL), 
leading to increased lipolysis of plasma TRL as well as increased accessibility of 
TRL for the action of LPL (Katsiki et al., 2013). Reduced apo C-III synthesis results 
in enhanced LPL-mediated catabolism of VLDL particles. This represents the most 
likely hypolipidaemic mechanism of fibrates (Staels et al., 1998; Noonan et al., 
2013). Studies have also shown that fibrates increase fatty acid uptake by 
stimulation of fatty acid transporter protein (FATP) and conversion to acyl-CoA by 
induction of acyl-CoA synthase activity. By enhancing β-oxidation and decreasing 
fatty acid synthesis, fibrates reduce fatty acid availability for triglyceride synthesis. 
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This process is further amplified by fibrate-induced inhibition of hormone-sensitive 
lipase in adipose tissue (Katsiki et al., 2013). Fibrate treatment also results in the 
formation of LDL cholesterol with a higher affinity for the LDL receptor, which is 
thus catabolised rapidly. Furthermore, the cholesteryl ester content of LDL 
cholesterol increases, resulting in larger, less-dense LDL particles. These changes 
also increase interactions of LDL particles with the LDL receptor, thereby 
improving LDL clearance (Goldenberg et al., 2008). It is also suggested that fibrate 
therapy induces a decrease in the pool of TRL leading to a reduction of net 
cholesteryl ester transfer from HDL to TRLs, which in association with unchanged 
lecithin:cholesterol acyl transferase (LCAT) activity, ultimately leads to an increase 
in cholesteryl ester and a decrease in TRIG content of HDL cholesterol (Staels et 
al., 1998). The LPL-mediated lipolysis of TRL and increase in HDL cholesterol 
precursor (apo A-I and apo A-II) synthesis also contributes to the rise in HDL 
cholesterol as well as a more efficient RCT (Staels et al., 1998).  
Evidence from recent studies suggest that fibrates are able to reduce total 
cholesterol by 8%, LDL cholesterol by 8% and TRIG by 15 – 50%, and increase 
HDL cholesterol by 9% (Loomba and Arora, 2010; McCullough et al., 2011). 
Fibrates are administered as monotherapy or in combination with other lipid-
lowering drugs, mainly statins, but also Ezetimibe, Colesevelam and niacin 
(Farnier, 2008). Fibrate-statin combinations have been shown to attain lipid targets 
to a greater extent than monotherapy in patients with mixed dyslipidaemia, and 
these changes were maintained long-term (up to 64 weeks)  (Farnier et al., 2010; 
Farnier et al., 2011). Common side effects fibrate therapy include gastrointestinal 
symptoms, increased liver function tests (hepatotoxicity), reversible increase in 
serum creatinine (nephrotoxicity) and myopathy (myalgia, myositis and 
rhadomyolysis) (Remick et al., 2008). 
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Table 1.3 Major genes involved in the PPARα-mediated action of fibrates on 
lipid metabolism and inflammation 
Target gene Function of gene product Gene 
expression 
Apo C-III Inhibitor of VLDL clearance ↓ 
Lipoprotein lipase Lipolysis, TRL ↑ 
Apo AI HDL formation, RCT ↑ 
Apo AII  HDL formation, RCT ↑ 
SR-BI/CLA-1 receptor Cellular cholesterol efflux (macrophage) ↑ 
ABCA 1 transporter  
Fatty acid binding protein 
Cellular fatty acid uptake ↑ 
Acyl CoA synthetase Fatty acid activation; acyl CoA esters ↑ 
β-oxidation pathway Fatty acid oxidation ↑ 
Acetyl CoA carboxylase Fatty acid synthesis ↓ 
Fibrinogen Blood clotting ↓ 
C reactive protein Acute phase reactant ↓ 
Cyclooxygenase-2 Fatty acid metabolism ↓ 
VCAM-1 Adhesion molecule ↓ 
Abbreviations: Apo, apolipoprotein; VLDL, very low-density lipoprotein; RCT, reverse 
cholesterol transport; TRL, triglyceride-rich lipoprotein; HDL, high-density lipoprotein; SR-
BI, the scavenger receptor, class B type 1; ABCA, ATP binding cassette transporter A1; 
VCAM-1, vascular cell adhesion molecule -1; ↑ indicates increase; ↓ indicates decrease 
(Staels et al., 1998; Bougarne et al., 2018). 
 
1.3.3.3 Bile acid sequestrants (or anionic exchange resins) 
Bile acid-binding resins are a class of lipid-lowering drugs used in the clinic to 
reduce elevated serum levels of total cholesterol and LDL cholesterol, whilst 
increasing low level of HDL cholesterol. Bile acid sequestrants include: 
Choletyramine, Colesevelam, Colestipol, and Colestimide (Zodda et al., 2018). 
Cholestyramine and colestipol are the two bile acids currently available (Shattat et 
al., 2014). Cholestyramine is a quaternary amine composed of styrene and 
divinylbenzene polymers, while Colestipolis is a copolymer of diethylenetriamine 
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and 1-chloro-2, 3-epoxypropane (Jain et al., 2007). Bile acid synthesis is the main 
pathway of cholesterol catabolism in the liver; it is estimated that about 500 mg of 
cholesterol is converted daily into bile acids in the adult human liver. When 
secreted into the intestine, bile acids play an important role in facilitating the 
absorption of fats from food (Russell, 2003).  
Bile acid sequestrants are positively charged resins that are neither absorbed 
systemically nor metabolised by digestive enzymes. They are administered orally. 
At the level of the stomach, they bind to the two main biliary acids (glycocholic acid 
and taurocholic acid) to form an insoluble complex that is excreted in the faeces 
(Shattat et al., 2014; Chang and Robidaux, 2017). This leads to a continuous, 
though partial, removal of bile acids from the enterohepatic circulation. 
Consequently, the decreased concentration of bile acids in the liver causes an 
obstruction of the 7α-hydroxylase inhibition feedback mechanism and leads to an 
increase in hepatic conversion of cholesterol to bile acids (Zodda et al., 2018). 
Also, the decrease in the concentration of hepatic cholesterol causes a number of 
compensatory effects, such as increased plasma LDL cholesterol and IDL 
cholesterol uptake by increasing the number of high affinity receptors for LDL 
cholesterol present on cell membranes, especially in the liver and induction of the 
HMG-CoA reductase enzyme (Figure 1.3). Despite the fact that bile acid 
sequestrants cause increased hepatic cholesterol synthesis, there is a lowering of 
cholesterol level in the plasma. Bile acid sequestrants have also been shown to 
reduce TRIG and induce a 5% increase in HDL cholesterol levels (Steinmetz and 
Schonder, 2005).  
Cholestyramine and Colestipol are two hygroscopic molecules with a high 
molecular weight (>1,000,000), effective in lowering total cholesterol and LDL 
cholesterol and reduces mortality and cardiovascular events by 7% and 14%, 
respectively (Steinmetz and Schonder, 2005). They are often prescribed to 
patients who do not respond adequately to dietary adjustments for the treatment of 
primary hypercholesterolaemia (Scaldaferri et al., 2013). However, both drugs are 
not indicated when the primary alteration is hypertriglyceridaemia and are not 
effective in patients with homozygous familial hypercholesterolaemia who do not 
have functional receptors, as it does not alter the removal of plasma LDL 
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cholesterol via non-receptor mechanisms, although they may be useful in 
heterozygous patients for receptor alterations (Zodda et al., 2018). 
 
 
Figure 1.3 Mechanism of action of bile acid sequestrants.  
Bile acid sequestrants bind to bile acids and reduce the bile acid pool. Decrease in 
bile acid pool leads to increased bile acid synthesis from cholesterol in the liver, 
thereby lowering the intrahepatic cholesterol pool, which in turn triggers the LDL 
receptors resulting in increased LDL cholesterol clearance (Zodda et al., 2018) 
 
A major limitation to the use of bile acid sequestrants as initial therapy is their poor 
tolerance. However, the most common side effects of bile acid sequestrants are 
gastrointestinal disturbances. These include constipation, nausea, indigestion, 
bloating and flatulence (Shattat et al., 2014). Chronic use of resins can interfere 
with digestion, fat absorption and liposoluble vitamins (vitamin A, D, K, K1), with 
the latter causing an increase in bleeding tendency due to hypoprothrombinaemia 
from vitamin K deficiency (Scaldaferri et al., 2013). Long term treatment with bile 
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acid sequestrants has been associated with a reduction in serum or erythrocyte 
folate (Zodda et al., 2018), osteoporosis due to calcium loss and aggravation of 
hypertriglyceridaemia by an unknown mechanism (Shattat et al., 2014). They may 
also delay or reduce the absorption of certain drugs such as Phenylbutazone, 
Warfarin, Chlorothiazide, Tetracycline, Penicillin G and Phenobarbital, 
preparations of thyroid hormone and thyroxine (Zodda et al., 2018). In addition, it 
may interfere with drugs (e.g. oestrogens) that, like bile acids, are subject to 
enterohepatic circulation (Scaldaferri et al., 2013). 
 
1.3.3.4 Niacin (or nicotinic acid derivatives)  
Niacin, also known as the water-soluble vitamin B3, vitamin PP, or nicotinic acid, is 
the oldest lipid lowering agent used to treat hyperlipidaemia and proved to 
decrease cardiovascular morbidity and total mortality (Shattat et al., 2014). It is 
reported as the most effective therapy available for the treatment of low HDL 
cholesterol levels (Carlson, 2005). Niacin is approved for the treatment of 
hypercholesterolaemia and hypertriglyceridaemia and is indicated for familial 
combined hyperlipidaemia in patients who do not respond to non-pharmacological 
approaches such as diet and exercise (Chapman et al., 2011). It is also indicated 
for the treatment of heterozygous familial hypercholesterolaemia (Zodda et al., 
2018). The mechanism of action of niacin is not fully elucidated (Chapman et al., 
2011). Niacin decreases high levels of VLDL cholesterol and LDL cholesterol, 
through mechanisms that do not involve cholesterol biosynthesis or catabolism. As 
a powerful inhibitor of the intracellular lipase system, it prevents lipolysis in 
adipose tissue and generates multiple effects that eventually lead to the reduction 
of plasma cholesterol and triglycerides (Gille et al., 2008, Kei and Elisaf, 2012). 
Reduction in lipolysis decreases free fatty acid mobilisation, reducing their levels in 
the liver, resulting in a decrease in the hepatic synthesis of triglycerides with 
consequent lower production of VLDL cholesterol. Nicotinic acid also increases the 
clearance of VLDL cholesterol via its ability to stimulate the activity of lipoprotein 
lipase; the decrease in VLDL cholesterol leads to reduced levels of LDL (Figure 
1.4) (Gille et al., 2008, Zodda et al., 2018).  
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Figure 1.4 Mechanism of action of niacin.  
Niacin directly inhibits diacylglycerol acyltransferase-2 (DGAT2) activity leading to a 
reduction in triglyceride (TRIG) synthesis and activation of Apo B degradation and 
effectively inhibiting the synthesis of Apo B containing lipoproteins, VLDL, LDL and Lp(a) 
(Cooper et al., 2015; Image adapted with permission from Elvisier). 
 
Niacin treatment has been plagued by low compliance rates due to some adverse 
effects of the drug. The most common side effect of niacin is skin vasodilation 
(flushing and itching), an annoying but harmless sensation felt by about 70% of 
patients receiving niacin and which causes about 20% of niacin-treated subjects to 
drop out of clinical trials (Birjmohun et al., 2005; Dunbar and Gelfand, 2010; Song 
and FitzGerald, 2013). This side effect can be reduced by taking aspirin, 
ibuprofen, or indomethacin before the drug (Gille et al., 2008). Gastrointestinal 
intolerance manifested by symptoms such as heartburn, indigestion, nausea, and 
diarrhoea or stomach pain is reported after niacin administration. However, these 
effects can be minimised by administering the drug with meals (Boden et al., 
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2011). Niacin is contraindicated in patients with liver disease, as it often causes a 
reversible increase in plasma levels of liver enzymes (e.g. alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase and lactate 
dehydrogenase). It is used with caution in patients with diabetes mellitus and gout, 
given its ability to raise glucose and uric acid levels (Safeer and Lacivita, 2000; 
Bodor and Offermanns, 2008). Niacin has also been known to reduce insulin 
sensitivity and, in combination with statins, may interact with other factors to reveal 
a predisposition to diabetes (Heemskerk et al., 2014). The combination of niacin 
and statin has also been associated with an increased risk of myopathy and 
rhabdomyolysis (Gille et al., 2008). 
 
1.3.3.5 Ezetimibe (or selective cholesterol absorption inhibitor) 
Ezetimibe, or 1-(4-fluorophenyl)-(3R)-[3-{4-fluorophenyl}-{3S}-hydroxyprophyl]-
(4S)-(4-hydroxyphenyl)-(2-azetidinone), is the first member of a group of drugs 
that selectively inhibit the intestinal absorption of phytosterols and dietary 
cholesterol (Lipka, 2003; Shattat et al., 2014; Zodda et al., 2018). Its mechanism 
of action involves targeting gastrointestinal cholesterol absorption within the brush 
border of the small intestine, where it selectively inhibits the cholesterol transport 
protein Nieman Pick C1 like protein (NPC1L1), thereby preventing uptake of 
intestinal luminal miscelles, which contain cholesterol, into enterocytes (Phan et 
al., 2012). Current evidence indicates that NPC1L1 protein works in conjunction 
with the adaptor protein 2 (AP2) complex and clathrin to facilitate internalisation of 
free cholesterol into the enterocyte. AP2 is a classical AP that facilitates the 
internalisation of molecules into cells, such as cholesterol entering clathrin-coated 
pits (Phan et al., 2012). The exact mechanism by which Ezetimibe reduces the 
entry of cholesterol into the enterocytes is not completely understood. Ge et al., 
(2008) suggest that Ezetimibe prevents NPC1L1/sterol complex from interacting 
with AP2 in clathrin coated vesicles.  It is also thought that ezetimibe may change 
the shape of NPC1L1 and make it incapable of binding to sterols or may interfere 
with the binding of free cholesterol to the cell membrane (Pearse, Smith and 
Owen, 2000; Phan et al., 2012). Through reduced cholesterol uptake, ezetimibe 
therapy also causes a depletion of hepatic LDL cholesterol stores, resulting in 
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upregulation of hepatic LDL receptors, which in turn causes LDL cholesterol 
uptake by the liver from the circulation. In addition to reducing gastrointestinal 
cholesterol absorption, it is also thought that ezetimibe inhibits hepatic NPC1L1, 
thereby reducing hepatic cholesterol absorption (Phan et al., 2012). However, 
ezetimibe does not appear to have an effect on the absorption of dietary lipid-
soluble vitamins and drugs (Hammersley and Signy, 2017). 
Ezetimibe is indicated both in association with statins, to reduce elevated levels of 
total cholesterol, LDL cholesterol, and Apolipoprotein B in patients with primary 
hypercholesterolaemia (familial or non-familial heterozygosity) that are not 
adequately controlled with statins alone, as well as in monotherapy in this same 
group of patients for whom statins are considered inappropriate or not tolerated 
(Davidson et al., 2002; Hammersley and Signy, 2017). It is also indicated for 
homozygous familial hypercholesterolaemia in combination with statins 
(atorvastatin or simvastatin) and homozygous familial sitosterolaemia, when the 
patients have not responded to diet, physical activity and other lifestyle 
intervention measures (Bove et al., 2017). Early trials demonstrated an additional 
reduction in LDL cholesterol levels of 12 – 19% when ezetimibe was taken in 
conjunction with statins (Ballantyne et al., 2003). However, whether ezetimibe 
therapy confers additional reduction in cardiovascular risk is still a controversy; 
little evidence of this has been reported (Hammersley and Signy, 2017). The 
safety of ezetimibe as monotherapy or in combination with other lipid modifying 
agents such as statins has been well documented (Robinson et al., 2009; Pandor 
et al., 2009).  
Ezetimibe is generally well tolerated; the most common side effects include 
headache, abdominal pain and diarrhoea. Ezetimibe is also associated with an 
increase in liver enzymes (alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase and lactate dehydrogenase); however, life threatening liver 
failure with Ezetimibe as monotherapy or in combination with statins is extremely 
rare, with only a handful of reported cases (Stolk et al., 2006; Tuteja et al., 2008; 
Castellote et al., 2008). Recent publication of the Simvastatin and Ezetimibe in 
Aortic Stenosis (SEAS) study raised concerns for cancer with treatment with 
Ezetimibe plus statin (Rossebo et al., 2008). However, a combined analysis of two 
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larger Ezetimibe-plus-statin trials, namely, the Study of Heart and Renal Protection 
(SHARP) and Improved Reduction of Outcomes: Vytorin Efficacy International 
Trial (IMPROVE-IT) studies that were carried out at the same time as the SEAS 
analysis did not support such a hypothesis (Peto et al., 2008; Phan et al., 2012).  
Ezetimibe is a safe alternative option for dyslipidaemic patients intolerant to other 
lipid lowering drugs, as well as a beneficial supplementary agent for patients who 
do not reach the recommended serum cholesterol level with their current 
hypolipidaemic treatment. However, as is the case with all new medications, 
physicians should be alert to recognise adverse effects associated with Ezetimibe 
and report them to the regulatory authorities (Florentin, Liberopoulos and Elisaf, 
2007). 
 
1.3.4 Role of Fenofibrate in managing dyslipidaemia 
Fenofibrate (FF) or 2-4[(4-chlorobenzoyl) phenoxy]-2-methylpropanoic acid, 1-
methylethyl ester is the most commonly prescribed fibric acid derivative for the 
management of dyslipidaemia (Lian et al., 2018). It is a third generation fibric acid 
derivative, widely used as a monotherapy or in combination with other agents, 
mainly statins, but also Ezetimibe and Colesevelam, to reduce blood levels of 
cholesterol (LDL and VLDL) and TRIG and increase HDL cholesterol levels in 
patients at risk of CVD and for  treatment of atherosclerosis (Farnier, 2008; Abbas 
et al., 2012). It is recommended for patients with hypertriglyceridaemia 
(Fredrickson types IV and V hyperlipidaemia) and hypercholesterolaemia 
(Frederickson types IIa and IIb) (Yang and Keating, 2009). Following oral 
administration, FF is rapidly hydrolysed by esterases in the liver and intestinal wall 
to its active metabolite, fenofibric acid (Lian et al., 2018). Like other fibric acid 
derivatives, the lipid lowering activity of FF is mediated through its interactions with 
PPARα, which regulates the gene expression of various enzymes involved in fatty 
acid oxidation and lipoprotein metabolism as illustrated in Figure 1.5 (Lian et al., 
2018). Important molecular features of FF compared with other fibric acid 
derivatives include the conversion of the phenoxy-2-methyl-2-propanoic acid chain 
in clofibrate and introduction of a chlorobenzoyl-ketone group for the chlorine atom 
in clofibrate (Najib, 2002). 
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FF stimulates the oxidation of free fatty acids in the liver, which results in the 
reduction of fatty acids for VLDL cholesterol synthesis and secretion. FF also 
increases the gene expression of lipoprotein lipase and decreases Apo C-III 
expression in the liver. Thus, FF lowers the concentration of TRIG, both by 
reducing the rate of synthesis and increasing the rate of hydrolysis of TRL (Staels 
et al., 1998; Keating and Croom, 2007; Farnier, 2008). Moreover, FF treatment 
reduces the proportion of small, dense LDL cholesterol, with the formation of 
larger, less dense LDL particles with a higher affinity for the LDL receptor and 
which are thus catabolised more rapidly (Chapman, 2006; Noonan et al., 2013). 
PPARα activation by FF also causes an increase in gene expression for both 
apolipoprotein A-I (Apo A-I) and apolipoprotein A-II (Apo A-II), decreases 
cholesteryl ester transfer protein-mediated transfer of cholesterol from HDL to 
VLDL, enhances cell cholesterol efflux by induction of cell ATP-binding cassette 
transporter (ABCA1) expression and decreases the scavenger receptor, class B 
type 1 (SR-B1) in the liver. ABCA1, Apo A-I and Apo A-II play an essential role in 
the nascent HDL cholesterol formation. ABCA1 exports excess cellular cholesterol 
and phosphatidylcholine (PC) to lipid free Apo A-I in serum, thereby generating 
nascent HDL cholesterol (Nagao et al., 2011; Ishigami et al., 2018). SR-B1 is an 
HDL receptor whose primary role is to mediate selective uptake or influx of HDL 
derived cholesteryl esters into cells and tissues. SR-B1 also facilitates the efflux of 
cholesterol from peripheral tissues, including macrophages, back to the liver (Shen 
et al., 2018). All these effects contribute to the increase in plasma HDL cholesterol 
concentrations. 
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Figure 1.5 Lipid lowering mechanism of FF.  
FF is hydrolysed by tissue and plasma esterases into fenofibric acid, which binds to and 
activates PPARα, and forms a heterodimer complex with RXR. The PPARα-RXR complex 
binds to specific PPREs to activate target gene transcription resulting in decreased TRIG, 
LDL particles and inflammation and increased HDL synthesis and RCT. Abbreviations: 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RCT, reverse cholesterol 
transport; PPARα, peroxisome proliferator-activated receptor-α; PPRE, peroxisome 
proliferator response elements; RXR, retinoid X receptor; ↑ indicates increase; ↓ indicates 
decrease (Ramasamy, 2016; Image adapted with permission from Elvisier). 
 
1.3.5 Pleiotropic effects of FF therapy 
Apart from its lipid-lowering effects, FF also has many pleiotropic effects which are 
believed to be mediated by the activation of PPARα (Paumelle and Staels, 2008). 
Evidence from various studies suggests that FF therapy improves endothelial 
function (Playford et al., 2002; Capell et al., 2003; Koh et al., 2005). Koh et al., 
(2005) reported that FF therapy significantly improved percent flow-mediated 
dilator response to hyperaemia, reduced inflammation marker levels, increased 
adiponectin levels, and improved insulin sensitivity in patients with 
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hypertriglyceridaemia or metabolic syndrome. In a recent study involving twenty-
four healthy normolipidaemic men and women (aged 50 - 70 years), Walker et al., 
(2012) demonstrated that treatment with FF improved vascular endothelial function 
by reducing oxidative stress and inducing an increase in endothelial nitric oxide 
synthase. FF has also been reported to exert anti-inflammatory activities via 
reduction in C reactive protein and a number of cytokines (e.g. interleukin 6, 
tumour necrosis factor-alpha). In a study involving patients with 
hypertriglyceridaemia and metabolic syndrome, Rosenson et al., (2008) reported 
that FF therapy reduced whole blood production of inflammatory cytokines and 
hepatic synthesised inflammatory proteins, via VLDL- and LDL-mediated 
pathways.  
Other effects of FF therapy include decreasing procoagulant factors such as 
fibrinogen and plasminogen activator inhibitor-1 and reduction of monocyte 
chemoattractant protein-1 (Maison et al., 2002; Paumelle and Staels, 2008). 
Among the fibrate class of anti-lipidaemic drugs, FF significantly reduces uric acid 
levels and has been suggested for the treatment of hyperuricaemia and gout 
(Feher et al., 2003; Jung et al., 2018). Increasing evidence from recent studies has 
demonstrated the potential of FF as an anti-cancer drug, although these were all 
based on in vitro studies. Reports suggest that FF exerts anti-cancer effects in 
several human cancer cell lines, such as breast, liver, glioma, prostate, pancreas, 
and lung cancer (Lian et al., 2018). 
 
1.3.6 Limitations of FF in the management of dyslipidaemia 
Although FF is generally well-tolerated, it has been associated with some adverse 
events which may be causally related: hepatitis, cholelithiasis, cholecystitis, 
hepatomegaly, myalgias, myasthenia, rhabdomyolysis, photosensitivity, eczema, 
and allergic pulmonary alveolitis. However, these events all occur in less than 10% 
of fenofibrate recipients (Guay, 2002). Just as with all other fibrates, FF enhances 
the formation of cholesterol gallstones by altering biliary composition and 
increasing the lithogenic index of bile (Liang et al., 2011; Kassim et al., 2018). 
Patients with pre-existing gallbladder disease are advised against its use (Guay, 
1999; Ghonem et al., 2015). In the Fenofibrate Intervention and Event Lowering in 
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Diabetes (FIELD) trial, patients allocated to FF at 200 mg/day had statistically 
significant, though only marginally greater, overall risk of pancreatitis and 
pulmonary embolism, than those allocated to placebo (Ting et al., 2011). The risk 
seems to increase when FF is combined with statins, most particularly simvastatin 
(McDonald et al., 2002).  
FF-associated rhabdomyolysis is a rare phenomenon although cases of 
rhabdomyolysis associated with fenofibrate alone or in combination with statins 
have been reported in patients with dyslipidaemia (Wu et al., 2009). 
Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release 
of intracellular muscle contents into the systemic circulation. The risk for serious 
muscle toxicity appears to be increased in elderly patients and in those with 
diabetes (Barker et al., 2003; Jacob et al., 2005), kidney failure and 
hypothyroidism (Satarasinghe et al., 2007). Despite its low prevalence, patient 
monitoring is strongly recommended because rhabdomyolysis may be very severe 
with fatal consequences (Kato et al., 2011).  
Cases of FF toxicity to the liver have also been reported and this appears to be 
dose related (Kobayashi et al., 2009; Gandhi et al., 2014). Mild, transient 
increases in serum transaminases have been reported in up to 20% of patients 
receiving FF, but values above three times the upper limit of normal have been 
reported in only 3 – 5% of cases. These abnormalities are usually asymptomatic 
and transient, resolving even with continuation of FF, but occasionally may require 
drug discontinuation. The mechanism of FF-induced hepatotoxicity is unclear. 
However, patients with metabolic syndrome and uncontrolled dyslipidaemia of long 
duration are considered to be at greater risk of developing hepatic steatosis 
(Macchesini et al., 2001). Monitoring of liver function is recommended for patients 
receiving FF and discontinuation if liver enzymes persist above the upper limit of 
normal (Gandhi et al., 2014).   
FF-associated creatininaemia is the most commonly reported adverse effect of FF 
therapy (Lipscombe et al., 2001; Ansquer et al., 2008; Ting and Keech, 2013; Kim 
et al., 2017). FF-associated creatininaemia is common in patients with chronic 
diseases such as diabetes, hypertension and chronic kidney failure. However, 
recent studies have shown that FF also affects kidney function in relatively healthy 
Fombon, I.S. (2020) 
30 
 
adults without CVD (Kim et al., 2017). The significance of this increase in serum 
creatinine with FF has been debated (Ting and Keech, 2013). The mechanism of 
FF-induced creatininaemia is not fully understood and kidney function monitoring 
is recommended for patients receiving FF therapy (Keech et al., 2005; Ncube et 
al., 2012). 
 
1.4 IMPACT OF FF ON KIDNEY FUNCTION 
The implication of dyslipidaemia as a risk factor for progressive kidney disease is 
extensively reported (Fox et al., 2004) and the acute increase in serum creatinine 
(CREA) level (or inferred nephrotoxicity) following treatment with FF has raised 
concerns about the safety of its use in patients with chronic kidney disease 
(Ansquer et al., 2008). Some studies and case reports suggest that FF can 
potentially cause further kidney damage in patients with underlying kidney disease 
(Broeders et al., 2000, Lipscombe et al., 2001). In addition to these case reports of 
patients with pre-existing kidney disease, increased serum CREA concentrations 
have been reported in patients with normal baseline kidney function taking FF 
(Ansquer et al., 2008). However, the effect of FF on kidney function remains 
unclear and is an important unmet clinical need in this field. Evidence from long-
term studies such as the FIELD study and the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) study, suggest that FF-associated increase in serum 
CREA is reversible (Davis et al., 2011; Mychaleckyj et al., 2012). In the FIELD 
study, after 5 years of treatment, the increase in serum CREA in patients allocated 
FF, subsided fully within six weeks of withdrawing treatment (to a lower level than 
in the placebo group) (Davis et al., 2011). A similar pattern of change was 
observed in the ACCORD Lipid trial (Mychaleckyj et al., 2012). These reports 
indicate that whatever the mechanisms of the increase in serum CREA during FF 
treatment, no permanent injury results. However, it is important to note that this 
FF-associated nephrotoxicity is interpreted on the basis of increases in serum 
CREA concentrations, with the presumption that serum CREA is a surrogate for 
the underlying kidney function (Ting and Keech, 2013).  
Suggestions that have been made to explain the mechanism of the increase in 
serum CREA level following FF therapy include; analytical interference with serum 
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CREA assay, increased metabolic production or reduced renal clearance of CREA 
(Abbas et al., 2012). In a retrospective study involving 10 adult male patients with 
hyperlipidaemia, Lipscombe et al., (2001) reported a concomitant increase in 
serum CREA and Urea concentrations following fibrate administration. Both 
parameters were decreased after discontinuation of the drug. They suggested that 
the most plausible cause of the deterioration of kidney function is one based on 
kidney haemodynamics, given the rapid and complete reversibility that was noted 
and the finding that most of the patients had risk factors for vascular disease.  
In a similar (retrospective) study, Tsimihodimos et al., (2001) reviewed the reports 
of patients treated with fibrates and reported significant increases in both serum 
CREA and Urea concentrations in patients administered clofibrate and FF, but no 
significant change in those treated with gemfibrozil. They proposed that with the 
exception of gemfibrozil, fibrates including FF, ciprofibrate and bezafibrate impair 
the generation of vasodilatory prostaglandins in the kidney, probably by activating 
PPARs which can down-regulate the expression of the inducible cyclooxygenase 
(COX-2) enzyme. COX-2 is an enzyme that catalyses the formation of 
prostaglandins. Gemfibrozil, in contrast to the other fibrates, fails to bind and 
activate PPARs which may account for the absence of nephrotoxicity observed 
(Tsimihodimos et al., 2001). Hence, they believed that the increase in serum 
CREA is due to FF-induced kidney impairment.  
With regards to analytical interference as the cause of the FF-associated increase 
in serum CREA, Hottelart et al., (2002) compared the Jaffe reaction with high-
performance liquid chromatography (HPLC) and suggested that the increase in 
serum CREA is most likely due to increased metabolic production, as urinary 
levels of CREA were not reduced and the glomerular filtration rate (GFR) 
measured by inulin (an independent marker for renal function) was not reduced. 
Ansquer et al., (2008) also compared the Jaffe colorimetric method and mass 
spectrometry and suggested that the increase in serum CREA is not method 
dependent. Recent studies have reported concomitant increases in serum CREA 
and serum cystatin C concentrations in patients administered FF therapy 
(Forsblom et al., 2010; Mychalekyj et al., 2012; Ncube et al., (2012).  
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Cystatin C is considered as an independent predictive marker of kidney function 
(Murty et al., 2013). The increase in serum cystatin C concentration following FF 
administration suggests that the impact of FF is not just on serum CREA alone. 
The clinical relevance of the increase in both markers needs to be assessed in a 
long-term outcome study of kidney function. There is much debate in the literature, 
but the mechanism of the FF-induced creatininaemia is still not fully understood 
and kidney function monitoring is recommended for patients receiving FF therapy, 
particularly in those with pre-existing kidney disease (Sica, 2009; Kim et al., 2017). 
 
1.5 MONITORING KIDNEY FUNCTION IN FF THERAPY 
The kidneys play a fundamental role in the metabolism of FF (Mckeage and 
Keating, 2011). Following oral administration, the FF is extensively absorbed and 
transported through the blood stream by albumin and is taken up mainly by the 
liver and kidney (Chapman, 1987). FF is excreted (60%) in the urine as fenofibric 
acid and its glucoronide conjugate (Mckeage and Keating, 2011). Coupled with its 
non dialyzable nature, a reduction in kidney function would therefore result in 
slower elimination of FF causing accumulation in blood and an increased risk of 
adverse effect as observed in patients with reduced kidney function administered 
FF for dyslipidaemia (Ting and Keech, 2013). Routine kidney function monitoring 
is therefore recommended in patients receiving FF therapy, most particularly in 
those with baseline chronic kidney disease (Davidson et al., 2007). However, 
accurate measurement of kidney function is methodically difficult because the 
kidney has several different interlinked functions, including excretion of waste 
products, regulation of water and electrolytes, acid-base homeostasis and 
hormone secretion (Levey and Inker, 2017). Kidney function is assessed in the 
clinic by methods that measure the GFR of the kidneys. 
The GFR is considered the best overall index for measurement of kidney function 
and correlates well with renal function impairment (Stevens and Levey, 2009; 
Levey and Inker, 2017). Glomerular filtration is the physiologic process of creating 
an ultrafiltrate of blood as it flows through the glomerular capillaries. In principle, 
the GFR is the product of the number of nephrons times the average single-
nephron glomerular filtration rate. Its determination also includes haemodynamic 
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factors within the glomerular capillary network and the properties of the capillary 
wall (Levey et al., 2014; Levey and Inker, 2017). The GFR cannot be measured 
directly in the human body. In practice, it is assessed by measuring the clearance 
or serum levels of filtration markers, exogenous or endogenous solutes that are 
mainly eliminated by glomerular filtration (Levey et al., 2014).  
An ideal marker of GFR is one that is only eliminated through the kidney via 
glomerular filtration, is freely filtered by the glomerulus (e.g. not subject to protein 
binding), not eliminated via tubular secretion, and is not reabsorbed after being 
filtered by the glomerulus (Seegmiller et al., 2018). The GFR is calculated by the 
kidney clearance or plasma disappearance of endogenous or exogenous markers. 
For a kidney clearance study, the blood concentration is monitored during a timed 
urine collection and the amount of the filtration marker excreted in the urine is 
measured. The GFR is calculated based upon the kidney elimination of the marker 
concentration in the blood during the collection. For a plasma disappearance 
study, the exogenous marker is administered as a single bolus. Blood is sampled 
multiple times after that to reconstruct a curve based on its elimination from the 
blood stream. The rate of elimination will then equal GFR (Schwartz et al., 2006; 
Seegmiller et al., 2018). 
 
1.6 ESTIMATING GFR USING EXOGENOUS MARKERS  
The gold standard for measuring GFR is the urinary clearance of inulin described 
by Homer Smith, against which other clearance methods and filtration markers are 
evaluated (Inker et al., 2015). Other exogenous markers which have been shown 
to produce measures of GFR that correlate well with inulin clearance include, 
isotopic markers e.g. 51Chromium ethylene-diamine tetra-acetic acid (51Cr-EDTA), 
99mTechnetium labelled diethylene-triamine- pentacetate (99mTc-DTPA) and 125I-
iothalamate, as well as non-radioisotopically labelled markers such as iohexol 
(Stevens and Levey, 2009). Although inulin clearance is considered the gold-
standard method for measuring GFR, the need for continuous infusion, multiple 
blood samples and urine collection, make it cumbersome and expensive for use in 
routine clinical practice (Lopez-Giacoman and Madero, 2015). In a recent report, 
Soveri et al., (2014) suggested that the kidney excretion of 51Cr-EDTA or 
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iothalamate, and plasma clearance of 51Cr-EDTA or iohexol, using inulin clearance 
as reference, were sufficiently accurate methods to measure GFR. However, all 
these methods (based on exogenous substances) still require the need of 
continuous infusion or bolus administration (subcutaneous or intravenous) and like 
inulin, their complexity limits their application in routine clinical practice and 
epidemiological studies, mostly for the length of time that the procedure entails 
(Lopez-Giacoman and Madero, 2015). They are costly and cumbersome and are 
generally used only in selected secondary situations. Surrogate markers, such as 
serum values of endogenous markers are used in routine practice (Ferguson and 
Waiker, 2012). 
 
1.7 ESTIMATING GFR USING ENDOGENOUS MARKERS  
Currently identified endogenous filtration markers include metabolites (e.g. CREA 
and urea) and low-molecular weight proteins (e.g. cystatin C, β-trace protein) 
(Levey and Inker, 2014). Filtered metabolites are often excreted in the urine, but 
may undergo renal tubular reabsorption or secretion, which may be assessed by 
comparing their urinary clearances to urinary clearance of exogenous filtration 
markers. Extrarenal elimination of endogenous markers can also be assessed by 
comparing their urinary excretion rate to their generation rate (Levey and Inker, 
2017).  By contrast, filtered plasma proteins are reabsorbed and degraded within 
the tubules with minimal appearance in the urine, making it more difficult to 
evaluate the renal tubular reabsorption, secretion and extrarenal elimination of 
low-molecular weight plasma proteins than metabolites (Inker et al., 2015). Factors 
affecting conventional endogenous markers of kidney function vary with the 
different markers and are summarised on Table 1.4. 
 
1.7.1 Urea as a marker for estimating GFR   
Historically, Urea was the first marker used to formally assess kidney function 
(Ferguson and Waikar, 2012). It is a major nitrogenous breakdown product of 
protein and amino acid catabolism, produced by the liver and distributed 
throughout intracellular and extracellular fluid. It is eliminated almost entirely 
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through urinary excretion, making it a suitable candidate for estimating GFR. In 
1827, Richard Bright associated the accumulation of Urea in blood with decrease 
in urine among individuals with kidney disease (Smith, 1951; Ferguson and 
Waikar, 2012). This led to the introduction of blood Urea nitrogen (BUN) into 
clinical medicine as a diagnostic test in the 1900s (Smith, 1951). The most 
frequently determined clinical indices for estimating kidney function depend on the 
concentration of BUN. It is useful in the differential diagnosis of acute kidney 
failure and pre-renal conditions where the BUN/CREA ratio is increased (Rosner 
and Bolton, 2006). Recent reports suggest that BUN is now generally considered 
as a suboptimal marker for estimating GFR (Gowda et al., 2010). Several 
limitations have been highlighted against its use in assessing GFR. Urea 
clearance is a poor indicator of GFR as its overproduction rate depends on several 
non-kidney related factors including diet and Urea cycles.  
Urea is readily absorbed by the tubules, particularly in conditions of volume 
depletion, resulting in increased concentrations while GFR is preserved. Apart 
from kidney disease (e.g. kidney failure and urinary track obstruction by kidney 
stones), increase in BUN concentrations is also observed in increased dietary 
protein intake, hypercatabolism, congestive heart failure, dehydration, 
corticosteroid use, fever, shock, gastrointestinal bleeding or during late pregnancy 
(Gowda et al., 2010; Ferguson and Waikar, 2012). Low levels are also seen in 
fluid excess, trauma, surgery, opioid use, malnutrition and anabolic steroid use 
(Gowda et al., 2010). Therefore, interpretation of BUN concentration has to be 
carefully considered in the clinical context. Although some studies have reported 
concomitant increases in BUN and serum CREA concentrations following FF 
administration, the impact of FF therapy on BUN have not been fully elucidated 
(Broeders et al., 2000) 
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Table 1.4 Factors affecting conventional markers of kidney function 
(Bagshaw, 2008) 
 
Serum marker 
Factors 
Increased Decreased 
Urea Decreased effective circulating 
volume 
Aggressive volume expansion 
 Increased dietary protein Pregnancy 
 Critical illness (fever, trauma, burns, 
sepsis) 
SIADH‡ 
 Gastrointestinal bleeding Dietary protein restriction 
 Drugs (corticosteroids, tetracyclines) Liver disease 
Creatinine Younger age Older age 
 Male sex Female sex 
 Large muscle mass Muscle wasting 
(neuromuscular diseases, 
malnutrition) 
 Ingestion of cooked meat Protein restriction (renal 
disease, liver disease) 
 Jaffe reaction (ketotic states, 
hyperglycaemia) 
Vegetarian diet 
 Drugs (cimetidine, trimethoprim) Jaffe reaction 
(hyperbilirubinaemia) 
 Vigorous exercise Amputation 
Cystatin C Older age  
 Male sex Female sex 
 Greater body mass Lower body mass 
 Smoker Immunosuppressive therapy 
(corticosteroids) 
 States of inflammation Hypothyroidism 
 Hyperthyroidism  
‡SIADH, syndrome of inappropriate antidiuretic hormone. 
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1.7.2 CREA as a marker for estimating GFR 
First identified in 1847 and later proposed as a filtration marker in 1926, CREA 
supplanted urea as a marker of GFR in the mid 1900s and remains the most 
widely used laboratory marker for estimation of GFR today (Ferguson and Waikar, 
2012). CREA is a small molecule (molecular weight 113-Dalton) derived from the 
breakdown of creatine phosphate in muscle as well as from dietary meat intake or 
creatine supplements (Lopez-Giacoman and Madero, 2015; Levey and Inker, 
2017). CREA generation is proportional to muscle mass, which can be estimated 
from age, sex, race and body size, but many other factors can affect CREA 
generation (Ferguson and Waikar, 2012). CREA is distributed in total body water, 
not protein bound, freely filtered across the glomerulus and is not reabsorbed by 
the kidney tubules and its concentration is inversely related to GFR (Ferguson and 
Waikar, 2012; Levey and Inker, 2017). It is also convenient and cheap to measure. 
In clinical practice, measured CREA clearance is also often assessed from the 
CREA excretion in a 24-hour urine collection and a single measurement of serum 
CREA in the steady state (Levey and Inker, 2017).  
Although CREA is the most commonly used kidney function biomarker in the clinic, 
the limitations of serum CREA and CREA clearance for the estimation of GFR are 
well documented (Sica, 2009).  Serum CREA levels are known to be affected by 
various factors that are independent of changes in GFR, such as, muscle mass, 
age, sex, race, catabolic state, medication use, tubular secretion and extrarenal 
elimination in severe kidney impairment (Levey et al., 2014). CREA concentrations 
may alter as its generation may not be simply a product of muscle mass but 
influenced by muscle function, muscle composition, activity, diet and health status 
(Banfi and Del Fabbro, 2006; Gowda et al., 2010). Several medications, such as 
cimetidine, trimethoprim, and possibly FF, competitively inhibit CREA secretion, 
leading to a rise in the serum CREA concentration without any effect on the GFR 
(Levey and Inker, 2017).  
Furthermore, CREA is contained in intestinal secretions and can be degraded by 
bacteria; gastrointestinal elimination of CREA is increased at higher levels of 
serum CREA but can be reduced by changes in gut flora due to antibiotic use 
(Levey and Inker, 2017). Clinically, it can be difficult to distinguish a rise in serum 
CREA concentration caused by inhibition of CREA secretion or extrarenal 
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elimination from a decline in GFR, especially in patients with low GFR (Inker et al., 
2015). Tubular secretion of CREA may increase proportionally relative to its 
glomerular filtration as kidney function declines, resulting in a significant 
overestimation of true GFR. As a result, an increase in serum CREA may not be 
observed until a substantial decrease in GFR has occurred (Ferguson and Waikar, 
2012).  
Historically, considerable variability has been known to exist with respect to serum 
CREA measurement, generally resulting in less accurate estimation of GFR when 
serum concentrations are within or slightly above the reference interval (Myers et 
al., 2006). This led to the launching of the Creatinine Standardisation Program in 
2008 by the National Kidney Disease Education Program (NKDEP) in 
collaboration with the International Federation of Clinical Chemistry (IFCC) and the 
European Communities Confederation of Clinical Chemistry to reduce 
interlaboratory variability in CREA assay calibration (Levey and Inker, 2017). 
Following on from this, most laboratories now use a CREA assay that has 
calibration traceable to an isotope dilution mass spectroscopy method, enabling 
interlaboratory comparison. However, the effect of standardisation still varies 
among clinical laboratories.  
Overall, standardisation has led to lower values for serum CREA and higher 
values for estimated GFR using CREA as a filtration marker than before 
standardisation (Levey and Inker, 2017). Also, measured CREA clearance, which 
is usually assessed from the CREA excretion in a 24-hour urine collection, and a 
single measurement of serum CREA in a steady state, is reported to be unreliable 
due to the variations in CREA excretion rates. Deviations from estimated CREA 
excretion can indicate errors in timing or completeness of urine collection, but 
cannot be relied upon due to wide variability in CREA generation (Inker, 2014). 
Collectively, the choice of CREA as a marker for assessing kidney function in 
patients receiving FF therapy is debatable as the underlying mechanism and 
clinical significance of the reversible increase in serum CREA witnessed during 
treatment are not fully understood. 
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1.7.3 Use of low-molecular weight proteins as markers of GFR 
Recent reports suggest that low molecular weight proteins such as cystatin C, 
beta-2 microglobulin and beta-trace protein are potential markers of GFR 
(Argyropoulos et al., 2017; Beker et al., 2018). These proteins are freely filtered by 
the glomerulus, reabsorbed and catabolised but not secreted by the kidney 
tubules. As a result, increases in plasma concentration of these proteins are 
associated with a reduction in GFR. The impact of FF on these novel markers of 
kidney function is not fully elucidated. Although recent studies have shown 
concomitant increase in serum CREA and cystatin C following FF therapy, the 
impact on B2M and BTP have not been reported (Ncube et al., 2012; Mychalekyj 
et al., 2012) 
 
1.7.3.1 Cystatin C (CYSC) as a marker of kidney function 
CYSC has been described as a promising endogenous marker and has generated 
considerable interest in recent years as a marker of GFR. It is a 122 amino acid 
low molecular weight protein (13 kDa) that is a cysteine protease inhibitor (Levey 
et al., 2014). It is produced at constant rate by all nucleated cells and distributed in 
extracellular fluid. The function of CYSC seems to be the protection of connective 
tissues from destruction by intracellular enzymes. It may also have some 
antibacterial or antiviral function (de Vries and Rabelink, 2013). CYSC is freely 
filtered by the glomerulus and approximately 99% is reabsorbed by the proximal 
tubular cells, where it is also almost completely catabolised, with the remainder 
eliminated largely intact in the urine (Levey and Inker, 2017). Earlier reports 
indicate that CYSC is not secreted by the renal tubules (Larteza et al., 2002), but 
recent  evidence suggests the existence of tubular secretion as well as extrarenal 
elimination, the latter estimated at 15 – 21% of urinary clearance (Levey and Inker, 
2017).  
Unlike serum CREA, serum CYSC concentration appears to be independent of 
age, sex, and muscle mass (Filler et al., 2005). It is suggested that CYSC may be 
more reliable than serum CREA-based methods in estimating GFR, particularly in 
those individuals with a mild reduction in GFR, in whom changes in serum CREA 
are typically not observed (the so-called creatinine blind range of GFR) (Herget-
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Rosenthal, Bökenkamp and Hofmann, 2007). Serum CYSC may also be superior 
to serum CREA in estimating mortality and cardiovascular outcomes (Herget-
Rosenthal et al., 2007; Ferguson and Waikar, 2012). Reports suggest that serum 
CYSC rises faster than serum CREA after a fall in GFR, suggesting that serum 
CYSC may be a an ideal marker for early detection of kidney impairment, as is 
often required for monitoring the effect of drugs on the kidney function (Herget-
Rosenthal et al., 2007).  
Several GFR-prediction equations based on serum CYSC have been proposed, 
including equations that incorporate both serum CREA and CYSC (Inker et al., 
2012; Grubb et al., 2014). The serum CYSC-based equations appear simpler and 
more accurate than serum CREA-based equations (Hojs et al., 2008). Although, 
these equations have shown only modest improvement in the accuracy of GFR 
estimation compared with serum CREA-based equations, there is increasing 
evidence that the use of serum CYSC outperforms serum CREA in the 
stratification of risk (Shiplak et al., 2013). Recent studies have shown that GFR 
equations that incorporate both serum CREA and CYSC perform better than those 
using either of these two markers (Inker et al., 2012). However, concerns have 
been raised about the lack of standardisation in serum CYSC measurement. A 
recent study by White et al., (2011) found that there were significant differences in 
serum CYSC measurement between laboratories even when the same assay was 
used from the same manufacturer.  
In response to these concerns, the IFCC in collaboration with the Institute for 
Reference Materials and Measurements has produced and characterised a serum 
CYSC reference material (ERM-DA471/IFCC). However, international 
standardisation of cystatin C assay is still in process and important differences 
remain (Eckfeldt et al., 2015; Bargnoux et al., 2017). Further limitation to the use 
of serum CYSC as a biomarker of kidney function includes the fact that circulating 
CYSC concentrations may be affected by other factors such corticosteroid 
administration, thyroid dysfunction, smoking, inflammation, adiposity and 
malignant neoplasms (e.g. breast, lung, colorectal and ovarian cancer) due to 
increased cell turnover (Levey and Inker, 2017; Jones et al., 2017).   
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1.7.3.2 Beta 2-microglobulin (B2M) 
B2M is an 11.8kDa protein associated with both classical and non-classical major 
histocompatibility complex (MHC) class 1 molecules expressed on the surface of 
all nucleated cells and is critical for antigen presentation (Argyropoulos et al., 
2017). It dissociates from the heavy chain in the setting of cellular turnover and 
enters the circulation as a monomer. B2M is freely filtered at the glomerulus and 
almost entirely (>99.9%) reabsorbed and metabolised in the proximal tubule 
(Argyropoulos et al., 2017). Although, serum concentrations of B2M appear to be 
largely independent of age and muscle mass (Filler et al., 2002), there does not 
appear to be a clear advantage of B2M over serum creatinine in detecting small 
changes in GFR (Ferguson and Waikar, 2012). First suggested as a biomarker for 
glomerular filtration in the 1980s, the potential of B2M as a candidate for a single-
marker equation has been limited because of its lack of specificity. Serum levels of 
B2M are impacted by the amount generated and shed by nucleated cells, body 
distribution kinetics and the amount eliminated through glomerular filtration 
(Argyropoulos et al., 2017). As an acute phase reactant, its serum level tends to 
increase in a variety of inflammatory and infectious disorders. Also, due to its 
ubitiquous presence on the surface of all cells, increase in B2M concentration is 
seen with diseases associated with high cell turnover, such as several 
malignancies (Filler et al., 2002; Beker et al., 2018).  
 
1.7.3.3 Beta-trace protein (BTP)  
BTP is another low molecular weight protein (23 -29 kDa) that has been 
investigated as a biomarker of GFR (Beker et al., 2018). Also known as lipocalin 
prostaglandin D2 synthase (L-PGDS), BTP is generated at a constant rate by glial 
cells in the central nervous system.  The variation in size depends on the degree 
of post-translational glycosylation, with the larger isoforms of BTP in serum and 
urine, and the smaller isoforms with truncated side chains in cerebrospinal fluid 
(Beker et al., 2018). It is freely filtered by the glomerulus and reabsorbed by the 
proximal tubule with minimal nonrenal elimination (Ferguson and Waikar, 2012). 
BTP was first noted to be raised in patients with chronic kidney disease in 1987, 
but its specific potential as a filtration marker was only suggested 10 years later, in 
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a study that observed very high concentrations of BTP in patients on 
haemodialysis (Hoffmann, Nimtz and Conradt, 1997; Beker et al., 2018).  
Recent studies suggest that serum BTP concentrations perform at a similar level 
to creatinine and CYSC, not only in the estimation of GFR, but also in the 
prediction of progressive kidney dysfunction (Spanaus et al., 2010). GFR 
equations based on BTP have been derived, but these have largely involved 
kidney transplant patients. Further validation of the equations is required in diverse 
populations (Beker et al., 2018). Like CYSC, corticosteroid administration appears 
to impact serum concentrations of BTP (Abbink et al., 2008), but unlike CREA, 
CYSC and B2M, there are currently no certified reference materials available for 
BTP. Hence, there is no standardisation amongst currently available BTP assays. 
Furthermore, given the known variation in post-translational modification which 
creates a variety of glycoprotein epitopes, immunoassays utilising different 
antibodies would be expected to give disparate BTP results (Beker et al., 2018). 
These suggest that much is still to be done to confirm the utility of BTP in the 
routine assessment of GFR and to establish reference laboratory standards to 
ensure inter- and intra-laboratory consistency in measurement. 
 
1.7.4 Use of equations to estimate GFR 
Given the limitations of CREA as a marker of kidney function, implementation of 
prediction equations has been used to estimate GFR from endogenous filtration 
markers. Most of these equations incorporate demographic and clinical variables 
(Earley et al., 2012). The most commonly used equations in clinical practice are 
shown in Table 1.5 and include the Cockroft and Gault (C&G) (1976) equation, the 
several iterations of the Modification of Diet in Renal Disease (MDRD) Study 
equations (MDRD-4 and MDRD-6), the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI, 2009) equation, and more recently the CKD-EPI CYSC 
equation and the equation that combines CREA and CYSC (Inker et al., 2012; 
Levey et al., 2014). 
The C&G formula was published as a bedside equation for estimated CREA. Until 
recently, it was solely used for drug dosing but has been widely adapted into 
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clinical practice due to its convenience and perceived accuracy (Hudson and 
Nolin, 2018). However, the C&G formula is an imprecise estimate of true GFR 
mainly due to its failure to adequately compensate for several non-GFR 
determinants of serum CREA. It is also based on a small and non-diverse study 
population (a selection of mostly men and all white patients) (Delanaye and 
Cohen, 2008; Casal et al., 2019). Since the standardisation of CREA, the C&G 
equation is barely used in clinical practice (Earley et al., 2012).  
The MDRD equation was developed from a large population of mostly white and 
non diabetic patients with CKD. The original equation included 6-variables but was 
subsequently simplified to a four variable equation that included age, sex, serum 
CREA and race differentiation as white or black (Lopez-Giacoman and Madero, 
2015). Unlike the C&G equation the MDRD equation does not require body weight 
or height. Although the MDRD equation has demonstrated high accuracy in 
individuals with CKD, it tends to underestimate GFR in healthy individuals resulting 
in false positive diagnosis of CKD in this population (Rule et al., 2004).  
The main objective of the CKD-EPI equation was to develop an equation that was 
superior to the MDRD, especially amongst those with GFR > 60 mL/min/1.73 m2 
(Lopez-Giacoman and Madero, 2015). Compared to the MDRD cohort, the CKD-
EPI had higher GFR (68 mL/min/1.73 m2) than MDRD (40 mL/min/1.73 m2), 
younger age, included diabetics, black individuals and kidney transplant recipients 
(Levey et al., 2009; Earley et al., 2012). However, reports have shown that the 
CKD-EPI equations produce lower estimates of CKD prevalence than the MDRD 
equation (Levey et al., 2009). In order to overcome the imprecision of CREA 
estimating equations, eGFR equations for CYSC (using CYSC alone, CYSC with 
demographic factors and CYSC with serum CREA and demographic factors were 
developed and compared with measured GFR using iothalamate and 51Cr-EDTA. 
Reports have shown that CYSC-based equations perform better than CKD-EPI 
equations (Lopez-Giacoman and Madero, 2015). Inker et al., (2012) have also 
shown that the combined equation including CYSC and CREA performs better 
than equations based on either CYSC or serum CREA and should be used in 
subjects where CKD needs to be confirmed. However, the impact of FF therapy on 
the GFR estimated using the different equations have not been fully elucidated. 
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Table 1.5 GFR estimating equations in widespread use 
Equations Expression 
C&G¥ CrCl (mL/min) = [(140 – Age) x Wt] / (0.813 x CREA) (x 0.85 if 
female) 
Where CREA is serum creatinine (µmol/L) 
MDRD§† GFR (mL/min/1.73 m2) = 175 x (CREA x 0.011312)-1.154 x (age)-0.203 x 
(1.212 if black) x (x 0.742 if female) 
Where CREA is serum creatinine (µmol/L) 
CKD-EPI‡ 
Creatinine 
GFR (mL/min/1.73 m2) = 141 x min ([CREA  x 0.011312]/k, 1)α x 
max ([CREA x 0.011312]/k, 1)-1.209 x 0.993Age x 1.018 (if female) x 
1.159 (if black) 
Where CREA is serum creatinine (µmol/L), min indicates the minimum 
of CREA/k or 1, max indicates the maximum of CREA/k or 1, k = 0.7 
(female) or 0.9 (male) and α = -0.329 (female) or -0.411 (male). 
CKD-EPI‡ 
Cystatin C 
GFR (mL/min/1.73 m2) = 133  min (CYSC/0.8, 1)-0.499  max 
(CYSC/0.8, 1)-1.328  0.996Age  0.932 (if female) 
Where CYSC is serum cystatin C (mg/L), min indicates the minimum 
of CYSC/k or 1, and max indicates the maximum of CYSC/k or 1. 
CKD-EPI‡ 
Creatinine & 
Cystatin C 
combined 
GFR (mL/min/1.73 m2) = 135 x min([CREA x 0.011312]/k, 1)α x 
max([CREA x 0.011312]/K, 1)-0.601 x min(CYSC/0.8, 1)-0.375 x 
max(CYSC/0.8, 1)-0.711 x 0.995Age x 0.969 (if female) x 1.08 (if black) 
Where CREA is serum creatinine (µmol/L), CYSC is serum cystatin C 
(mg/L), k is 0.7 (if female) and 0.9 (if male), α is -0.248 (if female) and 
-0.207 (if male), min indicates the minimum of CREA/k or 1, and max 
indicates the maximum of CREA/k or 1. 
¥C&G, Cockcroft & Gault; §MDRD, Modification of Diet in Renal Disease; ‡ CKD-EPI, 
Chronic Kidney Disease-Epidemiology Collaboration. †The so-called ‘simplified’ (four-
variable) ID-MS traceable form of the MDRD equation is shown, for use when serum 
creatinine is measured with a reference (ID-MS) procedure 
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1.8 AIMS AND OBJECTIVES 
Overall aim: Investigate the impact of FF, a widely used lipid-lowering drug, on 
clinical biomarkers of kidney function in adult patients with dyspilidaemia  
Part 1 - Investigate the impact of FF on routine biochemical parameters: 
1. Kidney function tests [creatinine, Urea, uric acid and electrolytes (sodium 
and potassium)].  
2. Liver function tests (albumin, total bilirubin, alanine aminotransferase, 
alkaline phosphatase, gamma glutamyl transferase and aspartate 
aminotransferase). 
3. Lipid profile (total cholesterol, triglycerides, high-density lipoprotein 
cholesterol, non-HDL cholesterol and cholesterol to HDL ratio) following 
FF therapy. 
4. Inflammatory marker (C reactive protein) and markers of muscle damage 
(creatine kinase and lactate dehydrogenase).  
5. Thyroid function tests (thyroid stimulating hormone, thyroxine and 
triiodothyronine). 
Part 2 – Investigate the utility of cystatin C as a marker of kidney function in 
patients receiving FF therapy with the following specific aims: 
1. To determine the analytical performance of Gentian Cystatin C using the 
Beckman Coulter AU640 analyser 
2. To investigate the impact of FF (160 mg/day) therapy on serum cystatin 
C and serum creatinine concentrations in patients with dyslipidaemia 
3. To compare changes in serum cystatin C-based eGFRs with serum 
creatinine-based eGFRs after FF therapy in patients with dyslipidaemia 
4. To examine the concordance between serum creatinine-based, and 
serum cystatin C-based equations for estimating GFR in patients receiving 
FF therapy for dyslipidaemia. 
Part 3 – Investigated the mechanism of cytotoxicity of FF in the kidney and muscle 
using rat renal proximal tubular cells (NRK52E), rat skeletal muscle cells (L6) and 
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human embryonic kidney cells (HEK293), and characterise the intracellular events 
involved with the following specific aims: 
1. To determine and compare the cytotoxicity of FF with 5-fluorouracil (5-
FU) in NRK52E, L6 and HEK293 cell lines using the MTS assay. 
2. To evaluate the role of oxidative stress in FF-induced cell death in 
NRK52E, L6 and HEK293 cell lines. 
3. To investigate the molecular mechanism of FF-induced cell death by 
western blot analysis for markers of apoptosis. 
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Chapter 2 
Materials and Methods 
2.1 - MATERIALS 
2.1.1 Materials used in clinical biomarkers studies 
The materials used in investigating changes in clinical biomarkers are summarised 
in Table 2.1 
Table 2.1 Materials used in studies involving clinical biomarkers 
Material (Reagents) Reference Manufacturer Location 
-glutamyltransferase  OSR6120 Beckman Coulter High Wycombe, UK 
Access 2 Reaction Vessels 81901 Beckman Coulter High Wycombe, UK 
Access 2 Sample Cup 0.5 mL 651412 Beckman Coulter High Wycombe, UK 
Access 2 Sample Cup 2 mL 81902 Beckman Coulter High Wycombe, UK 
Access 2 Substrate 61906 Beckman Coulter High Wycombe, UK 
Access 2 Wash Buffer II A16792 Beckman Coulter High Wycombe, UK 
Access Free T3  A13422 Beckman Coulter High Wycombe, UK 
Access Free T3 Calibrator A13430 Beckman Coulter High Wycombe, UK 
Access Free T4 Calibrator 33885 Beckman Coulter High Wycombe, UK 
Access Free T4 Reagent  33880 Beckman Coulter High Wycombe, UK 
Access TSH (3rd IS)  B63284 Beckman Coulter High Wycombe, UK 
Access TSH (3rd IS) Calibrator B63285 Beckman Coulter High Wycombe, UK 
Alanine aminotransferase  OSR6107 Beckman Coulter High Wycombe, UK 
Albumin  OSR6202 Beckman Coulter High Wycombe, UK 
Alkaline phosphatase OSR6204 Beckman Coulter High Wycombe, UK 
Aspartate aminotransferase  OSR6209 Beckman Coulter High Wycombe, UK 
BD Vacutainer® SST™ tubes 367956 Becton Dickinson Swindon, UK 
C reactive protein (Latex) OSR6299 Beckman Coulter High Wycombe, UK 
Citranox® 81912 Beckman Coulter High Wycombe, UK 
Cl – Electrode MU9196 Beckman Coulter High Wycombe, UK 
Cleaning Solution 66039 Beckman Coulter High Wycombe, UK 
Contrad 70* 81911 Beckman Coulter High Wycombe, UK 
Creatine Kinase (CK-NAC) OSR6279 Beckman Coulter High Wycombe, UK 
Creatinine  OSR6678 Beckman Coulter High Wycombe, UK 
CRP Latex Calibrator Normal 
(N Set) 
ODC0026 Beckman Coulter High Wycombe, UK 
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Gentian Cystatin C Calibrator  A52763 Gentian AS Moss, Norway 
Gentian Cystatin C Control  A57265 Gentian AS Moss, Norway 
Gentian Cystatin C A57261 Gentian AS Moss, Norway 
HDL Cholesterol  OSR6287 Beckman Coulter High Wycombe, UK 
HDL Cholesterol Calibrator ODC0011 Beckman Coulter High Wycombe, UK 
ISE Buffer 66320 Beckman Coulter High Wycombe, UK 
ISE High Serum Standard 66316 Beckman Coulter High Wycombe, UK 
ISE Internal Reference 66314 Beckman Coulter High Wycombe, UK 
ISE Low Serum Standard  66317 Beckman Coulter High Wycombe, UK 
ISE Low/High Urine Standard 66315 Beckman Coulter High Wycombe, UK 
ISE Mid Standard 66319 Beckman Coulter High Wycombe, UK 
ISE Reference 66318 Beckman Coulter High Wycombe, UK 
K – Electrode MU9195 Beckman Coulter High Wycombe, UK 
Lactate Dehydrogenase  OSR6227 Beckman Coulter High Wycombe, UK 
LIH OSR62166 Beckman Coulter High Wycombe, UK 
Liquichek Microalbumin 
Control Level 1 and 2 
378/379 Bio-Rad Irvine, USA 
Liquichek Urine Controls Level 
1 and 2 
397/398 Bio-Rad Irvine, USA 
Multichem P SP40PX Technopath Tipperary, Ireland 
Multichem-IA Plus IA310X Technopath Tipperary, Ireland 
Multichem™ S Plus CH101CRP 
CH102CRP 
CH103CRP 
Technopath Tipperary, Ireland 
Na – Electrode MU9194 Beckman Coulter High Wycombe, UK 
Serum Protein Multi-calibrator ODR3021 Beckman Coulter High Wycombe, UK 
System Calibrator  66300 Beckman Coulter High Wycombe, UK 
Total Bilirubin  OSR6112 Beckman Coulter High Wycombe, UK 
Total Cholesterol  OSR6516 Beckman Coulter High Wycombe, UK 
Triglyceride  OSR60118 Beckman Coulter High Wycombe, UK 
Urea Nitrogen (BUN) STAT OSR6141 Beckman Coulter High Wycombe, UK 
Uric acid  OSR6298 Beckman Coulter High Wycombe, UK 
Urine/CSF Albumin B46435 Beckman Coulter High Wycombe, UK 
Urine/CSF Albumin Calibrator B358859 Beckman Coulter High Wycombe, UK 
Urine/CSF Protein Calibrator OSR6170 Beckman Coulter High Wycombe, UK 
Urine/CSF Protein Reagent OSR6170 Beckman Coulter High Wycombe, UK 
Wash Solution OSR0001 Beckman Coulter High Wycombe, UK 
Abbreviations: HDL, high-density lipoprotein; LIH, lipaemia, icterus, haemlysis indices; 
ISE, ion-selective electrode; CSF, cerebrospinal fluid; CRP, C reactive protein. 
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2.1.2 Materials used in cell line studies 
The materials used in the cell line studies are listed in Table 2.2  
Table 2.2 Materials used in the cell line studies 
Material  Manufacturer Location 
Beta-mercaptoethanol Sigma-Aldrich Poole, UK 
Acrylamide/Bis-acrylamide 37, 5:1 
solution 
Sigma-Aldrich Poole, UK 
Amido Black 10B sodium salt Sigma-Aldrich Poole, UK 
Ammonium persulphate (APS) Sigma-Aldrich Poole, UK 
Bovine serum albumin (BSA) (standard 
grade) 
Seralabs Hull, UK 
CellTiter96® Aqueous One Solution Promega Southampton, UK 
Dulbecco’s Modified Eagle medium 
(DMEM) 
Fisher Scientific Loughborough, UK 
Ethanol (molecular biology grade) Sigma-Aldrich Poole, UK 
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific Loughborough, UK 
Hydrogen peroxide Sigma-Aldrich Poole, UK 
Isopropanol (molecular biology grade) Sigma-Aldrich Poole, UK 
Marvel milk powder  Tesco Welwyn Garden City, 
UK 
Methanol (technical grade) Fisher Scientific Loughborough, UK 
Nitrocellulose membrane (marked) Sigma-Aldrich Poole, UK 
Polyvinylidene difluoride (PVDF) 
membrane 
Fisher Scientific Loughborough, UK 
Sodium Dodecyl Sulphate (SDS) Fisher Scientific Loughborough, UK 
Sodium hydroxide Fisher Scientific Loughborough, UK 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich Poole, UK 
Trypsin-EDTA Fisher Scientific Loughborough, UK 
Trypan blue dye solution Fisher Scientific Loughborough, UK 
Tween-20 Sigma-Aldrich Poole, UK 
FF ≥ 99%, powder Sigma-Aldrich Poole, UK 
5-fluorouracil ≥ 99%, powder Sigma-Aldrich Poole, UK 
Annexin V-FITC apoptosis kit BioVision Mountain View, USA 
Foetal bovine serum (FBS) Fisher Scientific Loughborough, UK 
2’, 7’-dichlorofluorescein diacetate 
(DCFDA) 
Sigma-Aldrich Poole, UK 
Triton X-100 Sigma-Aldrich Poole, UK 
Phosphate buffered saline (PBS) tablets  Oxoid Hampshire, UK 
Bromophenol blue dye Sigma-Aldrich Poole, UK 
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2.1.3 Antibodies 
The antibodies used in this study are listed in Table 2.3 
Table 2.3 List of antibodies 
 
Antibody  
 
Antibody type 
 
Manufacturer 
 
Location 
Superoxide dismutase 
(SOD1) 
 
Rabbit polyclonal Abcam 
 
Cambridge, UK 
c-Jun N-terminal kinase 
(JNK) 
Rabbit polyclonal Abcam 
 
Cambridge, UK 
p38 (MAPK) 
 
Mouse monoclonal Abcam  
 
Cambridge, UK 
Bax 
 
Rabbit monoclonal Abcam 
 
Cambridge, UK 
Bcl-2 
 
Mouse monoclonal Abcam 
 
Cambridge, UK 
NFkB-p65 
 
Rabbit polyclonal Abcam  
 
Cambridge, UK 
β-actin Mouse monoclonal Abcam 
 
Cambridge, UK 
Goat anti-rabbit IgG-HRP 
linked 
Rabbit polyclonal Vector Labs  
 
Peterborough, 
UK 
Horse anti-mouse IgG-HRP 
linked 
Mouse polyclonal Vector Labs  
 
Peterborough, 
UK 
Abbreviations: MAPK, mitogen-activated protein kinase; NFκB, nuclear factor kappa-
light-chain-enhancer of activated B-cells; HRP, horseradish peroxidase; IgG, 
immunoglobulin G. 
 
2.1.4 Cell lines 
Rat renal proximal tubular (NRK-52E) cell-line was a donation from Dr Prabal 
Chatterjee (School of Pharmacy and Biomolecular Sciences, University of 
Brighton, UK), rat skeletal muscle (L6) cell-line and the human embryonic kidney 
(HEK293) cell-lines were purchased from the American Tissue Culture Collection 
(Teddington, UK). 
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2.2 – METHODS 
This study was carried out in three parts. The first part of the study was patient-
based and involved adult patients with dyslipidaemia who required treatment with 
FF. Changes in clinical biomarkers such as creatinine, Urea and uric acid following 
FF therapy have been reported in isolated cases, but its impact on routine clinical 
markers in patients with dyslipidaemia has not been determined. In this study, the 
impact of FF (160 mg/day) therapy on routine clinical biomarkers during 12 months 
of therapy was investigated. The biomarkers examined included markers of kidney 
function, liver function, lipid profile, thyroid function, inflammatory markers and 
markers of muscle damage. This part of the study was carried out at the 
laboratories of Southwest Pathology Services, Musgrove Park Hospital, Taunton, 
Somerset, UK.  
In the second part of the study, the impact of FF therapy on serum concentrations 
of CYSC, an endogenous marker of kidney function/damage was examined. The 
utility of serum CYSC as a marker of kidney function in patients receiving FF 
treatment for dyslipidaemia was also examined. The study compared changes in 
GFR estimated using serum CYSC-based equations to those estimated using 
serum CREA-based equations. This part of the study was carried out at the 
laboratories of Southwest Pathology Services, Musgrove Park Hospital, Taunton, 
Somerset, UK. Finally, the cytotoxicity of FF in kidney and muscle cells, and the 
mechanism of FF-associated toxicity were examined using cell line models. FF 
toxicity was tested in 3 cell lines: rat renal proximal tubular cells (NRK52E), rat 
skeletal muscle cells (L6) and the human embryonic kidney cells (HEK293). The 
cytotoxic effect of FF in these cell lines was compared with the toxicity of 5-
fluorouracil (5-FU), an anticancer drug used in the clinic and known to be toxic to 
kidney and muscle cells. 5-FU was used as a positive control for the experiments. 
In order to determine the mechanism of FF cytotoxicity in these cell lines, FF-
induced intracellular reactive oxygen species accumulation was determined in 
cells exposed to various concentrations of FF. Cells exposed to various doses of 
FF were examined for changes in proteins in apoptotic signalling. The cell-based 
study was carried out at the laboratories of the Centre for Research in Biosciences 
(CRIB), Faculty of Health and Applied Sciences, University of the West of 
England, Bristol, UK. 
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2.2.1 Ethical considerations 
The research protocol was approved by the National Research Ethics Service 
(NRES) Committee South West Exeter (REC reference: 14/SW/1104) and Site 
Specific Information (SSI) approval was obtained from the Research and 
Development (R&D) committees of both BHT and TST. Written informed consent 
was obtained from all participants. This study was also approved by the Faculty 
Research Degrees Committee of the University of the West of England, Bristol 
(see letters in appendix).  
 
2.2.2 Study participants 
Participants in this study included adult (male and female) patients diagnosed with 
dyslipidaemia who required treatment with FF. The participants were recruited 
from the lipid clinics at Burton Hospitals NHS Foundation Trust (BHT) and Taunton 
& Somerset NHS Foundation Trust (TST). Exclusion criteria included:  
 patients who had thyroid disease or whose medication for thyroid disease 
had not been stable for the past six months;  
 patients who had started or changed their oral contraceptive regimen in the 
past six months;  
 patients who had critical illness, severe malnutrition or known kidney 
impairment; 
 patients who lacked capacity to give informed consent.  
All the participants were treated with FF at 160 mg/day. Nineteen participants (14 
male and 5 female) were enrolled in this study: eleven (8 male, 3 female) were 
enrolled by the Burton Hospitals NHS Foundation Trust, while eight (6 male, 2 
female) were enrolled by the Taunton & Somerset NHS Foundation Trust. The 
median age of the participants was 50 years (range 34 - 70). Four participants (3 
male and one female) were withdrawn from the study due to failure to provide any 
post treatment samples. Fifteen participants (11 male, 4 female) provided the 
baseline sample and at least one post-treatment sample. Participants were placed 
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into various groups (A - E) based on sample provision (Table 2.4). Group A 
consisted of 13 participants (9 male and 4 female), median age 51 years (range 37 
– 65), and included all the participants who provided samples (serum and urine) at 
baseline and after 3 months of treatment with FF. In Group B, there were 10 
participants (7 male and 3 female), median age 51 years (range 37 – 63) and 
included all the participants who provided samples at baseline and after 6 months 
of treatment. Group C was made up of eight participants (5 male and 3 female), 
median age 51 years (range 37 – 63) and included all the participants who 
provided samples at baseline and after 12 months of FF therapy. In Group D, we 
included all the participants who gave samples at baseline, 3 and 6 months after 
starting FF. This group was made up of nine participants (6 male and 3 female) 
with median age 50 years (range 42 – 55). Participants who had given samples at 
all visits (baseline, 3, 6 and 12 months) were put in Group E. This group consisted 
of four participants (2 male and 2 female), with median age 51 years (range 43 – 
57). 
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Table 2.4 Groups of participants based on sample provision 
Group characteristics 
Group A 
Provided samples at baseline 
and 3 months (n=13) 
4 Female, 9 Male participants, aged 37 – 65 (median 51 
years) 
Participant 
code:  
B01, B02, B03, B04, B05, B06, B08, 
B10, B11, T01, T01, T02, T04, T05 
Group B 
Provided samples at baseline 
and 6 months (n=10) 
3 Female, 7 Male participants, aged 37 – 63 (median 51 
years) 
Participant 
code:  
B01, B02, B03, B04, B05, B06, B10, 
T02, T03, T04 
Group C 
Provided samples at baseline 
and 12 months (n=8) 
3 Female, 5 Male participants, aged 37 – 63 (median 51 
years) 
Participant 
code: 
B04, B05, B06, T01, T02, T03, T05, 
T08 
Group D 
Provided samples at 
baseline, 3 and 6 months 
(n=9) 
3 Female, 6 Male participants, aged 42 – 55 (median 50 
years) 
Participant 
code: 
B01, B02, B03, B04, B05, B06, B10, 
T02, T04 
Group E 
Provided samples at 
baseline, 3, 6 and 12 months 
(n=4) 
2 Female, 2 Male participants, aged 43 – 57 (median 51 
years) 
Participant 
code:  
B04, B05, B06, T02 
 
 
2.2.3 Sample collection, storage and analyses 
Fasting venous blood was collected from the participants during each visit to the 
clinics into plain vacutainer serum/plasma separator tubes (SST) and allowed to 
clot. The blood tubes were centrifuged at 3200 rpm (1843 g) for 10 minutes and 
the serum obtained was stored frozen at -80C until they were analysed. To avoid 
errors from inadequate collection of 24-hour urine samples, spot midstream urine 
samples were collected from each participant into plain universal containers at the 
time of blood collection and stored frozen at -80C. Baseline samples were 
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collected before FF intervention and follow-up samples were collected at 3, 6, and 
12 months after commencing treatment. All the patient samples were analysed as 
a batch to minimise interassay variations.  
Clinical biomarkers in patient samples were determined using the Beckman 
Coulter Olympus AU640 analyser system. The clinical biomarkers including 
methods and traceability are listed on Table 2.5. Unless otherwise stated, all 
serum biochemistry test parameters were calibrated using the Beckman Coulter 
System Calibrator (66300). The System Calibrator is a lyophilised human serum 
based product used to provide calibration for Beckman Coulter AU reagents for 
the quantitative determination of the relevant analytes on Beckman Coulter AU 
analysers. The System Calibrator was reconstituted in 5 mL deionised water and 
aliquots were stored frozen at -20 C for no longer than 7 days. The HDL-
cholesterol assay was calibrated using Beckman Coulter HDL calibrator 
(ODC0011). The HDL cholesterol calibrator was supplied in lyophilised form and 
was reconstituted in 3 mL deionised water. Reconstituted HDL calibrator aliquots 
were stored frozen at -20 ºC for no longer than 7 days. The CRP assay was 
calibrated using Beckman Coulter serum protein multi-calibrator (ODR3021), 
which is traceable to International Federation of Clinical Chemistry (IFCC) 
standard CRM 470 (RPPHS). The CRP calibrators were supplied ready to use.  
All serum enzyme tests (i.e. alanine aminotransferase, alkaline phosphatase, 
aspartate aminotransferase, creatine kinase, gamma-glutamyl transferase, and 
lactate dehydrogenase) were calibrated using the System Calibrator, with 
calibration values traceable to the Beckman Coulter Master Calibrator. Serum 
electrolytes (Na and K) were calibrated using the Beckman Coulter HIGH 
(Reference. number 66316) and LOW (Reference number. 66317) external serum 
standards. During calibration of ISE, both ISE MID Standard solution and the 
external standard (HIGH and LOW) solutions, which have known concentrations, 
were measured. Urine electrolytes were calibrated using the Beckman Coulter ISE 
High/Low Urine Standards (Reference. number. 66315), while urine total protein 
was calibrated using Beckman Coulter Urine/CSF Protein Calibrator (OSR6170) 
and urine albumin, using Beckman Coulter Urine/CSF Albumin Calibration kit 
(Reference number. B358859). All other urine tests parameters were calibrated 
using Beckman Coulter Urine Calibrator (B64606). 
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Quality control of serum biochemistry assays (unless otherwise stated) was 
performed using Multichem Plus S Controls (Technopath Clinical Diagnostics, 
Ballina, Co. Tipperary, Ireland) with values pre-determined using the Beckman 
Coulter AU640 analyser. The Multichem S Plus Controls is a multi-analyte quality 
control material used to monitor the precision of laboratory testing procedures for 
chemistry assays. The quality control materials were supplied ready to use and 
kept frozen. The quality control materials were defrosted away from light and 
treated the same as patient specimens and run in accordance with the 
manufacturers’ instructions, and following local laboratory policies for assay quality 
control. Urine albumin quality control was performed using Bio-Rad Liquichek 
Microalbumin Control Level 1 and Level 2 (Reference number. 378/379), while for 
all other urine tests, precision was performed using the Bio-Rad Liquichek Urine 
Chemistry Controls Level 1 and Level 2 (Reference number. 397/398). 
All tests procedures followed routine laboratory procedures for analysis. All the 
samples, reagents, calibrators and quality control materials were loaded on the 
analyser and were analysed by the automation system. Samples were tested after 
a satisfactory assay calibration and acceptable quality control performance. Test 
results were automatically calculated by the Beckman Coulter AU analyser system 
and the Labcentre Laboratory Information Management System (LIMS). 
Fombon, I.S. (2020) 
57 
 
Table 2.5 List of serum biochemistry and immunoassay parameters, 
methods and traceability 
Assay Method Traceability Reference 
range 
Unit 
Creatinine Jaffe IDMS 
(Method A) 
NIST SRM 967 L1 & 
L2 
50 - 120 
 
µmol/L 
 
Urea Urease/GLDH NIST SRM 909 L1 <75y: 2.5 – 6.6 
>75y: 3.9 – 9.9 
mmol/L 
 
Sodium Indirect ISE  136 - 145 
 
mmol/L 
 
Potassium Indirect ISE  3.5 – 5.0 
 
mmol/L 
 
Uric acid Uricase/POD IDMS Reference 
Method 
F: 154.7 – 357.0 
M: 208.3 – 428.4 
µmol/L 
 
Albumin Bromocresol 
Green 
Certified Reference 
Material (CRM) 470 
35 - 50 g/L 
Total Bilirubin DPD NIST SRM 916a 5 – 17 
 
µmol/L 
Alanine 
aminotransferase 
IFCC Modified 
without P5P 
Beckman Coulter 
Master Calibrator 
0 – 40 U/L 
Alkaline 
phosphatase 
IFCC Method Beckman Coulter 
Master Calibrator 
25 - 110 U/L 
Aspartate 
aminotransferase 
IFCC Modified 
without P5P 
Beckman Coulter 
Master Calibrator 
F<35 
M<50 
U/L 
Gamma-
glutamyltransferase 
Szasz 
(modified) 
 
Beckman Coulter 
Master Calibrator 
9 – 64 U/L 
Total Cholesterol CHO-POD CDC Reference 
Method (Abell-
Kendall) 
3.5 – 6.5 mmol/L 
HDL cholesterol CHO-POD 
 
US CDC Cholesterol 
reference method 
F: 1.3 – 1.5 
M: 1.0 – 1.3 
mmol/L 
Triglyceride GPO-POD IDMS Reference 
Method 
0.6 – 2.0 mmol/L 
Creatine kinase IFCC IFCC Reference 
Method 
30 - 223 U/L 
Lactate 
dehydrogenase 
SCE 1982    
37C 
Beckman Coulter 
Master Calibrator 
140 - 271 U/L 
C reactive protein Turbidimetry 
 
IFCC Standard  
CRM 470 (RPPHS) 
0 – 10 mg/L 
TSH Immunoassay Two-site (sandwich) 
assay 
0.34 – 5.6 mU/L 
Free T4 immunoassay  Two step assay 7.9 - 20 pmol/L 
Free T3 Immunoassay Competitive binding 
assay 
4.0 – 6.6 pmol/L 
 
 
 
Abbreviations: IDMS, Isotope Dilution Mass Spectrometry; NIST, National Institute of Standards and 
Technology; SRM, Standard Reference Material; GLDH, glutamate dehydrogenase; ISE, ion selective 
electrode; POD, GPO, glycerol phosphate oxidase; peroxidise; PETIA, particle-enhanced turbidimetric 
immunoassay; IFCC, International Federation of Clinical Chemistry; DPD, 3,5-dichlorophenyldiazonium 
tetrafluoroborate; P5P, pyridoxal-5-phosphate; CHO, choline oxidase; HDL, high-density lipoprotein; CDC, 
Centre for Disease Control; TSH, thyroid stimulating hormone; F, female; M, male 
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2.2.4 Determination of electrolyte by the indirect ISE method 
Serum and urine electrolytes (sodium and potassium) were measured by the 
indirect ion selective electrode (ISE) method using crown ether membrane 
electrodes. This method measures the electrical potential that develops between 
the inner and outer surfaces of an ion-selective electrode according to the Nernst 
Equation for the specific ion. The electrode (membrane) is made of a material that 
is selectively permeable to the ion being measured. The potential is measured by 
comparing it to the potential of a reference electrode. The electrical potential is 
translated into voltage. Since the potential of the reference electrode is held 
constant, the difference in voltage between the two electrodes is attributed to the 
concentration of the ion (Na or K) in the sample.  
First, ISE Reference Solution was pumped through the REF electrode and a 
reference measurement was taken. Next, Serum (20 µL) or urine (25 µL) was 
mixed with 10 µL of ISE Buffer solution in the dilution pot of the ISE unit. The 
diluted sample was aspirated and passed through the sodium and potassium 
electrodes (Flowcell), and the potential generated at the electrodes was 
measured. Excess diluted sample in the sample pot was pumped through the 
Bypass tubing to the waste. After a urine sample was processed, ISE Buffer 
Solution was delivered to the sample pot and pumped through the Flowcell to rinse 
the Flowcell. After each sample was processed, the ISE MID Standard was 
pumped through the Flowcell to condition the electrodes and take measurements 
and the solution was sent to the waste. When compared to an internal reference, 
the electrical potential was translated into voltage and then into the ion 
concentration of the sample.  
The assay range was 50 – 200 mmol/L for serum sodium, 10 – 400 mmol/L for 
urine sodium, 1.0 – 10 mmol/L for serum potassium and 2.0 – 200 mmol/L for 
urine potassium, while the reference range for serum sodium was 136 - 145 
mmol/L and serum potassium 3.5 – 5.0 mmol/L. There were no reference ranges 
for random urine electrolytes. 
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2.2.5 Measurement of CREA by the Jaffé (compensated) method 
Serum/urine CREA concentration was measured by a kinetic modification of the 
Jaffé procedure in which CREA in the sample reacts with picric acid at alkaline pH 
to form a yellow complex (Janovsky complex) (Debus et al., 2015). Although, this 
reaction is not completely specific for CREA, since other reducing substances 
such as glucose, pyruvate, ascorbic acid and acetoacetates will react with picrate 
to form a similar colour (Delanghe and Speekaert, 2011); Fabiny and 
Ertingshauesn (1971) had shown that alkaline CREA picrate reaches maximum 
colour development at a different rate than pseudo-creatinine material. Cook 
(1971) also utilized different reaction rates of alkaline picrate positive substances 
to obtain greater specificity with the Jaffé reaction. In this study, the protocol 
outlined in the Beckman Coulter Setting Sheet was followed.  
Briefly, 20 µL of serum was added to 120 µL of Reagent 1 (containing sodium 
hydroxide) and 120 µL of Reagent 2 (picric acid), while 1.2 µL of urine sample was 
added to 35 µL of Reagent 1 and 35 µL of Reagent 2. The mixture was incubated 
at 37 ºC. The rate of change in absorbance at 520/800 nm was measured and was 
proportional to the concentration of creatinine in the sample. Interference from 
protein in the serum creatinine measurement was mathematically corrected by 
subtracting 18 µmol/L from each test result (Wyuts et al., 2003). The dynamic 
range for serum and urine creatinine on the AU640 analyser was 23 – 2,218 
µmol/L and 0.088 – 35.36 mmol/L, respectively. The reportable range for serum 
CREA was 23 – 2,218 µmol/L, extending to 22,180 µmol/L with automatic on 
board dilution, while urine CREA was 0.088 – 35 mmol/L, extending to 141 mmol/L 
with automatic on board dilution on the AU640 analyser. Adult reference range for 
serum CREA was 60 – 120 µmol/L and urine CREA was 0 - 24 mmol/L.  
 
2.2.6 Measurement of urea by the urease/GLDH method  
Serum/urine urea levels were measured by an enzymatic method based on an 
adaptation of the method of Talke and Schubert (1965) using Beckman Coulter 
Urea STAT reagent. By this method, urea is hydrolysed in the presence of water 
and Urease to produce NH3 and CO2. The NH3 produced combines with 2-
oxoglutarate and nicotinamide adenine dinucleotide (NADH) in the presence of 
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glutamate-dehydrogenase (GLDH) in the reagent to yield glutamate and NAD+. 
Simultaneously, a molar equivalent of the reduced form of NADH was also 
oxidised. Two molecules of NADH were oxidised for each molecule of urea 
hydrolysed. The rate of change in absorbance at 340 nm, due to the 
disappearance of NADH, was directly proportional to the concentration of urea in 
the sample. In this study, serum (2.5 µL) or urine (2.0 µL) was incubated with 100 
µL of the Urea STAT reagent at 37ºC. The lowest detectable limit of serum and 
urine urea was 0.23 mmol/L and 2.92 mmol/L, respectively. However, the serum 
assay was linear within the range 0.8 – 50 mmol/L, while the urine assay was 
linear within the range 10 – 750 mmol/L. The adult reference range for serum urea 
concentration was 2.8 – 7.2 mmol/L. 
 
2.2.7 Determination of uric acid by the uricase/POD method 
Uric acid (UA) concentration in serum and urine samples was measured by an 
enzymatic method which involves measurement of oxygen consumed or hydrogen 
peroxide produced by uricase reaction. The procedure is a modification of the 
Fossati method (1980). By this method, UA is converted by uricase to allantoin 
and hydrogen peroxidase. The hydrogen peroxidase formed reacts with N, N-
bis(4-sulfobutyl)-3,5-dimethylaniline, disodium salt (MADB) and 4-
aminophenazone (p-aminophenol, PAP) in the presence of peroxidase to yield a 
chromophore, which is read bichromatically at 660/800 nm. The amount of dye 
formed is proportional to the concentration of uric acid in the sample.  
In this study, 7.0 µL of serum or 1.5 µL of urine sample was added to 60 µL of 
Reagent 1 in a cuvette and mixed. Reagent 2 (25 µL) was added and the mixture 
was incubated at 37ºC. The absorbance was measured at 660/800 nm. The assay 
was linear within a concentration range of 89 – 1785 µmol/L for serum and 119 – 
23,800 µmol/L for urine. According to Beckman Coulter the lowest level of 
detection in serum and urine was 2 µmol/L and 10 µmol/L, respectively. These 
represent the lowest measurable level of UA that can be distinguished from zero. 
The adult reference range for serum UA was 154.7 – 357.0 µmol/L for females and 
208.3 – 428.4 µmol/L for males. 
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2.2.8 Alanine aminotransferase activity assay 
Serum alanine aminotransferase (ALT) was determined using a procedure based 
on the principles outlined by Ladue and Wroblewski (1956), and a modification of 
the methodology recommended by the International Federation of Clinical 
Chemistry (IFCC) (Schumann et al., 2002). By this method, 10 µL of serum 
sample was added to 100 µL of Reagent 1 and mixed in a reaction cuvette. 
Reagent 2 (50 µL) was added to the mixture and then incubated at 37ºC. ALT in 
the sample transferred amino groups from alanine to 2-oxoglutarate to form 
pyruvate and glutamate. The pyruvate entered a lactate dehydrogenase (LDH) 
catalysed reaction with NADH to produce lactate and NAD+. The decrease in 
absorbance due to the consumption of NADH was directly proportional to the ALT 
activity in the sample and was measured at 340 nm. The lowest detectable level in 
serum was estimated at 2 U/L, while the assay was linear within an enzyme 
activity range of 3 – 500 U/L. The reference range of ALT in adults was 0 – 40 U/L. 
 
2.2.9 Alkaline phosphatase activity assay 
Alkaline phosphatase (ALP) activity was estimated in serum samples using a 
procedure based on the method developed by Bowers and McComb (1966) and 
formulated following the recommendation of IFCC (Schumann et al., 2002). Briefly, 
a serum sample (3.0 µL) was mixed with equal volumes (60 µL) of ALP Reagent 1 
and Reagent 2 in a cuvette and incubated at 37ºC. ALP in the sample catalysed 
the hydrolysis of 4-nitro-phenylphosphate (4-NPP) in the reagent to form 
phosphate and free 4-nitrophenol (4-NP), which in dilute acid solutions was 
colourless. Under alkaline conditions, 4-NP was converted to the 4-nitrophenoxide 
ion, a yellow quinonoid compound, in the presence of magnesium and zinc ions as 
cofactors. The rate of change in absorbance due to the formation of 4-NP was 
measured bichromatically at 410/480 nm and was directly proportional to the ALP 
activity in the sample. N-hydroxyethylethylenediaminetriacetic acid (HEDTA) was 
used as a chelating agent, and 2-amino-2-methyl-1-propanol (AMP) as phosphate 
acceptor at pH 10.4.  
In this method although Zn2+ ions are usually present in a total concentration of 1 
mmol/L, most are bound to HEDTA, leaving only a small, experimentally 
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determined optional concentration of free ions. A similar situation exists for Mg2+ 
ions. Thus HEDTA acts as a metal ion buffer, maintaining optimal concentrations 
of both ions (Tietz et al., 1983). The assay was linear within an enzyme activity 
range of 5 – 1500 U/L and the lowest detectable level according Beckman Coulter 
was estimated at 1 U/L. The reference range for serum ALP in adults older than 17 
years was 30 – 120 U/L. 
 
2.2.10 Serum Albumin estimation by the Bromocresol green method 
Serum Albumin (ALB) was measured by photometric test method based on the 
specific binding of bromocresol green (BCG), an anionic dye, to ALB in the sample 
at acid pH 4.2 to form ALB-BCG complex. Serum sample (2.0 µL) was added to 58 
µL of the reagent in a reaction vessel and the mixture was incubated at 37ºC. The 
reaction led to a colour change of the BCG dye from yellow-green to green-blue 
and a shift in the absorption wavelength which was measured bichromatically 
(600/800 nm). The intensity of the colour formed was proportional to the 
concentration of ALB in the sample. The lowest detectable level in serum was 
estimated at 0.15 g/L, although the assay was linear within a concentration range 
15 – 60 g/L. Adult reference range was estimated at 35 – 52 g/L. 
 
2.2.11 Determination of serum total bilirubin concentration 
Serum total bilirubin (TBIL) was determined by a photometric colour test, using 
Beckman Coulter Total Bilirubin kit (OSR6112). This TBIL reagent is a variation of 
the classical method. By this method, a stabilised diazonium salt, 3, 5-
dichlorophenyldiazonium tetrafluoroborate (DPD) reacts with conjugated bilirubin 
directly and with unconjugated bilirubin in the presence of an accelerator to form 
azobilirubin. The absorbance at 540 nm is proportional to the TBIL concentration. 
Serum sample (6.0 µL) was added to 30 µL of the reagent in a reaction cuvette 
and incubated at 37ºC. Caffeine and a surfactant were used as reaction 
accelerators. A separate sample blank was performed to reduce endogenous 
serum interference. The test was linear within a concentration range of 0 – 513 
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µmol/L and the lowest detectable level in serum was estimated at 0.20 µmol/L. 
Adult reference range was 5 – 17 µmol/L. 
 
2.2.12 Aspartate aminotransferase activity assay 
Serum aspartate aminotransferase (AST) activity was measured by a kinetic UV 
test method using a procedure that followed the modification of the methodology 
recommended by the IFCC (Schumann et al., 2002). When serum sample (10 µL) 
was mixed with equal volumes (50 µL) of AST Reagent 1 and Reagent 2, AST in 
the sample catalysed the transamination of aspartate and α-oxoglutarate, to form 
L-glutamate and oxaloacetate, the oxaloacetate produced was reduced to L-
malate by malate dehydrogenase, while NADH was simultaneously converted to 
NAD+. The decrease in absorbance due to the consumption of NADH was 
measured at 340 nm and was proportional to the AST activity in the serum 
sample. The test was linear within an enzyme activity range of 3 – 1000 U/L and 
the lowest detectable level was 1 U/L. The reference range for serum AST was 
less than 35 U/L in female (adult) and less than 50 U/L in male (adult).  
 
2.2.13 Determination of serum total cholesterol concentration  
Serum total Cholesterol (CHOL) was measured by an enzymatic colour test 
method. Briefly, 30 µL of serum sample was added to 45 µL of Total Cholesterol 
reagent in a cuvette and incubated at 37ºC. Cholesterol esters in the sample were 
hydrolysed by cholesterol esterase (CHE) to produce free cholesterol. The free 
cholesterol was, in turn, oxidised by cholesterol oxidase (CHO) to cholestene-3-
one with the simultaneous production of hydrogen peroxide (H2O2), which 
oxidatively coupled with 4-aminoantipyrine and phenol in the presence of 
peroxidase (POD) to yield a chromophore (quinoneimine). The change in 
absorbance due to the formation of the red quinoneimine dye was directly 
proportional to the concentration of cholesterol in the sample and was measured 
at 540/600 nm.  
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The lowest detectable level in serum was estimated at 0.02 mmol/L and the assay 
was linear within a concentration range of 0.5 – 18.0 mmol/L. The reference 
ranges based on the NCEP-ATP III recommendations (2001) were <5.2 mmol/L 
(desirable), 5.2 – 6.2 mmol/L (borderline high) and ≥6.0 mmol/L (high).  
 
2.2.14 Determination of serum triglyceride concentration 
Serum triglyceride (TRIG) level was measured by an enzymatic colour test method 
using a procedure that is based on a series of coupled enzymatic reactions. 
Serum sample (2.0 µL) was added to 100 µL of Reagent 1 and mixed in a cuvette. 
Reagent 2 (25 µL) was then added to the mixture and incubated at 37ºC. TRIG in 
the sample was hydrolysed by a combination of microbial lipases to give glycerol 
and fatty acids. The glycerol was phosphorylated by adenosine triphosphate in the 
presence of glycerol kinase (GK) to produce glycerol-3-phoaphate. The glycerol-3-
phosphate produced was oxidised to molecular oxygen in the presence glycerol 
phosphate oxidase (GPO) to yield H2O2 and dihydroxyacetone phosphate. The 
H2O2 formed reacted with 4-aminophenazone (4-AAP) and N, N-bis (4-sulfobutyl)-
3, 5-dimethylalanine, disodium salt (MADB) in the presence of peroxidase to 
produce a chromophore, which was read at 660/800 nm. The increase in 
absorbance was proportional to the concentration of TRIG in the sample. The 
lowest detectable level of TRIG in serum was estimated at 0.01 mmol/L and the 
test was linear within a concentration range of 0.1 – 11.3 mmol/L. Adult reference 
range was 0.6 – 2.0 mmol/L. 
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2.2.15 Determination of HDL-cholesterol concentration 
Serum HDL was determined by enzymatic colour test method. This method 
directly measures HDL-cholesterol without the need for any pre-treatment or 
centrifugation of the serum sample. Serum sample (1.2 µL) was added to 108 µL 
of reagent 1 (R1) containing anti-human-β-lipoprotein antibody that binds to 
lipoproteins other than HDL (LDL, VLDL, and chylomicrons). The antigen-antibody 
complexes formed block enzyme reactions with these lipoprotein. Reagent 2 (36 
µL), containing the enzymes cholesterol esterase (CHE) and cholesterol oxidase 
(CHO) was added to the reaction vessel. These enzymes reacted only with HDL to 
form H2O2 which was measured in a peroxidise condensation reaction in the 
presence of an enzyme chromogen system (N-ethyl-N-(2-hydroxy-3-sulfopropyl-
3.5-dimethoxy-4-flouranaline or F-DAOS), to yield a blue colour complex. The 
increase in absorbance of the blue dye was measured by colorimetric method at 
wavelength 600 nm and is directly proportional to the concentration of HDL in the 
sample.  
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The lowest detectable level of HDL in serum sample was calculated as 0.002 
mmol/L and the test was linear within a concentration range of 0.05 – 4.65 mmol/L. 
Samples with values above the measuring range were automatically diluted 1 in 5 
by the analyser using normal saline (diluents). This onboard dilution extended the 
measuring range to 0.05 - 23.25 mmol/L. The concentration of HDL in the sample 
was reported in mmol/L. Adult reference range was 0.7 – 2.2 mmol/L.  
 
2.2.16 Creatine kinase activity assay 
Serum creatine kinase (CK) activity was measured by a kinetic UV test method. 
Serum sample (3.0 µL) was added to 120 µL of Reagent 1 and mixed. Reagent 2 
(30 µL) was then added and the mixture was incubated at 37ºC. CK present in the 
sample catalysed the transfer of a phosphate group from creatine phosphate to 
adeninine diphosphate (ADP) to yield creatine and adenosine triphosphate (ATP). 
The ATP produced was used to phosphorylate glucose to produce glucose-6-
phosphate and ADP. This reaction was catalysed by hexokinase which required 
magnesium ions for maximum activity. The glucose-6-phosphate was oxidised by 
glucose-6-phoaphate dehydrogenase (G6P-DH) with simultaneous reduction of 
the coenzyme nicotinamide adenine dinucleotide (NADP) to give NADPH and 6-
phosphogluconate. The rate of increase in absorbance at 340/660 nm due to the 
formation of NADPH was directly proportional to the activity of CK in the sample. 
These reactions occurred in the presence of N-acetyl-L-cysteine (NAC) which was 
present as an enzyme reactivator.  
 
The lowest detectable level was estimated at 3 U/L, but the test was linear within 
an enzyme activity range of 10 – 2000 U/L. The reference range of CK in female 
was ≤ 145 U/L and ≤ 171 U/L in male (Schumann and Klauke, 2003). 
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2.2.17 Lactate dehydrogenase activity assay 
Serum lactate dehydrogenase (LDH) level was measured by a kinetic UV test 
based on the method recommended by the Scandinavian Committee on Enzymes 
(Horder and Gerhardt, 1985). Following Beckman Coulter setting up data, 3.0 µL 
of serum sample was added to 100 µL of Reagent 1 in a cuvette and then mixed. 
Next, 50 µL of Reagent 2 was added and the mixture was incubated at 37ºC. 
Lactate dehydrogenase in the sample catalysed the reduction of pyruvate to 
lactate at a neutral pH. This reaction was coupled with the oxidation of NADH to 
NAD+. The decrease in NADH is directly proportional to the enzyme activity in the 
sample and was measured at 340 nm. The lowest detectable level of LDH in 
serum was estimated at 15 U/L and the assay was linear within an enzymatic 
activity range of 50 – 3000 U/L. The reference range of serum LDH in adults was 
208 – 378 U/L. 
 
2.2.18 Measurement of C reactive protein concentration 
Serum C reactive protein (CRP) level was measured by a turbidimetric method 
using the Beckman Coulter CRP Latex reagent. By this method immune complex 
formed in solution scattered light in proportion to their size, shape and 
concentration, and the turbidimetric method measures the reduction of incidence 
light due to reflection, absorption or scatter. In this study, 2.0 µL of serum sample 
was mixed with 150 µL of CRP Latex Reagent 1 and 150 µL of Reagent 2 and the 
mixture was incubated at 37C. The rate of decrease in light intensity transmitted 
(increase in absorbance) through particles suspended in solution was the result of 
complexes formed during the antigen-antibody reaction. The lowest detectable 
level of serum CRP was 0.09 mg/L but the test was linear within a concentration 
range of 0.2 – 480 mg/L. The reference range was < 5 mg/L.  
 
2.2.19 Urine total protein by the Pyrogallol red-molybdate method 
Urine total protein (UPRO) was measured by a colorimetric method, based on the 
change in absorption which occurs when pyrogallol red-molybdate dye (reagent) 
binds basic amino acid groups of protein molecules in the urine sample to form a 
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purple-blue complex with maximum absorbance at 600 nm. Urine sample (2 µL) 
was added to 190 µL of Urine/CSF Protein reagent and incubated at 37C. Protein 
in the urine sample bound to pyrogallol red-molybdate dye and the change in 
absorbance due to the formation of the purple-blue complex was directly 
proportional to the concentration of protein in the sample and was measured at 
600 nm. The lowest detectable level of UPRO was estimated at 0.007 g/L, 
representing the lowest measurable level of total protein that can be distinguished 
from zero. The test was linear within a concentration range of 0.01 – 2.00 g/L and 
the reference range of UPRO was 0 – 0.1 g/L. 
 
2.2.20 Urine albumin concentration by the turbidimetric method 
Urine albumin or microalbumin (MALB) concentration was measured by 
turbidimetric method using the Beckman Coulter Urine/CSF Albumin reagent. 
Following the manufacturer’s information for use the analyser was set to mix 4 µL 
of urine sample with 138 µL of Urine/CSF Albumin Reagent 1 and 16 µL of 
Reagent 2. The mixture was incubated at 37C. Anti-human serum albumin 
antibodies in the reagent combined with albumin from the sample to form immune 
complexes that scattered light in proportion to their size, shape and concentration. 
The absorbance of these aggregates was proportional to the concentration of 
albumin in the urine sample. Change in absorbance was measured at 380 nm with 
subtraction of a reference wavelength at 800 nm. The assay was calibrated using 
Beckman coulter Urine/CSF Albumin Calibration kit (B358859) and quality control 
was performed using Liquichek Microalbumin Control Levels 1 and 2 (Ref. No. 
378/379) (Bio-Rad Laboratories, Hertfordshire, UK). The analytical range was 7 – 
450 mg/L. 
 
2.2.21 Determination of other urine parameters 
The following urine parameters were calculated using standard formulas.  
 Urine albumin creatinine ratio (UACR): 
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UACR (mg/mmol) = MALB (mg/L) / UCRE (mmol/L), where MALB is urine 
albumin concentration and UCRE is urine creatinine concentration. 
 Urine protein creatinine ratio (UPCR): 
UPCR (mg/mmol) = UPRO (mg/L) / UCRE (mmol/L), where UPRO is urine 
total protein concentration and UCRE is urine creatinine concentration. 
 Urine albumin protein ratio (UAPR): 
UAPR = UACR (mg/mmol) / UPCR (mg/mmol) 
 Fractional excretion of sodium (FENA): 
FENA (%) = [UNA (mmol/L)  CREA (mmol/L)] / [NA (mmol/L)  UCRE 
(mmol/L)]  100, where UNA is urine sodium concentration, CREA is serum 
creatinine concentration, NA is serum sodium concentration and UCRE is 
urine creatinine concentration. 
 Fractional excretion of Urea (FEUR): 
FEUR (%) = [UURE (mmol/L)  CREA (mmol/L)] / [UREA (mmol/L)  UCRE 
(mmol/L)]  100, where UURE is urine Urea concentration, CREA is serum 
creatinine concentration, UREA is serum Urea concentration and UCRE is 
urine creatinine concentration. 
 Fractional excretion of uric acid (FEUA): 
FEUA (%) = [UUA (mmol/L)  CREA (mmol/L)] / [UA (mmol/L)  UCRE 
(mmol/L)]  100, where UUA is urine uric acid concentration, CREA is 
serum creatinine concentration, UA is serum uric acid concentration and 
UCRE is urine creatinine concentration. 
 
2.2.22 Immunoassay parameters (Thyroid function tests)  
The immunoassays were performed on a Beckman Coulter Access 2 
Immunoassay analyser system using reagent kits supplied by Beckman Coulter 
(High, Wycombe, UK). The serum samples were assayed for thyroid function 
markers including, thyroid stimulating hormone (TSH), free T3 (FT3) and free T4 
(FT4), using enzyme-mediated chemiluminescence methods. The automated 
analysis employed various steps to determine the concentration of the analytes. 
Sample and reagent components were dispensed into a reaction vessel and 
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mixed. The reaction vessel was incubated for the required time for each assay and 
then washed three times in a magnetic field to remove unbound material. A 
substrate (Lumi-Phos⃰ 530) was added and the reaction vessel was incubated to 
allow the bound analyte complexes to react with the substrate. The substrate 
reacted with alkaline phosphatase bound to the paramagnetic particles to produce 
light. The light generated was measured by a luminometer in Relative Light Units 
(RLU). The RLU reading was converted to analyte concentration using a pre-
determined calibration curve. All the samples were processed after a successful 
calibration of the assay and acceptable quality control performance. Quality control 
was performed using Technopath Multichem IA Tri-level controls. Test results 
were automatically calculated by the Beckman Coulter Access 2 analyser system.  
 
2.2.22.1 Measurement of serum TSH concentration 
Serum TSH was determined using the Beckman Coulter Access TSH (3rd IS) 
assay in an automated two-site immunoenzymatic (“sandwich”) assay (Figure 
2.1). Serum sample (50 µL) was added to a reaction vessel containing 50 µL of 
mouse anti-human TSH-alkaline phosphatase conjugate. Buffered protein solution 
(50 µL) and 25 µL paramagnetic particles coated with immobilised mouse 
monoclonal anti-hTSH antibody was added and the mixture was incubated at 37C 
for 10 minutes. The human TSH (hTSH) in the sample bound to the immobilised 
monoclonal anti-hTSH antibody on the solid phase while the mouse anti-hTSH-
alkaline phosphatase conjugate reacted with a different antigenic site on the 
hTSH. After incubation, the reaction vessel was washed three times with Wash 
Buffer II. Materials bound to the solid phase were held in a magnetic field while 
unbound materials were washed away in the Wash Buffer II. Chemiluminescent 
substrate Lumi-Phos⃰ 530 was added to the reaction vessel and light generated by 
the reaction was measured with a luminometer and the light produced was directly 
proportional to the concentration of hTSH in the serum sample. The amount of 
analyte in the sample was determined from a stored, multi-point calibration curve. 
The assay was calibrated using the Beckman Coulter Access TSH (3rd IS) 
calibrators. Reference range was 0.34 – 5.6 mIU/L. 
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Figure 2.1 Schematic representation of the TSH assay using two-site 
(sandwich) immunoenzymatic assay by chemiluminescence.  
TSH in the sample bound to monoclonal anti-TSH antibody on the solid phase, while the 
mouse anti-hTSH-alkaline phosphatase conjugate reacted with a different antigenic site 
on the hTSH. After incubation at 37C for 10 minutes, unbound materials were washed 
away and materials bound to the solid phase were held in a magnetic field. 
Chemiluminescent substrate Lumi-Phos⃰ 530 was added and light generated by the 
reaction was measured by a luminometer (Source: Beckman Coulter, UK). 
Paramagnetic 
particles coated with 
mouse monoclonal 
anti-hTSH antibody 
Monoclonal          
anti-hTSH alkaline 
phosphatase 
conjugate 
Sample 
containing 
TSH 
Incubate at 
≈36.5C for 
≈10 minutes 
Sandwich formation Wash    
3 times 
Add 
substrate 
Incubate   
5 minutes 
Read 
light 
The signal produced is directly proportional to the concentration of TSH in the sample. 
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2.2.22.2 Measurement of serum FT4 (thyroxine) concentration 
The serum FT4 was measured using the Beckman Coulter Access Free T4 assay 
kit in a two-step enzyme immunoassay technique. Serum sample (30 µL) was 
added to a reaction vessel containing 50 µL monoclonal anti-Thyroxine (T4) 
antibody coupled to biotin, buffered protein solution and streptavidin-coated solid 
phase and the mixture was incubated at 36.5 C for 7 minutes. During this first 
incubation phase, the anti-T4 antibody coupled to biotin bound to the solid phase 
and the free T4 in the sample. After incubation, the reaction vessel was washed 
three times in Wash Buffer II. Materials bound to the solid phase were held in a 
magnetic field while unbound materials were washed away.  
Next, buffered protein solution and triiodothyronine (T3)-alkaline phosphate 
conjugate were added to the reaction vessel and further incubated at 36.5 C for 5 
minutes. The T3-alkaline phosphatase conjugate bound to the vacant anti-T4 
antibody binding sites. After incubation, the reaction vessel was again washed 
three times with Wash Buffer II and materials bound to the solid phase were held 
in a magnetic field while unbound materials were washed away. 
Chemiluminescent substrate Lumi-Phos⃰ 530 was added to the vessel and light 
generated by the reaction was measured with a luminometer. The light production 
was inversely proportional to the concentration of free T4 in the sample. The 
concentration of FT4 in the serum sample was determined from a multi-point 
calibration curve. The free T4 assay was calibrated using the Beckman Coulter 
Access Free T4 calibrators (Category Number 33885).  
Test results were determined automatically by the Beckman Coulter Access 2 
analyser system software. The assay range was 3.2 – 77.2 pmol/L (this is defined 
as the lowest detection limit and the maximum level of the master calibration 
curve). The reference range for serum FT4 was 7.9 – 20 pmol/L.  
 
2.2.22.3 Measurement of serum FT3 concentration  
The serum level of FT3 was measured using the Beckman Coulter Access Free 
T3 assay – a paramagnetic particle, chemiluminescent immunoassay for the 
quantitative determination of free triiodothyronine levels in human serum and 
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plasma. The Access Free T3 assay is a competitive binding immunoenzymatic 
assay. Serum sample (50 µL) was added to a reaction vessel containing 25 µL of 
anti-T3 monoclonal antibody conjugated to alkaline phosphatase and incubated at 
36.5C for 29 minutes. FT3 in the sample reacted with the anti-T3 antibody. Next, 
50 µL of particles coated with streptavidin and biotinylated T3 analog were added 
to the mixture. Unoccupied binding sites on the anti-T3 antibody were bridged to 
the particle through the T3 analog. After incubation in the reaction vessel was 
washed three times with Access Wash Buffer II. Materials bound to the solid 
phase were held in the magnetic field while unbound materials were washed 
away. The chemiluminescent substrate Lumi-Phos⃰ 530 was added to the vessel 
and light generated by the reaction was measured with a luminometer. The light 
production was inversely proportional to the concentration of FT3 in the serum 
sample. The concentration of FT3 in the sample was determined from the 
measured light production by means of the stored calibration data. The assay was 
calibrated using the Beckman Coulter Access Free T3 calibrators (Cat No. 
A13430). Test results were determined automatically by the Access 2 analyser 
software system. The assay analytical range was 1.4 – 46 pmol/L, while the 
reference range for FT3 was 4.0 – 6.6 pmol/L. 
 
2.2.23 Determination of serum CYSC by PETIA method 
Serum CYSC was determined by particle-enhanced turbidimetric immunoassay 
(PETIA) method, using the Gentian Cystatin C (Gentian AS) kit. This method is 
traceable to the certified cystatin C reference material (ERM®-DA471/IFCC). The 
assay was deployed on the Beckman Coulter AU640 analyser according to the 
manufacturers’ instructions. Serum sample (2 µL) was mixed with 150 µL of 
Reagent 1 (buffer) and the mixture incubated for five minutes. The diluted sample 
was reacted with a suspension of 30 µL of Reagent 2 containing latex enhanced 
particles coated with anti-CYSC antibodies (rabbit). The immunoparticles 
agglutinated with the human CYSC in the sample to form antigen-antibody 
complex (Figure 2.2). The degree of turbidity caused by the aggregate was 
determined by turbidimetry at 540 nm and was proportional to the amount of 
CYSC in the sample.  
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Serum CYSC level was obtained via interpolation on an established standard 
calibration curve. The assay was calibrated using Gentian Cystatin C calibrator kit 
(Ref #: A52763) which is standardised against the international calibrator standard 
ERM-DA471/IFCC and quality control was performed using Gentian Cystatin C 
Quality Control kit (Ref #: A52765), which is a two level (low and high) control. The 
assay was calibrated and quality controls run before the project samples were 
tested. The test results were automatically calculated in mg/L by the AU640 
analyser. The reference range was 0.53 – 1.01 mg/L. 
 
 
Figure 2.2 Gentian CYSC assay by particle enhanced turbidimetric 
immunoassay (PETIA) method.  
CYSC agglutinates with latex enhanced particles coated with anti-cystatin C antibodies to 
form antigen-antibody complex. The change in turbidity was measured at 540 nm and is 
directly proportional to the concentration of cystatin C (Source: Cobas, Roche Diagnostics 
Ltd, Rotkruez, Switzerland). 
 
2.2.24 Analytical performance of the Gentian CYSC method  
2.2.24.1 Gentian CYSC assay sensitivity 
The assay limit of blank (LoB), limit of detection (LoD) and limit of quantitation 
were determined using standard methods by the Clinical and Laboratory 
Standards Institute (CLSI) as published in the guideline EP17, Protocols for 
Determination of Limits of Detection and Limits of Quantitation (CLSI, 2004). To 
determine the LoB, aliquots of the assay diluent (blank sample) were tested to 
Fombon, I.S. (2020) 
75 
 
determine the lowest concentration that can be measured and then calculated the 
mean and corresponding standard deviation (SD) for 20 samples. Assuming a 
Gaussian distribution of the raw analytical signals from blank samples, the LoB 
represents 95% of the observed values. The LoB, LoD and LoQ were then 
evaluated based on the standard deviation of the blank using the following 
equations (Little, 2015): 
LoB = Mean blank + 1.645 SD blank (one sided 95%)  
LoD = Mean blank + 3.3  SD blank (one sided 95%  2) 
LoQ = Mean blank + 10  SD blank (One sided 95%  6) 
 
2.2.24.2 Gentian CYSC assay precision  
Assay precision was assessed using the Gentian Cystatin C quality control 
materials (Low and High) and pooled waste patient samples not more than 5 days 
old obtained from the SPS Blood Sciences Laboratory, Lisieuw Way, Taunton. The 
samples were collected into 3 sterile universal containers based on the serum 
CREA concentrations (pre-determined) as follows: 
Tube A: Serum creatinine concentration < 50 µmol/L (low level of CYSC) 
Tube B: Serum creatinine concentration 100 – 200 µmol/L (medium level CYSC) 
Tube C: Serum creatinine concentration > 500 µmol/L (high level CYSC) 
For intra-assay precision, the pooled serum from each tube was aliquoted into 10 
test tubes and analysed for CYSC. The quality control material (Low and High 
Levels) was also aliquoted into 10 tubes and run as a batch.  The inter-assay 
imprecision was determined by measuring the three levels of pooled serum 
samples (Low, medium and high) twice a day, over a period of 5 days, and the two 
levels of quality control material once a day over 10 days. The mean and standard 
deviation (SD) were calculated and the percentage coefficient of variation [CV (%)] 
was determined by dividing the standard deviation (SD) of each level by the mean 
and then multiplied by 100.  
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2.2.24.3 Gentian CYSC assay Linearity and recovery 
The method accuracy was assessed by evaluation of the linearity after dilution. A 
high-concentration serum pool (7.90 mg/L) was prepared from waste patient 
samples. The pool was then diluted serially in isotonic saline solution (0.9%, w/v) 
to give the following calculated (expected) concentrations of the high pool: 7.90, 
3.95, 1.98, 0.99, 0.49, and 0.25 mg/L. Each sample was measured in triplicate and 
the mean of the measured (detected) CYSC concentrations were plotted against 
the calculated (expected) values. Linear regression analysis was performed to 
calculate the corresponding correlation coefficient. The percentage recovery was 
calculated from the results of the diluted samples using the formula: 
 
 
 
2.2.24.4 Stability of CYSC in frozen serum samples 
The stability of CYSC in serum samples was assessed to determine whether it 
was affected by the storage condition. The concentration of CYSC (baseline) in 
some 40 waste patient samples was determined. The samples were less than 5 
days  collected the from storage (4ºC) at the Sothwest Pathology Services 
Laboratory, tested and then stored frozen at -80ºC for 30 months. The 
concentration of serum CYSC was again determined after storage and the results 
obtained were compared with the baseline values. 
 
2.2.24.5 Comparison of CYSC assay and the Jaffe CREA method 
The relation between serum  CYSC and serum CREA was examined in some 20 
patient serum samples across a wide range. Serum CYSC concentrations ranged 
from 0.7 – 6.93 mg/L and serum CREA concentrations ranged from 47 – 1101 
µmol/L. The linear regression analysis between the two methods was performed to 
establish the correlation coefficient. 
 Concentration Detected (mg/L) 
Concentration Expected (mg/L) 
 100 Recovery (%) = 
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2.2.25 Estimated glomerular filtration rate (eGFR) 
The GFR was estimated using five equations. First, eGFR from serum CREA 
concentrations was calculated according to the IDMS-traceable MDRD study 
equation (Levey et al., 2006) and by the CKD-EPI equation (Levey et al., 2009). 
Both equations take account of sex, age and ethnicity (black versus non-black). 
However, the ethnicity was not relevant in this study as the participants only 
included white British. Next, the eGFR was calculated using serum CYSC-based 
equations, namely the Gentian and CKD-EPI CYSC equations (Inker et al., 2012). 
Finally, the eGFR was calculated using the combined serum CREA and serum 
CYSC equation as proposed by Inker et al., (2012).  
 
2.2.26 Mammalian cell culture and cell line maintenance  
All the cell lines were maintained in 75 cm2 tissue culture flasks in Dulbecco’s 
Modified Eagle medium (DMEM) supplemented with 10% (v/v) FBS and grown at 
37°C in a humidified atmosphere of 5% CO2 and 95% air, as recommended by the 
manufacturers. When the cells were not being used for experiments, they were 
collected by trypsinisation, suspended in freezing medium [10% (v/v) DMSO in 
foetal bovine serum (FBS)] and stored overnight at -80ºC. The next day, the frozen 
aliquots where transferred to liquid nitrogen (-180ºC) for long term storage. The 
cells were stored in aliquots (1 mL) in cryovials.  
When required for the experiments, the cells were recovered from liquid nitrogen 
storage by rapidly defrosting in a water bath at 37C and the content of the 
cryovial (1 mL cell suspension) was transferred into a 75 cm2 tissue culture flask 
containing 9 mL of fresh culture medium. The cells were incubated overnight at 
37°C in a humidified environment of 5% CO2 and 95% air, and allowed to attach. 
Following attachment, medium was withdrawn from the flask and the cells washed 
briefly with phosphate buffered saline (PBS) to get rid of any unattached or dead 
cells. Fresh culture medium was added into the culture flask and the cells were 
incubated at 37ºC. The growth medium was changed every three days and cells 
were grown until 80% confluent, before subculture. 
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For subculture, spent culture medium was removed from the tissue flask and the 
flask was rinsed with 5 mL of sterile PBS. Next, 3 mL of pre-warmed (37C) 
trypsin-EDTA solution (0.25% trypsin, 0.1 mM EDTA) was added into the flask and 
spread to cover the adherent cells. The flask was incubated for about 5 minutes at 
37C and then checked under the microscope for complete detachment. 
Periodically, the flask was gently tapped from side to side to aid detachment of 
cells from the flask. When the cells were completely detached 3 mL of fresh 
serum-containing culture medium was added to neutralise the effect of trypsin, and 
the cells were collected into a 15 mL test tube and spun at 1000 revolutions per 
minute for 5 minutes. The supernatant was discarded and the pellet was re-
suspended in 3-5 mL fresh medium (depending on the size of the pellet) and a cell 
count was performed. A 50 µL aliquot of the suspension was transferred into a 500 
µL Eppendorf tube and mixed with 50 µL of 0.4% trypan blue dye solution and the 
cell density was counted using a glass haemocytometer (Improved Neubauer 
Counting Chamber) and a light microscope. Cells were seeded in the 96-well 
plates at a density of 5.0  103 cells/well for the viability assay and 2.5  104 
cells/well for ROS activity assay. In the 25 cm2 flasks the cells were seeded with 
2.0  105 cells, and in 75 cm2 flasks with 2.0  106 cells. 
 
2.2.27 Examination of changes in cell morphology 
The NRK52E, L6 and HEK293 Cells were seeded (2.5  106 cells) in 75 cm2 flasks 
and incubated overnight to attach. The medium was withdrawn from the flasks and 
replaced with fresh medium containing various concentrations of FF [0 (untreated), 
250, 500, and 1000 µM] and further incubated for 24 h at 37ºC. Change in cell 
morphology was examined by phase contrast microscopy. Images of the FF-
treated cells were taken using a Nikon Eclipse TE300 inverted microscope with 
phase-contrast objective (magnification 200) and the Nikon’s NIS-Elements 
Microscope Imaging software (Kingston, UK). 
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2.2.28 Cell viability assay 
Cell viability was determined using the CellTiter96 AQueous One Solution Cell 
Proliferation Assay kit; (MTS Promega, Madison, WI). The MTS assay is a 
colorimetric method for determining the number of viable cells in proliferation, 
based on the reduction of the MTS tetrazolium compound by dehydrogenase 
activities of viable cells to generate a coloured formazan product that is soluble in 
cell culture media. The amount of formazan produced is directly proportional to the 
number of living cells. NRK52E, L6 and HEK293 cells (5  103 cells/well) in 200 µL 
of complete medium were seeded in 96-well flat-bottomed culture plates and 
incubated overnight at 37 °C to attach. The next day, medium was withdrawn from 
the wells and replaced with fresh complete medium (100 µL/well) containing the 
various concentrations of FF (0, 7.8, 15.6, 31.5, 62.5, 125, 250, 500, and 1000 
µM) and 5-FU (0, 7.8, 15.6, 31.5, 62.5, 125, 250 and 500 µM). The cells were 
exposed to the drugs for 72 h at 37°C, and 20 µL of CellTiter 96 Aqueous One 
Solution was added to each of the wells containing medium and the culture plates 
incubated for one 1 hour in the dark. Absorbance was measured at 490 nm using 
a FLUOstar OPTIMA microplate reader (Aylesbury, UK). All experiments were 
repeated for at least 3 times with triplicate samples in each experiment.  
The data was transferred to Microsoft Excel spreadsheet for analysis. The effects 
on viability of the cells following exposure to FF and 5-FU were analysed and 
concentration-effect curves were generated as a plot of the fraction of viable cells 
versus drug concentration. Viability was expressed as a percentage of the 
untreated controls that were processed simultaneously. The IC50 was defined as 
the concentration that inhibited cell viability by 50% (50% reduction of absorbance) 
compared with untreated controls. The IC50 of the individual drugs (FF and 5-FU) 
in the different cell lines were established. The effect of FF on cell viability was 
compared with 5-FU, which is known to be toxic to kidney and muscle cells. 
 
2.2.29 Detection of intracellular reactive oxygen species (ROS) activity 
ROS activity in cells exposed to FF was determined using DCFDA Cellular ROS 
Detection Assay Kit (Abcam®). The assay uses the cell permeant reagent 2', 7'-
dichlorofluorescin diacetate (DCFDA), a fluorogenic dye that measures hydroxyl, 
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peroxyl and other ROS activity within the cell.  After diffusion into the cell, DCFDA 
is deacetylated by cellular esterases to a non-fluorescent compound, which is later 
oxidised by ROS into 2', 7'-dichlorofluorescin (DCF). DCF is a highly fluorescent 
compound which can be detected by fluorescence spectroscopy with maximum 
excitation and emission spectra of 485 nm and 535 nm respectively. 
NRK52E, L6 and HEK293 cells (2.5  104 cells/well)/100 µL were seeded in a 
dark, clear-bottom 96-well plate overnight to attach. Medium was withdrawn from 
the wells and replaced with fresh phenol red-free medium (100 µL/well) containing 
various concentrations of FF (0, 250, 500 and 1000 µmol/L) and 30 µmol/L H2O2 
(positive control) was added into the wells and incubated for 6 h at 37C. After 
drug exposure, 30 µM of DCFDA solution in a total volume of 200 µL phenol red-
free medium was added into each well and the plates were further incubated at 
37ºC for 45 minutes, wrapped in aluminium foil to protect from light. The 
fluorescence intensity was measured at excitation/emission wavelengths of 
485/535 nm using a Fluostar OPTIMA microplate reader (Aylesbury, UK). The 
results were expressed as percentage change in fluorescence intensity compared 
with control (untreated) cells. 
 
2.2.30 Detection of cell apoptosis by flow cytometry 
NRK52E, L6 and HEK293 cells (2.0  105 cells) were seeded in 25 cm2 flasks 
overnight to attach. The next day, medium was withdrawn from the flasks and 
replaced with fresh medium containing various concentrations of FF (250, 500, 
and 1000 µM). Untreated cells and cells treated with H2O2 (25 µM) were used as 
controls in the experiment. The cells were exposed to the treatments for 4 hours. 
After drug exposure, the cells were collected by trypsinisation, washed twice in 
PBS and stained using Annexin V-FITC Apoptosis Detection kit (BioVision, 
Mountain View, CA, USA), according to the manufacturers’ instructions. The cells 
were stained with Annexin V-FITC and propidium iodide at 1 µg/mL for 5 minutes, 
protected from light. Apoptosis was detected by flow cytometry on the BD AccuriTM 
C6 flow cytometer (Accuri Cytometers Ltd., St, Ives, UK). A minimum of 10,000 
cells were collected for each sample, and the data were analysed using the BD 
AccuriTM C6 software. The flow cytometry software was used to directly calculate 
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the percentage of apoptotic cells. The average percentage of apoptotic cells was 
calculated from at least two biological replicates.  
 
2.2.31 Extraction of cell lysate (protein extraction) 
NRK52E, L6 and HEK293 cells exposed to various concentrations of FF (0, 250, 
500 and 1000 µmol/L) for 72 hours were collected and whole protein extracted for 
Western blot analysis. Culture medium was withdrawn from the culture flasks and 
the cells were washed with PBS. The cells were collected by trypsinisation and the 
cell pellets were collected in Eppendorf tubes. The cell pellets were re-suspended 
in protein extraction (RIPA) buffer consisting of 50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1 % Triton X-100, 1 complete protease inhibitor, 
and 0.1% (w/v) sodium dodecyl sulphate (SDS). The cell suspension were 
incubated for 1 hour on ice-water bath and then sonicated for about 1 minute with 
a 10 second pause for every 10 seconds of sonication. The lysed cells were then 
centrifuged at 15000rpm for 10 minutes at 4C and the supernatant (whole protein 
extract) was collected into fresh Eppendorf tubes and protein concentration was 
determined using Amido Black assay or Bicinchoninic Acid assay (Noble and 
Bailey, 2009). The lysates were stored in the freezer at -80C until analysed by 
western blotting.  
 
2.2.32 Measurement of protein concentration  
We employed two methods to measure the concentration of protein in cell lysates. 
The choice of the method depended amongst other things on convenience and 
availability of test materials. The methods used in this study included Amido Black 
assay and Bicinchoninic acid (BCA) assay. 
2.2.32.1 Amido Black assay method 
Extracted protein sample (2.5 µL) was diluted in 267.5 µL of ultrapure water. The 
standard protein (1 mg/mL BSA) was also diluted (1 in 10) in ultrapure water and 
the working protein standard solutions were then prepared as shown in Table 2.6 
below. Tris-HCL buffer (30 µL) and 60 µL of 60% trichloroacetic acid (TCA) were 
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added to each sample including the standards and the preparations were mixed 
and incubated at room temperature for 5 minutes. A Buchner flask was assembled 
to create a vacuum and nitrocellulose membrane was added to the filter and 
washed 3 times with 6% TCA. The standards and samples were spotted on the 
nitrocellulose membrane and the membrane was washed with 6% TCA and warm 
water and allowed to dry. The membrane was stained in Amido Black stain for 2 
minutes, and then destained in several transfers of destains until the background 
was clear. 
 
Table 2.6 Table 2.6 Amido Black Standard Solutions 
BSA (µg/µL) BSA (µL) Ultrapure Water (µL) 
0 0 270 
1 10 260 
2.5 25 245 
5 50 220 
7.5 75 195 
10 100 170 
            Abbreviation: BSA, bovine serum albumin 
Each spot was carefully cut out and dissolved in 500 µL of eluent solution and the 
stain was allowed to dissolve completely. 200 µL of each sample was added to a 
96-well plate and the absorbance was read at 520 nm. A BSA standard curve was 
plotted and the concentration of each sample was obtained by interpolation on the 
standard curve.  
 
2.2.32.2 Bicinchoninic Acid (BCA) assay method 
The BCA working reagent was prepared by mixing 50 parts of BCA solution A with 
one part of BCA reagent B (50:1, Reagent A: B). Standard protein (BSA) and 
protein samples (25 µL) were added into each well of a 96-well plate and 200 µL 
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of working reagent was added into each well. Each standard and protein sample 
was run in triplicate. The 96-well plate was incubated at 37C for 30 minutes and 
protected from light. The absorbance was read at 562 nm on a microplate reader. 
The protein standard curve was plotted and used to calculate the concentration of 
the protein samples.  
 
2.2.33 SDS-PAGE Electrophoresis 
Pre-prepared 4-12% polyacrylamide gel (30% acrylamide, 1.5 M Tris HCl pH 8.8, 
0.5 MTris-HCl pH 6.8, 10% SDS, 10% APS, TEMED) was assembled into an 
electrophoresis tank using the cassette adapter and the tank was filled with 1  
running buffer (25 mM Tris-HCl pH 6.8, 192 mM glycine, 0.1% SDS). The protein 
samples were prepared by mixing 6.25 µL of loading buffer, 1 µL of β-
mercaptoethanol, 10 µg of protein extract and distilled water to make up a final 
volume of 25 µL. Each sample was incubated at 95 C for 10 minutes on a heating 
block and 20 µL was loaded into the gel. Protein ladder (Spectra ladder) was 
loaded into a separate well. The gel was electrophoresed at 100V for 20 minutes 
and then 160V for 80 minutes for the protein markers to clearly separate. 
 
2.2.34 Protein transfer (wet) and western blot analysis 
Whatman® gel blotting papers were soaked in 1 transfer buffer (25mM Tris-HCl 
pH8.3, 192 mM glycine, 20% methanol), while the PVDF membrane was first 
activated by incubation in absolute methanol for 5 minutes and then soaked in the 
transfer buffer (1). A transfer unit was setup by placing the SDS-PAGE gel on top 
of the PVDF membrane, and sandwiched by two layers of the blotting papers and 
sponges soaked in transfer buffer.  Protein was transferred at 60V and 500 mA 
overnight at 4ºC.  
When protein was transferred completely from the gel onto the PVDF membrane, 
the membrane was removed and washed 3 times in 10 mL of 1 TBS-T (10 
minutes per wash cycle) with gentle agitation. The membrane was blocked using 
1 TBS-T working solution supplemented with 5 % fat-free milk (Marvel) for at 
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least one hour at room temperature with gentle agitation, to prevent non-specific 
binding of primary and secondary antibodies to the protein-free areas of the PVDF 
membrane. The blocking buffer was withdrawn and primary antibody diluted in 
fresh blocking buffer (Table 2.6) was added into the staining tray containing the 
membrane. The membrane was incubated in primary antibody solution overnight 
at 4ºC with gentle agitation. After an overnight incubation, the primary antibody 
solution was withdrawn and the membrane was washed 3 times (10 minutes per 
wash cycle) in 10 mL of 1 TBS-T before secondary antibody diluted in blocking 
buffer (Table 2.7) was added and the membrane was incubated for 1 hour at room 
temperature, with gentle agitation. The PVDF membrane was washed three times 
(10 minutes per wash cycle) in 10 mL of 1 TBS-T and protein bands detected and 
evaluated. Visualisation and analysis of the protein bands was performed using 
the Li-cor Odyssey imaging systems and Image Studio Lite version 5.2 (Li-cor 
Biosciences). 
 
Table 2.7 Antibody dilutions used in this study 
Primary 
Antibody 
Primary 
Antibody 
Dilution  
Secondary Antibody  Secondary 
Antibody 
Dilution 
SOD1 1:500 Goat anti-rabbit IgG-HRP linked 1:500 
JNK 1:5000 Goat anti-rabbit IgG-HRP linked 1:1000 
p38 1:1000 Horse anti-mouse IgG-HRP linked 1:5000 
Bax 1:2000 Goat anti-rabbit IgG-HRP linked 1:5000 
Bcl-2 1:500 Horse anti-mouse IgG-HRP linked 1:2000 
p65 1:1000 Goat anti-rabbit IgG-HRP linked 1:4000 
β-actin 1:10000 Horse anti-mouse IgG-HRP linked 1:5000 
Abbreviations: JNK, c-Jun N-terminal kinases; SOD, superoxide dismutase 
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2.2.35 Statistical analysis 
The Graphpad Prism software version 7.0 was used for all statistical analysis. All 
participant test results were automatically calculated by the Beckman coulter AU 
analyser system and the Labcentre Laboratory Information Management System 
(LIMS). The data were first collected and entered into Microsoft Excel spreadsheet 
before being exported to Graphpad Prism software for analysis. All participant data 
were anonymously analysed. The data were presented as median and 
interquartile range (IQR) and significant differences were examined using the 
Wilcoxon signed rank tests for paired data and Mann-Whitney U test for unpaired 
data. Correlations between variables were determined using Spearman’s 
correlation coefficient. For changes in clinical biomarkers at different time points 
during 6 and 12 months of FF therapy in Group D and E participants, respectively, 
the Friedman test (a non-parametric alternative to repeated measures analysis of 
variance) with Dunn’s multiple comparison tests was used to analyse the data.  
Two-way ANOVA with Tukey’s multiple comparisons test was used to compare the 
impact of the different concentrations of FF and 5-FU on cell viability and to 
compare the IC50 of FF and 5-FU in the different cell lines, while the two-way 
ANOVA with Holm-Sidak’s multiple comparisons was used to compare the 
cytotoxicity of FF versus 5-FU in the different cell lines. Ordinary one-way ANOVA 
with Dunnett’s multiple comparisons test was used to compare the impact of the 
various concentrations of FF and 5-FF on cell viability versus control (untreated) 
cells, the impact of various concentrations of FF on intracellular ROS accumulation 
and the impact of FF on proteins involved in the various signalling pathways. 
Densitometry data was analysed using data obtained from the Li-Cor Odyssey 
Imaging Systems and the Image Studio Lite Version 5.2. The data were estimated 
as fold increase relative to loading control (ꞵ-actin).  
CKD was defined as eGFR < 60 mL/min/1.73 m2. The prevalence of CKD by 
stages calculated using the various eGFR equations was compared using the Chi-
squared test. Bias between eGFR equations was determined by the Bland-Altman 
analysis and presented as the absolute mean of the differences and SD around 
the mean. In all statistical data, p<0.05 was considered to be an indicator of 
statistical significance.   
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Chapter 3 
Effect of FF therapy on routine clinical biomarkers 
in patients with dyslipidaemia 
3.1 INTRODUCTION 
FF-associated creatininaemia (or inferred nephropathy) is a major side effect of FF 
(Attridge et al., 2013; Kim et al., 2017). Recent studies have demonstrated an 
increase in serum CREA concentration in patients receiving FF therapy. In a 
retrospective study involving patients without established CKD treated with fibrates 
(including FF), Tsimihodimos et al., (2001) showed that FF was associated with a 
significantly raised serum CREA and serum urea levels by 12% and 8% 
respectively. A recent report by Ncube et al., (2012) showed a significant increase 
in serum CREA (15.1%) and serum CYSC (9.9%) after patients with 
hyperlipidaemia were treated with FF at 267 mg/day for 3 months. The mechanism 
of the reversible increase in serum CREA is not fully understood, but kidney 
function monitoring has been recommended in patients receiving FF therapy. 
The effect of FF on liver function is not fully understood and reports from various 
studies have been contradictory. In a study with male F344/DuCrlCrlj (Fischer) rats 
administered a single dose of 400 mg/kg of FF, Kobayashi et al., (2009) reported 
slight increase in plasma transaminase activities directly related to the 
pharmacological action of the drug. They suggested that the increases were in 
parallel with increases in hepatic transaminase activities associated with increases 
in the transaminase genes in the liver and were not considered to be a 
consequence of hepatotoxicity from the drug. However, Fernandez-Miranda et al., 
(2008) reported improvement in liver function and metabolic syndrome; with 
minimal changes in liver histology after 16 patients with non-alcoholic fatty liver 
disease were administered 200 mg/day of FF for 48 weeks. It is recommended 
that regular monitoring of liver function be carried out during fibrate therapy and 
the drug discontinued if levels persisted above three times the upper limit of the 
normal reference range (Gandhi et al., 2014). 
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Reports show that inflammatory processes play a vital role in the pathogenesis of 
CVD, acute atherothrombotic events and atherosclerosis and occurrence of acute 
coronary syndromes (Belfort et al., 2010). High levels of CRP, which is a 
prototypic inflammatory marker, are associated with an increased risk for CVD 
(Belfort et al., 2010; Ye et al., 2011). Although the exact mechanism is unknown, 
many studies indicate that reducing CRP concentration leads to significant 
benefits with regards to future cardiovascular events (Ye et al., 2011). Studies 
have shown that FF individually or in combination with other drugs has an impact 
on serum CRP concentrations (Wi et al., 2010). However, results from FF trials 
have been inconsistent with some studies indicating a reduction (Muhlestein et al., 
2006; Kim, 2006; Wi et al., 2010), while others indicate no change or an increase 
in CRP (Fegan et al., 2005; Hogue et al., 2008). Ye et al., (2011) reported a 
significant decrease in CRP concentration in a meta-analysis that examined short-
term effects of FF.  
A similar finding was reported by Min et al., (2012) who showed a significant 
reduction in serum CRP concentration after FF therapy in hypertriglyceridaemic 
patients with high risks for CVD. However, Kim (2006) reported that FF 
administered at 200 mg/day, failed to reduce serum CRP levels in patients with 
hyperlipidaemia. Some explanations that have been made to explain this 
inconsistency in outcome include underpowered studies (with less than 50 patients 
per study), differences in dose and formulation of FF, variable lengths of follow up 
and the use of diverse participation pools (Ye et al., 2011). Therefore, the impact 
of FF therapy on serum concentration of CRP remains unclear. 
Several case studies have also linked FF therapy with rhabdomyolysis, a clinical 
and biochemical syndrome that results from skeletal muscle injury and subsequent 
release of muscle fibre cellular components, including myoglobin, creatine kinase, 
LDH, aldolase and AST, into the blood stream (Wu et al., 2009; Kato et al., 2011; 
Erdur et al., 2012; Wang and Wang, 2018). Risk factors of FF-associated 
rhabdomyolysis are not fully understood (Wu et al., 2009). Although only a few 
cases of rhabdomyolysis associated with FF alone or in combination with statins 
have been reported in patients with dyslipidaemia, patient monitoring is strongly 
recommended because rhabdomyolysis may be very severe with fatal 
consequences (Kato et al., 2011).  
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Reports on the effect of FF therapy on thyroid function are rare. Studies conducted 
to date have concentrated almost exclusively on cases of fibrate-induced 
rhabdomyolysis in patients with thyroid hypofunction (Satarasinghe et al., 2007; 
Krysiak et al., 2014). Dyslipidaemia is reported as a common metabolic 
abnormality in patients with hypothyroidism, either in its overt or subclinical form, 
and it appears that co-existing hypothyroidism predisposes individuals to the 
potentiation of muscle damage (Satarasinghe et al., 2007). The use of FF therapy 
for the treatment of dyslipidaemia in hypothyroidism has been linked with muscle 
damage and rhabdomyolysis, but it is not known whether FF treatment would 
cause hypothyroidism (Wang and Wang, 2018). Some case studies have 
recommended that all patients receiving FF and other hypolipidaemic drugs be 
screened for occult hypothyroidism which seems to aggravate the muscle damage 
due to the drugs, with or without other risk factors (Satarasinghe et al., 2007). 
The impact of FF therapy on routine clinical biomarkers in patients with 
dyslipidaemia has not been fully investigated. In this study, we examined the 
impact of FF therapy during a 12-month period on markers of kidney function, liver 
function, thyroid function, inflammatory marker (CRP) and markers of muscle 
damage (CK and LDH).  
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3.2 SPECIFIC AIMS 
The main aim of this chapter was to investigate the impact of FF administered at 
160 mg/day on routine clinical biomarkers in patients with dyslipidaemia. The 
specific aims were to examine the impact of FF on the following biomarkers: 
1. Markers of kidney function [CREA, urea, UA and electrolytes (Na and K)]. 
2. Markers of liver function (ALB, TBIL, ALT, ALP, GGT and AST). 
3. Lipid profile (CHOL, TRIG, HDL cholesterol, NHDL and CHRA)  
4. Inflammatory marker (CRP) and markers of muscle damage (CK and LDH). 
5. Thyroid function tests (TSH, FT4 and FT3). 
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3.3 RESULTS 
3.3.1 Impact of FF therapy on markers of kidney function 
In order to investigate the impact of FF on kidney function, changes in serum and 
urine markers of kidney function in the various groups of participants were 
examined. The concentrations of the biochemical parameters at various stages of 
treatment (e.g. 3, 6 and 12 months after commencing treatment) were compared 
with the baseline results. The criteria for defining the various conditions such as 
FF-associated creatininaemia (FAC), chronic renal failure (CRF), proteinuria, 
tubular pathology, glomerular proteinuria, prerenal disease and intrinsic renal 
disease or acute tubular necrosis are shown in Table 3.1.  
Table 3.1 Criteria for defining the various conditions of kidney function 
Description Criteria 
FAC  ≥ 20% increase in serum creatinine 
from baseline 
CRF  eGFR < 60mL/min/1.73 m2 
Proteinuria UACR > 3 mg/mol  
PCR > 15 mg/mol 
Tubular pathology UAPR < 0.4 together with proteinuria 
Glomerular proteinuria UAPR > 0.4 
 
Prerenal disease 
FENA < 1% 
FEUR < 35% 
FEUA < 10% 
 
Intrinsic renal disease or ATN 
FENA > 2% 
FEUR > 50% 
FEUA > 10% 
Prerenal or intrinsic renal disease FENA > 1% and < 2%, 
FEUR > 35% and < 50% 
Abbreviations: FENA, fractional excretion of sodium; FEUR, fractional excretion of Urea; 
FEUA, fractional excretion of uric acid; UAPR, urine albumin-protein ratio; PCR, protein-
creatinine ratio; UACR, urine albumin-creatinine ratio; eGFR, estimated glomerular 
filtration rate; ATN, acute tubular necrosis. 
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3.3.1.1 Impact of 3 months of FF therapy on kidney function tests  
The impact of 3 months of FF (160 mg/day) therapy on serum markers of kidney 
function in Group A participants is summarised in Table 3.2. The median serum 
CREA concentration increased significantly by 11.5% from baseline (p=0.0016, 
n=13). Individual participant results (Figure 3.1A) also showed an increase in 
serum CREA concentration in 11 participants (84.6%, n=13). Three of the 
participants in this group (23.1%) had FAC (serum CREA ≥ 20 µmol/L), although 
the change in their serum CREA concentration was not considered clinically 
significant. A 26% increase in median serum urea concentration was observed, 
although this was not statistically significant (p=0.3359, n=13). Individual 
participant results showed that serum urea concentration was increased in seven 
participants (53.8%, n=13). However, in five participants (38.5%, n=13), a 
decrease in serum urea level was also observed (Figure 3.1B). A small but 
statistically significant reduction in median serum Na concentration was observed 
(p=0.0010, n=13), although the change in median serum K concentration was not 
statistically significant (p=0.8441, n=13). Individual participant results showed a 
decrease in serum Na level in 11 participants (84.6%, n=13) (Figure 3.1C). Also, 
the median serum UA concentration was decreased significantly after 3 months of 
FF therapy (p=0.0002, n=13). Individual participant results showed a decrease in 
serum UA concentration in all the participants in this group (Figure 3.1D).  
The results also showed a significant reduction in median eGFR estimated using 
both the MDRD (p=0.0039, n=13) and CKD-EPI CREA equations (p=0.0229, 
n=13). Individual results showed a decrease in eGFR level in 10 participants (77%, 
n=13) with both equations (Figure 3.1E and Figure 3.1F). With the MDRD 
equation, two of the participants (15.4%, n=13) had baseline CRF (i.e. GFR<60 
mL/min/1.73 m2), while four of the participants (30.8%, n=13) had CRF after 3 
months of FF therapy. However, with the CKD-EPI CREA equation, only one of 
the participants (7.7%, n=13) had CRF at baseline while four participants (30.8%, 
n=13) had CRF after 3 months of FF therapy. The change in eGFR in these 
participants was not considered to be clinically significant as none of them 
required any change in treatment plan. 
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Table 3.2 Changes in serum markers of kidney function after 3 months of FF 
therapy in Group A participants 
Parameters Baseline 3 Months p value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
Serum CREA (µmol/L) 87 (70 – 101) 97 (72 – 121) 0.0015*** 
Serum Urea (mmol/L) 5.0 (3.9 – 6.1) 6.3 (3.9 – 6.9) 0.2358 
Serum Na (mmol/L)  141 (139 – 143) 139 (137 – 140) 0.0010*** 
Serum K (mmol/L) 4.4 (4.0 – 4.6) 4.5 (4.3 – 4.5) 0.8441 
Serum UA (µmol/L) 363 (333 – 486) 305 (240 – 348) 0.0002*** 
MDRD (mL/min/1.73 m2) 78 (67 – 87) 73 (55 – 77) 0.0039** 
CKD-EPI CREA (2009) 
(mL/min/1.73 m2) 
84 (68 – 98) 81 (59 – 87) 0.0229* 
Data are presented as median (IQR). IQR: interquartile range; CREA; creatinine, K, 
potassium; Na, sodium; UA, uric acid; MDRD: Modification of Diet in Renal Disease; CKD-
EPI CREA: Chronic Kidney Disease Epidemiology Collaboration creatinine equation 
(2009). Significant difference between the median concentrations at baseline and after 3 
months of FF therapy was determined using the Wilcoxon signed-rank test. *P < 0.05, **P 
< 0.01 and ***P < 0.001 vs baseline value. 
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Figure 3.1 Effect of 3 months of FF therapy on serum markers of kidney 
function in Group A Participants.  
Scatter plots showing serum concentrations of (A) serum CREA, (B) serum urea, (C) 
serum Na, (D) serum UA, (E) MDRD, (F) CKD-EPI CREA at baseline and after 3 months 
of FF therapy in individual participants in Group A; CREA, creatinine; Na, sodium, UA, uric 
acid; MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney 
Disease Epidemiology Collaboration creatinine (2009) equation. Significant difference 
between the median concentrations at baseline and after 3 months of FF therapy was 
determined using the Wilcoxon signed-rank test; p<0.05 was considered statistically 
significant (n=13). 
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The impact of 3 months of FF therapy on urine markers of kidney function is 
summarised in Table 3.3. The results showed significant reduction in median urine 
CREA concentration from 14 mmol/L (IQR 12 – 23 mmol/L) at baseline to 12 
mmol/L (IQR 9.5 – 20 mmol/L) after 3 months of FF therapy (p=0.0325, n=13). 
Figure 3.2A showed that urine CREA concentration was reduced in 12 
participants (92.3%, n=13) after 3 months of FF treatment. The median urine K 
concentration was also reduced significantly from baseline values (p=0.0105, 
n=13). Individual participant results showed a decrease in urine K concentration in 
11 participants (84.6%, n=13) (Figure 3.2B). The median urine urea and urine Na 
did not change significantly. Also, there was no significant change in urine ALB, 
urine protein and urine UA, hence no significant changes in UACR, UPCR and 
UAPR as shown in Table 3.3. In all the participants urine protein was normal (i.e. 
UACR < 3 mg/mmol and/or UPCR < 15 mg/mmol). 
The median UUACR was reduced significantly by 30.4% from the baseline level 
after 3 months of FF treatment (p<0.0001, n=13). Results from individual 
participants showed that UUACR was reduced in all the participants (Figure 
3.2C). A significant increase in FENA (Figure 3.2D, p=0.0459, n=13), FEUR 
(Figure 3.2E, p=0.0118, n=13) and FEUA (Figure 3.2F, p=0.0061, n=13) was also 
observed, suggesting increased excretion of Na, urea and UA. However, all the 
participants had FENA < 1% and FEUR < 50%, which suggests that any change in 
the kidney function was most likely due to prerenal causes rather than from an 
intrinsic kidney disease. One of the participants in this group had FEUA > 10% 
after 3 months of FF, which may be attributed to the increase in renal UA 
clearance associated with the uricosuric effect of FF therapy, a phenomenon 
which has been widely reported (Uetake et al., 2010).  
The results from Group A participants suggest that administration of FF at 160 
mg/day for 3 months would cause a moderate increase in serum CREA and urea 
and moderate reduction in kidney function. The results also suggest that treatment 
with FF at 160 mg/day for 3 months would significantly decrease serum UA level 
through increased excretion. The reduction in UA may be beneficial in patients 
with gout (hyperuricaemia). 
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Table 3.3 Effect of 3 months of FF treatment on urine markers of kidney 
function. 
Parameters Baseline  3 Months p value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
Urine CREA (mmol/L) 14 (12 – 23) 12 (10 – 20) 0.0105* 
Urine Urea (mmol/L) 313 (236 – 377) 298 (218 – 391) 0.3757 
Urine UA (mmol/L) 2.7 (1.7 – 3.5) 2.2 (1.3 – 3.0) 0.3396 
Urine Na (mmol/L) 113 (87 – 126) 117 (80 – 147) 0.7737 
Urine K (mmol/L) 105 (70 – 133) 73 (46 – 94) 0.0105* 
Urine ALB (mmol/L) 2.3 (1.4 – 8.9) 3.2 (1.0 – 7.2) 0.4746 
Urine Protein (g/L) 0.10 (0.07 – 0.23) 0.07 (0.07 – 0.16) 0.0718 
UACR (mg/mmol) 0.12 (0.09 – 0.51) 0.19 (0.07 – 0.62) 0.5293 
UPCR (mg/mmol) 8.0 (4.5 – 9.0) 7.0 (6.0 – 9.0) 0.8662 
UAPR  0.03 (0.01 – 0.06) 0.03 (0.01 – 0.06) 0.7971 
UUACR (mmol/mmol) 4.6 (4.0 – 5.9) 3.2  (2.7 – 3.8) 0.0002*** 
FENA (%) 0.39 (0.25 – 0.48) 0.60 (0.37 – 0.72) 0.0459* 
FEUR (%) 33 (24 – 38) 36 (33 – 46) 0.0103* 
FEUA (%) 2.7 (2.3 – 6.0) 6.5 (4.2 – 7.7) 0.0061** 
 
 
 
  
Data are presented as median (IQR). IQR: interquartile range; CREA, creatinine; Na, 
sodium; K, potassium; ALB, albumin; UACR: urine albumin-creatinine ratio; UPCR: urine 
protein-creatinine ratio; UAPR: urine albumin-protein ratio; UUACR: urine uric acid-
creatinine ratio; FENA: fractional excretion of sodium; FEUR: fractional excretion of Urea, 
FEUA: fractional excretion of uric acid. Statistical significant difference between the 
median concentrations at baseline and after 3 months of FF therapy was determined using 
the Wilcoxon signed-rank test. *P<0.05, **P<0.01 and ***p<0.001 vs baseline value. 
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Figure 3.2 Effect of 3 months of FF therapy on urine markers of kidney 
function.  
Scatter plots showing levels of (A) urine CREA, (B) urine Potassium, (C) UUACR, (D) 
FENA, (E) FEUR and (F) FEUA at baseline and after 3 months of FF therapy in individual 
participants in Group A. CREA, creatinine; UUACR, urine uric acid creatinine ratio; FENA, 
fractional excretion of sodium; FEUR, fractional excretion of urea; FEUA, fractional 
excretion of uric acid. Statistical significant difference between the median concentrations 
at baseline and after 3 months of FF therapy was determined using the Wilcoxon signed-
rank test. P<0.05 was considered statistically significant (n=13). 
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3.3.1.2 Impact of 6 months of FF therapy on kidney function tests in Group B 
participants  
Changes in the markers of kidney function after 6 months of FF therapy were 
examined in Group B participants. This Group consisted of 10 patients (7 male 
and 3 female) between 37 and 63 years of age, who had provided study samples 
before and after 6 months of FF (160 mg/day therapy). Changes in serum markers 
of kidney function in Group B participants are summarised in Table 3.4. The 
median serum CREA concentration increased by 9.1% from baseline, although 
this was not statistically significant (p=0.1934, n=10). Individual participant results 
showed that serum CREA concentration was increased in eight participants (80%, 
n=10) (Figure 3.3A). None of the participants had FAC after 6 months of FF 
therapy. A significant increase in median serum urea concentration from 5.4 
mmol/L (IQR 4.1 – 6.0 mmol/L) at baseline to 6.3 mmol/L (IQR 4.5 -7.0 mmol/L) 
was observed (p=0.0316, n=10). Individual participant results also showed that 
serum urea level was increased in eight participants (80%, n=10) (Figure 3.3B). A 
concomitant increase in serum CREA and serum urea concentrations was 
observed in six participants (60%, n=10) after 6 months of FF therapy.  
The changes in median serum Na and serum K were not statistically significant. 
Median serum UA concentration was reduced significantly by 12.9% (p=0.0059, 
n=10), compared with the baseline values. Figure 3.3C showed that serum UA 
level was reduced in nine participants (90%, n=10). There was no significant 
change in median MDRD and CKD-EPI CREA (p=0.2031 and p=0.5332, 
respectively), although both equations showed a slight reduction in eGFR after 6 
months of FF. Individual participant results showed that the eGFR was reduced in 
seven participants (70%, n=10), when eGFR was calculated using both formulas 
(Figure 3.3D-E). It was also observed that in one of the participants who had CRF 
at baseline, their kidney function was improved (i.e. eGFR≥60 mL/min/1.73 m2) 
after 6 months of treatment with FF, while one other patient developed a CRF after 
6 months of therapy. However, the change in their kidney function was not 
considered to be clinically significant as they did not require any change in 
treatment plan.  
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Table 3.4 Effect of 6 months of FF therapy on serum markers of kidney 
function. 
Parameters Baseline 6 Months p value 
Number of participants 10 10  
Age [Years; median 
(range)] 
51 (37 – 63) 51 (37 – 63)  
Serum CREA (µmol/L) 88 (71 – 98) 96 (76 – 108) 0.1934 
Serum Urea (mmol/L) 5.4 (4.1 – 6.0) 6.3 (4.5 – 7.0) 0.0273* 
Serum Na (mmol/L)  141 (139 – 143) 140 (138 – 141) 0.0508 
Serum K (mmol/L) 4.6 (4.2 – 4.8) 4.4 (4.3 – 4.8) 0.7785 
Serum UA (µmol/L) 373 (335 – 463) 325 (273 – 386) 0.0059** 
MDRD (mL/min/1.73 m2) 75 (68 – 85) 70 (61 – 80) 0.2031 
CKD-EPI CREA (2009) 
(mL/min/1.73 m2) 
81 (71 - 97) 79 (66 – 91) 0.5332 
 
 
 
 
 
 
Data are presented as median (IQR). IQR: interquartile range; CREA; creatinine, K, 
potassium; Na, sodium; UA, uric acid; MDRD: Modification of Diet in Renal Disease; 
CKD-EPI CREA: Chronic Kidney Disease Epidemiology Collaboration creatinine (2009) 
equation. Statistical significant difference between the median concentrations at 
baseline and after 6 months of FF therapy was determined using the Wilcoxon signed-
rank test. *p<0.05, **p<0.01 and ***p<0.001 vs baseline value (n=10). 
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Figure 3.3 Effect of 6 months of FF therapy on serum markers of kidney 
function.  
Scatter plots showing serum concentrations of (A) serum CREA, (B) serum urea, (C) 
serum UA (D) MDRD, (E) CKD-EPI CREA at baseline and after 6 months of FF therapy in 
individual study participants in Group B; CREA: creatinine; UA: uric acid; MDRD: 
Modification of Diet in Renal Disease; CKD-EPI CREA: Chronic Kidney Disease 
Epidemiology Collaboration creatinine (2009) equation. Statistical significant difference 
between the median concentrations at baseline and after 6 months of FF therapy were 
analysed using the Wilcoxon signed-rank test. P< 0.05 was considered as statistically 
significant (n=10). 
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The impact of 6 months of FF therapy on urine markers of kidney function is 
summarised in Table 3.5. Nine participants in this group provided urine sample at 
baseline and after 6 months of FF therapy. The median UPCR and UUACR were 
significantly reduced (p=0.0469 and p=0.0078, respectively), while the median 
FEUA was significantly increased (p=0.0195, n=9) after 6 months of FF therapy. 
Changes in all the other urine markers of kidney function were not statistically 
significant. Although the change in median urine K and UACR were not statistically 
significant, the median urine K and UACR were reduced by 34.2% and 42.9%, 
respectively. Individual participant results are shown in Figure 3.4. Urine protein 
and UACR levels were each reduced in six participants (66.7%, n=9), while urine 
K and UPCR levels were reduced in seven participants (77.8%, n=9). The greatest 
impact in terms of number of participants affected was on the level UUACR, which 
was reduced in eight of the nine participants (88.9%). The FEUA was seen to 
increase in seven participants (77.8%, n=9). The greatest change in the levels of 
UPCR and FEUA was observed in participant with the higher baseline values. It 
was also observed that FEUA was not increased in participants with baseline 
values less than 2%. All the participants also had a FENA < 1%, and FEUR < 
50%, which suggest that any changes in the kidney function were due to pre-renal 
conditions. 
These results suggest that administering FF at 160 mg/day for 6 months would 
cause moderate concomitant increase in serum CREA and urea and a significant 
reduction in serum UA concentrations. However, the impact on eGFR estimated 
using the MDRD and CKD-EPI CREA equations was not significant. The results 
also suggest that the decrease in serum UA was as a result of increased excretion 
as shown by the increase in FEUA. Furthermore, the decrease in serum UA level 
induced by FF therapy was not related to changes in the kidney function as serum 
UA levels in this group of participants were significantly reduced even though the 
change in serum CREA was not significant. 
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Table 3.5 Effect of 6 months of FF therapy on urine markers of kidney 
function in Group B participants 
Parameters Baseline 6 Months p value 
Number of participants 9 9  
Age [Years; median 
(range)] 
51 (37 – 63) 51 (37 – 63)  
Urine CREA (mmol/L) 14 (12 – 25) 15 (11 – 20) 0.4258 
Urine Urea (mmol/L) 311 (236 – 400) 330 (288 – 371) 0.8203 
Urine UA (mmol/L) 2.5 (1.5 – 3.1) 2.0 (1.1 – 3.1) 0.4961 
Urine Na (mmol/L) 118 (74 – 126) 110 (63 – 130) 0.8203 
Urine K (mmol/L) 114 (73 – 159) 75 (61 – 106) 0.0547 
Urine ALB (mmol/L) 2.3 (1.3 – 7.6) 2.3 (0.1 - 8.8) 0.2734 
Urine Protein (g/L) 0.10 (0.06 – 0.27) 0.08 (0.05 – 0.15) 0.1328 
UACR (mg/mmol) 0.28 (0.06 – 0.49) 0.16 (0.01- 0.52) 0.3906 
UPCR (mg/mmol) 8.0 (5.5 – 9.0) 6.0 (4.5 – 8.0) 0.0469* 
UAPR 0.03 (0.01 – 0.06) 0.03(0.00 – 0.06) 0.8711 
UUACR (mmol/mmol) 4.6 (4.0 – 5.9) 2.9 (2.6 – 4.9) 0.0078** 
FENA (%) 0.40 (0.24 – 0.51) 0.43 (0.32 – 0.70) 0.1719 
FEUR (%) 33 (24 – 40) 38 (27 – 48) 0.3555 
FEUA (%) 2.5 (1.8 – 4.8) 5.1 (2.0 – 8.8) 0.0195* 
 
 
 
Data are presented as median (IQR). IQR: interquartile range; UACR: urine albumin-
creatinine ratio; UPCR: urine protein-creatinine ratio; UAPR: urine albumin-protein ratio; 
UUACR: urine uric acid-creatinine ratio; FENA: fractional excretion of sodium; FEUR: 
fractional excretion of Urea, FEUA: fractional excretion of uric acid. Statistical significant 
difference between the median concentrations at baseline and after 6 months of FF 
therapy were analysed using the Wilcoxon signed-rank test. *P < 0.05 and **P < 0.01 vs 
baseline value. 
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Figure 3.4 Effect of 6 months of FF therapy on urine markers of kidney 
function.  
Scatter plots showing (A) Urine Protein (g/L), UACR (mg/mmol), (C) urine K (mmol/L), (D) 
UPCR (mg/mmol), (E) UUACR (mmol/mmol) and (F) FENA (%) at baseline and after 6 
months of FF therapy in individual participants in Group B; UACR, urine albumin-
creatinine ratio; UPCR, urine protein-creatinine ratio; UUACR, urine uric acid-creatinine 
ratio; FENA, fractional excretion of sodium. Statistical significant difference between 
median concentrations at baseline and after 6 months of FF therapy was analysed using 
the Wilcoxon signed-rank test, p values <0.05 were considered significant (n=9). 
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3.3.1.3 Impact of 12 months of FF therapy on kidney function tests  
Changes in serum markers of kidney function after 12 months of FF therapy in 
Group C participants are presented in Table 3.6. The results showed that after 12 
months of FF therapy, there was no significant change in all the serum markers of 
kidney function, except in the eGFR calculated using the CKD-EPI CREA equation 
which indicated that kidney function was significantly reduced after 12 months of 
FF therapy (p=0.0391, n=8). However, both the median serum CREA and urea 
concentrations were increased by 11.8% from baseline (p=0.0703 and p=0.2500, 
respectively), while median serum UA was reduced by 9.7% (p=0.0781).  
Results from individual participants showed that serum CREA concentration was 
increased in six participants (75%, n=8) (Figure 3.5A). Two of the participants 
(25%, n=8) developed FAC after 12 months of treatment. In both cases, baseline 
serum CREA concentration was relatively higher than in all other participants. 
Serum urea concentration was also increased in six participants (75%, n=8) 
(Figure 3.5B), while in seven participants (87.5%, n=8), the serum UA level was 
reduced Figure 3.5C). The eGFR estimated using the MDRD and CKD-EPI 
equations showed that kidney function was reduced in six of the participants (75%, 
n=8) (Figure 3.5D and Figure 3.5E). Results from both equations showed that two 
participants (25%, n=8) developed CRF after 12 months of FF therapy. All the 
changes in serum markers of kidney function were not clinically significant. 
Changes in the urine markers of kidney function following 12 months of FF therapy 
are shown in Table 3.7 and Figure 3.6. The results showed a significant increase 
in FENA (Figure 3.6A; p=0.0156, n=8) and FEUA (Figure 3.6B; p=0.0234, n=8), 
indicative of an increase in the excretion of Na and UA, respectively. FEUR was 
also increased in six of the participants (75%, n=8) (Figure 3.6C, p=0.0625, n=8). 
Changes in all other urine markers were not statistically significant.  
These results suggest that 12 months of FF therapy administered at 160 mg/day 
would cause a moderate but non-significant increase in serum CREA and urea 
and a mild reduction in kidney function, estimated by the MDRD and CKD-EPI 
CREA equations. Twelve months of FF would also cause a moderate reduction in 
serum UA concentration due to increased excretion as indicated by the increase in 
FEUA. 
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Table 3.6 Effect of 12 months of FF therapy on serum markers of kidney 
function in Group C participants 
Parameters Baseline 12 Months p value 
Number of participants 8 8  
Age [Years; median (range) 53 (40 – 65) 53 (40 – 65)  
Serum CREA (µmol/L) 85 (61 – 98) 95 (59 – 119) 0.0703 
Serum Urea (mmol/L) 5.1 (3.8 – 7.2) 5.7 (3.7 – 7.7) 0.2500 
Serum Na (mmol/L) 139 (139 – 141) 138 (137 – 140) 0.0703 
Serum K (mmol/L) 4.1 (4.0 – 4.6) 4.3 (4.1 – 4.6) 0.7653 
Serum UA (µmol/L) 351 (326 – 425) 317 (286 – 365) 0.0781 
MDRD (mL/min/1.73 m2) 82 (68 – 91) 73 (55 – 94) 0.1484 
CKD-EPI CREA (2009) 
(mL/min/1.73 m2) 
91 (72 – 100) 80 (59 – 100) 0.0391* 
 
 
 
 
 
 
Data are presented as median (IQR); CREA, creatinine; UA, uric acid; IQR, interquartile 
range; MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney 
Disease Epidemiology Collaboration creatinine equation. Statistical significant difference 
between median concentrations at baseline and after 6 months was analysed using the 
Wilcoxon signed-rank test.  *p<0.05 
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Figure 3.5 Effect of 12 months of FF therapy on serum markers of kidney 
function in Group C participants.  
Scatter plots showing (A) Serum CREA, (B) Serum Urea and (C) Serum UA 
concentrations at baseline and after 12 months of FF therapy in individual study 
participants in Group C; CREA, serum creatinine; UA, serum uric acid; FF, fenofibrate. 
MDRD: Modification of Diet in Renal Disease; CKD-EPI CREA: Chronic Kidney Disease 
Epidemiology Collaboration creatinine (2009) equation. Statistical significant difference 
between the median concentrations at baseline and after 12 months of FF therapy was 
analysed using the Wilcoxon signed-rank test. P<0.05 was considered statistically 
significant (n=8). 
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Table 3.7 Effect of 12 months of FF treatment on urine markers of kidney 
function in Group C participants 
Parameters Baseline 12 Months p value 
Number of participants 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
Urine CREA (mmol/L) 13 (12 – 24) 10 (8.2 – 13) 0.0547 
Urine Urea (mmol/L) 325 (220 – 385) 264 (194 – 383) 0.4609 
Urine UA (mmol/L) 2.3 (1.9 – 3.3) 2.1 (1.1 – 3.2) 0.6474 
Urine Na (mmol/L) 88 (60 – 121) 105 (59 – 139) 0.4609 
Urine K (mmol/L) 70 (63 – 125) 59 (41 – 73) 0.1094 
Urine ALB (mmol/L) 5.3 (2.2 – 17) 2.4 (0.3 – 3.5) 0.1484 
Urine Protein (g/L) 0.10 (0.05 – 0.24) 0.08 (0.03 – 0.10) 0.0781 
UACR (mg/mmol) 0.44 (0.15 – 0.59) 0.21 (0.05 – 0.36) 0.3438 
UPCR (mg/mmol) 8.0 (4.8 – 9.0) 8.0 (6.0 – 8.8) 0.5938 
UAPR 0.06 (0.03 – 0.11) 0.03 (0.01 – 0.06) 0.2183 
UUACR (mmol/mmol) 4.5 (3.9 – 5.4) 3.5 (2.6 -5.2) 0.3828 
FENA (%) 0.34 (0.24 – 0.43) 0.59 (0.42 – 0.85) 0.0156* 
FEUR (%) 36 (25 – 40)  45 (40 – 49) 0.0625 
FEUA (%) 2.8 (2.4 – 6.0) 6.1 (5.6 – 8.5) 0.0234* 
 
 
 
 
 
Data are presented as median (IQR). IQR: interquartile range; UACR: urine albumin-
creatinine ratio; UPCR: urine protein-creatinine ratio; UAPR: urine albumin-protein ratio; 
UUACR: urine uric acid-creatinine ratio; FENA: fractional excretion of sodium; FEUR: 
fractional excretion of Urea, FEUA: fractional excretion of uric acid. Statistical 
significant difference between the median concentrations at baseline and 6 months was 
analysed using the Wilcoxon signed-rank test. *P<0.05 vs baseline value. 
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Figure 3.6 Effect of 12 months of FF therapy on urine markers of kidney 
function in Group C participants.  
Scatter plots showing (A) FENA (%), (B) FEUA (%) (C) FEUR (%) levels at baseline (0) 
and after 12 months in individual participants in Group C; FENA, fractional excretion of 
sodium; FEUR, fractional excretion of urea; FEUA, fractional excretion of uric acid. 
Statistical significant difference between the median concentrations was analysed using 
the Wilcoxon signed-rank test; p<0.05 were considered significant (n=8). 
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3.3.1.4 Changes in markers of kidney function during 6 months of FF therapy  
Changes in kidney function parameters during a period of six months of FF 
therapy were examined in nine participants (6 male and 3 female) who had 
provided samples at three visits (i.e. baseline, 3 months and 6 months). Results of 
the changes in serum markers of kidney function are presented in Table 3.8, while 
changes in individual participants are shown in Figure 3.7. A significant increase 
in median serum CREA concentration was observed after 3 months (p=0.0423, 
n=9) but after 6 months of FF treatment, the median serum CREA level was not 
significantly different from the baseline value (p=0.5846, n=9). The Friedman’s test 
showed that the difference between the median serum CREA concentrations at 
the different time points was statistically significant (p=0.0266). The difference 
between the median serum Na and serum UA concentration at different time 
points was also statistically significant (p=0.066 and p=0.0029, respectively). Post 
hoc analysis using the Dunn’s test showed a small but statistically significant 
reduction in median serum Na concentration after 3 months of FF therapy 
(p=0.0096), but after 6 months of treatment, the median serum Na level was not 
significantly different from the baseline values.  
The median serum UA was also reduced significantly after 3 months of FF 
treatment (p=0.0065). However, after 6 months of treatment, the median UA had 
increased by 12.5% from the 3-month value, but remained significantly lower than 
the baseline concentration (p=0.0286). The changes in the median serum urea, K 
and eGFR calculated using the MDRD and CKD-EPI CREA equations were not 
statistically significant. However, a moderate reduction in the median eGFR 
estimated using both MDRD and CKD-EPI CREA equations was observed after 3 
months, but the levels did not change significantly after six months of FF treatment 
as the values were similar to those obtained after 3 months of FF therapy.  
Individual participant results showed that in eight participants (88.9%, n=9), serum 
CREA concentration was increased after the first 3 months of FF therapy and then 
slightly reduced after 6 months of the treatment, but remained higher than the 
baseline values (Figure 3.7A). On the other hand, the serum Na concentration 
was reduced in all the participants after 3 months of treatment and then increased 
slightly after the following 3 months (Figure 3.7B). Also, serum UA was reduced in 
eight participants (88.9%, n=9) during the first 3 months of treatment, but was 
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slightly increased in five participants (55.6%, n=9) and continued to decrease in 
four participants (44.4%, n=9) after 6 months of FF therapy (Figure 3.7C). It was 
observed that eGFR calculated by the MDRD and CKD-EPI CREA equations, was 
reduced during the first 3 months and then slightly increased after 6 months in the 
majority (66.7%, n=9) of the participants, although in most cases the 6-month 
value was lower than baseline values (Figure 3.7D&E).  
Changes in urine markers of kidney function at the different points during 6 months 
of FF therapy are shown in Table 3.8 and Figure 3.8. All the urine parameters 
were within acceptable reference ranges. The Friedman test revealed that the 
changes in median urine CREA concentration (p=0.0303), UAPR (p=0.0388), 
UUACR (p=0.0048) and FENA (p=0.0303) were statistically significant. Post Hoc 
analysis showed that urine CREA concentration and FENA were significantly 
increased after 3 months of FF therapy (Figure 3.8A, P=0.0373 and Figure 3.8D, 
p=0.0373, respectively). However, after 6 months of treatment, both parameters 
were slightly reduced although the levels after 6 months of treatment were higher 
than the baseline values. Similarly, the median UAPR was increased during the 
first 3 months of FF therapy but after 6 months, a small decrease (20%, p=0.2404) 
was observed and the value after 6 months of treatment was also higher than the 
baseline value (Figure 3.8B). On the other hand, the median UUACR was 
significantly decreased after the initial 3 months of treatment (p=0.0081), but a 
small increase (12.9%), compared with 3-month value, was observed after 6 
months of continuous FF therapy (Figure 3.8C). The median UUACR after 6 
months was lower than the baseline values. The changes in all the other urine 
markers were not statistically significant. 
Collectively, these results suggest that the impact of FF on kidney function is 
reversible. The impact appears to be greatest during the first 3 months of 
treatment than during the later stages of treatment. The results also showed that 
urine CREA was reduced as serum CREA was increased, which suggests that 
FAC maybe associated to decreased excretion of CREA. Furthermore, the results 
from this study showed that FF therapy is associated with increased excretion of 
Na and UA as evidenced by the increase in FENA and FEUA.  
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Data are presented as median (IQR); CREA, creatinine; Na, sodium; K, potassium; UA, uric acid; MDRD, Modification of Diet in Renal 
Disease; CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration creatinine (2009) equation; significant difference between 
median concentration at the different time points was analysed using the Friedman test with Dunn’s multiple comparison test; ¹significantly 
different from baseline (p<0.05), ²significantly different from baseline (p<0.01), *statistically significant difference between group medians at 
the different time points *p<0.05, **p<0.01. 
Parameters Baseline 3 Months 6 Months P value 
Number of participants 9 9 9  
Age [years; median (range)] 50 (42 – 55) 50 (42 – 55) 50 (42 – 55)  
Serum CREA (µmol/L) 87 (70 – 96) 97 (71 – 121)¹ 94 (73 – 107) 0.0266* 
Serum Urea (mmol/L) 5.8 (4.2 – 6.1) 5.9 (3.9 – 6.9) 6.2 (4.4 – 7.2) 0.0542 
Serum Na (mmol/L) 141 (140 – 143) 139 (139 – 140)² 140 (139 – 142) 0.0066** 
Serum K (mmol/L) 4.6 (4.1 – 4.7) 4.4 (4.3 – 4.7) 4.3 (4.3 – 5.0) 0.9414 
Serum UA (µmol/L) 360 (333 – 471) 305 (221 – 336)² 343 (258 – 386)¹ 0.0029** 
MDRD (mL/min/1.73 m2) 78 (69 – 85) 73 (55 – 78) 70 (63 – 81) 0.1966 
CKD-EPI CREA (2009) (mL/min/1.73 m2) 84 (70 – 97) 81 (59 – 89) 81 (68 – 92) 0.1966 
Table 3.8 Changes in serum markers of kidney function during 6 months of FF therapy in Group D participants 
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Figure 3.7 Changes in serum markers of kidney function during 6 months of FF 
therapy.  
Scatter plots showing (A) serum CREA, (B) serum Na and (C) serum UA in individual 
participants at baseline (0), 3 and 6 months after commencing FF treatment in individual 
participants in Group D. CREA, creatinine; Na, sodium; UA, uric acid; MDRD, Modification of 
Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration 
creatinine equation (2009); statistical significant difference between median concentrations at 
different time points was analysed using the Friedman test with Dunn’s multiple comparison 
test; *p<0.05; **p<0.01 (n=9). 
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Table 3.9 Changes in urine markers of kidney function during six months of FF treatment in Group D participants 
Parameter Baseline 3 months 6 months P value 
Number of participants 8 8 8  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63) 51 (37 – 63)  
Urine CREA (mmol/L) 16 (13 – 26) 12 (11 – 18)¹ 16 (11 – 20) 0.0303* 
Urine Urea (mmol/L) 329 (283 – 403) 295 (188 – 337) 342 (315 – 373) 0.1197 
Urine Na (mmol/L) 121 (87 – 126) 139 (83 – 152) 112 (73 – 133) 0.2851 
Urine K (mmol/L) 122 (85 – 171) 74 (70 – 110) 84 (63 – 107) 0.1197 
Urine UA (mmol/L) 2.5 (1.3 – 3.3) 1.8 (1.3 – 2.3) 2.2 (1.0 – 3.2) 0.5306 
Urine ALB (mg/L) 3.5 (0.9 – 8.4) 3.6 (1.3 – 7.9) 4.3 (0.1 – 9.7) 0.4861 
Urine Protein (g/L) 0.14 (0.06 – 0.27) 0.07 (0.06 – 0.13)¹ 0.10 (0.07 – 0.16) 0.1083 
UACR (mg/mmol) 0.25 (0.04 – 0.50) 0.30 (0.09 -0.66) 0.27 (0.01 – 0.52) 0.0515 
UPCR (mg/mmol) 8 (5 -9) 6 (6 – 9) 7 (4 – 8) 0.0791 
UAPR 0.02(0.01 – 0.06) 0.05 (0.02 – 0.07) 0.04 (0.00 – 0.06) 0.0388* 
UUACR (mmol/mmol) 4.7 (4.1 – 5.9) 3.1 (2.7 – 4.0)³ 3.5 (2.6 – 5.2)² 0.0048** 
FENA (%) 0.34 (0.23 – 0.49) 0.64 (0.37 – 0.80) 0.43 (0.30 – 0.59) 0.0303* 
FEUR (%) 32 (23 – 39) 36 (30 – 43) 36 (27 – 45) 0.3553 
FEUA (%) 2.5 (1.5 – 3.3) 4.3 (3.4 – 6.5) 4.3 (1.4 – 5.9) 0.1495 
Data are presented as median (IQR); CREA, creatinine; Na, sodium; K, potassium; UA, uric acid; ALB, albumin; UACR, urine albumin-
creatinine ratio; UPCR, urine protein-creatinine ratio; UAPR, urine albumin-protein ratio; UUACR, urine uric acid-creatinine ratio; FENA, 
fractional excretion of sodium; FEUR, fractional excretion of urea; FEUA, fractional excretion of uric acid. Significant difference between 
median concentration at the different time points was analysed using the Friedman test with Dunn’s multiple comparison test; ¹significantly 
different from baseline (p<0.05); ²significantly different from baseline (p<0.01); ³significantly different from baseline (p<0.001); *significant 
difference between group medians; *p<0.05, **p<0.01.   
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Figure 3.8 Changes in urine markers of kidney function during 6 months of FF 
therapy.  
Scatter plots showing levels of (A) urine CREA, (B) UAPR (C) UUACR and (D) FENA at 
baseline (0), 3 and 6 months after commencing treatment in individual participants in Group 
D. FF, fenofibrate; CREA, creatinine; UAPR, urine albumin-protein ratio; UUACR, urine uric 
acid-creatinine ratio; FENA, fractional excretion of sodium; significant difference between 
median concentrations at the different time points was analysed using the Friedman test with 
Dunn’s multiple comparison test; *p<0.05, **p<0.01, (n=8). 
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3.3.1.5 Changes in markers of kidney function during 12 months of FF therapy  
In this section, changes in serum and urine markers of kidney function were 
examined in four study participants at 3, 6 and 12 months after commencing FF 
therapy. The changes in serum and urine markers of kidney function are presented in 
Table 3.10 and Table 3.11, respectively. The Friedman test showed that the 
difference between the median UA concentration at the various time points was 
statistically significant (p=0.0190). Post hoc analysis using the Dunn’s test showed 
that the median serum UA concentration was significantly reduced after 6 months of 
FF treatment, compared with the baseline value (p=0.0370, n=4). The changes in all 
the other parameters were not statistically significant. However, median serum CREA 
and urea concentrations were increased after 3 months of treatment by 24.7% and 
10.2%, respectively. It was observed that after 3 months, median serum CREA and 
urea decreased steadily throughout the following nine months, although the serum 
CREA level remained slightly higher than the baseline value after 12 months of 
treatment. These results suggest that FAC is partially reversible when FF treatment 
is administered in a long-term. 
 Individual participant results (Figure 3.9) showed that participants with higher serum 
CREA concentration or mildly reduced kidney function (eGFR 60 – 89 mL/min/1.73 
m2) at baseline had a greater increase in their serum CREA concentration after 
starting FF treatment compared to those with lower serum CREA concentration or  
eGFR > 90 mL/min/1.73 m2. The eGFR calculated using MDRD and CKD-EPI CREA 
equations were reduced during the first 3 months of treatment but partially recovered 
after 12 months of continuous FF treatment. Changes in the urine markers were not 
statistically significant. These results also showed the reversibility of kidney 
impairment after 12 months of FF therapy. However, the changes in kidney function 
were not clinically significant as none of the participants in this group required any 
change in treatment plan during this period of therapy. 
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Table 3.10 Changes in serum markers of kidney function during 12 months of FF treatment in Group E participants  
Parameters Baseline 3 Months 6 Months 12 Months P value 
Number of participants 4 4 4 4  
Age [years; median (range)] 51 (43 – 57) 51 (43 – 57) 51 (43 – 57) 51 (43 – 57)  
Serum CREA (µmol/L) 77 (60 – 99) 96 (68 – 122) 90 (67 – 117) 85 (59 – 118) 0.0933 
Serum Urea (mmol/L) 4.9 (2.9 – 7.1) 5.4 (3.8 – 7.1) 5.3 (4.1 – 7.5) 4.2 (3.4 – 6.8) 0.8885 
Serum Na (mmol/L) 141 (140 – 143) 139 (137 – 139) 139 (137 – 142) 139 (138 – 140) 0.0828 
Serum K (mmol/L) 4.4 (4.1 – 4.6) 4.3 (4.2 – 4.8) 4.8 (4.2 – 5.4) 4.4 (3.9 - 4.8) 0.8577 
Serum UA (µmol/L) 338 (318 – 425) 310 (223 – 327) 293 (218 – 332)1 307 (233 – 320) 0.0190* 
MDRD (mL/min/1.73 m2) 82 (69 – 93) 66 (54 – 81) 68 (57 – 78) 74 (56 – 96) 0.0819 
CKD-EPI CREA (2009) 
(mL/min/1.73 m2) 
91 (75 – 102) 74 (58 – 92) 76 (61 – 89) 83 (60 – 103) 0.0819 
 
 
 
 
Data are presented as median (IQR); CREA, creatinine; Na, sodium; K, potassium; UA, uric acid; MDRD, Modification of Diet in Renal 
Disease; CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2009); significant difference between 
median concentration at the different time points was analysed using the Friedman test with Dunn’s multiple comparison test; ¹significantly 
different from baseline (p<0.05), *statistically significant difference between the median concentrations at the different time points, *p<0.05. 
Fombon, I.S. (2020) 
116 
 
 
Figure 3.9 Changes in markers of kidney function during 12 months of FF 
therapy.  
Scatter plots showing (A) serum CREA, (B) serum Na and (C) serum UA in individual 
participants at baseline (0), 3, 6 and 12 months after commencing FF treatment in individual 
participants in Group E. CREA, creatinine; UA, uric acid; MDRD, Modification of Diet in Renal 
Disease; CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration creatinine 
equation (2009); statistical significant difference between medians at different time points 
was analysed using the Friedman test with Dunn’s multiple comparison test, *p<0.05; (n=4). 
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Table 3.11 Changes in urine markers of kidney function after 12 months of FF therapy  
Parameter Baseline 3 months 6 months 12 months P value 
Number of participants 4 4 4 4  
Age [years; median (range)] 51 (43 – 57) 51 (43 – 57) 51 (43 – 57) 51 (43 – 57)  
Urine CREA (mmol/L) 20 (12 – 31) 15 (6 – 19) 14 (11 – 19) 11 (10 – 15) 0.4321 
Urine Urea (mmol/L) 346 (220 – 515) 307 (159 – 364) 361 (284 – 463) 264 (195 – 370) 0.5076 
Urine Na (mmol/L) 105 (67 – 126) 139 (93 – 157) 112 (78 – 147) 136 (131 – 149) 0.1411 
Urine K (mmol/L) 121 (80 – 182) 73 (48 – 104) 69 (61 – 98) 67 (58 – 84) 0.1585 
Urine UA (mmol/L) 3.0 (2.0 – 3.6) 1.8 (1.4 – 2.2) 2.4 (1.8 – 3.9) 2.6 (1.9 – 4.2) 0.7539 
Urine ALB (mg/L) 5.3 (2.8 – 16.3) 4.6 (3.5 – 11.2) 4.3 (0.7 – 9.6) 3.2 (1.4 – 13.6) 0.6366 
Urine Protein (g/L) 0.18 (0.09 – 0.29) 0.09 (0.07 – 0.16) 0.10 (0.07 – 0.15) 0.10 (0.09 – 0.13) 0.2443 
UACR (mg/mmol) 0.44 (0.16 – 0.59) 0.50 (0.22 – 1.09) 0.33 (0.05 – 0.52) 0.26 (0.10 – 1.37) 0.4657 
UPCR (mg/mmol) 9 (8 – 9) 8 (6 – 14) 7 (5 – 10) 9 (7 – 13) 0.4724 
UAPR 0.06 (0.02 – 0.06) 0.06 (0.04 – 0.08) 0.04 (0.01 – 0.06) 0.03 (0.01 – 0.10) 0.4736 
UUCR (mmol/mmol) 4.5 (4.0 – 5.5) 2.7 (2.7 – 4.1) 2.8 (2.6 – 4.1) 4.8 (3.2 – 6.5) 0.1851 
FENA (%) 0.26 (0.21 – 0.40) 0.64 (0.44 – 1.41) 0.52 (0.33 – 0.74) 0.75 (0.45 – 1.04) 0.2377 
FEUR (%) 32 (22 – 40) 40 (31 – 46) 43 (38 – 48) 44 (34 – 48) 0.1871 
FEUA (%) 2.58 (2.39 – 5.43) 4.31 (4.16 – 6.52) 5.38 (3.94 – 10.10) 6.51 (5.58 – 8.47) 0.1824 
Data are presented as median (IQR); CREA, creatinine; Na, sodium; K, potassium; UA, uric acid; ALB, albumin; UACR, urine albumin-
creatinine ratio; UPCR, urine protein-creatinine ratio; UAPR, urine albumin-protein ratio; UUACR, urine uric acid-creatinine ratio; FENA, 
fractional excretion of sodium; FEUR, fractional excretion of urea; FEUA, fractional excretion of uric acid. Statistical significant difference 
between median concentrations at the different time points was analysed using the Friedman test with Dunn’s multiple comparison test. 
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3.3.1.6 Summary of the effect of FF therapy on kidney function tests 
Results from all the groups showed moderate increase in serum CREA 
concentration after 3 months of commencing FF therapy, with median levels that 
were modestly higher than the baseline values. It was observed that the serum 
CREA levels decreased as treatment was continued after 6 months and 12 
months of FF treatment. The eGFR calculated using the MDRD and CKD-EPI 
CREA equations were decreased as serum CREA concentration was increased 
during the first three months of FF therapy and were reversed as serum CREA 
levels decreased after treatment was continued for 6 months and 12 months. The 
increase in serum CREA was also accompanied by a moderate increase in serum 
Urea (an independent biomarker of kidney function). The concomitant increase in 
serum CREA and serum Urea, together with the decrease in eGFR by MDRD and 
CKD-EPI equations, is indicative of a genuine impact of FF therapy on the kidney 
function. The data also confirms that the FAC is partially reversible when FF is 
administered in the long-term. Serum Na and serum UA concentrations were also 
decreased with FF therapy.  
Data from urine analysis suggest that the decrease in serum Na and AU was due 
to increased excretion as demonstrated by increased FENA and FEUA, 
respectively. This study did not show any significant impact of FF therapy on urine 
proteins as urine ALB, urine protein and all related urine ALB and protein 
parameters, namely UACR, UPCR and UAPR were within the normal reference 
ranges. 
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3.3.2 Impact of FF therapy on markers of liver function 
First, changes in liver function tests after 3, 6 and 12 months FF (160 mg/day) 
therapy was examined. Serum concentrations of the various markers of liver 
function (TBIL, ALB, ALP, ALT, AST and GGT) after 3, 6 and 12 months of FF 
treatment compared with baseline values are shown in Table 3.12. In Group A 
participants (n=13), changes in the liver enzymes after 3 months of treatment were 
compared with baseline values. The results showed a significant decrease in 
median serum ALP (p=0.0002, n=13) and serum GGT (p=0.0005, n=13) 
concentrations after 3 months of FF therapy. There was no significant change in 
the median serum ALB, TBIL, ALT and AST concentrations (p=0.1807, p=0.8555, 
p=0.6694, and p=0.6426, respectively).  
Results from individual study participants did not show any significant changes in 
serum ALB and TBIL concentrations after 3 months of FF therapy (Figure 3.10A & 
3.10B, respectively). It was observed that the serum ALT concentration was 
increased in eight participants (61.5% n=13), but reduced in the other five 
participants (38.5%, n=13) in this group (Figure 3.10C). Serum ALP and GGT 
levels were also reduced in all the participants, while serum AST concentration 
was reduced in eleven participants (84.6% n=13), as shown in Figure 3.10D-F. 
Together, these results showed that FF therapy administered for 3 months would 
not impact serum ALB and TBIL levels, but would cause a moderate reduction in 
serum AST and a significant decrease in serum ALP and GGT levels in patients 
with dyslipidaemia. The greatest changes in the liver enzymes were observed in 
participants with higher baseline values. 
In Group B participants, it was also observed that the median serum ALP 
(p=0.0039, n=10) and GGT (p=0.0020, n=10) concentrations were significant 
reduced after 6 months of FF therapy (Table 3.12). The median AST 
concentration was also moderately reduced from 28 U/L (IQR 24 – 42 U/L) at 
baseline to 23 U/L (IQR 20 – 30 U/L), although this was not statistically significant 
(p=0.1875, n=10). No significant change in median serum TBIL, ALB and ALT 
concentrations after 6 months of FF therapy. The results from individual study 
participants are presented in Figure 3.11.  
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Serum ALB and TBIL concentrations at baseline and after 6 months of FF therapy 
were similar and the changes in both parameters were within the normal reference 
ranges (Figure 3.11 A-B). Serum ALT concentration was reduced (by 3.6 – 
55.1%) in seven participants (70%, n=10) (Figure 3.16C), while the serum ALP 
concentration was also reduced in nine participants (90%, n=10). Serum GGT and 
AST concentrations were also reduced in seven participants (70%, n=10) as 
shown in Figure 3.11D-F. These results indicate that administration of FF for 6 
months would cause a moderate decrease in serum AST level, but would 
significantly reduce serum levels of ALP and GGT in the patients. These results 
are similar to those obtained after 3 months of FF therapy in Group A participants. 
Again, the greatest impact in liver enzymes was observed in participants with 
higher baseline values. 
In Group C participants, a significant reduction in median serum ALP (p=0.0078, 
n=8) and AST (p=0.0469, n=8) were observed after 12 months of FF therapy and 
although the changes in median serum ALT and GGT concentrations were not 
statistically significant, the median concentration of both markers were decreased 
by 20.8% (p=0.1016, n=8) and 48.1% (p=0.0781, n=8), respectively (Table 3.12). 
Changes in median serum ALB and TBIL levels were not statistically significant 
(p=0.2031, n=8 and p=0.6875, n=8, respectively). Individual participant results 
also showed no notable changes in serum ALB and TBIL concentrations after 12 
months of FF therapy (Figure 3.12A-B). However, the serum ALT concentration 
was reduced in 62.5% (5/8) of the participants, serum ALP concentration was 
reduced in all the participants, and serum GGT and AST were reduced in 75% 
(7/8) of the participants as shown in Figure 3.12C-F.  
Collectively, the results from Group A - C participants suggest that administration 
of FF at 160 mg/day would lead to a mild reduction in serum ALT and AST 
concentrations and a significant reduction in ALP and GGT in most of the patients, 
with a greater impact in participants with higher baseline values.  
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Table 3.12 Impact of FF therapy on liver function tests after 3, 6 and 12 
months compared with baseline values 
Parameters Baseline 3 Months P value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
TBIL (mmol/L) 8 (6 – 12) 9 (7 – 12) 0.1807 
ALB (mmol/L) 42 (40 - 46) 42 (41 – 45) 0.8555 
ALT (U/L) 21 (15 – 31) 20 (17 - 28) 0.6694 
 ALP (U/L) 74 (65 – 82) 54 (49 – 60) 0.0002*** 
AST (U/L) 28 (24 – 45) 27 (22 – 43) 0.6426 
GGT (U/L) 57 (42 – 122) 41 (23 – 90) 0.0005*** 
Parameters Baseline 6 Months P value 
Number of participants 10 10  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63)  
TBIL (mmol/L) 8 (6 - 13) 8 (6 – 11) 0.7500 
ALB (mmol/L) 44 (41 – 46) 44 (41 – 45) >0.9999 
ALT (U/L) 20 (16 – 47) 21 (14 – 25) 0.7815 
 ALP (U/L) 74 (63 – 82) 55 (48 - 65) 0.0039** 
AST (U/L) 28 (24 – 42) 23 (20 – 30) 0.1875 
GGT (U/L) 56 (43 – 79) 35 (22 – 57) 0.0020** 
Parameters Baseline 12 Months P value 
Number of participants 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
TBIL (mmol/L) 11 (6 – 13) 7 (6 – 12) 0.6875 
ALB (mmol/L) 43 (41 – 47) 42 (40 – 43) 0.2031 
ALT (U/L) 24 (18 – 35) 19 (14 – 24) 0.1016 
ALP (U/L) 79 (69 – 93) 59 (46 – 74) 0.0078** 
AST (U/L) 29 (25 – 39) 22 (20 – 34) 0.0469* 
GGT (U/L) 54 (22 – 67) 28 (21 – 49) 0.0781 
Data are presented as median (IQR). IQR, interquartile range; ALB, albumin; TBIL, total 
bilirubin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate 
aminotransferase; GGT, gamma glutamyl transferase; statistical significant difference 
between the median concentrations were determined using the Wilcoxon signed-rank test; 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.10 Effect of 3 months of FF therapy on the liver function tests 
Scatter plots showing the concentrations of (A) serum ALB, (B) Serum TBIL, (C) serum 
ALT, (D) serum ALP, (E) serum GGT and (F) serum AST at baseline (0), and after 3 
months of FF therapy in individual participants. ALB, albumin; TBIL, total bilirubin; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; 
AST, aspartate aminotransferase. Statistical significant difference between the median 
concentrations at baseline and after 3 months of FF therapy was analysed using the 
Wilcoxon signed-rank test; p<0.05 was statistically significant (n=13). 
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Figure 3.11 Effect of 6 months of FF therapy on the liver function tests  
Scatter plots showing the concentrations of (A) serum ALB, (B) Serum TBIL, (C) serum 
ALT, (D) serum ALP, (E) serum GGT and (F) serum AST at baseline (0), and after 6 
months of FF therapy in individual participants. ALB, albumin; TBIL, total bilirubin; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; 
AST, aspartate aminotransferase. Statistical significant difference between the median 
concentrations at baseline and after 6 months of FF therapy was analysed using the 
Wilcoxon signed-rank test; p<0.05 was statistically significant (n=10).  
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Figure 3.12 Effect of 12 months of FF therapy on the liver function tests  
Scatter plots showing the concentrations of (A) serum ALB, (B) Serum TBIL, (C) serum 
ALT, (D) serum ALP, (E) serum GGT and (F) serum AST at baseline (0), and after 12 
months of FF therapy in individual participants. ALB, albumin; TBIL, total bilirubin; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; 
AST, aspartate aminotransferase. Statistical significant difference between the median 
concentrations at baseline and after 12 months of FF therapy was analysed using the 
Wilcoxon signed-rank test. P<0.05 was considered to be statistically significant (n=8). 
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Next, changes in the liver function tests were examined at different time points 
during 6 months and 12 months of FF (160 mg/day) therapy in Group D and E 
participants, respectively. In Group D participants, the liver function test results at 
3 and 6 months of FF therapy were compared with baseline values. The median 
serum TBIL, ALB and ALT concentrations did not change significantly at either 3 
or 6 months of FF therapy compared with the baseline values (Table 3.13, Figure 
3.13A-C). The results showed a significant decrease in median ALP (p=0.0035, 
p=9) and GGT (p=0.0005, n=9) during the 6 months of FF therapy. During the first 
3 months of treatment, median serum ALP concentration fell from 73 U/L (IQR 63 
– 77 U/L) at baseline to 53 U/L (IQR 47 – 59 U/L) (p=0.0140, n=9) and remained 
significantly lower than the baseline value after 6 months of FF therapy (p=0.0140, 
n=9) (Figure 3.13D). Also, median serum GGT concentration was decreased from 
54 U/L (IQR 42 – 91 U/L) at baseline to 30 U/L (23 – 65 U/L) after 3 months of 
treatment (p=0.0140, n=9) and remained significantly lower than the baseline 
value after 6 months (p=0.0044, n=9) (Figure 3.13F). A small but non-statistically 
significant reduction in median serum AST concentration was observed i.e. from 
27 U/L (IQR 24 – 43 U/L) at baseline to 24 U/L (IQR 22 – 38 U/L) after 3 months 
and 22 U/L (IQR 21 – 28 U/L) after 6 months of FF therapy (p=0.2863, n=9) as 
shown in Figure 3.13E. 
Changes in liver function tests during 12 months of FF treatment are summarised 
in Table 3.14. The results showed that median serum ALB, and TBIL 
concentrations did not change significantly at either 3, 6, or 12 months of FF 
therapy compared with baseline values. Individual participant results did not show 
any noticeable changes in serum ALB concentrations, while changes in serum 
TBIL concentration varied among the participants as shown in Figure 3.14A and 
Figure 3.14B, respectively. A small but non-statistically significant decrease in 
median serum ALT concentration (by 15%) was observed after 6 months of 
treatment. After 12 months, the median ALT level was slightly increased although 
at this time point the value remained lower than the baseline value (p=0.1719, 
n=4). Individual participant results also showed a gradual decrease in serum ALT 
concentration during the first 6 months (Figure 3.14C).  
The Friedman test showed significant changes in median serum ALP and GGT 
concentrations during the 12 months FF treatment (P=0.0190 and p=0.0477, 
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respectively). Post hoc analysis using the Dunn’s multiple comparison analysis 
revealed that the difference between the median ALP concentrations at baseline 
and after 6 months of FF therapy was statistically significant (p=0.0370, n=4). 
Individual participant results showed that serum ALP was reduced in all the 
participants during the first 3 months and remained lower than baseline value 
throughout the study period (Figure 3.14D). Also, the median GGT concentration 
was steadily reduced throughout the study period i.e. from 48 U/L (22 – 213 U/L) 
at baseline to 21 U/L (14 – 220 U/L) after 12 months of FF therapy (p=0.0477, 
n=4). Individual participant results (Figure 3.14E) showed a decrease in GGT 
concentration in all the participants after 3 months of FF therapy. Median serum 
AST concentration was reduced from 26 U/L (25 – 51 U/L) at baseline to 21 U/L 
(19 – 22 U/L) after 6 months and the level remained lower than the baseline value 
throughout the study period. Individual participant results are shown in Figure 
3.14F.  
Generally, the results showed that all the liver enzymes (ALT, ALP, GGT and AST) 
were reduced following the administration of FF (160 mg/day). Also, results from 
individual participants indicated that the greatest changes in liver enzymes 
occurred in patients with higher baseline values. In one of the study participants 
(Group E), baseline serum GGT was four times higher than the upper reference 
limit (i.e. > 64 U/L), but all the other liver function tests were within clinical 
reference ranges. However, the AST/ALT ratio was greater than 2, suggestive of 
an alcohol liver disease. In the course of FF therapy, it was observed that the 
serum GGT level decreased from 266 U/L (AST/ALT = 3) at baseline to 206 U/L 
(AST/ALT=2.5) after 3 months and 145 U/L (AST/ALT=1.7) after 6 months of 
treatment. However, after 12 months of FF treatment serum GGT concentration 
had increased to 286 U/L (i.e. higher than baseline value) and AST/ALT = 2.3. 
These results indicated a relapse of alcoholic liver disease during the 12 months of 
FF therapy. The reason for the relapse is unclear.  
The results from this study suggest that FF therapy does not impact on serum ALB 
and TBIL but would cause a moderate reduction in liver enzymes, with a greater 
impact on serum ALP and GGT levels. The results also showed that the greatest 
changes in liver enzymes occur in participants with higher baseline values.  
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Table 3.13 Changes in serum liver function tests during 6 months of FF 
therapy  
Parameters Baseline 3 Months 6 Months P value 
Number of participants 9 9 9  
Age [years; median 
(range)] 
50 (42 – 55) 50 (42 – 55) 50 (42 – 55)  
TBIL (mmol/L) 7 (6 – 12) 7 (7 – 12) 7 (6 – 12) 0.5324 
ALB (mmol/L) 43 (40 – 46) 42 (41 – 45) 43 (41 – 46) 0.6279 
ALT (U/L) 19 (15 – 38) 19 (17 – 28) 19 (14 – 25) 0.2781 
ALP (U/L) 73 (63 – 77) 53 (47 – 59)1 54 (47 – 59)1 0.0035** 
AST (U/L) 27 (24 - 43) 24 (22 – 38) 22 (21 – 28) 0.2863 
GGT (U/L) 54 (42 – 91) 30 (23 – 65)1 30 (21 – 67)2 0.0005*** 
Data are presented as median (IQR); ALB, albumin; TBIL, total bilirubin; ALT, alanine 
aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; AST, 
aspartate aminotransferase; statistical significant difference between median 
concentration at the different time points was analysed using the Friedman test with 
Dunn’s multiple comparison test; ¹significantly different from baseline (p<0.05), 
²significantly different from baseline (p<0.01), **p<0.01, ***p<0.001. 
 
 
 
 
 
 
Fombon, I.S. (2020) 
128 
 
 
Figure 3.13 Changes in liver function tests during 6 months of FF therapy  
Scatter plots showing individual participant levels of (A) serum ALB, (B) Serum TBIL, (C) 
serum ALT, (D) serum ALP, (E) serum GGT and (F) serum AST concentrations at 
baseline (0), and after 6 months of FF therapy. ALB, albumin; TBIL, total bilirubin; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; 
AST, aspartate aminotransferase. The Friedman test with Dunn’s multiple comparison test 
was used to analyse the significance difference between the median concentrations at the 
different time points. *p<0.05, **p<0.01, (n=9).  
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Table 3.14 Changes in liver function tests during 12 months of FF therapy in Group E participants 
Parameters Baseline 3 Months 6 Months 12 Months P value 
Number of participants 4 4 4 4  
Age [years; median (range)] 51 (43 – 57) 51 (43 – 57) 51 (43 – 57) 51 (43 – 57)  
TBIL (mmol/L) 9 (6 – 12) 8 (6 – 11) 7 (5 – 8) 8 (7 – 13) 0.1875 
ALB (mmol/L) 43 (40 – 45) 42 (40 – 45) 42 (40 – 45) 42 (40 – 42) 0.9080 
ALT (U/L) 20 (18 – 25) 17 (13 – 19) 14 (12 – 16) 17 (11 – 20) 0.1719 
ALP (U/L) 73 (64 – 91) 56 (49 – 59) 52 (47 – 55)1 51 (43 – 60) 0.0190* 
AST (U/L) 26 (25 – 51) 23 (21 – 37) 21 (19 – 22) 22 (21 – 39) 0.0596 
GGT (U/L) 48 (22 - 213) 27 (16 – 162) 21 (14 – 114) 21 (14 – 220) 0.0477* 
Data are presented as median (IQR); ALB, albumin; TBIL, total bilirubin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, 
gamma glutamyl transferase; AST, aspartate aminotransferase; statistical significant difference between median concentrations at the 
different time points was analysed using the Friedman test with Dunn’s multiple comparison test; ¹significantly different from baseline 
(p<0.05), *p<05. 
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Figure 3.14 Changes in serum liver function tests during 12 months of FF 
therapy in Group E participants.  
Scatter plots showing individual participant levels of (A) serum ALB, (B) Serum TBIL, (C) 
serum ALT, (D) serum ALP, (E) serum GGT and (F) serum AST concentrations at 
baseline (0), and after 12 months of FF therapy. ALB, albumin; TBIL, total bilirubin; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; 
AST, aspartate aminotransferase. The Friedman test with Dunn’s multiple comparison 
tests was used to analyse the significance difference between the median concentrations 
at the different time points. *p<0.05 (n=4). 
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3.3.3 The impact of FF therapy on lipid profile 
The main aim of FF therapy is to reduce elevated levels of triglyceride, and 
increase low levels of HDL cholesterol in patients with dyslipidaemia. In this study, 
the impact of FF (160 mg/day) therapy on the lipid profile (CHOL, HDL, TRIG, 
CHRA and NHDL) was examined after 3, 6, and 12 months of commencing 
treatment. The results (Median and IQR) at baseline and after 3, 6 and 12 months 
after commencing treatment are summarised on Table 3.14. In Group A 
participants, a significant increase in the median serum HDL cholesterol 
concentration from 0.87 mmol/L (0.70 – 1.20 mmol/L) at baseline to 0.93 mmol/L 
(0.81 – 1.20 mmol/L) after 3 months of FF therapy was observed (p=0.0200, 
n=13). The results also showed a reduction in the median serum TRIG 
concentration by 36.7% after 3 months of FF therapy, although this change was 
not statistically significant (p=0.1672, n=13). The changes in serum levels of 
CHOL, CHRA and NHDL were not statistically significant.  
Individual participant results showed that after 3 months of FF therapy, CHOL was 
increased in eight participants (61.5%, n=13) (Figure 3.15A). As expected, serum 
HDL cholesterol concentration was increased in 10 participants (76.9%, n=13), 
while serum TRIG concentration was also decreased in 10 participants (76.9%, 
n=13) as shown in Figure 3.15B-C. Apart from reducing high levels of TRIG and 
increasing HDL levels, the aim of treatment in dyslipidaemia is also to reduce high 
levels of CHRA and NHDL, both of which are used to assess the risk of heart 
disease. After 3 months of FF therapy, CHRA was decreased in six participants 
(46.2%, n=13), while NHDL was decreased in five participants (38.5%, n=13) 
(Figure 3.15D-E). These results indicate that treatment with FF (160 mg/day) for 3 
months would cause a significant increase in serum HDL concentration, a 
moderate decrease in serum TRIG concentration, but would not cause any 
significant changes in CHOL, CHRA and NHDL levels. The greatest change in 
serum TRIG was observed in participants with higher baseline values.  
In Group B participants, changes in the lipid profile were not statistically significant 
(Table 3.14). Individual participant results showed that serum CHOL concentration 
was increased in five of the participants (50%, n=10) (Figure 3.16A). Serum HDL 
concentration was increased in eight of the participants (80%, n=10) and serum 
TRIG concentration was also reduced in eight of the participants (80%, n=10) 
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(Figure 3.16B-C). The CHRA was decreased in six of the participants (60%, 
n=10), while the NHDL concentration was reduced in five of the participants (50%, 
n=10) (Figure 3.16D-E). These results suggest that administration of FF at 160 
mg/day for 6 months would cause a moderate increase in HDL cholesterol 
concentration and decrease in serum TRIG concentration in patients with 
dyslipidaemia. The results also showed that administering FF (160 mg/day) for 6 
months would not significantly impact on CHOL, CHRA and NHDL levels in 
patients with dyslipidaemia, although individual results showed that CHRA and 
NHDL levels were reduced in some participants. 
In Group C participants, the changes in lipid profile were not statistically significant 
(Table 3.14). However, median CHOL, TRIG and NHDL concentrations were 
reduced by 22.2% (p=0.3828, n=8), 20.4% (p=0.8438, n=8), and 23.8% 
(p=0.4609, n=8), respectively. Individual participant results also showed that 
serum CHOL concentration was decreased in six participants (75%, n=8), while 
serum HDL cholesterol was increased in five participants (62.5%, n=8) (Figure 
3.17A-B). Serum TRIG concentration was also reduced in four participants (50%, 
n=8) and the greatest changes in TRIG levels were observed in participants with 
relatively higher baseline levels (Figure 3.17C). The CHRA and NHDL levels were 
also reduced in 50% and 75% of the participants, respectively (Figure 3.17D-E). 
Put together, these results suggest that FF administered at 160 mg/day would 
cause a moderate decrease in serum TRIG and a moderate increase in HDL 
levels in patients with dyslipidaemia. Although the impact of the treatment varied 
amongst the participants, the greatest impact on TRIG level was observed in 
participants with a relatively higher baseline concentration of TRIG. Aldo, the 
impact on the CHRA and NHDL varied amongst the participants. 
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Table 3.15 Impact of 3, 6, and 12 months of FF therapy on the lipid profile in 
patients with dyslipidaemia 
Parameters Baseline 3 Months P value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
CHOL (mmol/L) 5.1 (3.6 – 8.6) 5.8 (4.8 – 6.8) 0.8533 
HDL (mmol/L) 0.87 (0.70 – 1.20) 0.93 (0.81 – 1.20) 0.0200* 
TRIG (mmol/L) 4.9 (2.9 – 6.1) 3.1 (1.8 – 4.5) 0.1672 
CHRA  5.1 (4.4 – 7.1) 6.0 (4.6 – 6.3) 0.8257 
NHDL (mmol/L) 4.2 (2.8 – 7.6) 4.7 (3.7 – 5.9) 0.9460 
Parameters Baseline 6 Months P value 
Number of participants 10 10  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63)  
CHOL (mmol/L) 5.1 (3.2 – 7.7) 5.4 (4.0 -6.2) 0.9805 
HDL (mmol/L) 0.87 (0.67 – 0.98) 0.98 (0.77 – 1.00) 0.1016 
TRIG (mmol/L) 3.5 (3.0 – 5.5) 2.8 (2.1 – 3.3) 0.0645 
CHRA  5.0 (4.1 – 8.7) 5.3 (4.2 – 7.1) 0.6426 
NHDL (mmol/L) 4.1 (2.3 – 6.8) 4.4 (3.0 – 5.1) 0.9219 
Parameters Baseline 12 Months P value 
Number of participants 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
CHOL (mmol/L) 7.2 (5.3 – 8.8) 5.6 (5.1 – 7.4) 0.3828 
HDL (mmol/L) 1.10 (0.87 – 1.30) 1.00 (0.86 – 1.30) 0.7422 
TRIG (mmol/L) 4.9 (3.2 – 5.8) 3.9 (2.1 – 6.8) 0.8438 
CHRA  5.5 (4.3 – 7.6) 5.7 (4.6 – 6.8) >0.9999 
NHDL (mmol/L) 6.3 (4.1 – 7.9) 4.8 (4.0 – 6.1) 0.4609 
Data are presented as median (IQR); CHOL, cholesterol; HDL, high-density lipoprotein 
cholesterol; TRIG, triglyceride; CHRA, cholesterol to HDL cholesterol ratio; NHDL, non-
HDL cholesterol; statistical significant difference between median concentrations was 
determined using the Wilcoxon signed-rand test; *p<0.05. 
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Figure 3.15 Effect of 3 months of FF therapy on the lipid profile  
Scatter plots showing concentrations of (A) serum CHOL, (B) serum HDL cholesterol, (C) 
serum TRIG, (D) CHRA and (D) NHDL at baseline and after 12 months of FF therapy in 
individual participants in Group A. CHOL, cholesterol; HDL, high-density lipoprotein 
cholesterol; TRIG, triglyceride; CHRA, cholesterol to HDL cholesterol ratio; NHDL, non-
HDL cholesterol; FF, fenofibrate; statistical significant difference between median 
concentrations was determined using the Wilcoxon signed-rank test. A p<0.05 was 
considered as statistically significant. 
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Figure 3.16 Effect of 6 months of FF therapy on the lipid profile in Group B 
participants.  
Scatter plots showing concentrations of (A) serum CHOL, (B) serum HDL cholesterol, (C) 
serum TRIG, (D) CHRA and (D) NHDL at baseline and after 6 months of FF therapy in 
individual participants in Group B. CHOL, cholesterol; HDL, high-density lipoprotein 
cholesterol; TRIG, triglyceride; CHRA, cholesterol to HDL cholesterol ratio; NHDL, non-
HDL cholesterol; FF, fenofibrate; statistical significant difference between median 
concentrations was determined using the Wilcoxon signed-rank test. A p<0.05 was 
considered as statistically significant. 
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Figure 3.17 Effect of 12 months of FF therapy on the lipid profile  
Scatter plots showing concentrations of (A) serum CHOL, (B) serum HDL cholesterol, (C) 
serum TRIG, (D) CHRA and (D) NHDL at baseline and after 12 months of FF therapy in 
individual participants in Group C. CHOL, cholesterol; HDL, high-density lipoprotein 
cholesterol; TRIG, triglyceride; CHRA, cholesterol to HDL cholesterol ratio; NHDL, non-
HDL cholesterol; FF, fenofibrate; significant difference between median concentrations 
was determined using the Wilcoxon signed-rank test. A p<0.05 was considered as 
statistically significant. 
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Changes in the lipid profile during 6 and 12 months of FF (160 mg/day) therapy 
were examined in Group D and Group E participants, respectively. Results from 
Group D participants are shown in Table 3.15 and Figure 3.18. In this group, the 
lipid profile was measured at baseline, 3 months and 6 months after commencing 
FF therapy. The Friedman test revealed significant differences between median 
serum HDL cholesterol concentrations at baseline, 3 and 6 months (p=0.0035, 
n=9) and Dunn’s post hoc test showed that median serum HDL cholesterol 
concentration after 3 months and 6 months of FF therapy was significantly higher 
than the baseline value (p=0.0140 and p=0.0140, respectively, Figure 3.18B). The 
median serum CHOL, TRIG, CHRA and NHDL levels did not change significantly 
at either 3 months or 6 months of FF therapy compared with baseline values 
(Figures 3.18). The results also showed great variation on the impact of FF 
therapy on the lipid profile in the individual participants at the different time points.  
In Group E, changes in the lipid profile at 3, 6 and 12 months were compared with 
baseline values in four participants. The results are presented in Table 3.16 and 
Figure 3.19. The Friedman test showed that there was no significant difference 
between the median serum CHOL, HDL cholesterol, TRIG, CHRA and NHDL at 
the different time points during the 12 months of FF therapy (p=0.6615, p=0.3895, 
p=0.1584, 0.6968 and p=0.5239, respectively). However, it was observed that the 
median serum TRIG level was decreased as the duration of treatment was 
increased i.e. from 5.06 mmol/L (IQR 3.74 – 13.68 mmol/L) at baseline to 2.24 
mmol/L (IQR 1.63 – 10.62 mmol/L) after 12 months of FF therapy. The median 
serum HDL cholesterol concentration was increased from 0.88 mmol/L (IQR 0.68 
– 1.13 mmol/L) at baseline to 1.01 mmol/L (IQR 0.84 – 1.18 mmol/L) during the 12 
months of FF therapy.  
Collectively, these results suggest that FF (160 mg/day) therapy would cause a 
moderate but significant increase in serum HDL cholesterol and a moderate 
reduction in serum TRIG concentrations when administered in a long-term. Also, 
the greatest impact of FF (160 mg/day) therapy on the lipid profile was observed 
after the first 3 months of treatment. In this study, the greatest changes in the 
parameters were observed in participants with relatively higher baseline values. 
Also, FF administered at 160 mg/day did not have any significant impact on serum 
CHOL, CHRA and NHDL cholesterol levels. 
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Table 3.16 Changes in the lipid profile during six months of FF therapy  
Data are presented as median (IQR); CHOL, cholesterol; HDL, high-density lipoprotein 
cholesterol; TRIG, triglyceride; CHRA, cholesterol to HDL cholesterol ratio; NHDL, non-
HDL cholesterol; statistical significant difference between median concentrations at the 
different time points during 6 months of FF therapy was analysed using the Friedman test 
with Dunn’s multiple comparison test; ¹significantly different from baseline (p<0.05), 
**p<0.01. 
 
 
Parameters 
 
Baseline 
 
3 Months 
 
6 Months 
 
P value 
Number of 
participants 
 
9 
 
9 
 
9 
 
 
Age [Years; 
median (range)] 
 
50 (42 – 55) 
 
50 (42 – 55) 
 
50 (42 – 55) 
 
 
CHOL (mmol/L) 
 
5.1 (2.9 – 8.1) 
 
5.8 (3.7 – 6.8) 
 
5.5 (3.8 – 6.5) 
 
0.7407 
 
HDL (mmol/L) 
 
0.86 (0.65 – 0.89) 
 
0.91 (0.79 – 1.08)¹ 
 
0.95 (0.77 – 1.01)¹ 
 
0.0035** 
 
TRIG (mmol/L) 
 
3.9 (2.9 – 5.8) 
 
3.1 (2.0 – 4.5) 
 
3.0 (2.3 – 3.5) 
 
0.2744 
 
CHRA 
 
5.1 (4.4 – 9.3) 
 
6.0 (4.9 – 6.3) 
 
5.8 (4.4 – 7.1) 
 
0.9712 
 
NHDL (mmol/L) 
 
4.2 (2.1 – 7.3) 
 
4.9 (2.8 – 5.9) 
 
4.4 (2.9 – 5.5) 
 
0.6854 
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Figure 3.18 Changes in lipid profile during 6 months of FF therapy  
Scatter plots showing levels of (A) serum CHOL, (B) serum HDL cholesterol, (C) serum 
TRIG, (D) CHRA and (E) NHDL at baseline (0), 3 and 6 months after commencing FF 
therapy in individual participants in Group D. FF, fenofibrate; CHOL cholesterol; TRIG, 
triglyceride; HDL, high-density lipoprotein cholesterol; CHRA, cholesterol to HDL 
cholesterol ratio; NHDL, non-HDL cholesterol. Statistical significance difference between 
the median concentrations at the different time points during 6 months of FF therapy was 
analysed using Friedman test with Dunn’s multiple comparison tests. *p<0.05, (n=9). 
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Table 3.17 Changes in serum lipid profile during 12 months of FF therapy  
 
Parameters 
 
Baseline 
 
3 Months 
 
6 Months 
 
12 Months 
 
P value 
 
Number of participants 
 
4 
 
4 
 
4 
 
4 
 
 
Age [years; median (range)] 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
 
CHOL (mmol/L) 
 
6.5 (4.0 – 8.6) 
 
5.7 (4.8 – 7.3) 
 
5.5 (4.7 – 5.8) 
 
5.3 (4.6 – 6.5) 
 
0.6696 
 
HDL (mmol/L) 
 
0.88 (0.68 – 1.13) 
 
0.92 (0.90 – 1.18) 
 
0.98 (0.82 – 1.26) 
 
1.01 (0.84 – 1.18) 
 
0.3857 
 
TRIG (mmol/L) 
 
5.06 (3.74 – 13.68) 
 
3.08 (2.37 – 8.33) 
 
2.65 (1.70 – 3.05) 
 
2.24 (1.63 – 10.62) 
 
0.4275 
 
CHRA 
 
6.4 (4.2 – 12.9) 
 
6.2 (5.2 – 6.4) 
 
5.3 (4.4 – 5.3) 
 
5.6 (4.2 – 7.2) 
 
0.4913 
 
NHDL (mmol/L) 
 
5.45 (3.06 – 7.86) 
 
4.80 (3.85 – 6.13) 
 
4.40 (3.75 – 4.71) 
 
4.29 (3.50 – 5.61) 
 
0.6346 
Data are presented as median (IQR); CHOL, cholesterol; HDL, high-density lipoprotein cholesterol; TRIG, triglyceride; CHRA, cholesterol to 
HDL cholesterol ratio; NHDL, non-HDL cholesterol; statistical significant difference between median concentrations at the different time 
points during 12 months of FF therapy was analysed using the Friedman test with Dunn’s multiple comparison test. Significant difference 
was considered as a p value <0.05.  
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Figure 3.19 Changes in lipid profile in during 12 months of FF therapy  
Scatter plots showing serum levels of (A) serum CHOL, (B) serum DL cholesterol (C) 
serum TRIG, (D) CHRA and NHDL at baseline (0), 3, 6 and 12 months  after 
commencing FF therapy in individual participants in Group D. FF, fenofibrate; CHOL 
cholesterol; TRIG, triglyceride; HDL, high-density lipoprotein cholesterol; CHRA, 
cholesterol to HDL cholesterol ratio; NHDL, non-HDL cholesterol; n=4. 
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3.3.4 Impact of FF therapy on markers of inflammation and muscle damage  
The impact of FF therapy on markers of inflammation (CRP) and muscle damage 
(CK and LDH) was examined after 3, 6, and 12 months and result compared with 
baseline values. The results are summarised in Table 3.17. Generally, FF (160 
mg/day) therapy did not have any significant impact on the serum CRP, CK and 
LDH levels in all the Groups of participants. The impact of FF therapy on the 
serum CRP level in the individual participants is shown in Figure 3.20. Although, 
the median serum CRP concentration in Group A participants was reduced by 
69.4% after 3 months of FF therapy compared to baseline values, the difference 
was not statistically significant (p=0.4219, n=13). In Group B participants, the 
median CRP concentration was instead increased by 31.3% after 6 months of 
treatment (p=0.4844, n=10) and by 16% after 12 months in Group C participants 
(p=0.5313, n=8).  
Results from Group D participants in which the evolution of serum CRP was 
examined in nine participants during 6 months of FF therapy, showed that the 
median CRP concentration was initially reduced by 44.4% compared to baseline 
value i.e. from 1.8 mg/L (IQR 1.1 – 7.9 mg/L) at baseline to 1.0 mg/L (IQR 1.0 – 
8.1 mg/L) after 3 months of treatment, but was again increased to 2.4 mg/L (IQR 
1.0 – 8.5 mg/L) after 6 months of treatment. A similar trend was also observed in 
Group D during 12 months of FF therapy involving four participants. These results 
suggest that the change in serum CRP concentration was not necessarily due to 
the impact of FF therapy. 
Individual participant results (Figure 3.20) showed that in two of the participants 
(B01 and B05) who had baseline values greater than the upper reference range (5  
mg/L), the CRP concentration was further increased by 29.9% and 3.8%, 
respectively, after 3 months of treatment and by 105% and 11.3%, respectively, 
after 6 months of treatment. It was further observed that in both participants, their 
serum CRP level remained higher than the upper reference limit throughout the 
treatment period. All other participant results were within the reference range 
throughout the study period. These results also suggest that the impact of FF on 
serum CRP level does not depend on the baseline value. 
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Changes in the median serum concentrations of CK and LDH after 3, 6 and 12 
months were not statistically significant as shown in Table 3.17. However, it was 
observed that the median serum CK concentration was reduced after 3, 6 and 12 
months of FF therapy by 30.4% (n=13), 18.1% (n=10) and 2.5% (n=8), 
respectively (Figure 3.21). On the other hand, the median serum LDH 
concentration was increased by 2% (n=13) and 10.9% (n=10) after 3 months in 
Group A and 6 months in Group B participants, respectively. In Group C 
participants, the median LDH concentration was reduced by 3% (n=8). These 
results suggest that changes in the levels of CK and LDH were not related to FF-
induced muscle damage. In muscle injury, both CK and LDH levels are expected 
to rise.   
In Group D and E participants, changes in CK and LDH levels were examined at 
different time points during 6 months and 12 months of treatment, respectively 
(Figure 3.22). In Group D participants, the median CK concentration was reduced 
by 44% after 3 months of treatment (p=0.4719, n=13) and then increased by 
38.5% after 6 months of FF therapy (p=0.4719). On the other hand, the median 
serum LDH concentration was increased from 250 U/L (IQR 215 – 317) at 
baseline to 262 U/L (IQR 214 – 311 U/L) after 3 months of treatment and then 
decreased by 7.6% to 242 U/L (IQR 189 – 332 U/L) after 6 months of FF 
treatment. A similar trend was observed in Group E participants, where the median 
serum CK concentration was initially decreased following administration of FF (160 
mg/day) and then gradually increased as treatment was continued in the long-
term. In Group E, the median serum LDH was initially increased after the first 3 
months of FF therapy and then slightly decreased as treatment was continued. 
Individual participant results showed that in one of the participants marked as T01, 
a concomitant increase in serum CK and LDH concentrations was observed during 
six months of FF therapy (Figure 3.22A and Figure 3.22B). The clinical 
significance of these changes in both markers is unclear as none of the 
participants reported any symptoms associated with muscle injury. Also the 
changes in all the markers were not clinically significant to trigger any change in 
the treatment plan or withdrawal of FF therapy. Collectively, these results suggest 
that FF administered at 160 mg/day is not associated with any risk of muscle injury 
in patients with dyslipidaemia. 
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Table 3.18 Effect of FF therapy on serum CRP, CK and LDH concentrations in 
patients with dyslipidaemia  
Parameters Baseline 3 Months p value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
Serum CRP (mg/L) 3.6 (1.1 – 5.0) 1.1 (1.0 – 4.9) 0.4219 
Serum CK (U/L) 112 (64 – 142) 78 (59 – 144) 0.7607 
Serum LDH (U/L) 263 (217 – 305) 268 (240 – 300) >0.9999 
Group B Baseline 6 Months p value 
Number of participants 10 10  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63)  
Serum CRP (mg/L) 1.6 (1.2 – 6.6) 2.1 (1.0 – 6.9) 0.4844 
Serum CK (U/L) 116 (64 – 144) 95 (71 – 144) 0.7891 
Serum LDH (U/L) 247 (214 – 322) 274 (189 – 363) >0.9999 
Group C Baseline 12 Months p value 
Number of participants 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
Serum CRP (mg/L) 2.5 (1.2 – 4.1) 2.9 (1.0 – 4.5) 0.5313 
Serum CK (U/L) 121 (92 – 141) 118 (84 – 159) 0.8438 
Serum LDH (U/L) 304 (217 – 441) 295 (217 – 377) 0.7789 
Data are presented as median (IQR). IQR, interquartile range; CRP, C reactive protein; CK, 
creatine kinase; LDH, lactate dehydrogenase; statistical significant difference between the 
median concentrations was analysed using the Wilcoxon signed-rank test; p<0.05 was 
considered to be statistically significant. 
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Figure 3.20 Impact of FF therapy on serum CRP concentration. 
Scatter plots showing changes in serum CRP concentration in individual participants (A) after 
3 months (n=13), (B) after 6 months (n=10), (C) after 12 months (n=8) and at different time 
points during (D) 6 months (n=9) and (E) 12 months of FF therapy. CRP, C reactive protein; 
FF, fenofibrate; The impact of FF therapy on serum CRP varied among individual 
participants, particular in participants B01 and B05 who started with a relatively higher 
baseline value. 
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Figure 3.21 Impact of FF therapy on markers of muscle damage.  
Scatter plots showing individual participant level of CK and LDH after 3 months (A-B), 6 
months (C-D) and 12 months (E-F) of FF therapy. CK, creatine kinase; LDH, lactate 
dehydrogenase; FF, fenofibrate; statistical significant difference between median 
concentrations at baseline and after FF therapy was analysed using the Wilcoxon signed-
rank test, p<0.05 was considered as statistically significant. 
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Figure 3.22 Changes in markers of muscle damage during 6 and 12 months of 
FF therapy.  
Scatter plots showing serum levels of CK and LDH in individual participants during 6 months 
(A-B) and 12 months (C-D) of FF therapy. The impact of FF therapy varied among the 
participants. In the participant marked as T04, serum CK and LDH increased from baseline 
to 6 months .FF, fenofibrate; CK, creatine kinase; LDH, lactate dehydrogenase. 
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3.3.5 Effect of FF therapy on thyroid function tests 
The impact of FF therapy on thyroid function was assessed by measuring serum 
levels of TSH, FT4 and FT3 in study participants at baseline and 3, 6 and 12 months 
after commencing treatment with FF administered at 160 mg/day. Changes in thyroid 
function tests in Group A – C participants following FF therapy are shown in Table 
3.18. In Group A, the changes in TSH, FT4 and FT3 were not statistically significant. 
All individual participant results were within the normal reference ranges (Figure 
3.23). In Group B and C, a small but significant increase in the median FT4 
concentration was observed after 6 months (p=0.0469, n=10) and 12 months 
(p=0.0234, n=8) of FF therapy. Changes in the median serum TSH and FT3 
concentrations were not statistically significant. Also, changes in individual participant 
results were not clinically significant as all the results were within the normal 
reference ranges (Figure 3.24 and Figure 3.25). 
Next, changes in markers of thyroid function at different time periods during 6 months 
and 12 months FF therapy were examined in Group D and E participants, 
respectively. In Group D participants, the Friedman test showed that the difference 
between the median TSH concentrations at the different time points was statistically 
significant (p=0.0080, n=13). Post hoc analysis using the Dunn’s test showed that the 
median serum TSH concentration was increased from 1.55 mU/L (IQR 1.10 – 3.02 
mU/L) at baseline to 1.59 mU/L (IQR 1.33 – 3.13 mU/L) after 3 months of FF therapy 
(p=0.2969, n=9) and then reduced significantly during the following 3 months to 1.45 
mU/L (IQR 1.10 – 2.43 mU/L) (p=0.0096, n=9). The changes in the median serum 
FT4 and FT3 concentrations during the 6 months treatment period were not 
statistically significant. In group E, changes in the median serum TSH and FT4 
concentrations were not statistically significant. However, the difference between the 
median serum FT3 concentrations at the different time points was statistically 
significant (p=0.0313, n=4). Results from individual participants did not show any 
clinically significant changes as all the parameters were within normal reference 
ranges (Figure 3.26). 
These results suggest that administration of FF at 160 mg/day would not impact on 
thyroid function in patients with dyslipidaemia. 
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Table 3.19 Effect of FF therapy on thyroid function tests 
Parameters Baseline 3 Months p value 
Number of participants 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
Serum TSH (mIU/L) 1.7 (1.0 – 2.8) 2.4 (1.3 – 3.3) 0.0713 
Serum FT4 (pmol/L) 10 (9.5 – 11.0) 11 (9.3 – 12.0) 0.0635 
Serum FT3 (pmol/L) 4.7 (4.2 – 5.0) 4.8 (4.4 – 5.6) 0.2100 
Group B Baseline 6 Months p value 
Number of participants 10 10  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63)  
Serum TSH (mIU/L) 1.4 (1.0 - 2.5) 1.4 (1.0 – 2.4) 0.5469 
Serum FT4 (pmol/L) 10.0 (9.7 – 11.0) 11.0 (11.0 – 12.0) 0.0469* 
Serum FT3 (pmol/L) 4.7 (4.2 – 5.0) 5.0 (4.2 – 5.3) 0.5020 
Group C Baseline 12 Months p value 
Number of participants 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
Serum TSH (mIU/L) 2.2 (1.0 – 3.1) 2.5 (1.1 – 4.2) 0.5469 
Serum FT4 (pmol/L) 10.0 (8.9 – 11.0) 11.0 (8.7 – 12.0) 0.0234* 
Serum FT3 (pmol/L) 4.8 (4.4 – 5.4) 4.8 (4.3 – 5.4) 0.8359 
Data are presented as median (IQR). IQR, interquartile range; TSH, thyroid stimulating 
hormone; IQR, interquartile range; FT4, free T4 or free thyroxine; FT3, free T3 or free 
triiodothyronine; statistical significant differences between the median concentrations were 
analysed using the Wilcoxon signed-rank test; *p<0.05. 
 
Fombon, I.S. (2020) 
150 
 
 
Figure 3.23 Effect of 3 months of FF therapy on thyroid function tests.  
Scatter plots showing levels of (A) serum TSH, (B) serum FT4 and (C) serum FT3 at 
baseline and after 3 months of FF therapy in individual participants in Group A. TSH, thyroid 
stimulating hormone; FT4, free T4; FT3, free T3; statistical significant difference between the 
median concentration and baseline and after 3 months of FF therapy was determined using 
the Wilcoxon signed-rank test; p<0.05 was considered to be statistically significant (n=13). 
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Figure 3.24 Effect of 6 months of FF therapy on thyroid function tests.  
Scatter plots showing levels of (A) serum TSH, (B) serum FT4 and (C) serum FT3 at 
baseline and after 6 months of FF therapy in individual participants in Group A. TSH, thyroid 
stimulating hormone; FT4, free T4; FT3, free T3; statistical significant difference between the 
median concentration and baseline and after 6 months of FF therapy was determined using 
the Wilcoxon signed-rank test; p<0.05 was considered to be statistically significant (n=10). 
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Figure 3.25 Effect of 12 months of FF therapy on thyroid function tests.  
Scatter plots showing levels of (A) serum TSH, (B) serum FT4 and (C) serum FT3 at 
baseline and after 12 months of FF therapy in individual participants in Group A. TSH, thyroid 
stimulating hormone; FT4, free T4; FT3, free T3; statistical significant difference between the 
median concentration and baseline and after 12 months of FF therapy was determined using 
the Wilcoxon signed-rank test; p<0.05 was considered to be statistically significant (n=8). 
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Figure 3.26 Changes in the thyroid function tests during 6 and 12 months of FF 
therapy.  
Scatter plots showing levels of serum TSH, FT4 and FT3 in individual participants during 6 
months (A-C) and 12 months (D-F) of FF therapy. TSH, thyroid stimulating hormone; FT4, 
free T4; FT3, free T3; significant difference between the median concentration and baseline 
and after 12 months of FF therapy was determined using the Wilcoxon signed-rank test; 
p<0.05 was considered to be statistically significant (n=8). 
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3.4 DISCUSSION 
FF is undoubtedly a very important hypolipidaemic drug and the most commonly 
prescribed fibric acid derivative, used primarily to reduce serum TRIG and LDL 
cholesterol levels, and increase HDL cholesterol levels in patients with dyslipidaemia 
(Farnier, 2008). Based on recently published studies, FF is a useful option for 
patients with primary combined dyslipidaemias or secondary dyslipidaemias, such as 
those associated with diabetes mellitus, metabolic syndrome or HIV infection. 
Additionally, in cases of refractory dyslipidaemia, the combination of FF with statins is 
a therapeutic option (Tsimihodimos et al., 2005). FF has also been shown to have 
pleitropic effects such as anti-inflammatory, anti-oxidant, and anti-thrombotic qualities 
(Playford et al., 2002; Koh et al., 2005; Walker et al., 2012). However, its association 
with severe adverse effects including kidney injury, liver damage, myalgia and 
rhabdomyolysis has limited its use in certain individuals (Davidson et al., 2007; 
Ahmad et al., 2017; Wang and Wang, 2018).  
Recent studies have suggested that FF therapy may impact differentially on different 
biomarkers (Ncube et al., 2012; Gandhi et al., 2014; Wang and Wang, 2018). 
However, such studies have focused on the impact of FF on individual markers, 
organs or systems and reports on how FF affects routine clinical biomarkers in 
patients with dyslipidaemia are rare or lacking. In this study, the impact of 3 – 12 
months of FF therapy was investigated in various groups of patients with 
dyslipidaemia. Patients were grouped based on provision of test samples from 
baseline (i.e. before they had started treatment with FF) to 12 months after starting 
treatment. All the participants were followed up in primary care settings and were 
administered FF at 160 mg/day.  
As expected, this study showed that FF therapy reduced serum TRIG levels and 
improved on low levels of HDL cholesterol. It was also confirmed that FF therapy is 
associated with moderate increase in serum creatinine and Urea concentrations and 
a reduction in kidney function estimated using the routinely used MDRD formula and 
the CKD-EPI CREA equations for assessing kidney function. This study also shows 
that FF-associated kidney dysfunction is reversible when FF is administered in the 
long-term. The results also showed that FF therapy reduced serum UA levels by 
increasing urine UA clearance. In this study, FF therapy was also shown to 
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moderately reduce liver function enzymes (ALT, AST GGT and most notably the 
ALP). The impact of FF therapy on the liver function enzymes was greater in 
participants with higher baseline value. However, there was no significant impact of 
FF therapy on the inflammatory marker (CRP), markers of muscle damage (CK and 
LDH), and thyroid function tests. 
 
3.4.1 FF increased serum CREA, reduced UA and impacted kidney function 
Evidence from various studies have shown that FF therapy is associated with 
increase in serum CREA levels (or inferred nephrotoxicity) (Tsimihodimos et al., 
2005; Ansquer et al., 2008; Forsblom et al., 2010; Ncube et al., 2012). Consistent 
with these reports, this study showed that FF (160 mg/day) therapy caused a 
moderate increase in serum CREA and serum urea concentrations, and a decrease 
in kidney function estimated using the MDRD and CKD-EPI CREA (2009) equations. 
The increase in serum CREA concentration was statistically significant after the first 
3 months of FF therapy (p=0.0016, n=13). In a recent study, Ncube et al., (2012) 
reported similar increases in serum CREA and CYSC after 3 months of FF (267 
mg/day) in patients with hyperlipidaemia. This suggests that FF-associated 
creatininaemia occurs irrespective of the dose of the drug administered. Also, 
previous studies have shown that FF-associated creatininaemia was partially 
reversed when the drug was withdrawn (Michaleckyj et al., 2012; Park et al., 2017). 
The results from this study have also demonstrated that the increase in serum CREA 
was partially reversible even when treatment was administered in the long term (12 
months).  
The clinical significance of this reversible increase in serum CREA observed with FF 
therapy is unclear. However, several hypotheses have been proposed to explain the 
underlying mechanism. One of such views is that FF therapy impairs the synthesis of 
vasodilatory prostaglandins in the kidney, leading to decreased dilation of the afferent 
arteriole, thereby compromising glomerular capillary pressure and a reduced 
perfusion of the kidneys (Tsimihodimos et al., 2005). Other studies have indicated 
that FF competitively inhibits CREA secretion in the proximal tubular lumen leading to 
accumulation in the blood (Lipscombe et al., 2001). Some reports also suggest that 
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FF therapy leads to over-production of CREA from damaged muscles (Hottelart, et 
al., 2002). Abbas et al., (2012) suggested analytical interference with methods used 
to measure CREA concentration is responsible for the increase in CREA 
concentration observed with FF therapy. Evidence from studies by Hottelart et al., 
(2002) and Ansquer et al., (2008) comparing the Jaffe colorimetric method with the 
high performance liquid chromatography (HPLC) and mass spectrometry, 
respectively, suggest that the increase in serum CREA observed during FF therapy is 
not method dependent.  A more generally accepted view is that FF therapy leads to a 
decrease in GFR and consequently an increase in serum CREA (Ncube et al., 2012). 
In this study, none of the participants complained of muscle pains, or demonstrated 
serum CK or an LDH level that was clinically significant during the treatment period. 
These results make over-production of creatinine less likely the cause of FF-
associated creatininaemia. Although spot urine creatinine concentration decreased 
significantly as serum CREA was increased during the first three months of FF 
therapy, inhibition of CREA secretion or decrease CREA excretion cannot be 
excluded as possible causes of the increase in serum CREA, because urine CREA 
can vary a lot based on diet, exercise and hydration levels (Pimenta et al., 2016). 
The results from this study suggest that a reduction in GFR is the major cause of the 
increase of serum CREA in patients receiving FF treatment. The concomitant 
increase in serum CREA and serum urea concentrations (independent markers of 
kidney function), suggests that the decrease in GFR is a major cause of the increase 
in serum CREA in patients receiving FF therapy. Thus, indicating a genuine impact of 
FF therapy on the kidney function. 
Previous studies have also shown that FF therapy reduces serum UA levels in 
patients with and without gout. In a double-blind, placebo-controlled trial over 6 
weeks in men with hypertriglyceridaemia, Bastow et al., (1988) observed a 20% 
reduction in serum UA with FF but not with bezafibrate (another fibric acid derivative). 
In another placebo-controlled study, Feher et al., (1999) also showed that FF 
administered for 12 weeks reduced serum UA by 31% in patients with type 2 
diabetes mellitus and hypercholesterolaemia. Noguchi et al., (2004) had also shown 
that FF (300 mg/day) for 12 weeks decreased serum uric acid concentration by 36% 
and increased FEUA by 62% in hyperlipidaemic patients. In a longer-term study in 
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patients with either mixed hyperlipidaemia or hypercholesterolaemia treated with FF, 
De La Serna and Cardaso (1999) demonstrated a 23% reduction in serum UA at 3 
months, which was maintained for 2 years. A recent study by Waldman et al., (2018) 
also showed that FF reduced serum UA by 20%, and almost halved gout events over 
5 years of treatment in adult patients with type 2 diabetes.  
This study also confirmed that FF administered at 160 mg/day is associated with a 
significant reduction in serum UA levels in dyslipidaemic patients with normal 
baseline UA levels, via increased` renal UA clearance. The results also showed that 
the impact of FF on serum UA decreased as treatment was continued in the longer-
term. This unique effect of FF compared with other fibric acid derivatives, on renal 
UA clearance has been attributed to its unique chemical structure (Desager et al., 
1980). The mechanism is considered to be through the inhibition of a protein 
encoded by the gene SLC22A12, also known as urate transporter 1 or URAT1 by 
fenofibric acid, the major metabolite of FF. URAT1 is the central mediator in the 
transport of uric acid from the kidney into the blood (Uetake et al., 2010).  
 
3.4.2 FF therapy associated with a reduction in liver enzymes 
Here, the impact of FF therapy on routine clinical biomarkers of liver function, namely 
ALB, TBIL, ALT, ALP, AST and GGT, was examined. Several studies have reported 
that serum ALT and AST levels were increased in some patients who received fibrate 
therapy (Chatrenet et al., 1993; Bernard et al., 1994). The increase in these liver 
enzymes is generally mild (less than three times the upper limit of normal), 
sometimes transient and not accompanied by any finding suggestive of 
hepatotoxicity (Kobayashi et al., 2009). However, results from this study 
demonstrated a decrease in liver enzymes, with a significant reduction in serum ALP 
and GGT, but also a moderate reduction in serum AST and ALT following FF (160 
mg/day) treatment. The decrease in serum ALP and GGT enzymes was greater in 
participants with higher baseline values. 
Liver plays a crucial role in lipid metabolism. Defective fatty acid homeostasis 
regulation may induce lipotoxic tissue damage, including hepatic steatosis (Browning 
and Horton, 2004). PPARα is the most abundant isoform of PPAR in hepatocytes 
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and is involved in many aspects of lipid metabolism (Kersten, 2014), including fatty 
acid degradation, synthesis, transport, storage, lipoprotein metabolism and 
ketogenesis during fasting (Kersten et al., 1999). Fibrates, including FF, bind PPARα 
nuclear receptors and following dimerisation with RXR forms PPRE that in turn 
regulates gene transcription. FF is also known to modify the transaminase gene 
expression without cytotoxicity via the PPARα pathway activation (Thulin et al., 
2008).  
Previous studies on the effect of FF on liver function have provided contrasting 
reports. While some studies have suggested that FF therapy improves liver function 
(Gandhi et al., 2014), cases of chronic active hepatitis of autoimmune origin and 
severe fibrosis have been reported after treatment with FF (Chatrenet et al., 1993; 
Bernard et al., 1994). Results from in vitro studies have shown that FF can modify 
the expression of the ALT and AST genes in animal and human hepatocytes and to 
increase the activities of these enzymes in a PPARα-dependent manner in human 
hepatocytes (Thulin et al., 2008). The gene modification and elevations of the 
enzyme activities of ALT and AST in the hepatocytes are considered to be related to 
the pharmacological action of FF, independently of any toxic phenomenon 
(Tomkiewiecz et al., 2004). Kobayashi et al., (2009) reported increase in plasma ALT 
and AST activities in rats treated with 400 mg/kg of FF after 24 and 48 hours, 
respectively, and suggested that plasma ALT is more sensitive than AST to FF 
therapy. The increases in plasma ALT and AST were slight and not accompanied by 
any changes in other liver function tests including LDH, ALP, and TBIL levels.  
In this study, FF (160 mg/day) treatment caused a moderate reduction in serum ALT 
and AST and a significant reduction in serum ALP and GGT concentrations as 
described in earlier studies by Ganotakis et al., (2002). These findings are also 
consistent with those of Gandhi et al., (2014) who demonstrated a significant 
reduction in levels of GGT, ALT and ALP, following treatment with fibrates in patients 
with a metabolic syndrome. The greatest impact was observed on serum ALP levels. 
This study also revealed that the impact of FF therapy on the liver enzymes was 
greater in patients with higher baseline values. The mechanisms underlying the 
decrease in serum ALP by fibrates remain undefined. However, it is speculated that 
changes in hepatic fat deposition may be involved in the profound decrease in serum 
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cholestatic enzymes (Mikhailindis et al., 1998). In another hypothesis, Day et al., 
(1993) suggest that the decrease in liver ALP activity is attributed to reduction in the 
rate of liver ALP release, resulting from a reduction in the rate of hepatic bile acid 
secretion. The decrease in ALP activity has been used as a reliable marker for 
patients’ compliance to fibrate therapy (Mikhailindis et al., 1998).  
 
3.4.3 FF reduced serum TRIG and increased HDL cholesterol levels 
FF therapy is used primarily to reduce elevated levels of TRIG, but it may also 
reduce LDL cholesterol levels and induce a moderate increase in HDL cholesterol in 
patients with mixed dyslipidaemia (Farnier, 2008). Previous studies have shown that 
FF monotherapy decreases serum TRIG levels by 20% - 50% and increases HDL 
cholesterol levels by 10% - 50% (Knopp et al., 1987; Sasaki et al., 2002; Birjmohun 
et al., 2005). Results of the FIELD study, a 5-year, randomised, placebo-control trial 
testing the safety and efficacy of FF 200 mg in type 2 diabetic patients showed that 
FF decreased serum TRIG and LDL cholesterol levels moderately (by 29% and 12%, 
respectively) and increased HDL cholesterol by 5% after 4 months of therapy (Keech 
et al., 2005). A recent study by Ncube et al., (2012) demonstrated that FF (267 
mg/day) reduced serum TRIG and serum CHOL levels by 38.8% and 22.2%, 
respectively, but did not have any significant effect on serum HDL cholesterol level 
after 3 months of treatment.  
This study showed the FF therapy reduced median serum TRIG concentration (20% 
– 37%) and increased median HDL cholesterol concentration (7% – 13%), but did not 
impact serum CHOL levels in all the groups of participants. FF reduces serum TRIG 
levels by inhibiting their synthesis and stimulating their clearance. A number of 
mechanisms have been described through which FF reduces serum TRIG levels. In 
one of these mechanisms, FF induces fatty acid oxidation, thereby reducing the 
availability of fatty acids for the synthesis and secretion of VLDL, which contains a 
very high amount of TRIG (Gotto, 1990; Minnich et al., 2001). FF may also augment 
LPL activity leading to increased hydrolysis of TRIG on several lipoproteins (Staels et 
al., 1998). It is also reported that FF can reduce serum TRIG by decreasing apo C-II 
and apo C-III expressions in the liver via PPAR-α activation, thereby enhancing 
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catabolism of TRLs. Apo C proteins are crucial for TRIG metabolism. Apo C-III delays 
catabolism of TRLs by inhibiting their binding to the endothelial surface and 
subsequent lipolysis by LPL (Malmendier et al., 1989).  
This study also showed a moderate rise (7% - 13%) in serum HDL cholesterol 
concentration after 3 - 6 months of FF treatment. This is consistent with the findings 
of the FIELD study, which showed a moderate increase in HDL cholesterol after 4 
months of treatment. FF is known to improve HDL cholesterol levels by promoting 
apo A-I and apo-II synthesis in the liver, which may contribute to the increase in 
serum HDL concentrations and a more efficient RCT pathway (Staels et al., 1998). 
FF may increase pre-ꞵ1-HDL cholesterol levels in patients with metabolic syndrome, 
reduce total plasma cholesteryl ester transfer protein activity, induce the activity of 
ABCA1, member of the human transporter subfamily, also known as the cholesterol 
efflux regulatory protein (CERP), and may also induce hepatic lipase activity.  
Results from various studies have shown that FF decreases serum CHOL levels in 
patients with dyslipidaemia. It is suggested that FF and other drugs of the fibrate 
class reduce CHOL by decreasing CHOL synthesis via inhibition of HMG-CoA 
reductase and increasing CHOL excretion in the bile pool (Schneider et al., 1985; Li 
and Chiang, 2009). The evidence from this study did not demonstrate any 
improvement in serum CHOL levels and suggests that FF administered at 160 
mg/day may not be effective for reducing serum CHOL levels in patients with mixed 
dyslipidaemia. 
 
3.4.4 Impact of FF therapy on markers of inflammation and muscle damage 
Serum CRP is the most frequently tested inflammatory marker and high serum levels 
have been associated with increased risk of CVD (Ridker, 2003). Dyslipidaemia 
together with inflammatory processes play an important role not only in the 
pathogenesis of atherosclerosis but also in the occurrence of acute coronary 
syndromes (Ross, 1999; Libby, 2001). FF therapy has been shown to reduce serum 
CRP levels in both experimental studies and clinical trials (Hao et al., 2012; Min et 
al., 2012; Noureldein et al., 2015). Thus, suggesting that FF therapy may also have a 
role in curbing inflammation in patients with dyslipidaemia. However, the anti-
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inflammatory effect of FF remains controversial because in other studies FF therapy 
failed to reduce serum levels of CRP (Kim, 2006; Mulvey et al., 2012).  
This study showed that FF (160 mg/day) therapy did not reduce serum CRP levels in 
patients with dyslipidaemia. This study supports the reports by Kim (2006) and 
Mulvey et al., (2012). Kim (2006) showed that treatment with FF (200 mg/day) for 2 
months failed to reduce serum CRP levels in hypertriglyceridaemic patients. In 
another related study, Mulvey et al., (2012) also demonstrated that FF 145 mg/day 
for 8 weeks did not cause a significant reduction in CRP and failed to suppress 
inflammatory responses in healthy volunteers. This contradicts reports by Wu et al., 
(2007) who demonstrated a 36% decrease in serum high-sensitivity CRP level in 
patients with metabolic syndrome after 12 weeks of FF therapy and those by Min et 
al., (2012) who also reported a reduction in serum CRP levels after 2 months of FF 
(200 mg/day) therapy in hyperlipidaemic patients with high CRP and/or low LDL 
CHOL levels and without severe overweight. The reason for such disparities has not 
been established. 
All fibrates are associated with rhabdomyolysis either in monotherapy or combined 
with statins and other agents. The highest rates of fibrate-associated rhabdomyolysis 
have been reported with gemfibrozil, followed by bezafibrate, FF, ciprofibrate, and 
clofibrate (Wu et al., 2009). Evidence of FF-associated rhabdomyolysis has been 
described in several case studies and close supervision of patients treated with FF, 
and patient education about potential side effects have been advocated (Barker et 
al., 2003). This study did not show any significant impact of FF (160 mg/day) therapy 
on skeletal muscles as patient results were within acceptable reference ranges for 
both CK and LDH. Also, none of the patients reported any symptoms that may be 
associated with muscle injury. These findings suggest that FF (160 mg/day) 
treatment is safe in dyslipidaemic patients with normal baseline kidney function and 
thyroid function. However, close patient monitory is still recommended in patient 
receiving FF therapy, most particularly in those with increased risks of 
rhabdomyolysis. 
Fombon, I.S. (2020) 
162 
 
3.4.5 Thyroid function tests unchanged by FF therapy 
Previous studies have shown that hypothyroidism is closely associated with both 
dyslipidaemia and kidney dysfunction (Yuan et al., 2015). In a research study in 
Colorado, Canaris et al., (2000) demonstrated that lipid levels increased in a graded 
fashion as thyroid function declined. In the Nord-Trondelag Health Study (HUNT), 
Asvold et al., (2011) demonstrated that CKD was more common in subjects with 
hypothyroidism; even within the reference range. The prevalence of CKD was shown 
to gradually increase as serum thyrotropin levels increased. These results suggested 
that both kidney function and lipid metabolism could be modulated by thyroid 
function. Evidence from several case studies has shown that hypothyroidism (overt 
or subclinical form) is a risk factor for FF-associated rhabdomyolysis in patients with 
dyslipidaemia (Kato et al., 2011).  
Reports by Gullu et al., (2005) showed that simvastatin administered to patients with 
subclinical hypothyroidism secondary to autoimmune thyroid disease led to a 
reduction in serum TSH levels, accompanied by an increase in free thyroid 
hormones. According to the authors of this study, this effect was due to proapoptotic 
properties of statins. Krysiak et al., (2011) reported that FF exhibited a similar effect 
to that of simvastatin on the secretory function of human monocytes and lymphocytes 
and on system inflammation in mixed dyslipidaemia with type 2 diabetes. However, 
no previous studies have examined the effect of FF on thyroid function. This study 
has shown that FF (160 mg/day) does not have any significant impact on thyroid 
function in dyslipidaemic patients with normal baseline thyroid function. The results 
suggest that the decrease in kidney function observed with FF therapy in this study 
was not associated with changes in thyroid function.  
 
3.5 SUMMARY 
This study confirms that FF (160 mg/day) is associated with a moderate increase in 
serum CREA and serum urea concentrations, and a decrease in GFR estimated 
using the MDRD and CKD-EPI Creatinine (2009) equations. The study results also 
showed that treatment with FF at 160 mg/day would cause a significant reduction in 
serum UA via increased urinary excretion of UA. Another important finding of this 
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study is that FF (160 mg/day) would reduce liver function enzymes (ALT, AST, GGT 
and ALP) in patients with dyslipidaemia. The clinical significance of the decrease in 
liver enzymes is unclear. As expected, FF therapy caused a moderate reduction 
serum TRIG level and an increase in HDL cholesterol level but did not have any 
significant impact on serum CHOL level. FF therapy also failed to reduce serum CRP 
levels and had no significant impact on skeletal muscle enzymes and markers of 
thyroid function.  
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Chapter 4 
Utility of CYSC as biomarker of kidney function in 
patients receiving FF treatment for dyslipidaemia 
4.1 INTRODUCTION 
FF is the preferred hypolipidaemic drug for the treatment of dyslipidaemia 
characterised by elevated levels of TRIG and reduced levels of HDL cholesterol, with 
or without elevated LDL cholesterol (Tziomalos and Athyros, 2006). However, due to 
its association with elevated levels of serum CREA (inferred nephrotoxicity); routine 
kidney function monitoring has been recommended in patients receiving FF, 
particularly in those with pre-existing CKD (Davidson et al., 2007, Mychaleckyj et al., 
2012; Ncube et al., 2012). The GFR is considered as the best overall measure of 
kidney function (Stevens et al., 2006). It is a measure of the volume of fluid that is 
filtered from the kidney glomerular capillaries into the Bowman’s capsule per unit of 
time. However, reference methods for estimating the GFR such as the use of 
exogenous markers (inulin, 51CrEDTA, 99mTcDTPA, 125I-iothalamate and iohexol) are 
impractical in the clinical setting and for large research studies, because they are 
complex, time-consuming, labour-intensive and expensive and require administration 
of substances that make them incompatible with routine monitoring (Hojs et al., 2011, 
Stevens, et al., 2006).  
Assessment of kidney function in clinical practice is largely dependent on 
measurement of serum CREA, CREA clearance and estimates of glomerular filtration 
rate (eGFR) derived from serum CREA-based equations (Stevens et al., 2006). 
However, serum CREA is not a very sensitive marker in diagnosing early stages of 
kidney disease. Several limitations of serum CREA and CREA clearance for the 
estimation of GFR are well documented (Sica, 2009). It is known that the serum level 
of CREA increases above the normal upper reference range when there is more than 
50% reduction in GFR, leading to delayed diagnosis of kidney disease (Prigent, 
2008). Serum levels of CREA are also affected by several factors that are 
independent of changes in GFR such as muscle mass, age, gender, race, medication 
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use, catabolic state, tubular secretion and extra-renal elimination in severe renal 
impairment (Perrone et al., 1992). Although anthropometric data have been 
incorporated into various serum creatinine-based formulas in an attempt to improve 
the estimation, GFR from serum CREA are reported to be affected by bias and 
imprecision, and their use in clinical diagnostics have been questionable (Hojs et al., 
2011). Also, the methods used to measure serum creatinine have been shown to 
interfere with the accuracy of the GFR estimation formulae (Hojs et al., 2008). 
Among several novel endogenous biomarkers of kidney function that have been 
tested, CYSC has been proposed as the best alternative marker to CREA, which can 
detect early kidney disease (Hojs et al., 2008, Bolignano, et al., 2010). CYSC is a 
non-glycosylated, 13.3-kDa protein belonging to the cystein protease inhibitor family 
(Shiplak et al., 2013). It is produced in the body by all nucleated cells at a relatively 
constant rate and is freely filtered across the glomerular membrane and almost 
completely reabsorbed and catabolised by the proximal tubules of the kidneys. Unlike 
serum CREA, serum CYSC level is independent of muscle mass, gender, race and 
metabolic state (Bagshaw and Bellomo, 2010). It is also shown to be a sensitive early 
indicator of decreased renal function. However, further studies are recommended to 
fully evaluate the potential advantages and limitations of CYSC before it is ready to 
supplant CREA as the most widely used GFR marker. Previous studies by Forsblom 
et al., (2010), Ncube et al., (2012) and Mychaleckyj et al., (2012) demonstrated 
concomitant increase in serum CREA and serum CYSC following short-term and 
long-term administration of FF treatment, but whether CYSC is a better biomarker 
than CREA in monitoring kidney function in patients receiving FF therapy is not fully 
elucidated. 
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4.2 SPECIFIC AIMS 
CYSC has been proposed as a better marker of assessing the kidney function. In this 
study, we investigated whether serum CYSC is a better marker than serum CREA for 
monitoring kidney function in patients receiving FF therapy, with the following 
objectives: 
1. To determine the analytical performance of Gentian CYSC assay using the 
Beckman Coulter AU640 analyser. 
2. To investigate the impact of FF (160 mg/day) therapy on serum CYSC and 
CREA concentrations in patients with dyslipidaemia. 
3. To compare changes in serum CYSC- and CREA-based eGFRs in patients 
administered FF therapy for dyslipidaemia. 
4. To examine the concordance between serum CREA- and CYSC-based 
equations for estimating GFR in patients administered FF therapy for 
dyslipidaemia. 
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4.3 RESULTS 
4.3.1 Analytical performance of Gentian CYSC on the Beckman Coulter AU640 
analyser 
Gentian CYSC Assay precision 
The intra-assay (within-run) precision of the Gentian CYSC assay on the Beckman 
Coulter Olympus AU640 analyser was determined by measuring 10 aliquots of each 
of three pools of serum samples prepared in the laboratory to give a low, normal and 
high concentration of serum CYSC, respectively. All the aliquots were analysed in a 
single batch. The inter-assay (between-run) precision was determined by measuring 
aliquots of the three serum pools and two levels of control materials supplied by the 
manufacturer, across ten working days. The intra-assay and inter-assay coefficients 
of variation (CV) for the Gentian CYSC on the AU640 analyser are summarised on 
Table 4.1. All the CV for the serum pools were lower than the values estimated by 
the Gentian CYSC kit manufacturers’ i.e. 1.76 and 3.88% for quality controls level 1 
(target value: 0.95 mg/L) and level 2 (target value: 3.52 mg/L), respectively. This 
suggests a better precision for determining serum CYSC on the AU640 analyser 
using the Gentian CYSC kit than specified by the manufacturers. 
Gentian CYSC Assay Sensitivity 
The limit of blank (LoB), limit of detection (LoD) and limit of quantification (LoQ) for 
the Gentian CYSC assay on the Olympus AU640 analyser were determined as 0.07 
mg/L, 0.13 mg/L, and 0.36 mg/L, respectively. These results support the 
manufacturer’s claim of an LoQ of less than 0.5 mg/L for the AU680 systems, which 
are modified versions of the AU640 analysers. 
Gentian CYSC Assay Linearity and analytical recovery 
Assay linearity was confirmed by making measurements using solutions containing 
known concentrations of CYSC. The linear regression analysis showed a line with a 
good correlation coefficient (y = 1.005x + 0.5179; R2 = 0.9988) over the entire range 
tested (from 0.21 – 7.9 mg/L). The maximum deviation between estimated and 
measured CYSC was 3.8%, while the rest of the samples showed deviations of less 
than 2.0% (Figure 4.1). To determine the analytical recovery of the assay, a pool of 
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serum sample was diluted in normal saline (0.9%, w/v) to give six separate sera and 
then analysed. Analytical recovery ranged from 84% to 107%, with the lowest 
recovery seen in the most diluted sample (Table 4.2). The results suggest that the 
assay tends to under-recover below the LoQ (0.36 mg/L) and slightly over-recovers 
within the linear limit of the assay (0.45 – 8.0 mg/L). 
Comparison of Gentian CYSC Assay using the Olympus AU640 analyser and 
the Jaffe CREA method 
A comparison of the Gentian CYSC assay on the Olympus AU640 analyser and the 
Jaffe (compensated) CREA method was made using 20 serum samples and 
following the CLSI EP9-A3 guideline. The results showed a strong positive 
correlation (r = 0.9830, p<0.0001) between the two methods within the range 0.70 – 
4.09 mg/L, with intercept at 0.45 mg/L (95% CI 0.29 – 0.64) and a slope of 0.008 
mg/L (95% CI 0.007 – 0.009) (Figure 4.2). 
Stability of CYSC in serum sample 
The stability of CYSC was examined in 40 serum samples stored at -80C for 30 
months. The samples were subjected to a single freeze thaw cycle. The difference 
between the median CYSC concentration before (0.79 mg/L; IQR 0.69 – 7.60 mg/L) 
and after storage (0.72 mg/L; IQR 0.60 – 7.8 mg/L) was not statistically significant 
(p=0.1863, n=40). These results suggest that storage of serum samples for 30 
months at -80C did not have any significant impact on the level of CYSC in the 
samples.  
Collectively, these results confirmed the manufacturers’ specifications of the various 
parameters tested and suggest that Gentian CYSC assay performs well and often 
exceed the manufacturers’’ specifications on the Beckman Coulter AU640 analyser 
and can be used to analyse and/or compare serum CYSC and serum CREA as 
biomarkers of kidney function in patient samples within the range of specifications. 
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Table 4.1 Summary of imprecision data of the Gentian CYSC on Olympus 
AU640 analyser 
 Pool 1 Pool 2 Pool 3 QC1* QC2* 
Intra-assay      
Mean (mg/L) 0.87 2.48 6.10   
SD¥ 0.01 0.03 0.06   
CV§ (%) 0.91 1.26 0.99   
Inter-assay      
Mean (mg/L) 0.88 2.53 6.19 0.89 3.38 
SD¥ 0.01 0.04 0.10 0.02 0.13 
CV§ (%) 1.36 1.42 1.54 1.78 3.88 
*QC, quality control; 
¥
SD, standard deviation; 
§
CV, coefficient of variation (n=10). 
 
Table 4.2 Analytical recovery of the Gentian CYSC* assay on Olympus AU640 
analyser 
Pool 
(dilution) 
Estimated (mg/L) Measured (mg/L) Recovery (%) 
Neat 7.90 7.90 100 
1:2 3.95 4.20 106.3 
1:4 1.98 2.07 104.5 
1:8 0.99 1.05 106.1 
1:16 0.49 0.52 106.1 
1:32 0.25 0.21 84 
*CYSC, serum cystatin C 
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Figure 4.1 Representative plot of the linearity of the Gentian CYSC assay.  
A patient sample was diluted with increasing amounts of normal saline (0.9% NaCl) 
and CYSC concentration was measured in the diluted samples. Data shows measured 
values of CYSC (y-axis) plotted against the estimated values of CYSC (x-axis). The 
solid line represents the linear regression line; the dotted line represents the upper and 
lower 95% confidence intervals. Each sample was run in triplicate (n=6). 
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Figure 4.2 Correlation between Gentian CYSC and CREA by the Jaffe 
(compensated) method on the AU640 analyser.  
Serum samples not more than 5 days old kept at 4 - 8°C were analysed on the Beckman 
Coulter AU640 analyser for serum CYSC and CREA and correlation between the two assays 
was determined using the Spearman’s correlation coefficient (r=0.9786, p<0.001, n=15); 
CYSC, cystatin C; CREA, creatinine. 
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4.3.2 Impact of FF therapy on serum CREA, CYSC and eGFR calculated using 
CREA- and CYSC-based equations  
The impact of FF therapy on serum CYSC and serum CREA levels was examined 
during 12 months of FF therapy in patients with dyslipidaemia. Changes in GFR 
estimated using CREA-based equations were compared with those calculated by 
CYSC-based formulas. The participants were placed into five groups (A – E) based 
on samples provided as described earlier (Chapter 2.2.2 – Study participants). The 
serum CREA-based formulas used in this study included the MDRD and CKD-EPI 
CREA equations, while the serum CYSC-based formulas were the Gentian and CKD-
EPI CYSC equations. The performance of the combined CKD-EPI CREA-CYSC-
based equation derived by Inker et al., (2012) was also examined. First, the impact of 
FF therapy administered for 3, 6 and 12 months on the concentration of serum 
CREA, serum CYSC and the eGFR calculated using the various equations was 
examined. Results of the various parameters measured before starting treatment and 
after 3, 6 and 12 months of FF therapy are summarised in Table 4.3.  
In Group A, the impact of 3 months of FF therapy on serum CYSC, CREA and the 
eGFR calculated using the various equations was examined in 13 participants (9 
male and 4 female) with median age 51 years (range 37 – 65 years). The results 
showed a significant increase in the median serum CREA concentration (p=0.0015, 
n=13), but the change in the median serum CYSC concentration was not statistically 
significant (p=0.1619, n=13). A significant reduction in the median eGFR was 
observed when it was calculated using MDRD and CKD-EPI CREA equations 
(p=0.0039 and p=0.0229, respectively). The changes in the median eGFR calculated 
using the Gentian and CKD-EPI CYSC equations were not statistically significant 
(p=0.3140 and p=0.1853, respectively). However, a statistically significant reduction 
in the eGFR was observed with the CKD-EPI CREA-CYSC equation (p=0.0422, 
n=13).  
Results from individual participants at baseline and after 3 months of FF therapy are 
presented in Figure 4.3. After 3 months of FF therapy, serum CREA concentration 
was increased in 11 participants (84.6%, n=13), while serum CYSC was increased in 
10 participants (76.9%, n=13). A concomitant increase in serum CREA and CYSC 
concentrations was observed in nine participants (69.2%, (n=13), while in two 
Fombon, I.S. (2020) 
173 
 
subjects an increase in serum CREA was accompanied by a decrease in serum 
CYSC. A decrease in both parameters was also observed in one subject, where a 
4.2% decrease in serum CREA was accompanied by a 27.9% decrease in serum 
CYSC. In one subject, the serum CREA level was not changed, but serum CYSC 
was increased by 18.8%. The change in eGFR in the individual study participants 
reflected the change in their serum CREA and serum CYSC concentrations; i.e. the 
eGFR was reduced in the participants in whom serum CREA and serum CYSC levels 
were increased and the eGFR was increased in those whose serum CREA and 
serum CYSC levels were reduced. These results suggest that administration of FF at 
160 mg/day for 3 months would cause a moderate increase in serum CREA and 
CYSC concentrations, and a mild reduction in kidney function in some patients. The 
impact of FF was greater on serum CREA than CYSC and also varied among the 
participants. 
The impact of 6 months of FF therapy on serum CYSC serum CREA and the eGFR 
calculated using the different equations was examined in 10 participants.(7 male and 
3 female) in Group B, median age 51 years (range 37 – 63 years). As shown in 
Table 4.3, the changes in the median serum CREA and serum CYSC concentrations 
after 6 months of FF therapy were not statistically significant. However, a 14.5% 
increase in the median serum CREA was observed. Also, the changes in the median 
eGFR calculated using both the serum CREA-based and serum CYSC-based 
equations were not statistically significant. Individual study participant results showed 
that serum CREA concentration was increased in eight participants (80%, n=10), 
while serum CYSC concentration was increased in five participants (50%, n=10). 
Both serum CREA and serum CYSC were increased in four participants (40%, n=10), 
while in four others, an increase in serum CREA was accompanied by a decrease in 
serum CYSC. In one subject, a decrease in serum CREA was accompanied by a 
decrease in serum CYSC, and in another, serum CREA was decreased by 8.9% 
while serum CYSC was increased by 10.3% (Figure 4.4). 
Results from individual participants also showed that the eGFR was reduced in 
seven participants (70%, n=10) when it was calculated using the MDRD and CKD-
EPI CREA equations. However, with the Gentian, CKD-EPI CYSC and CKD-EPI 
CREA-CYSC equations, the eGFR was reduced in five participants (50%, n=10). 
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These results suggest that FF administered at 160 mg/day for 6 months would cause 
a moderate increase in the serum CREA and CYSC concentrations and a mild 
reduction in kidney function estimated using both serum CREA- and CYSC-based 
equations. These results also showed a greater impact on serum CREA than on 
serum CYSC and that the CREA-based equations tend to underestimate the GFR, 
compared with the CYSC-based equations. The impact of FF on serum CREA and 
CYSC also varied amongst the participants. 
In Group C, the impact of 12 months of FF therapy on serum CREA, CYSC and the 
eGFR calculated using the different equations was examined in eight participants.(5 
male and 3 female) with median age 53 years (range 40 – 65 years). The median 
serum CREA and serum CYSC did not change significantly from baseline values. 
However, the median serum CREA was increased by 11.8% (p=0.0703, n=8) and 
serum CYSC by 6.6% (p>0.9999, n=8). The median eGFR was significantly reduced 
when it was calculated using the CKD-EPI CREA equation (p=0.0391, n=8). 
Changes in the eGFR estimated using all the other equations were not statistically 
significant. Individual participant results showed that the serum CREA concentration 
was increased in six participants (75%, n=8), while serum CYSC was increased in 
four participants (50%, n=8) (Figure 4.5). A concomitant increase in both markers 
was observed in three participants (37.5%, n=8). In three others an increase in serum 
CREA was accompanied by a decrease in serum CYSC concentration. However, in 
one subject, a 5.2% increase in serum CREA was accompanied by a 28.6% increase 
in serum CYSC (Figure 4.5). 
Again, these results suggest that FF therapy administered for 12 months had greater 
impact on serum CREA than on serum CYSC. The CREA-based eGFR equations 
underestimated the eGFR compared with CYSC-based equations. The results also 
suggest that the impact of FF therapy on serum CREA, CYSC and the eGFR 
calculated using the CREA- and CYSC-based equations decreases as treatment 
time is increased. 
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Table 4.3 Effect of FF therapy on serum CYSC, serum CREA and eGFR 
calculated using CYSC-based and CREA-based equations 
Parameters Baseline 3 Months P value 
Number of patients (n) 13 13  
Age [Years; median (range)] 51 (37 – 65) 51 (37 – 65)  
Serum CREA (µmol/L) 87 (70 – 101) 97 (72 – 121) 0.0015** 
Serum CYSC (mg/L) 1.0 (0.73 – 1.20) 0.99 (0.74 – 1.40) 0.1619 
MDRD
¥
 (mL/min/1.73 m
2
) 78 (67 – 87) 73 (55 – 77) 0.0039** 
Gentian CYSC
‡
 (mL/min/1.73 m
2
) 76 (65 – 127) 81 (52 – 125) 0.3140 
CKD-EPI CREA
§
 (mL/min/1.73 m
2
) 84 (68 – 98) 81 (59 – 87) 0.0229* 
CKD-EPI CYSC
#
 (mL/min/1.73 m
2
) 77 (66 – 116) 77 (57 – 103) 0.1853 
CKD-EPI CREA-CYSC
†
 (mL/min/1.73 m
2
) 85 (70 – 106) 72 (67 – 94) 0.0422* 
Parameters Baseline 6 Months P value 
Number of patients (n) 10 10  
Age [Years; median (range)] 51 (37 – 63) 51 (37 – 63)  
Serum CREA (µmol/L) 88 (71 – 98) 96 (76 108) 0.1934 
Serum CYSC (mg/L) 1.1 (0.67 – 1.20) 1.0 (0.65 – 1.30) >0.9999 
MDRD
¥
 (mL/min/1.73 m
2
) 75 (68 – 85) 70 (61 – 80) 0.2031 
Gentian CYSC
‡
 (mL/min/1.73 m
2
) 74 (64 – 144) 80 (56 – 156) 0.4766 
CKD-EPI CREA
§
 (mL/min/1.73 m
2
) 81 (71 – 97) 79 (66 – 91) 0.5332 
CKD-EPI CYSC
#
 (mL/min/1.73 m
2
) 73 (66 – 108) 77 (60 – 118) 0.6406 
CKD-EPI CREA-CYSC
†
 (mL/min/1.73 m
2
) 82 (71 – 103) 84 (67 – 98) 0.6094 
Parameters Baseline 12 Months P value 
Number of patients (n) 8 8  
Age [Years; median (range)] 53 (40 – 65) 53 (40 – 65)  
Serum CREA (µmol/L) 85 (61 – 98) 95 (59 - 119 0.0703 
Serum CYSC (mg/L) 0.76 (0.60 – 1.10) 0.81 (0.50 – 1.10) >0.9999 
MDRD
¥
 (mL/min/1.73 m
2
) 82 (68 – 91) 73 (55 – 94) 0.1484 
Gentian CYSC
‡
 (mL/min/1.73 m
2
) 120 (68 – 171) 111 (70 – 230) 0.9453 
CKD-EPI CREA
§
 (mL/min/1.73 m
2
) 91 (72 – 100) 80 (59 – 100) 0.0391* 
CKD-EPI CYSC
#
 (mL/min/1.73 m
2
) 98 (69 – 118) 100 (69 – 135) 0.7266 
CKD-EPI CREA-CYSC
†
 (mL/min/1.73 m
2
) 97 (74 – 109) 92 (59 – 121) 0.7969 
Data are presented as median (IQR); IQR, interquartile range. CREA, creatinine; ¥MDRD, 
Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); ‡CYSC, cystatin C; #CKD-EPI CYSC, Chronic 
Kidney Disease Epidemiology Collaboration Cystatin C (2012); †CKD-EPI CREA-CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C (2012); 
significant differences between the median concentrations were determined using the 
Wilcoxon signed-rank test; *p<0.5, **p<0.01. 
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Figure 4.3 Effect of 3 months of FF on serum CREA, CYSC and eGFR 
calculated by the different equations after 3 months of FF therapy.  
Scatter plots showing individual participant’s levels of (A) serum CREA, (B) serum CYSC, 
and eGFR calculated by (C) MDRD, (D) Gentian, (E) CKD-EPI CREA, (F) CKD-EPI CYSC 
and (G) CKD-EPI CREA-CYSC at baseline (0) and 3 months of FF therapy. Significant 
differences between median concentrations were analysed using the Wilcoxon signed rank 
test, p<0.05 was considered to be statistically significant. 
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Figure 4.4 Effect of 6 months of FF on serum CREA, CYSC and eGFR 
calculated using the CREA- and CYSC-based equations. 
Scatter plots showing individual participant’s levels of (A) serum CREA, (B) serum CYSC, 
and eGFR calculated by (C) MDRD, (D) Gentian, (E) CKD-EPI CREA, (F) CKD-EPI CYSC 
and (G) CKD-EPI CREA-CYSC at baseline (0) and 6 months of FF therapy. Significant 
differences between median concentrations were analysed using the Wilcoxon signed rank 
test; p<0.05 was considered to be statistically significant. 
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Figure 4.5 Effect of 12 months of FF on serum CREA, CYSC and eGFR 
calculated using CREA- and CYSC-based equations.  
Scatter plots showing individual participant’s levels of (A) serum CREA, (B) serum CYSC, 
and eGFR calculated by (C) MDRD, (D) Gentian, (E) CKD-EPI CREA, (F) CKD-EPI CYSC 
and (G) CKD-EPI CREA-CYSC at baseline (0) and 12 months of FF therapy. Significant 
differences between median concentrations were analysed using the Wilcoxon signed rank 
test, p<0.05 was considered to be statistically significant. 
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Next, changes in serum CREA, CYSC and eGFR calculated using both parameters 
were examined in nine participants (6 male and 3 female), median age 53 years 
(range 42 – 65 years) during 6 months of FF therapy. The results obtained at 
baseline, 3 and 6 months after commencing treatment with FF are summarised in 
Table 4.4. The Friedman test indicated that there was a statistically significant 
difference between the median serum CREA and CYSC concentrations at the 
different time points during the 6 months of FF therapy (p=0.0266 and p=0.0476, 
respectively). Post hoc analysis using Dunn’s multiple comparison test showed a 
significant increase in median serum CREA after 3 months (p=0.0286, p=9), but not 
after 6 months. The median serum CYSC was increased by 12.0% after 3 months, 
but was slightly reduced after 6 months of treatment, although the level remained 
higher than baseline value after 6 months of treatment.  
The median eGFR calculated using the MDRD and CKD-EPI CREA equations did 
not change significantly at either 3 or 6 months (p=0.1267 and p=0.1966, 
respectively). However, changes in median eGFR calculated using the Gentian, 
CKD-EPI CYSC and CKD-EPI CREA-CYSC at the different time points during the 6 
months FF therapy was statistically significant (p=0.0476, p=0.0476 and p=0.0231, 
respectively). A significant decrease in the median eGFR was observed after 3 
months with the CKD-EPI CREA-CYSC but not after 6 months of FF therapy. 
Individual participant results showed an initial increase in serum CREA and CYSC 
levels after 3 months and a slight decrease in both parameters after 6 months of 
treatment, although the serum CREA and CYSC concentrations after 6 months of 
treatment remained higher than the baseline value in most of the subjects (Figure 
4.6). A reduction in the eGFR was also observed after the first 3 months of treatment 
and after 6 months, the eGFR was slightly increased although the values after 6 
remained lower than the baseline values (Figure 4.6). 
These results suggest that the impact of FF therapy on the kidney function is greater 
during the first 3 months of treatment, but impact tends to decrease as treatment is 
continued for 6 months. The results confirmed that FF-induced increase in serum 
CREA and CYSC is partially reversible when treatment is administered in the long-
term. The increase in both serum CREA and serum CYSC (independent markers of 
kidney function) suggest that FF therapy genuinely impacts on the kidney function.  
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Table 4.4 Changes in serum CREA, CYSC and eGFR calculated using serum CREA- and CYSC-based equations during 6 
months of FF therapy 
Parameters Baseline 3 Months 6 Months p-value 
Number of patients (n) 9 9 9  
Age [Years; median (range)] 50 (42 – 55) 50 (42 – 55) 50 (42 – 55)  
Serum CREA (µmol/L) 87 (70 – 96) 97 (71 – 121)1 94 (73 – 107) 0.0266* 
Serum CYSC (mg/L) 1.08 (0.69 – 1.17) 1.21 (0.84 – 1.37) 1.12 (0.79 – 1.29) 0.0476* 
MDRD
¥
 (mL/min/1.73 m2) 78 (69 – 85) 73 (55 – 78) 70 (63 – 81) 0.1267 
Gentian CYSC
‡
 (mL/min/1.73 m2) 72 (65 – 146) 61 (51 – 105) 68 (56 – 116) 0.0476* 
CKD-EPI CREA
§
 (mL/min/1.73 m2) 84 (70 – 97) 81 (59 - 89) 81 (68 – 92) 0.1966 
CKD-EPI CYSC
#
 (mL/min/1.73 m2) 69 (66 – 113) 63 (55 – 93) 73 (59 – 105) 0.0476* 
CKD-EPI CREA-CYSC
†
 (mL/min/1.73 m2) 79 (70 – 106) 70 (61 – 86) 81 (66 - 94) 0.0231* 
Data are presented as median (IQR); CREA, creatinine;
 ¥
MDRD, Modification of Diet in Renal Disease; 
§
CKD-EPI CREA, Chronic Kidney 
Disease Epidemiology Collaboration Creatinine (2009); 
‡
CYSC, Cystatin C; 
#
CKD-EPI CYSC, Chronic Kidney Disease Epidemiology 
Collaboration Cystatin C (2012); 
†
CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012); Significant difference between the median concentrations at the different time points were analysed using the Friedman test with 
Dunn’s multiple comparison test; *p<0.05; n=9. 
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Figure 4.6 Changes in serum CREA, serum CYSC and eGFR calculated using 
serum CREA- and CYSC-based equations during 6 months of FF therapy. 
Scatter plots showing individual participant’s levels of (A) serum CREA, (B) Serum CYSC, 
(C) MDRD, (D) Gentian, (E) CKD-EPI CREA, (F) CKD-EPI CYSC and (G) CKD-EPI CREA-
CYSC at baseline (0), 3 and 6 months after commencing FF therapy in nine individual 
participants. Significant difference between median concentrations was analysed using the 
Friedman test with Dunn’s multiple comparison test; *p<0.05, n=9. 
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Furthermore, the impact of FF therapy on serum CREA, serum CYSC and eGFR 
levels during a 12 month period of treatment was examined in four (2 male and 2 
female) participants, median age 51 years (range 42 – 55 years). The median (IQR) 
levels of serum CREA, serum CYSC and eGFR calculated using the CREA- and 
CYSC-based equations at baseline, 3, 6 and 12 months after commencing treatment 
with FF are summarised in Table 4.4. The results showed no significant difference in 
the median levels of all the markers during the treatment period. However, an initial 
increase in the median serum CREA (23.4%) and serum CYSC (43.5%) was 
observed after 3 months of treatment, but the levels were reduced in the course of 
treatment after the following nine months. Similarly, the median eGFR levels were 
initially reduced after 3 months of FF therapy, reflecting the increase in serum CREA 
and serum CYSC and then gradually increased during the following nine months of 
FF therapy.  
Individual study participant results showed that the serum CYSC concentration 
returned to baseline values, but the serum CREA concentration remained slightly 
higher than baseline values (Figure 4.7). It was also observed that the eGFR levels 
returned to baseline values after 12 months of treatment when the eGFR was 
calculated using serum CYSC-based and the combined CREA-CYSC-based 
equations. The median serum CREA-based eGFR returned to values slightly lower 
than the baseline values after 12 months of treatment. These results suggest a 
complete recovery of the kidney function after 12 months of treatment when the 
eGFR was calculated using the CYSC-based equations and a partial recovery when 
the eGFR was calculated using the serum CREA-based equations (Figure 4.7).  
The results have shown that FF therapy is associated with a moderate increase in 
serum CREA and CYSC concentrations with a greater impact on serum CREA 
concentration than serum CYSC concentration. The increase in both serum CREA 
and CYSC (an independent marker of kidney function) is indicative of a genuine 
impact of FF therapy on the kidney function. This study has also shown that the 
impact of FF therapy on the kidney function is partially reversible when eGFR 
assessed by the serum CREA-based eGFR equations and completely reversible 
when assessed using the serum CYSC-based or the combined serum CREA-CYSC-
based eGFR equations. 
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Table 4.5 Changes in serum CREA, CYSC and eGFR, calculated using serum CREA- and CYSC-based equations in 
during 12 months of FF treatment. 
Parameters Baseline 3 Months 6 Months 12 Months p-value 
Number of patients (n) 4 4 4 4  
 
Age (years; range) 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
51 (43 – 57) 
 
 
Serum CREA (µmol/L) 
 
77 (60 – 99) 
 
95 (68 – 122) 
 
90 (70 – 117) 
 
85 (59 – 118) 
 
0.0933 
 
Serum CYSC (mg/L) 
 
0.69 (0.55 – 1.09) 
 
0.99 (0.68 – 1.50) 
 
0.91 (0.54 – 1.31) 
 
0.70 (0.50 – 0.86) 
 
0.3545 
 
MDRD
¥
 (mL/min/1.73 m2) 
 
82 (69 – 93)  
 
60 (54 – 81) 
 
68 (57 – 78) 
 
74 (56 – 96) 
 
0.0819 
 
CKD-EPI CREA
§
 (mL/min/1.73 m2) 
 
91 (75 – 102) 
 
74 (58 – 92) 
 
76 (61 – 89) 
 
83 (60 – 103) 
 
0.0819 
 
Gentian CYSC
‡
 (mL/min/1.73 m2)  
 
146 (74 – 188) 
 
83 (48 – 151) 
 
101 (55 – 206) 
 
134 (102 – 230) 
 
 
0.3545 
 
CKD-EPI CYSC
#
 (mL/min/1.73 m2) 
 
113 (74 – 126)  
 
81 (50 - 110) 
 
 
90 (57 – 127) 
 
111 (96 – 135) 
 
 
0.3545 
 
CKD-EPI CREA-CYSC
†
 (mL/min/1.73 m2) 
 
106 (76 – 116) 
 
76 (54 – 103) 
 
83 (59 - 113) 
 
101 (78 – 121) 
 
0.1576 
 
Data are presented as median (IQR). CREA, creatinine;
 ¥
MDRD, Modification of Diet in Renal Disease; 
§
CKD-EPI CREA, Chronic 
Kidney Disease Epidemiology Collaboration Creatinine (2009); 
‡
CYSC, Cystatin C; 
#
CKD-EPI CYSC, Chronic Kidney Disease 
Epidemiology Collaboration Cystatin C (2012); 
†
CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration 
Creatinine and Cystatin C (2012); Significant difference between the median concentrations at the different time points were analysed 
using the Friedman test with Dunn’s multiple comparison test; p<0.05 was considered to be significant. 
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 Figure 4.7 Changes in serum CREA, serum CYSC and eGFR calculated by 
different equations during 12 months of FF therapy.  
Scatter plots showing the levels of (A) serum CREA, (B) Serum CYSC, (C) MDRD, (D) 
Gentian eGFR, (E) CKD-EPI CREA, (F) CKD-EPI CYSC and (G) CKD-EPI CREA-CYSC 
at baseline (0), 3, 6 and 12 months after commencing FF therapy in four participants. 
Significant differences between median concentrations was analysed using the Friedman 
test with Dunn’s multiple comparison test; n=4. 
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Collectively, these results show that FF (160 mg/L) therapy is associated with a 
moderate increase in serum CREA and CYSC concentrations but with a greater 
impact on serum CREA than CYSC. The impact of FF on the markers of kidney 
function is highest during the first 3 months of treatment and gradually reduces as 
treatment time is increased. Although both biomarkers decreased as FF therapy 
was continued for 12 months, serum CREA remained slightly higher than baseline, 
while cystatin C returned to baseline values. These results suggest that FF 
therapy may have a greater impact on serum CREA than on serum CYSC. The 
eGFR calculated using both serum CREA- and CYSC-based equations was 
decreased during the first 3 months of FF therapy, reflecting the increase in the 
serum markers. While kidney function completely recovered after 12 months of 
treatment when assessed using serum CYSC-based equations, results from 
serum CREA-based equations showed that kidney function remained lower than 
baseline values after 12 months of FF therapy. These results suggest that kidney 
function may be underestimated when calculated using serum CREA-based 
equations compared with the CYSC-based equations. 
 
4.3.3 Comparison between serum CREA- and serum CYSC-based equations 
for calculating the GFR in patients administered FF therapy   
The mean (±SD) of the eGFR calculated using the various equations at baseline, 
3, 6 and 12 months are shown in Figure 4.10. The results revealed that serum 
CYSC-based eGFRs were higher than those obtained by the CREA-based 
equations. The Gentian CYSC equation produced relatively higher eGFR values 
compared with all other equations, while the lowest eGFR values were produced 
by the MDRD equation. The absolute mean difference between the eGFR 
calculated using the MDRD equation and Gentian equation was 17 mL/min/1.73 
m2 at baseline (n=19), 22 mL/min/1.73 m2 in the 3 months group (n=13), 35 
mL/min/1.73 m2 in the 6 months group (n=10) and 77 mL/min/1.73 m2 in the 12 
months group (n=8). These results show an increase in the mean difference 
between the eGFR obtained using MDRD and the Gentian equation in the groups 
as the length of treatment was increased. The reason for this disparity is unclear. 
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The eGFR derived by CKD-EPI CREA, CKD-EPI CYSC and CKD-EPI CREA-
CYSC equations were similar (i.e. 87 ± 16 mL/min/1.73 m2, 87 ± 17 mL/min/1.73 
m2 and 87 ± 16 mL/min/1.73 m2, respectively) with absolute mean difference of <1 
mL/min/1.73 m2 between them. The mean difference between eGFR calculated 
using these three equations and eGFR calculated using the MDRD equation was 
approximately 7 mL/min/1.73 m2. Also, the mean difference between these three 
equations and the MDRD equation increased as treatment time was increased. 
For instance, in the 3 months Group, the absolute mean difference between CKD-
EPI CREA, CKD-EPI CYSC and CKD-EPI CREA-CYSC ranged from 3 – 5 
mL/min/1.73 m2, while in the 6 months and 12 months groups the absolute mean 
difference ranged from 4 – 10 mL/min/1.73 m2 and 8 – 22 mL/min/1.73 m2, 
respectively. These results suggest that as kidney function changes following FF 
therapy the ability of each of these equations to determine eGFR differed 
increasingly.  
The prevalence of the CKD stages in the various groups of participants classified 
using the MDRD, CKD-EPI CREA, Gentian, CKD-EPI CYSC and CKD-EPI CREA-
CYSC equations are presented in Table 4.6. None of the participants in this study 
was classified as having severely decreased kidney function (defined as eGFR < 
30 mL/min/1.73 m2) using any of the equations. In all the groups, the MDRD 
equation showed the lowest number of participants with normal kidney function 
(i.e. GFR > 90 mL/min/1.73 m2). At baseline, 21% (4 out of 19) of the participants 
were classified with normal kidney function (i.e. GFR > 90 mL/min/1.73 m2) using 
the MDRD equation. This was significantly lower than the percentage obtained 
using the CKD-EPI CREA equation (53%, n=10, p=0.0436). The percentage of 
participants with normal kidney function was the same (42%, n=8) with Gentian, 
CKD-EPI CYSC and CKD-EPI CREA-CYSC equations, although the difference 
with MDRD equation was not statistically significant (p=0.1627).  
Also, in all the groups, the MDRD equation showed the highest proportion of 
participants with mild kidney disease (defined as eGFR 60 – 89 mL/min/1.73 m2) 
compared with all the other equations. Both the CREA-based equations and the 
combined CREA-CYSC-based equation showed a higher proportion of participants 
with mild kidney disease than CYSC-based equations. In Group B, the prevalence 
of mild kidney disease obtained with the MDRD equation (80%, n=10) was 
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significantly higher than the prevalence obtained with the Gentian equation (20%, 
n=10, p=0.0073), while in Group C, the CYSC-based equations classified more 
participants as having normal kidney function (eGFR>90 mL/min/1.73 m2) than 
both CREA-based equations. 
This study also examined the discrepancy between eGFR derived using the 
MDRD equation (routinely used in the clinics) and eGFR calculated using the other 
equations. At baseline, results of the MDRD equation showed that six participants 
(31.5%, n=19) had a mild kidney disease (eGFR 60 - 89 mL/min/1.73 m2), but 
reclassification with the CKD EPI CREA indicated that all the six participants had 
normal kidney function (eGFR > 90 mL/min/1.73 m2). This suggests that the 
MDRD equation underestimates the GFR compared with the CKD-EPI CREA 
equation, although both equations are based on the serum CREA concentration. 
Forty-two percent (8 out of 19) discrepancy was also observed between MDRD 
and both CYSC-based (Gentian and CKD-EPI CYSC) equations. For instance, in 
six participants, the MDRD equation indicated mild to moderate kidney function 
whereas both CYSC-based equations showed normal kidney function. In two other 
cases, both the Gentian and CKD-EPI CYSC equations indicated a mild kidney 
disease, whereas the MDRD results were greater than 90 mL/min/1.73 m2. 
It was observed that in most cases the CKD-EPI CREA-CYSC equation showed 
similar results with the CYSC-based equations rather than with the CREA-based 
equations. However, a disparity was observed in two cases, where the CKD-EPI 
CYSC and Gentian CYSC equations showed normal kidney function, while the 
CKD-EPI CREA-CYSC equation indicated mild a kidney function disease. This 
suggests that the CYSC-based equations would produce relatively higher GFR 
compared with the CKD-EPI CREA-CYSC equation. Discordant results were also 
observed in two other cases where the CKD-EPI CYSC and Gentian CYSC 
equations showed mild reduction in kidney function but the CKD-EPI CREA-CYSC 
equation indicated that both had normal kidney function. This pattern of discrepant 
results between the various equations was observed in all the groups of 
participants, although in Groups A – C, the CREA-based equations tended to 
agree with each other while the two CYSCC-based equations also agreed with 
each other.  
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These results suggest that compared with all the other equations examined in this 
study, the MDRD equation which is used routinely in the clinics tends to produce 
lower estimates of the GFR in patients with normal kidney function, most 
particularly during the early stages of kidney disease. This has been attributed to 
the fact that the MDRD equation was derived from patients with CKD who had a 
mean eGFR of 39.8 mL/min/1.73 m2 (Omuse et al., 2017). The utility of the MDRD 
equation in screening for CKD in asymptomatic patients is questionable given that 
subjectively healthy individuals have eGFR in the range where the MDRD 
equation has been shown to be inaccurate (i.e. > 60 mL/min/1.73 m2) (Omuse et 
al., 2017). 
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Figure 4.8 Comparison of eGFR calculated using serum CREA- and 
CYSC-based equations after 12 months of FF therapy.  
The GFR was estimated using the MDRD, CKD-EPI CREA, Gentian, CKD-EPI CYSC 
and CKD-EPI CREA-CYSC equations at baseline (n=19), and 3 months (n=13), 6 
months (n=10) and 12 months (n=8) after commencing fenofibrate (160 mg/day) 
therapy in patients with dyslipidaemia. FF fenofibrate; MDRD, Modification of Diet in 
Renal Disease; CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration 
Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, Chronic Kidney Disease 
Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-CYSC, Chronic 
Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C (2012); Data 
are presented as mean ± standard deviation. 
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Table 4.6 Frequency of CKD stages in the various groups according to the 
equations used in this study 
 
CKD* Stages 
 
MDRD¥ 
 
CKD-EPI 
CREA§ 
 
Gentian 
CYSC‡ 
 
CKD-EPI 
CYSC# 
 
CKD-EPI 
CREA-
CYSC† 
Baseline (n = 19)      
>90 mL/min/1.73 m2 4 (21%) 10 (53%) 8 (42%) 8 (42%) 8 (42%) 
60 – 89 mL/min/1.73 m2 13 (68%) 8 (42%) 10 (53%) 10 (53%) 11 (58%) 
30 – 59 mL/min/1.73 m2 2 (11%) 1 (5%) 1 (5%) 1 (5%) 0 (0%) 
< 30 mL/min/1.73 m2 0 (0%) 0 (0%) 0 (5%) 0 (0%) 0 (0%) 
Group A (n = 13)      
>90 mL/min/1.73 m2 0 (0%) 1 (8%) 4 (31%) 4 (31%) 4 (31%) 
60 – 89 mL/min/1.73 m2 9 (69%) 8 (61%) 5 (38%) 5 (38%) 7 (54%) 
30 – 59 mL/min/1.73 m2 4 (31%) 4 (31%) 4 (31%) 4 (31%) 2 (15%) 
< 30 mL/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Group B (n = 10)      
>90 mL/min/1.73 m2 1 (10%) 3 (30%) 5 (50%) 4 (40%) 3 (30%) 
60 – 89 mL/min/1.73 m2 8 (80%) 6 (60%) 2 (20%) 4 (40%) 6 (60%) 
30 – 59 mL/min/1.73 m2 1 (10%) 1 (10%) 3 (30%) 2 (20%) 1 (10%) 
< 30 mL/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Group C (n = 8)      
>90 mL/min/1.73 m2 2 (25%) 3 (37.5%) 5 (62.5%) 5 (62.5%) 4 (50) 
60 – 89 mL/min/1.73 m2 4 (50%) 3 (37.5%) 2 (25%) 2 (25%) 2 (25%) 
30 – 59 mL/min/1.73 m2 2 (25%) 2 (25%) 1 (12.5%) 1 (12.5%) 2 (25%) 
< 30 mL/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Data shown are number (percentage of the participants in the group). *CKD, chronic 
kidney disease; ¥MDRD, Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic 
Kidney Disease Epidemiology Collaboration Creatinine (2009); ‡CYSC, Cystatin C; #CKD-
EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); †CKD-
EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and 
Cystatin C. 
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4.3.4 Concordance analysis of serum CREA vs serum CYSC as biomarkers 
for monitoring kidney function  
First, the possible correlation between serum CYSC, serum CREA and eGFR 
calculated using the serum CREA- and CYSC-based equations was analysed at 
baseline and after 3, 6 and 12 months after commencing treatment with FF (160 
mg/day). At baseline the Spearman’s correlation analysis was performed between 
the various parameters using data from all the 19 participants (Tables 4.7). The 
results showed that there was no significant correlation between serum CREA and 
serum CYSC (r=0.3503, p=0.141, n=19). As expected, a strong negative 
correlation was observed between serum CREA and the eGFR calculated using 
the MDRD (r=-0.8509; p<0.001, n=19) and the CKD-EPI CREA (r=-0.8748; 
p<0.001, n=19) equations. Similarly, serum CYSC correlated well with eGFR 
calculated using the Gentian formula (r=-0.9596; p<0.001, n=19) and the CKD-EPI 
CYSC equation (r=-0.9996; p<0.001, n=19).  
It was observed that both serum CREA and serum CYSC correlated well with the 
eGFR obtained using CKD-EPI CREA-CYSC equation (r=-0.5898; p=0.008 and 
r=-0.8285; p<0.001, respectively), although serum CYSC showed a better 
correlation with the CKD-EPI CREA-CYSC than serum CREA. The serum CYSC-
based equations also showed stronger correlation with the CKD-EPI CREA-CYSC 
equation than the CREA-based equations. Although the correlation coefficient 
between the serum CREA-based and serum CYSC-based equations was not 
statistically significant, all the equations used in this study had a weak-strong 
positive correlation with each other as shown in Table 4.7.  
The weak positive correlation observed at baseline between serum CREA and 
CYSC indicates that as serum CREA increases, there is a lower likelihood of 
serum CYSC increasing. Serum CYSC and CYSC-based eGFRs correlated better 
with eGFR calculated using the CKD-EPI CREA-CYSC equation than serum 
CREA and eGFR calculated using the CREA-based equations.  
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Table 4.7 Spearman’s correlation coefficient between serum CREA, serum 
CYSC and the eGFR calculated using serum CREA- and CYSC-based 
equations at baseline 
 
Parameters 
Spearman 
correlation 
coefficient (r) 
 
p value 
(n=19) 
CREA vs CYSC 0.3503 0.141 
CREA vs MDRD¥ -0.8509 <0.001*** 
CREA vs CKD-EPI CREA§ -0.8748 <0.001*** 
CREA vs CKD-EPI CYSC# -0.2878 0.232 
CREA vs Gentian CYSC‡ -0.3527 0.139 
CREA vs CKD-EPI CREA-CYSC† -0.5898 0.008** 
CYSC vs MDRD¥ -0.2321 0.339 
CYSC vs CKD-EPI CREA§ -0.2203 0.365 
CYSC vs CKD-EPI CYSC# -0.9596 <0.001*** 
CYSC vs Gentian CYSC‡ -0.9996 <0.001*** 
CYSC vs CKD-EPI CREA-CYSC† -0.8285 <0.001*** 
MDRD¥ vs CKD-EPI CREA§ 0.9736 <0.001*** 
MDRD¥ vs CKD-EPI CYSC# 0.2495 0.303 
MDRD¥ vs CKD-EPI CREA-CYSC† 0.6324 0.004** 
MDRD¥ vs Gentian CYSC‡ 0.2339 0.335 
Gentian CYSC‡ vs CKD-EPI CREA§ 0.2212 0.363 
Gentian CYSC‡ vs CKD-EPI CYSC# 0.9578 <0.001*** 
Gentian CYSC‡ vs CKD-EPI CREA-CYSC† 0.8280 <0.001*** 
CKD-EPI CREA§ vs CKD-EPI CYSC# 0.2565 0.289 
CKD-EPI CREA§ vs CKD-EPI CREA-CYSC† 0.6282 0.004** 
CKD-EPI CYSC# vs CKD-EPI CREA-CYSC† 0.8662 <0.001*** 
¥MDRD, Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); ‡CYSC, cystatin C; CREA, creatinine; 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C; Spearman’s correlation coefficient; *p<0.05, **p<0.01, ***p<0.001, n=19. 
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In Group A, the correlation between the various parameters was examined after 3 
months of FF therapy in 13 participants. The Spearman’s correlation coefficients 
are presented in Table 4.8. A statistically significant positive correlation was 
observed between serum CREA and serum CYSC (r=0.6088, p=0.030, n=13), 
suggesting that serum CYSC concentration increased as serum CREA 
concentration was increased. As expected, a statistically significant negative 
correlation was also observed between serum CREA concentration and the MDRD 
(r=-0.8950, p<0.001, n=13) and CKD-EPI CREA (r=-0.8619, p<0.001, n=13) 
equations, indicating that the eGFR obtained by both equations decreased as the 
serum CREA concentration increased. Similarly, serum CYSC showed a strong 
negative correlation with the Gentian eGFR (r=-1.0000, p<0.001) and the CKD-EPI 
CYSC equations (r=-0.9931, p<0.001). 
There was no statistically significant correlation between serum CYSC 
concentration and the MDRD (r=-0.4558, p=0.118) and CKD-EPI CREA (r=-
0.3522, p=0.236) equations, suggesting that there was less likelihood for the 
eGFR calculated using both equations to decrease as serum CYSC concentration 
was increased. However, the correlation between serum CREA concentration and 
both CYSC-based eGFRs (Gentian and CKD-EPI CYSC) was statistically 
significant (r=-0.6088, p=0.030 and r=-0.5887, p=0.037, respectively). This 
suggested that the eGFR calculated using both CYSC-based equations decreased 
as serum CREA concentration was increased. The CKD-EPI CREA-CYSC 
equation showed statistically significant positive correlation with the Gentian 
(r=0.9269, p<0.001) and CKD-EPI CYSC (r=0.9256, p<0.001) equations and a 
moderate but statistically significant positive correlation with the MDRD (r=0.6833, 
p=0.012) and CKD-EPI CREA-CYSC (r=0.6072, p=0.030) equations. However, the 
correlation between the CREA-based eGFRs and the CYSC-based eGFRs was 
not statistically significant.  
These results suggest that after 3 months of FF therapy serum CYSC increased 
as serum CREA was increased, although there was no significant correlation 
between serum CREA- and the serum CYSC-based eGFR equations. However, 
the CKD-EPI CREA-CYSC eGFR was more likely to increase with an increase in 
the CYSC-based eGFRs than with an increase in the CREA-based eGFRs.  
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Table 4.8 Spearman’s correlation coefficient between serum CREA, serum 
CYSC and eGFR calculated using serum CREA- and CYSC-based equations 
after 3 months of FF therapy  
 
Parameters 
Spearman 
correlation 
coefficient (r) 
 
p value 
(n=13) 
CREA vs CYSC 0.6088 0.030* 
CREA vs MDRD¥ -0.8950 <0.001*** 
CREA vs CKD-EPI CREA§ -0.8619 <0.001*** 
CREA vs CKD-EPI CYSC# -0.5887 0.037* 
CREA vs Gentian CYSC‡ -0.6088 0.030* 
CREA vs CKD-EPI CREA-CYSC† -0.7903 0.002** 
CYSC vs MDRD¥ -0.4558 0.118 
CYSC vs CKD-EPI CREA§ -0.3522 0.236 
CYSC vs CKD-EPI CYSC# -0.9931 <0.001*** 
CYSC vs Gentian CYSC‡ -1.0000 <0.001*** 
CYSC vs CKD-EPI CREA-CYSC† -0.9269 <0.001*** 
MDRD¥ vs CKD-EPI CREA§ 0.9695 <0.001*** 
MDRD¥ vs CKD-EPI CYSC# 0.4552 0.119 
MDRD¥ vs CKD-EPI CREA-CYSC† 0.6833 0.012* 
MDRD¥ vs Gentian CYSC‡ 0.4558 0.118 
Gentian CYSC‡ vs CKD-EPI CREA§ 0.3522 0.236 
Gentian CYSC‡ vs CKD-EPI CYSC# 0.9931 <0.001*** 
Gentian CYSC‡ vs CKD-EPI CREA-CYSC† 0.9269 <0.001** 
CKD-EPI CREA§ vs CKD-EPI CYSC# 0.3421 0.251 
CKD-EPI CREA§ vs CKD-EPI CREA-CYSC† 0.6072 0.030* 
CKD-EPI CYSC# vs CKD-EPI CREA-CYSC† 0.9256 <0.001** 
¥MDRD, Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); ‡CYSC, Cystatin C; CREA, creatinine; 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C; Spearman’s correlation coefficient; *p<0.05, **p<0.01, ***p<0.001, n=13. 
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In Group B, the correlation between the various parameters was examined after 6 
months of FF therapy in 10 participants. The Spearmen correlation coefficients 
between the various parameters are presented in Table 4.9. The correlation 
between serum CREA and serum CYSC was not statistically significant (r=0.5593, 
p=0.097). The results showed a strong negative correlation between serum CREA 
and MDRD eGFR (r=-0.9483, p<0.001) and between serum CREA and CKD-EPI 
CREA eGFR (r=-0.9515, p<0.001). A strong negative correlation was observed 
between serum CYSC and Gentian eGFR (r=-1.0000, p<0.001) and CKD-EPI 
CYSC eGFR (r=-0.9848, p<0.001). The correlation between serum CREA and 
both CYSC-based eGFRs was not statistically significant. Table 4.9 also shows 
that correlation between serum CYSC and both serum CREA-based eGFR 
equations was not statistically significant.  
The correlation between serum CYSC and CKD-EPI CREA-CYSC eGFR (r=-
0.9666, p<0.001) was stronger than the correlation between serum CREA and 
CKD-EPI CREA-CYSC eGFR (r=-0.6606, p=0.044). As expected, a strong positive 
correlation was observed between MDRD eGFR and CKD-EPI CREA eGFR 
(r=0.9848, p<0.001) and between Gentian eGFR and CKD-EPI CYSC eGFR 
(r=0.9848, p<0.001). The correlation between the CREA-based eGFRs and 
CYSC-based eGFRs was not statistically significant. The results also revealed a 
comparatively stronger correlation between CKD-EPI CREA-CYSC eGFR and 
both CYSC-based eGFRs [Gentian (r=0.9666, p=0.001) and CKD-EPI CYSC 
(r=0.9636, p<0.001)] than between CKD-EPI CREA-CYSC eGFR and both CREA-
based eGFRs [MDRD (r=0.5654, p=0.1649) and CKD-EPI CREA (r=0.5349, 
p=0.115)]. 
The results from this group were similar to those obtained at baseline and after 3 
months of FF therapy, except that the correlation between serum CREA and 
serum CYSC was not statistically significant as was observed after 3 months of 
treatment. These results also suggest that CREA-based eGFRs would decrease 
as serum CREA increases and CYSC-based eGFRs would decrease as serum 
CYSC is increased, although the correlation between CREA-based eGFRs and 
CYSC-based eGFRs was no significant. CKD-EPI CREA-CYSC eGFR showed 
stronger correlation with cystatin CYSC-based eGFRs than with CREA-based 
eGFRs. 
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Table 4.9 Spearman’s correlation coefficient between serum CREA, serum 
CYSC and eGFR calculated using serum CREA- and CYSC-based equations 
after 6 months of FF therapy  
 
Parameters 
Spearman 
correlation 
coefficient (r) 
 
p value 
CREA vs CYSC 0.5593 0.097 
CREA vs MDRD¥ -0.9483 <0.001*** 
CREA vs CKD-EPI CREA§ -0.9515 <0.001*** 
CREA vs CKD-EPI CYSC# -0.5030 0.144 
CREA vs Gentian CYSC‡ -0.5596 0.097 
CREA vs CKD-EPI CREA-CYSC† -0.6606 0.044* 
CYSC vs MDRD¥ -0.4512 0.191 
CYSC vs CKD-EPI CREA§ -0.3708 0.289 
CYSC vs CKD-EPI CYSC# -0.9848 <0.001*** 
CYSC vs Gentian CYSC‡ -1.0000 <0.001*** 
CYSC vs CKD-EPI CREA-CYSC† -0.9666 <0.001*** 
MDRD¥ vs CKD-EPI CREA§ 0.9848 <0.001*** 
MDRD¥ vs CKD-EPI CYSC# 0.4012 0.251 
MDRD¥ vs CKD-EPI CREA-CYSC† 0.5654 0.093 
MDRD¥ vs Gentian CYSC‡ 0.4512 0.191 
Gentian CYSC‡ vs CKD-EPI CREA§ 0.3708 0.289 
Gentian CYSC‡ vs CKD-EPI CYSC# 0.9848 <0.001*** 
Gentian CYSC‡ vs CKD-EPI CREA-CYSC† 0.9666 <0.001*** 
CKD-EPI CREA§ vs CKD-EPI CYSC# 0.3091 0.387 
CKD-EPI CREA§ vs CKD-EPI CREA-CYSC† 0.4909 0.155 
CKD-EPI CYSC# vs CKD-EPI CREA-CYSC† 0.9636 <0.001*** 
¥MDRD, Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); ‡CYSC, Cystatin C; CREA, creatinine; 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin  Spearman’s correlation coefficient; *p<0.05, **p<0.01, ***p<0.001, n=10. 
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In Group C, the correlation between the various parameters was examined after 
12 months of FF therapy in eight participants. The Spearman correlation 
coefficients between the various parameters are presented in Table 4.10. A non-
statistically significant positive correlation was observed between serum CREA 
concentration and serum CYSC concentration (r=0.6667, p=0.083). Serum CREA 
concentration showed strong negative correlation with the MDRD (r=-1.0000, 
p<0.001) and CKD-EPI CREA (r=-1.0000, p<0.001) equations. The relationship 
between Serum CREA concentration and the serum CYSC-based eGFR 
equations was not statistically significant. A strong negative correlation was also 
observed between serum CYSC concentration and the Gentian (r=-1.0000, 
p<0.001) and CKD-EPI CYSC (r=-1.0000, p<0.001) equations, but the correlation 
between serum CYSC and serum CREA-based eGFR equations was not 
statistically significant. 
The results also showed a strong positive correlation between the two CREA-
based eGFR equations (MDRD vs CKD-EPI CREA, r=1.0000, p<0.001), and 
between the two CYSC-based eGFR equations (Gentian vs CKD-EPI CYSC, 
r=1.0000, p<0.001). A non-statistically significant moderate positive correlation 
was observed between the CREA-based eGFRs and CYSC-based eGFRs 
(r=0.6667, p=0.083). It was observed that eGFR obtained with the CKD-EPI 
CREA-CYSC equation correlated better with serum CYSC (r=-0.9542, p<0.001) 
and CYSC-based equations (r=0.9524, p=0.001) than with serum CREA (r=-
0.8333, p=0.015) and the CREA-based eGFR equations (r=0.8333, p=0.15).  
These results suggest that an increase in serum CREA after 12 months of FF 
therapy was not likely to be accompanied by an increase in serum CYSC 
concentration. However, an increase in serum CREA concentration was strongly 
related with a decrease in eGFR estimated using the CREA-based equations but 
not with a decrease in eGFR calculated using the CYSC-based equations. The 
results also suggest that an increase in serum CYSC concentration was related to 
a decrease in the CYSC-based eGFRs. The results also suggest that changes in 
serum CYSC would impact changes in eGFR estimated using the CKD-EPI 
CREA-CYSC than would changes in serum CREA.  
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Table 4.10 Spearman’s correlation coefficient between serum CREA, serum 
CYSC and eGFR calculated using serum CREA- and CYSC-based equations 
after 12 months of FF therapy  
Parameters Spearman 
correlation 
coefficient (r) 
 
p value 
(n=8) 
CREA vs CYSC 0.6667 0.083 
CREA vs MDRD¥ -1.0000 <0.001*** 
CREA vs CKD-EPI CREA§ -1.0000 <0.001*** 
CREA vs CKD-EPI CYSC# -0.6667 0.083 
CREA vs Gentian CYSC‡ -0.6667 0.083 
CREA vs CKD-EPI CREA-CYSC† -0.8333 0.015* 
CYSC vs MDRD¥ -0.6667 0.083 
CYSC vs CKD-EPI CREA§ -0.6667 0.083 
CYSC vs CKD-EPI CYSC# -1.0000 <0.001*** 
CYSC vs Gentian CYSC‡ -1.0000 <0.001*** 
CYSC vs CKD-EPI CREA-CYSC† -0.9542 <0.001*** 
MDRD¥ vs CKD-EPI CREA§ 1.0000 <0.001*** 
MDRD¥ vs CKD-EPI CYSC# 0.6667 0.083 
MDRD¥ vs CKD-EPI CREA-CYSC† 0.8333 0.015* 
MDRD¥ vs Gentian CYSC‡ 0.6667 0.083 
Gentian CYSC‡ vs CKD-EPI CREA§ 0.6667 0.083 
Gentian CYSC‡ vs CKD-EPI CYSC# 1.0000 <0.001*** 
Gentian CYSC‡ vs CKD-EPI CREA-CYSC† 0.9524 0.001** 
CKD-EPI CREA§ vs CKD-EPI CYSC# 0.6667 0.083 
CKD-EPI CREA§ vs CKD-EPI CREA-CYSC† 0.8333 0.015* 
CKD-EPI CYSC# vs CKD-EPI CREA-CYSC† 0.9524 0.001** 
¥MDRD, Modification of Diet in Renal Disease; §CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); ‡CYSC, Cystatin C; CREA, creatinine; 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C. Spearman’s correlation coefficient; *p<0.05, **p<0.01, ***p<0.001, n=8. 
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Next, the level of agreement between the different eGFR equations was assessed 
using the Bland-Altman analysis. Since none of the equations used in this study 
can be considered as the perfect reference, the absolute bias (or mean difference) 
and precision (or standard deviation around the bias) between the different 
equations were examined. Table 4.11 shows the bias (mean difference) and 
precision (SD around the bias) between the different eGFR equations at baseline. 
At baseline, the best levels of bias were observed between the CKD-EPI CREA-
CYSC and CKD-EPI CYSC equations (absolute bias = 0.3 ± 12.1 mL/min/73 m2), 
between the CKD-EPI CREA-CYSC and CKD-EPI CREA equations (absolute bias 
= 0.3 ± 15.1 mL/min/73 m2) and between the CKD-EPI CREA and CKD-EPI CYSC 
equations (absolute bias = 0.6 ± 26.9 mL/min/1.73 m2). On the other hand, the 
highest levels of bias was observed between the Gentian equation and the MDRD 
equation (absolute bias = 17.2 ± 42.7 mL/min/1.73 m2), and between the Gentian 
equation and CKD-EPI CREA equations (absolute bias = 10.5 ± 42.9 mL/min/1.73 
m2).  
Bland-Altman plots of the differences between the eGFR calculated using the 
MDRD equation and all the other equations at baseline are shown in Figure 4.9. 
The results show that the MDRD equation produced relatively lower eGFR values 
compared with all the other equations used in this study. This is demonstrated by 
the negative bias between the MDRD equation and all the other equations. The 
CKD-EPI CREA, CKD-EPI CYSC and CKD-EPI CREA-CYSC showed similar level 
of bias against the MDRD equation. The highest level of deviation around the 
mean difference, which indicates a high level of imprecision, was also observed 
between the CKD-EPI CREA and Gentian equations and between the MDRD and 
Gentian equations. Agreement between the other equations is shown in Figure 
4.10. It was observed that the precision (SD around the bias) between the different 
eGFR equations increased as the level of eGFR increased.   
The results showed larger differences at baseline between the CREA- and CYSC-
based equations, suggestive of greater disparity between these equations at 
baseline, and lower differences between CKD-EPI CYSC and the CKD-EPI CREA-
CYSC, CKD-EPI CREA and CKD-EPI CREA-CYSC and between the CKD-EPI 
CREA and CKD-EPI CYSC equations, indicating agreement between them. 
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Table 4.11 Bland-Altman analysis showing the absolute bias (mean 
difference) (bold) and precision (SD around the bias) (italic) between the 
eGFR equations at baseline 
 
Baseline 
(n=19) 
 
MDRD¥ 
 
CKD-EPI 
CREA§ 
 
GENTIAN 
 
CKD-EPI 
CYSC# 
 
CKD-EPI 
CREA-CYSC† 
 
MDRD¥ 
 
XXXXXX 
 
6.7 
 
17.2 
 
7.3 
 
7 
 
CKD-EPI 
CREA§ 
 
3.5 
 
XXXXXXX 
 
10.5 
 
0.6 
 
0.3 
 
GENTIAN 
 
42.7 
 
42.9 
 
XXXXXXX 
 
9.9 
 
10.2 
 
CKD-EPI 
CYSC# 
 
26.8 
 
26.9 
 
20.6 
 
XXXXXXX 
 
0.3 
 
 
CKD-EPI 
CREA-CYSC† 
 
15.3 
 
15.1 
 
28.7 
 
12.1 
 
XXXXXXXXX 
All data are expressed in mL/min/1.73 m2; ¥MDRD, Modification of Diet in Renal Disease; 
§CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009); 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C. 
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Figure 4.9 Bland-Altman plots between the MDRD and the other equations at 
baseline  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=19. 
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Figure 4.10 Bland-Altman plots between the Gentian, CKD-EPI CREA, CKD-
EPI CYSC, and the CKD-EPI CREA-CYSC equations at baseline  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=19. 
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The level of agreement between the different eGFR equations after 3 months of 
FF therapy is summarised in Table 4.12. Again, the lowest levels of bias was 
observed between the CKD-EPI CYSC and CKD-EPI CREA-CYSC equations (2.5 
± 10.2 mL/min/1.73 m2), and between the CKD-EPI CREA and CKD-EPI CREA-
CYSC equations (2.6 ± 13.9 mL/min/1.73 m2), while the highest level of bias was 
observed between the MDRD and the Gentian equations (22.2 ± 39.3 mL/min/1.73 
m2). The differences between the MDRD and the other eGFR equations are shown 
in Figure 4.11, while differences between all the other equations are shown in 
Figure 4.12. The results showed that after 3 months of FF therapy, eGFR 
calculated using the MDRD equation was lower than those calculated using all the 
other equations. Larger differences were also observed between the CREA-based 
and the CYSC-based equations. It was observed that the difference between the 
MDRD and CKD-EPI CREA equations at baseline (6.7 ± 3.5 mL/min/1.73 m2) was 
similar to the value obtained after 3 months of FF therapy (6.9 ± 3.2 mL/min/1.73 
m2). These results also suggest greater disagreement between the MDRD and the 
Gentian equation. 
Table 4.12 Bland-Altman analysis showing the absolute bias (mean 
difference) (bold) and precision (SD around the bias) (italic) between the 
eGFR equations after 3 months of FF therapy 
 
3 Months 
(n=13) 
 
MDRD¥ 
 
CKD-EPI 
CREA § 
 
GENTIAN 
 
CKD-EPI 
CYSC# 
 
CKD-EPI 
CREA-CYSC† 
 
MDRD¥ 
 
XXXXXX 
 
6.9 
 
22.2 
 
12.1 
 
9.5 
 
CKD-EPI CREA § 
 
3.2 
 
XXXXXXX 
 
15.2 
 
5.2 
 
2.6 
 
GENTIAN 
 
39.3 
 
39.3 
 
XXXXXXX 
 
10.1 
 
12.6 
 
CKD-EPI CYSC# 
 
23.1 
 
23.9 
 
18.9 
 
XXXXXXX 
 
2.5 
 
CKD-EPI CREA-
CYSC† 
 
13.3 
 
13.9 
 
26.3 
 
10.2 
 
XXXXXXXXX 
All data are expressed in mL/min/1.73 m2; ¥MDRD, Modification of Diet in Renal Disease; 
§CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009); 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C (2012), n=13. 
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Figure 4.11 Bland-Altman plots between the MDRD and the other equations 
after 3 months of FF therapy.  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=13. 
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Figure 4.12 Bland-Altman analysis between the Gentian, the CKD-EPI CREA, 
CKD-EPI CYSC, and the CKD-EPI CREA-CYSC equations after 3 months of 
FF therapy  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=13. 
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The Bland-Altman analyses of the bias and precision between the eGFR 
calculated using the different equations after 6 months of FF therapy are given in 
Table 4.13. The results showed once again that the larger differences were 
obtained between the CREA- and CYSC-based equations. The highest differences 
were observed between the MDRD and the Gentian equations and between the 
Gentian and CKD-EPI CREA equations. Lower differences were also observed 
between the CKD-EPI CYSC and CKD-EPI CREA-CYSC equations and between 
the CKD-EPI CREA and CKD-EPI CREA-CYSC equations. Figure 4.13 depicts 
the difference between the MDRD and all the other equations, while the 
differences between the other equations are shown in Figure 4.13. 
The results showed that in Group C participants, the MDRD equation also 
produced the lowest estimates of the GFRs showed by the negative bias between 
the MDRD and all the other equations. The best levels of agreement were 
observed between the CKD-EPI CREA-CYSC equation and the CKD-EPI CYSC 
and the CKD-EPI CREA equations, respectively.  
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Table 4.13 Bland-Altman analysis showing absolute bias (mean difference) 
(bold) and precision (SD around the bias) (italic) between the eGFR 
equations after 6 months of FF therapy 
6 Months 
(n=10) 
MDRD¥ CKD-EPI 
CREA§ 
GENTIAN CKD-EPI 
CYSC# 
CKD-EPI 
CREA-CYSC† 
 
MDRD¥ 
 
XXXXX 
 
6.5 
 
35.9 
 
15 
 
11.4 
 
CKD-EPI 
CREA§ 
 
4.1 
 
XXXXXXX 
 
29.4 
 
8.5 
 
4.9 
 
GENTIAN 
 
67.4 
 
67.0 
 
XXXXXXX 
 
20.9 
 
24.5 
 
CKD-EPI 
CYSC# 
 
30.6 
 
30.0 
 
39.9 
 
XXXXXXX 
 
3.6 
 
CKD-EPI 
CREA-CYSC† 
 
17.4 
 
16.6 
 
51.1 
 
13.7 
 
XXXXXXXX 
All data are expressed in mL/min/1.73 m2; ¥MDRD, Modification of Diet in Renal Disease; 
§CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009); 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C. 
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Figure 4.13 Bland-Altman plots between the MDRD and the other equations 
after 6 months of FF therapy.  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=10. 
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Figure 4.14 Bland-Altman analyses between the different eGFR equations 
after 6 months of FF therapy.  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=10. 
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The differences between the eGFR calculated using the various equations used in 
this study after 12 months of FF therapy are shown in Table 4.14. The results 
showed that the larger differences were observed between the CREA- and CYSC-
based equations. The highest level of bias between the CREA- and CYSC-based 
equations was observed in Group C participants, compared with all the other 
groups. The highest level of differences were observed between the MDRD and 
the Gentian equations and between the Gentian and CKD-EPI CREA equations, 
while the lowest level of differences were observed between the MDRD and CKD-
EPI CREA equations and between the CKD-EPI CYSC and CKD-EPI CREA-
CYSC equations. Figure 4.15 shows the difference between the MDRD and the 
other equations, while Figure 4.16 shows the differences between the other 
equations. The results showed that in this group the Gentian equation produced 
highest eGFR values while the MDRD equation generated the lowest eGFR 
values.  
Table 4.14 Bland-Altman analysis showing the absolute bias (mean 
difference) (bold) and precision (SD around the bias) (italic) between the 
equations after 12 months of FF therapy 
 
12 Months 
(n=8) 
 
MDRD¥ 
 
CKD-EPI 
CREA§ 
 
GENTIAN 
 
CKD-EPI 
CYSC# 
 
CKD-EPI 
CREA-CYSC† 
 
MDRD¥ 
 
XXXXXX 
 
5.4 
 
77.5 
 
27.1 
 
18.8 
 
CKD-EPI 
CREA§ 
 
3.7 
 
XXXXXXX 
 
72.1 
 
21.8 
 
13.4 
 
GENTIAN 
 
106.7 
 
105.7 
 
XXXXXXXX 
 
50.4 
 
58.8 
 
CKD-EPI 
CYSC# 
 
28.5 
 
27.3 
 
85.6 
 
XXXXXXXX 
 
8.4 
 
CKD-EPI 
CREA-CYSC† 
 
19.1 
 
17.7 
 
90.0 
 
11.0 
 
XXXXXXXXX 
All data are expressed in mL/min/1.73 m2; ¥MDRD, Modification of Diet in Renal Disease; 
§CKD-EPI CREA, Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009); 
#CKD-EPI CYSC, Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); 
†CKD-EPI CREA-CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine 
and Cystatin C. 
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Figure 4.15 Bland-Altman plots between the MDRD and the other equations 
after 12 months of FF therapy  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=8. 
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Figure 4.16 Bland-Altman plots between the Gentian, the CKD-EPI CREA, 
CKD-EPI CYSC, and the CKD-EPI CREA-CYSC equations after 12 months of 
FF therapy  
The Bland-Altman plots showing the difference and the mean of the eGFR estimated 
using the different equations. The mean difference is indicated by the centre line, whereas 
the outer lines represent the limits of agreement between the equations (mean ± 2SD); 
MDRD, Modification of Diet in Renal Disease; CKD-EPI CREA, Chronic Kidney Disease 
Epidemiology Collaboration Creatinine (2009); CYSC, Cystatin C; CKD-EPI CYSC, 
Chronic Kidney Disease Epidemiology Collaboration Cystatin C (2012); CKD-EPI CREA-
CYSC, Chronic Kidney Disease Epidemiology Collaboration Creatinine and Cystatin C 
(2012), n=8. 
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Generally, the best level of agreement was observed between the CKD-EPI CYSC 
and CKD-EPI CREA-CYSC equations, and between the CKD-EPI CREA and the 
CKD-EPI CREA-CYSC equations. The results also showed that the MDRD 
equation produced the lowest eGFR values, while the Gentian equation produced 
the highest eGFR values. Hence, the highest differences were observed between 
the MDRD and the Gentian equations. It was also observed that the level of bias 
or difference between the various eGFR equations tended to increase as the 
duration of FF treatment was increased, with the only exception seen between the 
MDRD and CKD-EPI CREA equations, which showed a similar level of bias in all 
the groups of participants. The mean difference between MDRD and CKD-EPI 
CREA in all the groups ranged from 5.4 – 6.9 mL/min/1.73 m2. This low level of 
bias indicate agreement between MDRD and CKD-EPI CREA equations, although 
in all the participants, eGFR calculated using the MDRD equation was lower than 
eGFR by the CKD-EPI CREA equation. Such a level of agreement was not seen 
between cystatin C-based equations. 
The disparity between Gentian eGFR and MDRD eGFR also increased as 
treatment time was increased i.e. 17.2 mL/min/1.73 m2 at baseline, 22.2 
mL/min/1.73m2 after 3 months, 35.9 mL/min/1.73 m2 after 6 months and 77.5 
mL/min/1.73 m2 after 12 months. However, a low level of bias was observed 
between CKD-EPI CREA and CKD-EPI CYSC, but this also increased through the 
groups as treatment time increased. In terms of precision, MDRD and CKD-EPI 
CREA demonstrated the lowest standard deviation around the bias in all the 
groups; 3.5 mL/min/1.73 m2 at baseline, 3.2 mL/min/1.73 m2 in the 3 months 
group, 4.1 mL/min/1.73 m2 in the 6 months group and 3.7 mL/min/1.73 m2 in the 
12 months group. In contrast, the highest standard deviation values (low precision) 
occurred between Gentian eGFR and both creatinine-based eGFRs (MDRD and 
CKD-EPI CREA).  
In summary, the CYSC-based equations produced higher GFR estimates than the 
CREA-based equations. The lowest eGFR values were produced by the MDRD 
equation, while the highest values were produced by the Gentian equation. The 
best level of agreement was observed between the CKD-EPI CYSC and the CKD-
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EPI CREA-CYSC followed by CKD-EPI CREA and CKD-EPI CREA-CYSC. 
Agreement was observed between the two CREA-based equations but not 
between the CYSCC-based equations. The best precision levels were obtained 
between the MDRD and CKD-EPI CREA equations while Gentian equation 
showed high variations with all other equations. The highest deviation was 
observed between Gentian and MDRD in the 12 months group (106.7 mL/min/1.73 
m2). 
 
4.4 DISCUSSION 
FF-associated creatininaemia or inferred nephrotoxicity is a well-established 
phenomenon, although the mechanism by which FF increases serum CREA is not 
fully understood (Bonds et al., 2012). Therefore, kidney function monitoring has 
been recommended in patients receiving FF therapy (Kim et al., 2017). 
Suggestions that have been made to explain the increase in serum CREA in FF 
therapy include an increase in metabolic production of CREA (Hottelart et al., 
2002), decreased CREA secretion in renal tubules (Ansquer et al., 2008), 
alteration of renal haemodynamics (Lipscombe et al., 2001), and/or the direct 
effect of PPARα on the synthesis of vasodilatory prostaglandins in the kidney 
(Tsimihodimos et al., 2001). It has also been suggested that FF therapy causes 
analytical interference on the serum CREA methods (Hottelart et al., 1999; 
Ansquer et al., 2008). These together with other limitations of serum CREA such 
as age, gender, race, diet, exercise (Thomas et al., 2017) strengthen the case for 
another biomarker of kidney function in patients receiving FF therapy.  
Several reports have suggested that CYSC is a better marker of kidney function 
than CREA (Madero et al., 2006; Inker and Okparavero, 2011; Akerblom et al., 
2015). However, the effect of FF on serum CYSC level in patients with 
dyslipidaemia has not been fully elucidated. Here we discuss the impact of FF on 
CYSC levels and the utility of serum CYSC as a marker of kidney function in 
patients receiving FF therapy for hypertriglyceridaemia. There are four main 
findings from this study:  
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 First, the analytical performance of the Gentian CYSC assay on Beckman 
Coulter AU640 analyser, a routine laboratory platform, exceeded the 
manufacturer’s specification.  
 Secondly, this study confirmed that FF therapy increased both serum CREA 
and serum CYSC levels mainly during the early period of therapy in patients 
with dyslipidaemia, and suggested that the increase in serum CREA 
concentration might be partially reversible while the increase in serum 
CYSC concentration is completely reversible.  
 Thirdly, eGFR calculated using CYSC-based equations were higher than 
those derived from the CREA-based equations.  
 Finally, correlation between serum CREA and serum CYSC varied during 
the study, with a significant correlation only observed when after 3 months 
of FF therapy, i.e. when the impact of FF on both serum CREA and CYSC 
was greatest. The CREA-based eGFR equations did not correlate well with 
eGFR calculated using CYSC-based equations. The combined creatinine- 
and cystatin C-based eGFR formula showed stronger correlation and 
agreement with the serum CYSC and CYSC-based equations than with 
serum CREA and CREA-based equations. 
 
4.4.1 Analytical performance of Gentian CYSC exceeds manufacturer’s 
specifications on Beckman Coulter AU640 analyser 
First, the analytical performance of Gentian CYSC on the Beckman Coulter AU640 
analyser was examined. In order to be useful as a biomarker of kidney function in 
clinical practice, the Gentian CYSC assay has to be measured as part of the 
kidney profile using existing equipment already available in the laboratory. Most of 
the CYSC kits available in the market are designed to be used on specialist 
immunoassay platforms. In this era where cost reduction is the primary force 
driving healthcare reform, the use of a single dedicated analyser would not only 
interrupt workflow but have significant additional staffing requirements for provision 
of a 24-hour service that is required for most UK hospital settings (Ash, 1996; 
Addicott et al., 2015). As an immunoturbidimetric assay, the Gentian CYSC 
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obviates this need and appears to be a suitable method for monitoring kidney 
function in patients receiving FF therapy.  
The imprecision studies showed low within-run and between-run imprecision of 
less than 5%. These levels of imprecision were similar to those obtained in a 
previous study by Flodin et al., (2007) on an Architect ci8200 analyser using 
CYSC reagents from Dako (Glostrup, Denmark) and are comparable to the values 
specified by the kit manufacturers’ of Gentian CYSC (Moss, Norway). The 
imprecision of the pooled serum samples were below the minimum acceptable 
imprecision of 3.5% initially suggested by Ricos et al., in 1999 and updated in 
2014 by Minchinela et al. Acceptable linearity and recovery was also observed 
over the entire range tested with linear dilution of patient sample. 
These results are also in agreement with the reports by Flodin and Larsson (2009) 
who demonstrated a maximum deviation of 4.3% between the estimated and 
measured CYSC values on the Abbott ci8200 analyser. A strong positive 
correlation was also observed between serum CYSC and serum CREA within the 
range of 0.70 – 6.93 mg/L of cystatin C. This study also showed that CYSC was 
stable in serum samples stored at -80C for 30 months, and therefore suggests 
that storage did not have any statistically significant impact on the level of serum 
CYSC. In terms of analytical performance and laboratory organisation, these 
results suggest that the Gentian CYSC is eminently suitable for routine clinical use 
and can replace serum CREA as a maker for assessing and monitoring the kidney 
function. 
 
4.4.2 Impact of FF therapy on serum CYSC, serum CREA and eGFR 
calculated using CYSC- and CREA-based equations  
In the next step, the impact of FF therapy on serum CREA; serum CYSC and 
kidney function (GFR) estimated using both CREA-based and CYSC-based 
equations was examined. This study showed moderate increases in serum CREA 
and serum CYSC concentrations during the first 3 months of FF (160 mg/day) 
therapy in patients with dyslipidaemia. Previous studies, both short-term and long-
term, have shown that FF therapy is associated with an increase in both serum 
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CREA and serum CYSC levels (Ansquer et al., 2008; Ncube et al., 2012; 
Mychaleckyj et al., 2012).  
In a 6-week randomised crossover trial in healthy people, Ansquer et al., (2008) 
reported a statistically significant increase in plasma CREA (mean difference = 
9.72 µmol/L, p<0.05, n=24) and plasma CYSC (mean difference 0.18mg/L, 
p=0.02, n=24) levels after six weeks of FF (160 mg/day) therapy. These reports 
were supported by Ncube et al., (2012), who also reported a concomitant increase 
in serum CREA (mean difference = 7.0 µmol/L, p<0.005, n=12) and serum CYSC 
(mean difference = 0.10 mg/L, p<0.01, n=12) levels after 3 months of FF (264 
mg/day) therapy in hyperlipidaemic patients. The results from this study are 
consistent with both reports. However, in their studies FF therapy was associated 
with a statistically significant increase in both biomarkers, while in this study the 
change in serum CYSC was not statistically significant.  
The disparity with the present study may be due to the nature of the participants or 
dose/length of FF administered. This study excluded patients who had diabetes or 
renal disease, unlike in the study by Ncube et al., (2012) which included 
participants with diabetes mellitus. Also, participants in the study by Ncube et al., 
(2012) were administered a higher daily dose of FF (264 mg/day) therapy. Similar 
to the study by Ansquer et al., (2008) all the participants in our study were 
administered FF (160 mg/day) therapy, although these authors had administered 
the drug over a shorter period (six weeks). The present study confirms that FF 
therapy is associated with an increase in both serum CREA and CYSC levels.  
FF therapy also caused a moderate reduction in kidney function (GFR), estimated 
by both CREA-based and CYSC-based equations. The decrease in eGFR by the 
MDRD (p=0.0025, n=13), CKD-EPI CREA (p=0.0190, n=13), and CKD-EPI CREA-
CYSC (p=0.0392, n=13) equations was statistically significant, while the changes 
in the Gentian (p=0.3568, n=13) and CKD-EPI CYSC (p=0.1988, n=13) equations 
were not statistically significant. The median eGFR estimated using both CREA-
based and CYSC-based equations did not change by more than 10% after 3 
months of FF therapy. Ncube et al., (2012) reported a similar decrease in eGFR 
following 3 months of treatment with FF (264mg/day) in hyperlipidaemic patients 
and suggested the change in eGFR indicated deterioration in kidney function.  
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In their study, Ncube et al., (2012) had estimated the GFR using the MDRD 
equation, which is known to underestimate the GFR (Stevens et al., 2007; 
MacIsaac et al., 2015). However, a long-term study by Forsblom et al., (2010) had 
demonstrated a concomitant decrease in CREA clearance and eGFR by FF, 
although the eGFR was estimated using CREA-based equations. The results from 
this study showed a decrease in eGFR by both CREA-based eGFRs (MDRD and 
CKD-EPI CREA) and cystatin C-based eGFRs (Gentian and CKD-EPI CYSC), 
thus indicating a genuine impact of FF on the kidney function. 
This study has also shown that the increase in both serum CREA and CYSC was 
reversible when treatment was continued for up to 12 months. This is consistent 
with reports by Park et al., (2017), who demonstrated that FF-associated increase 
in serum CREA was partially reversible when FF was administered for 3 – 6 years 
to hypertriglyceridaemic patients with hypertension. A similar report by 
Mychaleckyj et al., (2012) in the ACCORD study showed that FF-associated 
increases in serum CREA and serum CYSC were reversed 51 days after 
withdrawal of FF. Unlike in both reports where reversibility was achieved following 
discontinuation of FF therapy, in this study serum CYSC concentration and GFR 
estimated using CYSC-based equations were completely reversed and serum 
CREA concentration and eGFR calculated using CREA-based formulas were 
partially reversed, when treatment was administered in the long-term. The results 
of the present study suggest that reversal of FF-associated increase in serum 
CREA, CYSC and reduced kidney function estimated by both CREA-based and 
CYSC-based equations occurred even as treatment was continued.  
 
4.4.3 Comparison of CYSC- and CREA-based eGFRs in patients 
administered FF therapy 
Previous studies have shown that both MDRD and CKD-EPI equations tend to 
underestimate eGFR in healthy populations and, more generally, in patients with 
normal or near normal serum CREA values (Froissart et al., 2005; Delanaye and 
Cohen, 2008; Glassock and Winearls, 2008).  This study has shown that the 
eGFR calculated using CYSC-based equations were higher than those derived 
from CREA-based equations. The MDRD equation, which is used routinely in the 
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clinics to assess kidney function, produced the lowest median eGFR in all the 
groups, while the Gentian equation produced the highest values. These results are 
consistent with the report by Han et al., (2012) who showed that CYSC-based 
eGFR was higher than CREA-based values in live kidney donors. In a recent 
study, Szopa et al., (2015) also reported that eGFR calculated by the CYSC-based 
formula was higher than CREA-based eGFR in patients with Type 2 diabetes.  
This study has also shown that the MDRD equation identified the lowest proportion 
of participants with normal kidney function (i.e. eGFR >90 mL/min/1.73 m2) and 
the highest proportion with mild kidney disease (i.e. eGFR: 60 – 89 mL/min/1.73 
m2), compared with all other eGFR equations. This therefore confirms that the 
MDRD equation underestimated the GFR in these patients. Since reference GFR 
was not measured in this study due to the complexity of the assay, further studies 
would be required using measured GFR values to establish the differences 
between the CREA- and CYSC-based equations compared with the measured 
GFR.   
The CKD-EPI CREA equation was proposed by the Levey’s group (2009) and 
expected to perform better than the MDRD equation, especially in the higher GFR 
range (eGFR>60 mL/min/1.73 m2). Indeed, this study showed that in all the 
groups, median eGFR was higher when calculated using the CKD-EPI CREA than 
with MDRD equation. More participants were identified as having normal kidney 
function (GFR > 90 mL/min/1.73 m2) with the CKD-EPI CREA equation than with 
the MDRD equation. The number of participants with moderately reduced kidney 
function (GFR < 60 mL/min/1.73 m2) was similar in all the groups when GFR was 
calculated using both equations. This similarity in the prevalence of participants 
with CKD (i.e. GFR < 60 mL/min/1.73 m2) may be due to the low number of 
participants in this study. The results from this study suggest that the CKD-EPI 
CREA equation performed better than the MDRD equation in monitoring kidney 
function in dyslipidaemic patients with normal or mild kidney impairment 
administered FF therapy. However, both MDRD and CKD-EPI CREA equations 
remain dependent on the limitations of serum CREA and their precision has been 
reported as imperfect (Levey et al., 2009). 
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Previous studies have shown that eGFRs obtained from various CYSC-based 
equations differed widely (Lee et al., 2014; Cheuiche et al., 2019). Lee et al., 
(2014) demonstrated that eGFR estimated using six CYSC-based equations 
differed widely in patients with CKD. The reason for this variation is still unclear. 
The CYSC-based equations used in their study included: Larson et al., 2004; Hoek 
et al., 2003; Le Bricon et al., 2000; Filler and Lepage (2003); Orebero-cystatin 
derived using DAKO CYSC reagents (Filler and Lepage, 2003) and Orebro-
cystatin derived using Gentian CYSC reagents (Filler and Lepage, 2003). In this 
study, the Gentian eGFR was higher than the CKD-EPI CYSC values in all the 
groups of participants. However, the prevalence of CKD by stages was similar 
between the two equations, except in Group D where the Gentian equation 
showed slightly higher proportion with normal kidney function and therefore a 
lower proportion with mild kidney disease than the CKD-EPI equation. The reason 
for the differences in the equations is unclear. However, unlike the CKD-EPI 
CYSC equation, which has been tested in various populations, data supporting the 
use of the Gentian equation is scarce, making the option for this equation less 
reliable for use in the clinics (Inker et al., 2012; Yang et al., 2017).  
Recent studies have reported the superior diagnostic accuracy of serum CYSC 
based equations over other markers and equations in monitoring kidney function in 
various disease conditions (Yang et al., 2017). The reason for such superiority 
relies on the fact that the concentration of serum CYSC is less influenced by 
muscle mass than serum CREA (Seronie-Vivien et al., 2008). This study has 
shown that the eGFR calculated using the CYSC-based equations were higher 
than those calculated using CREA-based equations in all the groups of 
participants. It has been suggested that serum CYSC-based eGFR 
underestimates kidney function in advanced CKD stages because CYSC does not 
increase along with the CKD stage Uemura et al., (2011). This study could not 
confirm this suggestion because the participants in this study did not have 
advanced CKD. However, the results showed that eGFR differed widely between 
CREA-based and CYSC-based equations for participants with eGFR<60 
mL/min/1.73 m2. However, in Group B participants, it was observed that both 
CYSC equations showed a higher proportion of participants with CKD (GFR<60 
mL/min/1.73 m2) than the CREA-based equations. It was also observed across 
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the groups that some participants classified by the MDRD equation as having 
stage 3 kidney disease (i.e. eGFR<60mL/min/1.73 m2) were reclassified by the 
CYSC-based equations as having stage 2 kidney disease (i.e. eGFR 60 – 89 
mL/min/1.73 m2) and vice versa. The reason for such discrepancies is not clear. 
The median eGFR calculated using the CKD-EPI CREA equation was comparable 
to the values obtained using CKD-EPI CYSC and CKD-EPI CREA-CYSC 
equations. The authors of both CKD-EPI CYSC and CKD-EPI CCREA-CYSC 
equations, which were derived from an impressive sample size (5592 subjects in 
the development dataset and 1119 in the validation dataset) had demonstrated 
better performance of the combined serum CREA and CYSC equation compared 
to the individual CKD-EPI equations (Inker et al., 2012). Recent studies confirmed 
the good performances of the two CKD-EPI CYSC-based equations in an elderly 
population (n=394; median age, 80 [range74-79] years) recruited from nephrology 
clinics and the community (Kilbride et al., 2013) and in 670 kidney transplant 
recipients from 3 centres undergoing GFR measurements (Mason et al., 2013). 
Mindikoglu et al., (2013) showed that the equation was superior to conventional 
equations for estimating GFR in patients with liver cirrhosis; however, the 
diagnostic performance was not as good as reported in non-cirrhotic subjects. In 
another study, Obiols et al., (2013) demonstrated that the CKD-EPI CREA-CYSC 
equation was more accurate and precise in hypertensive patients with higher GFR. 
In this study, the CKD-EPI CREA-CYSC formula also showed the lowest 
proportion of participants with GFR<60 mL/min/1.73 m2 in all the groups, except in 
Group C where the values were similar to those obtained using the CREA-based 
formulas. These results suggest that the CKD-EPI CREA-CYSC-based equation 
performed better than all the other equations used in this study to monitor kidney 
function in patients with dyslipidaemia. It is important to emphasise that in this 
study the GFR was not measured, so further investigation we be required to 
confirm this finding. 
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4.4.4 Agreement between serum CREA- and CYSC-based equations for 
determining eGFR in patients administered FF 
Finally, the possible correlation and agreement between the various eGFR 
equations was examined. This study showed a significant positive linear 
correlation between serum CREA and serum CYSC only after 3 months of FF 
therapy (r=0.6088, p=0.030, n=13), corresponding to when the greatest increase in 
serum CREA and CYSC levels was observed. No statistically significant linear 
correlation was observed between the two biomarkers in the other groups. As 
expected, serum CREA showed strong negative correlation with the eGFR 
calculated using the CREA-based equations, while serum CYSC also correlated 
well with the eGFR calculated using the CYSC-based equations. There was also 
no significant correlation between the CREA-based equations and CYSC-based 
equations in all the groups, except in Group A participants where a moderate but 
statistically significant correlation was observed between serum CREA and eGFR 
by the CKD-EPI CYSC equation (r=-0.5887, p=0.037) and the Gentian equation 
(r=-0.6088, p=0.030). These results suggest that a significant increase serum 
CREA would be accompanied by significant changes in the eGFR estimated using 
the CYSC-based equations.  
The results from this study are in contrast with previous reports by Randers et al., 
(1998) and Elnokeety et al., (2017). Randers et al., (1998) investigated serum 
CYSC, serum and urine CREA and GFR by 99mTc-DTPA clearance in 66 patients 
with various kidney diseases and 61 patients on dialysis and reported a significant 
linear correlation between serum CYSC and serum CREA in those with GFR 
higher than 30 mL/min/1.73 m2. Similarly, in a recent study involving 80 patients 
with type 2 diabetes, Elnokeety et al., (2017) reported a significant linear 
correlation between serum CYSC and serum CREA. Unlike both studies in which 
the participants consisted of patients with an underlying kidney disease or 
diabetes, the present study did not include participants with any form of kidney 
impairment. It is unclear whether such disparity with this study is related to the 
participants involved in this study.  
The Bland-Altman analyses showed low bias and high precision (or low SD around 
the bias) between the MDRD and CKD-EPI CREA equations, which suggest a 
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good level of agreement between the CREA-based equations. Such level of 
agreement was not observed between the two CYSC equations, in fact, very high 
bias results and low precision was observed between Gentian eGFR and all the 
other equations, with exceptionally low precision between Gentian eGFR and 
eGFR calculated using the CREA-based equations. These results suggest that the 
Gentian equation differed widely from the other equations in estimating the GFR. 
However, the CKD-EPI CREA-CYSC equation showed better concordance with all 
the CKD-EPI equations although precision was poor (>10 mL/min/1.73 m2) in all 
the Groups. It has been suggested in a previous study by Delanaye et al., (2013) 
that bias is dependent on the GFR level. In this study, the level of GFR varied 
greatly with the different equations and therefore we cannot verify the validity of 
that suggestion. It is also important to note that a perfect concordance between 
the various equations does not necessarily mean that the results of these 
equations are correct. Indeed, in the absence of a measured GFR, it is possible 
that all five equations overestimated or underestimated the GFR. 
This study have shown that while the CREA-based equation tends to 
underestimate the GFR, the eGFR appears to be overestimated by Gentian 
equation, making the CKD-EPI CREA-CYSC equation the best option for 
calculating the eGFR. The CKD-EPI CREA-CYSC equation has also been shown 
in this study to correlate well with both serum CREA and serum CYSC. However, 
this equation requires measuring both serum CYSC and serum CREA 
concentrations and therefore less cost-effective for routine clinical practice. The 
results also showed low bias and high precision between the CKD-EPI CYSC and 
CKD-EPI CREA equations and between the CKD-EPI CYSC equation and CKD-
EPI CREA-CYSC equations in all the groups. It can therefore be concluded that 
serum CYSC and the CKD-EPI CYSC equation is the best alternative to the use of 
serum CREA and the MDRD equation for monitoring the kidney function in 
patients administered FF for dyslipidaemia.  
Some limitations to this study have been well recognised:  
 First, this study was conducted on a small number of participants, mainly 
patients with dyslipidaemia who required FF therapy and whose kidney 
function was relatively normal. As such, these results cannot be generalised 
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over a larger scale, but calls for larger prospective studies to establish the 
best equation for monitoring kidney function in this cohort.  
 Second, the GFR was not measured by a gold standard method, as this is 
technically complex and expensive for use in the clinical practice. This 
means the accuracy of the serum CYSC- and CREA-based eGFR 
equations could not be tested against the measured GFR.  
 Third, serum CREA concentration was determined by the Jaffé reaction 
method which is less specific and has less precision compared with the 
enzymatic method. However, the calibration of the Beckman Coulter Jaffe 
creatinine method used in this study is traceable to an isotope dilution mass 
spectrometry (IDMS) reference method using the National Institutes of 
Standards and Technology (NIST) Standard Reference Material 967, 
although traceability does not address non-specificity. The Jaffé method is 
routinely used in the clinics because it is cheap and readily available. 
 Lastly, the study participants were all Caucasian adults and as such do not 
include any variations that may occur due to ethnicity. 
4.4.5 Summary 
This study has shown that the performance of the Gentian CYSC assay on a 
routine laboratory platform (AU640 analyser) meets the manufacturers’ 
specifications. The results have also demonstrated that FF therapy is associated 
with a moderate increase in serum CREA and CYSC concentrations in patients 
with dyslipidaemia. This study has also confirmed that the increase in serum 
CREA and CYSC induced by FF therapy is reversible, when treatment is 
administered in a long term (i.e. 12 months).  
The study has also shown that the increase in serum CREA and CYSC was 
accompanied by a reduction in kidney function estimated using both CREA- and 
CYSC-based equations, thereby indicating that FF therapy genuinely impacts the 
kidney function. While the kidney function recovered completely after 12 months 
therapy, when assessed with CYSC-based equations, it was only partially 
recovered with the CREA-based equations. Serum CYSC-based eGFRs were 
higher than serum CREA-based eGFRs, suggesting that the MDRD equation, 
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which is routinely used in the clinics, may be underestimating kidney function in 
patients with dyslipidaemia who are administered FF therapy.  
A good level of agreement and correlation was observed between the CKD-EPI 
CREA-CYSC equation and all the other equations (except the Gentian equation) 
making it a good replacement for the MDRD equation. However, the use of this 
equation in clinical practice would not be cost effective, because it would require 
testing both serum CREA and CYSC concentrations each time. The CKD-EPI 
CYSC equation which also showed a good level of agreement with all the other 
equations emerged as a better option and together with serum CYSC would 
provide an alternative to serum CREA and the MDRD equation for assessing and 
monitoring the kidney function in patients administered FF therapy for 
dyslipidaemia.  
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Chapter 5 
Mechanisms of FF cytotoxicity in kidney and 
muscle cell lines 
5.1 - INTRODUCTION 
In this chapter, the cytotoxicity of FF in kidney and muscle cells was investigated. 
Reports from in vitro studies on the toxicity of FF in different cell lines have been 
contradictory. While increasing evidence suggest that FF exerts anti-proliferative 
and pro-apoptotic properties in some cell lines, some studies have demonstrated a 
protective effect of FF in other tissues (Lian et al., 2018; Wang et al., 2018). For 
instance, FF has been shown to not only slow the progression of diabetic 
retinopathy and other microvascular complications in patients with Type 2 diabetes 
(Keating, 2011; Noonan et al., 2013; Czupryniak et al., 2016), but also protect 
against retinopathy, nephropathy, and cardiac pathological changes in Type 1 
diabetes (Chen et al., 2013; Cheng et al., 2016; Zhang et al., 2016). In other 
studies, FF inhibited aldosterone-induced apoptosis in adult rat ventricular 
myocytes via stress-activated kinase-dependent mechanisms (De Silva et al., 
2009). Zuo et al., (2015) described a renoprotective role of FF in fatty acid-induced 
apoptosis in renal proximal tubular cells (HK-2). A similar report by Thongnuanjan 
et al., (2016) showed that FF reduced apoptosis induced by cisplatin (anticancer 
drug) in renal proximal tubular cells (LLC-PK1 and HK-2). On the other hand, 
evidence has shown that FF inhibited the proliferation of various cell lines 
including human hepatocellular carcinoma HepG2 (Jiao and Zhao, 2002), prostate 
cancer (DU-145 and LNCap) (Wybieralska et al., 2011; Zhao et al., 2013) and 
neuroblastoma cell line (SH-SY5Y) (Su et al., 2015).  
Recent studies by Li et al., (2014) showed that FF inhibited the proliferation of 
breast cancer cell lines via activation of the nuclear factor kappa B (NFκB) 
pathway. NFκB is a protein complex that controls DNA transcription and cell 
survival. In human, NF-кB is made up of five subunits [p50/p105, p52/p100, ReLA 
(p65), RelB and c-Rel], with the p65 being the most abundant form (Nakanishi and 
Toi, 2005). In a quiescent state, NFκB (p65) is inactive in the cytoplasm where it 
combines with the inhibitor of κB (IκB), mainly IκBα, which is regulated by IκB 
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kinase (IKKα/β). Under the effect of some stimuli, IκBα is phosphorylated by 
IKKα/β, and then undergoes ubiquitination and degradation to release p65. 
Afterwards, p65 translocates into the nucleus and promotes transcription of genes. 
Li et al., (2014) demonstrated an increase in nuclear p65, accompanied by up-
regulation of phosphorylated IKKα/B and down-regulation of phosphorylated IκBα 
in the cytoplasm of MDA-MB-231 breast cancer cells exposed to FF. Similarly, 
Lian et al., (2018) demonstrated that FF induced cell death in human prostate 
cancer (PC-3) cells. Other mechanisms of FF-induced cell death have also been 
described and tend to vary in different tissues (Koltai, 2015). 
The impact of FF on the kidneys and the potential mechanisms of FF-induced 
cytotoxicity have not been described in the literature. Since the kidneys and 
skeletal muscles are involved in the metabolism and excretion of FF and its active 
metabolite, mainly fenofibric acid, and the skeletal muscles are the primary source 
of creatinine, FF toxicity to the kidney and skeletal muscles was investigated (in 
vitro) using cell line models, to establish the cause of FF-associated 
creatininaemia.  
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5.2 – SPECIFIC AIMS 
In this chapter, the mechanism of FF cytotoxicity in the kidney and muscle was 
investigated using renal proximal tubular cells (NRK52E), skeletal muscle cells 
(L6) and human kidney cells (HEK293), and the intracellular events involved were 
characterised. The specific aims included: 
1. To determine and compare the cytotoxicity of FF with 5-FU (positive 
control) in NRK52E, L6 and HEK293 cell lines using the MTS assay. 
2. To evaluate the role of oxidative stress in FF-induced cell death in NRK52E, 
L6 and HEK293 cell lines 
3. To investigate the molecular mechanism of FF-induced cell death by 
western blot analysis. 
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5.3 - RESULTS 
5.3.1 FF induces morphological changes in NRK52E, L6 and HEK293 cell 
lines 
To determine the cytotoxicity of  FF in kidney and muscle cells, changes in the 
morphology of NRK52E, L6 and HEK293 cells was examined after the cells were 
exposed to different concentrations of FF (250, 500 and 1000 µM) or control 
(untreated) cells grown in 75 cm2 culture flasks for 24 hours. As shown in Figure 
5.1, FF induced morphological changes in the cell lines tested and consistently 
reduced the density of the cells in a concentration-dependent manner. Control 
(untreated) NRK52E cells showed a confluent monolayer of cells, which appeared 
polyhedral and exhibited classic cobblestone morphological characteristics with 
intact cell-to-cell contact, showing cell processes, strong adherence, and high 
contrast. When exposed to 250 µM FF, the NRK52E cells increased in size 
(hypertrophied), but retained their shape and cell-to-cell contact. With 500 µM FF 
treatment, over fifty percent of the NRK52E cell population showed fibroblast-like 
appearance after 24 h exposure. The transformed cells became elongated or 
spindle-shaped, and lost their cobblestone growth pattern. With 1000 µM FF 
treatment, more than seventy percent of the NRK52E cells had lost their cell-to-
cell contact, became rounded and detached from the plate and appeared dead 
and floating in the medium. 
In the L6 cell line, Control (untreated) cells formed a monolayer of spindle-shaped 
cells with normal nuclei and in close contact with one another. After exposure to 
250 µM FF for 24 h, morphological changes observed included gradual loss of 
their characteristic spindle shape, loss of cell-to-cell contact, formation of 
intracytoplasmic vacuolations, and shrinkage of cell body. The cells treated with 
500 µM FF became rounded, with massive vacuolations in the cytoplasm, 
shrinkage of cell body, decrease in cell volume, cell contrast and number of 
adherent cells. Over sixty percent of the cells appeared dead and floating in the 
medium.  With the 1000 µM FF treatment, more than ninety percent of the cells 
appeared dead, completely detached and floating in the medium.  
The HEK293 cells also showed morphological changes when exposed to 250 µM 
FF for 24 h. The FF-treated cells displayed nuclear condensation, became round 
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and lucent. However, there were also many cells (about 60%) that 
morphologically, appeared to be unaffected by FF treatment in that they were 
similar in appearance to the control (untreated) cells, although they were 
detached. With 500 µM FF treatment, about seventy percent of the HEK293 cells 
exhibited signet-ring cell morphology with the increase in FF concentration (500 
and 1000 µM). After treatment with 1000 µM FF for 24 h, about 80 percent of the 
cells were observed to be rounded, completely detached and floating in the 
medium. These results suggest that FF maybe toxic to NRK52E, L6 and HEK293 
cell lines. 
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Figure 5.1 Representative photomicrograph showing morphological 
changes in NRK52E, L6 and HEK293 cells exposed to FF.  
Equal number of cells (2.5 x 106/10 mL medium) for each cell line were seeded and 
allowed to attach for 24 h. Cells were then exposed to FF (0 – 1000 µM) for 24 h and 
images were taken using inverted phase contrast microscopy (magnification 200x). All 
three cell lines showed apoptotic morphological changes with increasing FF doses (n=3).  
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5.3.2 FF reduces cell viability of NRK52E, L6 and HEK293 cells  
Next, the effect of FF on cell viability of NRK52E, L6 and HEK293 cell lines was 
assessed in the cells cultured for 72 hours in the presence of FF, compared with 
the cytotoxicity of 5-fluorouracil (5-FU) within the range (0 – 500 µM), used as 
positive control for the experiments. 5-FU is an age-old anticancer drug currently 
used to treat various types of cancer. As shown in Figure 5.2, FF and 5-FU 
decreased cell viability of all three cell lines in a dose-dependent manner that also 
depended on the cell line. As expected, all the cells were more sensitive to 5-FU 
than FF (Figure 5.2A-C). The HEK293 cells showed greater sensitivity to 5-FU 
(IC50 = 10.98 ± 2.40 µM) than L6 cells (IC50 = 14.30 ± 0.14 µM) and NRK52E cells 
(IC50 = 43.36 ± 0.41 µM) as shown by the half maximal inhibitory concentration 
(IC50) values for FF and 5-FU calculated from the dose-log response curves 
(Table 5.1). The L6 cells were more sensitive to FF than NRK52E and HEK293 
cells (Figure 5.3A).  
To confirm that ethanol used to prepare the drug solutions did not significantly 
affect cell viability, NRK52E and L6 cells were exposed to ethanol (0 – 855 
mmol/L) for 72 hours and cell viability was measured using the MTS assay. 
Ethanol up to 5% (855 mmol/L) did not produce any significant inhibitory effect on 
cell viability of the NRK52E and L6 cells (Figure 5.3B). The maximum amount of 
ethanol in the drug solution was 3.6% (616 mmol/L). These results suggest that 
within the therapeutic plasma range (13.8 – 83.1 µM) (Cizkova et al., 2016) FF is 
not toxic to kidney and muscle cells. However, at very high doses, FF may be toxic 
to kidney and muscle cells in a dose-dependent manner, with the muscle cells 
being more sensitive to FF than kidney cells. 
 
 
 
 
Fombon, I.S. (2020) 
231 
 
 
 
 
Figure 5.2 Dose-response curves of the effect of FF and 5-FU on viability of (A) NRK52E, (B) HEK293 and (C) L6 cells. 
Cells (5.0  103 cells /well) in 96-well plates were treated with increasing concentrations of FF and 5-FU (0 – 500 µmol) for 72 hours and 
cell viability was measured using the MTS assay. Black curve: cells incubated with FF, red curve: cells incubated in 5-FU, black dotted 
line represents point of 50% viability. Data are expressed as mean ± standard deviation of three independent experiments performed in 
triplicate. 
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Table 5.1 Half-maximal inhibitory concentration (IC50)* of FF compared with 
5-FU in NRK52E, HEK293 and L6 cell lines after 72 hours of treatment 
Cell lines FF (µM) 5-fluorouracil (µM) 
NRK52E >1000 43.4 ± 0.4 
HEK293 >1000 11.0 ± 2.4 
L6 267.2 ± 30.8 14.3 ± 0.1 
  
  
 
 
*IC50 values were calculated from linear regression of the dose-log response curves 
after 72 hours of exposure to FF and 5-FU, determined by the MTS assay. Values 
expressed are mean ± SD of at least 3 independent experiments performed in triplicate.  
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Figure 5.3 Dose-response curves of the effect of FF and ethanol on cell viability of NRK52E, HEK293 and L6 cells. 
Cells (5.0  103/well) in 96-well plates were exposed to various treatments for 72 hours and cell viability was determined using MTS 
assay and change in absorbance measured at 500 nm. (A) Effect of FF on the viability of NRK52E cells (black curve), L6 cells (red 
curve) and HEK293 cells (green curve) after 72 hours of treatment. (B) Effect of ethanol (vehicle) on the viability of NRK52E cells 
(black curve) and L6 cells (red curve) after 72 hours of treatment. Data are expressed as Mean ± SD of three independent experiments 
performed in triplicate. 
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5.3.3 FF induces the accumulation of ROS in NRK52E, L6 and HEK293 cells 
To understand the mechanism by which FF induced differential cell death in the 
NRK52E, L6 and HEK293 cells, this study investigated whether FF treatment was 
associated with accumulation of oxidative stress in the cells. Oxidative stress 
caused by reactive oxygen species (ROS) has been shown to lead to cellular 
damage and cell death. ROS activity was measured in NRK52E, L6 and HEK293 
cells exposed to different concentrations of FF (0, 250, 500 and 1000 µM) for 6 
hours using the DCFDA assay. The DCFDA forms a fluorescent compound, DCF, 
in response to ROS oxidation. Cells treated with 30 µM H2O2 were used as 
positive control for the experiments. The results are presented in Figure 5.4 as 
percentage changes in ROS activity compared with control (untreated) cells in 
each cell line.  
The results showed that FF increased intracellular ROS activity in all the three cell 
lines in a dose-dependent manner. In the NRK52E cell line, ROS activity 
increased significantly by up to 30% in the cells exposed to 1000 µM FF, 
compared with control (untreated) cells (Figure 5.4A, p<0.001). In the L6 cell line, 
ROS activity also increased by 12%, 24% and 29% when the cells were exposed 
to 250, 500 and 1000 µM FF, respectively, although the difference compared with 
control (untreated) cells was not statistically significant (Figure 5.4B).  Similarly, in 
the HEK293 cell line, ROS activity increased by 10%, 15% and 27% in cells 
exposed to 250, 500 and 1000 µM FF, respectively, compared with control 
(untreated) cells (Figure 5.4C, p=0.003).  
These results suggest that FF reduces cell viability of NRK52E, L6 and HEK293 
cell lines by increasing intracellular ROS production (oxidative stress) leading to 
significant damage to the cell structure.  
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Figure 5.4 Increase in intracellular ROS in (A) NRK52E, (B) L6 and (C) HEK293 cells in response to FF toxicity.  
Cells were treated with different concentrations of FF (250, 500 and 1000 µM) for 6 hours and intracellular ROS activity was determined 
using DCFDA assay. DCF fluorescent intensity at 500 nm was measured relative to control (untreated cells). Cells treated with H2O2 (30 µM) 
were used as positive control for the experiments. Data are expressed as mean ± SEM of 3 independent experiments performed in triplicate; 
*p < 0.05, **p < 0.01, ***p < 0.001 vs control.  
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5.3.4 Effect of FF on Bax and Bcl-2 expression in NRK52E, L6 and HEK293 
cells 
In order to investigate whether FF reduced the viability of NRK52E, L6 and 
HEK293 cells by mediating apoptosis-inducing effects in the cells, the impact of FF 
on Bcl-2 family proteins expression was determined by western blot analysis. 
Given that Bax is associated with the apoptosis-promoting process, and Bcl-2 is 
associated with the apoptosis-inhibiting process, both of which are key regulators 
of apoptosis, the effects of FF on their protein expression was analysed. Bax and 
Bcl-2 in whole cell extracts from NRK52E, L6 and HEK293 cells exposed to 
various concentrations of FF (0, 250, 500 and 1000 µM) for 72 hours were 
evaluated.  
Immunoblots and densitometric analysis of the Bax and Bcl-2 relative to β-actin 
expression for the three cell lines are shown in Figure 5.5, Figure 5.6 and Figure 
5.7. In all the cell lines, a slight increase in the Bax expression was observed in 
the cells exposed to 250 µM FF and 500 µM FF, but no change in Bax expression 
in the cells exposed to 1000 µM FF. The increase in Bax expression in the 
HEK293 cells exposed to 250 µM FF and 500 µM FF was statistically significant 
(Figure 5.7, p=0.019 and 0.0049, respectively). Similarly, a slight increase in Bcl-2 
expression was observed in the cells exposed to 250 µM FF and 500 µM FF in all 
the three cell lines, but no change in Bcl-2 expression in the cells exposed to 1000 
µM FF.  
These results suggest that FF caused cell death in these cell lines by inducing 
oxidative stress via intracellular ROS accumulation, which in turn causes an 
imbalance in Bax and Bcl-2 proteins leading to the activation of the caspase 
complexes and apoptosis. The data also suggests that at a high concentration 
(exposure to 1000 µM FF), cell death was induced via a Bax/Bcl-2 independent 
pathway, possibly by autophagy or necrosis.  
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Figure 5.5 Expression of Bax and Bcl-2 in NRK52E cells exposed to FF.  
Cells were treated as indicated relative to control cells for 72 h. Protein expression was determined by western blot analysis. Data is 
expressed relative to actin and control samples.  (A) Sample western blot and chemiluminescent analysis of Bax relative to actin 
expression (B) Sample western blot and chemiluminescent analysis of Bcl-2 relative to actin expression; Data are expressed as mean 
± SD of 3 independent experiments performed in triplicate; *p < 0.05, ****p < 0.0001.  
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Figure 5.6 Expression of Bax and Bcl-2 in L6 cells exposed to FF.  
Cells were treated as indicated relative to control cells for 72 h. Protein expression was determined by western blot analysis. Data is 
expressed relative to actin and control samples. (A) Sample western blot and chemiluminescent analysis of Bax relative to actin 
expression (B) Sample western blot and chemiluminescent analysis of Bcl-2 relative to actin expression; Data are expressed as mean 
± SD of 3 independent experiments performed in triplicate; *p < 0.05, ***p < 0.001.  
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Figure 5.7 Expression of Bax and Bcl-2 in HEK293 cells exposed to FF.  
Cells were treated as indicated relative to control cells for 72 h. Protein expression was determined by western blot analysis. Data is 
expressed relative to actin and control samples.  (A) Sample western blot and chemiluminescent analysis of Bax relative to actin expression 
(B) Sample western blot and chemiluminescent analysis of Bcl-2 relative to actin expression; Data are expressed as mean ± SD of 3 
independent experiments performed in triplicate; *p<0.05, **p<0.01, ****p < 0.0001. 
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5.3.5 Impact of FF on the expression of NFκB in NRK52E, L6 and HEK293 cell 
lines 
Since NFκB has a well established role in balancing between cell survival and 
apoptosis (Srinivas et al., 2016; Miyata et al., 2018), the effect of FF treatment on 
the level of its pathway related protein (NFκB p65) was investigated. In normal 
quiescent cells, NFκB p65 is inactive in the cytoplasm where it combines with IκB 
proteins, mainly IκBα, which is regulated via activation of IκB Kinase (IKK), mainly 
IKKα/ꞵ. Under some stimuli, IκBα is phosphorylated by IKKα/ꞵ, and then 
undergoes ubiquitination to release p65. The p65 released translocates to nucleus 
and promotes the transcription of target genes. The expression of NFκB p65 in 
NRK52E, L6 and HEK293 cells exposed to FF (250, 500 and 1000 µM) versus 
untreated (control) cells was assessed. Immunoblots and densitometric analysis of 
the NFκB p65 relative to β-actin expressions for the three cell lines are shown in 
Figure 5.8.  
The results showed no significant change in the expression of NFκB p65 protein in 
the NRK52E cells exposed to the different concentrations of FF (Figure 5.8A). 
However, in the L6 cell line, NFκB p65 expression was significantly increased in 
the cells exposed to 250 µM FF (p<0.0001) and 500 µM FF (p<0.0001), although 
the level of NFκB p65 expression tended to decrease with increase in FF 
concentration (Figure 5.8B). The level of NFκB p65 in the L6 cells treated with 
500 µM FF was still significantly higher than in control (untreated) cells (p=0.0073). 
NFκB p65 expression in L6 cells treated with 1000 µM FF was similar to the level 
in control (untreated) cells. In the HEK293 cell line, NFκB p65 expression was 
significantly decreased in the cells exposed to 250 µM FF and 1000 µM compared 
with control cells (Figure 5.8C, p<0.0001 and p=0.0342, respectively).  
These results suggest that FF-induced cytotoxicity via activation of the NFκB 
signalling pathway. This study also suggest that in the NRK52E and HEK293 cell 
lines, and at a higher concentration (i.e. 1000 µM FF) in the L6 cell line, in which 
NFκB p65 expression was unchanged or decreased in all the cell lines compared 
with the control, cytotoxicity was induced by mechanisms independent of the NFκB 
p65 signalling pathway, possibly by necrosis. 
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Figure 5.8 Effect of FF on NFκB p65 expression in NRK52E, L6 and HEK293 cell lines.  
Cells were treated as indicated relative to control cells for 72 h and NFκB p65 expression was determined by western blot analysis. 
Chemiluminescent blots of NFκB p65 and actin expression in (A) NRK52E, (B) L6 and (C) HEK293 cell lines. Normalized band intensity 
relative to actin; Data are expressed as mean ± SEM of 3 independent experiments performed in triplicate; *p<0.05, **p<0.01, ****p< 
0.0001. 
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5.3.6 Impact of FF on MAPK signalling proteins in NRK52E, L6 and HEK293 
cell lines 
The impact of FF on MAPK signalling pathway in NRK52E, L6 and HEK293 cell 
lines was investigated. Since activation of MAPK signalling such as c-Jun N-
terminal kinase (JNK) and p38 MAPK pathways is associated with induction of 
apoptosis by stress agents, changes in JNK and p38 MAPK protein expressions in 
NRK52E, L6 and HEK293 cells exposed to FF (0 – 1000 µM) for 72 hours was 
examined. Figure 5.9 shows immunoblots and densitometric analysis of the JNK 
relative to β-actin expressions for the NRK52E, L6 and HEK293 cell lines exposed 
to the different concentrations of FF. The JNK protein was activated in all three cell 
lines when the cells were exposed to 1000 µM FF. At lower concentrations (i.e. 
250 and 500 µM), FF exposure did not have any significant impact on JNK protein 
expression in the NRK52E cell line (Figure 5.9A). However, in the L6 and HEK293 
cell lines, JNK expression was significantly reduced when the cells were exposed 
to 250 µM FF (Figure 5.9B, p=0.0007 and Figure 5.9C, p=0.0011, respectively).  
These results indicate that with the lower concentrations, FF suppressed JNK 
expression in the L6 and HEK293 cell line, but with the higher concentration (i.e. 
1000 µM); FF activated the JNK signalling pathway and induced toxicity of 
NRK52E, L6 and HEK293 cells. Immunoblots and densitometric analysis of the 
p38 protein relative to β-actin expressions for the NRK52E, L6 and HEK293 cell 
lines exposed to the different concentrations of FF are presented in Figure 5.10. 
The results showed a slight increase in p38 expression in the NRK52E cells 
exposed to the various concentrations of FF (Figure 5.10A), while in the L6 cell 
line a statistically significant increase in p38 expression compared with the control 
cells was observed in the different treatment groups (Figure 5.10B). However, in 
the HEK293 cell line, p38 expression was decreased compared with baseline 
levels (Figure 5.10C).  
Collectively, these results suggest that FF induced toxicity in the L6 cell line 
occurred via the activation of the MAPK (JNK and p38) signalling pathway. The 
data also suggests that in the NRK52E and HEK293 cell lines, which showed no 
change or decrease in the expression of JNK and p38 FF induced toxicity via 
MAPK-independent mechanism. 
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Figure 5.9 Expression of JNK protein in NRK52E, L6 and HEK293 cell lines treated with FF.  
Cells were treated as indicated relative to control cells for 72 h and NFκB p65 expression was determined by Western blot analysis. 
Chemiluminescent blots of JNK and actin expression in (A) NRK52E, (B) L6 and (C) HEK293 cell lines. Normalized band intensity 
relative to actin; Data are expressed as mean ± SEM of 3 independent experiments performed in triplicate; **p<0.01, ***p<0.001, 
****p<0.0001. 
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Figure 5.10 Effect of FF on MAPK p38 expression in NRK52E, L6, and HEK293 cell lines.  
Cells were treated as indicated relative to control cells for 72 h and p38 expression was determined by western blot analysis. 
Chemiluminescent blots of NFκB p65 and actin expression in (A) NRK52E cell line, (B) L6 cell line, and (C) HEK293 cell line. 
Normalized band intensity relative to actin. Data are expressed as mean ± SEM of 3 independent experiments performed in 
triplicate; *p<0.05, **p<0.01. 
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5.4 DISCUSSION 
In this study the toxicity of FF to the kidney and muscle was investigated as the 
potential cause of the creatininaemia observed in patients administered FF 
therapy for dyslipidaemia. Evidence from previous studies in human HepG2 
hepatoma cell line (Jiao and Zhao, 2002) and breast cancer cell lines (Li et al., 
2014) showed that FF induced toxicity to the cells in a dose-dependent manner. In 
a recent report, Li et al., (2014) showed that FF was toxic to breast cancer cell 
lines. They reported that FF toxicity was dose- and cell line-dependent with the 
triple negative cell lines showing greater sensitivity to FF than other breast cancer 
cell lines. Reports on the toxicity of FF to kidney cells are scarce in the literature. 
In this study the impact of FF on cell viability of NRK52E, L6 and HEK293 cell lines 
was examined. The results showed that FF reduced cell viability of NRK52E, L6 
and HEK293 cells in a dose- and cell line-dependent manner, with the L6 cell line 
showing greater sensitivity to FF therapy than the kidney cell lines (NRK52E and 
HEK293). 
 
5.4.1 FF induces ROS accumulation in NRK52E, L6 and HEK293 cell lines 
Cytotoxicity is a complex process that is often mediated through DNA-adduct, 
oxidative stress, transcriptional factors and stress signalling leading to cell death. 
Recent studies have shown that FF inhibits cell growth by inducing intracellular 
ROS accumulation leading to cellular imbalance and change in mitochondrial 
membrane potential (MMP). This in turn causes the release of cytochrome C and 
subsequent activation of caspase, and result to cell death by apoptosis (Drukala et 
al., 2010; Zhao et al., 2013; Lian et al., 2018). Evidence from studies in human 
hepatoma HepG2 cell line have shown that treatment with FF increased 
intracellular ROS activity and decreased glutathione (GSH, an important cellular 
antioxidant) leading to impairment in mitochondrial function in the HepG2 cells 
(Jiao and Zhao, 2002). Jiao and Zhao (2002) suggested that ROS accumulation 
was upstream of the signals for cell death in HepG2 cells treated with FF. 
In a similar study, Wybieralska et al., (2011) showed that FF promoted intracellular 
ROS accumulation in DU-145 prostate cancer cell line leading to suppression of 
‘contact-stimulated’ cell motility. A recent study by Zhao et al., (2013) also 
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demonstrated that FF exerted apoptosis properties in a prostate cancer cell line 
(LNCaP) by inducing oxidative stress. The FF-induced increase in intracellular 
ROS activity in these cells was accompanied by a decrease in the activity of 
superoxide dismutase (SOD) and malondialdehyde (MDA) (Zhao et al., 2013). 
Consistent with these reports, this study showed that FF induced intracellular ROS 
accumulation in a dose-dependent manner in the NRK52E, L6 and HEK293 cell 
lines. Preliminary results from this study also showed an increase in SOD activity 
in response to FF exposure (Appendix). Increase in SOD activity is considered as 
an adaptive response to assault by a toxic agent. However, in a sustained 
exposure to the assault, SOD activity decreased with increased ROS, leading to 
oxidative stress. Increased ROS accumulation also causes increased lipid 
peroxidation and protein carbonylation, which results in cellular imbalance, change 
of MMP and the release of cytochrome C (Su et al., 2019). Finally, release of 
cytochrome C causes activation of the caspase complex, which in turn leads to 
cell apoptosis (Latham et al., 2001). The results from this study suggest that 
oxidative stress due to intracellular ROS accumulation is a potential mechanism by 
which FF induces cell death in the kidney and muscle cells. 
 
5.4.2 FF induces cytotoxicity of kidney and muscle cells via activation of 
NFκB and MAPK signalling pathway 
In order to elucidate the mechanism of FF-induced cell death in NRK52E, L6 and 
HEK293 cell lines, Bax and Bcl-2 expression in the cells exposed to different 
doses of FF for 72 hours was analysed by western blotting. The mitochondrial 
pathway of apoptosis, and particularly MMP, is regulated by proteins belonging to 
the Bcl-2 family (Leibowitz and Yu, 2010). Bax and Bcl-2 are key regulators of the 
cell apoptosis pathway. The balance between anti-apoptotic and pro-apoptotic 
proteins is crucial for the survival of the cell. Increased Bax/Bcl-2 ratio has been 
associated with cell death via the mitochondrial pathway of apoptosis (Leibowitz 
and Yu, 2010).  
Previous studies have shown that FF down-regulated Bcl-2 expression and 
caused apoptosis in a mantle cell lymphoma cell line (Zak et al., 2010) and a 
prostate cancer cell line (Zhao et al., 2013). In a recent study, Li et al., (2014) 
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detected notable decrease in Bcl-xl expression and increase in Bad expression, 
but Bcl-2 expression was not significantly changed in the breast cancer cells. It 
has been suggested that Bad binds more strongly to Bcl-xl than Bcl-2, and it can 
reverse the anti-apoptosis activity of Bcl-xl, but not that of Bcl-2 (Hirai and Wang, 
2001). This study showed that cell exposure to FF caused an increase in Bax 
expression in the kidney and muscle cells. However, at higher concentrations cell 
death appeared to occur via other mechanisms that are independent of the Bcl-2 
family protein signalling pathway, possibly by necrosis. The results from this study 
did not show a strong relationship between Bax and Bcl-2 in the cell lines. Studies 
in a breast cancer cell line had also shown that FF-induced apoptosis was 
regulated by more intimate relationship between Bcl-xl and Bad than between Bcl-
2 and Bad (Hirai and Wang, 2001; Li et al., 2014). Further studies are 
recommended to detect the expression of other pro-apoptotic and anti-apoptotic 
proteins in NRK52E, L6 and HEK293 cells exposed to FF in order to fully 
understand the role of apoptotic processes in FF-induced cell death in these cell 
lines. 
Finally, the possibility of ROS accumulation in the cells leading to the activation of 
the NFκB and MAPK signalling pathways was examined. Increased ROS 
production has also been associated with activation of various cellular signalling 
pathways and transcription factors including MAPK, nuclear factor (erythroid-
derived 2)-like 2 (Nrf2)/Kelch like-ECH-associated protein 1(Keap1), NFκB and 
tumour suppressor p53, which can activate cell survival and/or cell death 
processes such as autophagy and apoptosis (Covarrubias et al., 2008; Bae, et al., 
2011; Kaminskyy and Zhivotovsky, 2014; Zhang et al., 2016). Evidence of an 
interrelation between ROS and NFκB has been reported in the literature (Morgan 
and Liu, 2010). A series of studies have also shown that exogenously generated 
ROS influenced the activation of the NFκB pathway by inhibiting the 
phosphorylation of IκBα by IKK, thereby preventing their ubiquitination and 
degradation and inhibiting the activation of the NFκB pathway (Schoonbroodt and 
Piette, 2000; Takada et al., 2003). In addition, IKK is also reported as a primary 
target for ROS in influencing NFκB and the s-glutathionylation of IKKꞵ by ROS 
results in inhibition of IKKꞵ activity (Raynaert et al., 2006).  
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Cumulative evidence from recent studies has shown that FF has bidirectional 
modulatory effects on NFκB activity in different cell lines. In breast cancer cells, Li 
et al., (2014) reported that FF activated the NFκB pathway by increasing the DNA 
binding of NFκB via down-regulation of phosphorylated-IκBα, which sequesters 
NFκB protein in the cytoplasm. But Zak et al., (2010) reported that NFκB was 
down-regulated in FF-induced apoptosis in mantle cell lymphoma. In a similar 
report, Liang et al., (2013) showed that FF inhibited the NFκB pathway in lung 
cancer by decreasing DNA binding of NFκB, without increasing IκBα protein. This 
study showed that FF significantly up-regulated NFκB p65 expression in L6 cell 
line. The expression of NFκB p65 in the NRK52E cell line did not change 
significantly, but was significantly down-regulated in the HEK293 cell line. Both 
NRK52E and HEK293 cell lines were less sensitive to FF treatment as shown by 
the MTS assay. Consistent with the findings of Li et al., (2014), the results from 
this study suggests that FF induced cell death in the L6 cell line by increasing 
ROS production and activation of the NFκB pathway.  
The MAPK cascades are major intracellular signal transduction pathways 
associated with various cellular processes such as cell growth, differentiation, 
development, cell cycle, survival and cell death (Ravingerova et al., 2003). 
Members of the MAPK cascades include the extracellular signal-related kinases 
(ERK1/2), the c-Jun N-terminal kinases (JNK), the p38 kinase (p38), and the big 
MAP kinase 1 (BMK1/ERK5) pathways (Pritchard and Hayward, 2013). Since 
cellular stress is the main inducer of the JNK and p38 MAPK pathways (Zhang et 
al., 2016), we investigated the effect of FF on these protein expressions. Evidence 
from previous studies suggests that FF is associated with the inhibitory effect of 
JNK and activation of p38 expression in different cell lines. In a recent study, Lian 
et al., (2018) reported that FF induced apoptotic cell death of prostate cancer (PC-
3) cells via a mechanism that involved increased p38 MAPK and AMPK 
phosphorylation but did not significantly change the phosphorylation levels of 
PI3K, AKT and JNK, although inhibition of p38 MAPK or AMPK by their respective 
inhibitors did not change the effect of FF-induced cell death. In other studies, FF 
inhibited JNK and p38 expression thereby protecting proximal tubular cells from 
cisplatin-induced cytotoxicity (Thongnuanjan et al., 2016). Consistent with these 
reports the results from this study showed that at lower concentrations of FF, JNK 
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was unchanged or down-regulated. However, at higher concentrations, FF 
activated JNK in all three cell lines. 
 
5.5 SUMMARY 
This study has demonstrated using cell line models that within plasma therapeutic 
concentrations, FF is non toxic in kidney (NRK52E and HEK293) and muscle (L6) 
cell lines, however, at higher concentrations; FF has been shown to be toxic to the 
cells in a dose-dependent manner. FF toxicity was also cell line-dependent, with 
L6 cells showing greater sensitivity to FF than the NRK52Eand HEK293 cells. It 
can be concluded that the potential mechanism of FF cytotoxicity involves ROS 
accumulation and oxidative stress leading to cytotoxicity via an imbalance in 
proapoptosis protein (Bax) and antiapoptosis protein (Bcl-2), together with 
activation of the NFκB and MAPK signalling pathways. The results from this study 
have also shown that at very high doses, FF may induce cell death by other 
mechanisms such as necrosis. Preliminary data from flow cytometry analysis of 
cells exposed to different concentrations of FF (0,250, 500, 1000 µmol/L) and 
stained using propidium iodide and Annexin V-FITC showed that high 
concentrations of FF caused cell death via mechanism(s) that was not associated 
with apoptosis (Appendix). Further studies are recommended to examine whether 
necrosis is involved in FF-induced cell death. 
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Chapter 6 
Discussion, conclusion and future work 
6.0 – DISCUSSION AND CONCLUSION 
The main aim of this study was to investigate FF toxicity and its impact on clinical 
biomarkers with the following objectives; first to examine the impact of FF (160 
mg/day) therapy on routine clinical biomarkers including markers of kidney 
function, liver function, lipid profile, muscle damage, inflammatory markers and 
markers of thyroid function. Secondly, to examine the utility of serum CYSC as a 
marker of kidney function in patients administered FF therapy and finally to 
investigate the mechanism of FF toxicity in kidney and skeletal muscle using cell 
line models i.e. kidney (NRK52E and HEK293) and skeletal muscle (L6) cells.  
First, it was hypothesised that FF impacted clinical biomarkers in a non-selective 
manner. This study has shown that FF (160 mg/day) therapy had different impacts 
on routinely tested clinical biomarkers including lipid profile, kidney function, liver 
function, thyroid function, markers of inflammation, and muscle damage (Figure 
6.1). FF therapy is used primarily to reduce high levels of serum TRIG and 
increase low levels of HDL cholesterol, but may also reduce high levels of LDL 
cholesterol in patients with mixed dyslipidaemia (Farnier, 2008). As expected, FF 
therapy reduced serum TRIG levels whilst increasing HDL cholesterol levels. 
Serum TRIG levels were moderately reduced during the first 12 months of therapy, 
whilst serum HDL cholesterol level was significantly increased after 3 months 
(p=0.0200, n=13) and moderately reduced after 6 months of FF treatment. The 
impact of FF on lipids has been described extensively in the literature (Staels et 
al., 1998; Farnier, 2008). However, in this study FF therapy did not have any 
significant impact on CHOL and LDL levels. This study reconfirms the reports of 
large scale and long-term follow-up trials with FF such as the FIELD study and 
recent studies on the impact of FF on the lipid profile (Keech et al., 2005; Ncube et 
al., 2012). 
This study also confirmed that FF therapy is associated with nephrotoxicity. 
Several studies (short-term and long-term) have reported an increase in serum 
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CREA and CYSC levels during FF therapy (Hottelart et al., 2002; Keech et al., 
2005; Ansquer et al., 2008; Ncube et al., 2012). The results from this study have 
shown that FF therapy caused an increase in CREA, urea and CYSC levels, 
mainly during the first 3 months of therapy, although the increases in these 
biomarkers of kidney function were clinically moderate. These findings are 
consistent with those reported by Ansquer et al., (2008) in a 6-week randomised 
crossover trial in healthy adults and later supported by Ncube et al., (2012) in a 
recent study involving patients with hyperlipidaemia, respectively. However, in this 
study the increase in CYSC level was not statistically significant. The difference 
with the other studies may be attributed to the nature of participants and 
dose/length of FF therapy. Unlike the study by Ncube et al., (2012), which included 
patients with diabetes, the participants in this study were apparently healthy 
individuals with normal baseline kidney function. Also, in the study by Ncube et al., 
(2012) the participants were administered FF at 264 mg/day, while the participants 
in this study had received FF at 160 mg/day. The concomitant increase in these 
three independent markers of kidney function (CREA, BUN and CYSC) together 
with a decrease in eGFR is indicative of a decrease in kidney function. This study 
therefore supports the theory that FF therapy has a genuine impact on kidney 
function, rather than a change in CREA metabolism or analytical interference of 
serum CREA assay as previously postulated (Hottelart et al., 2002; Ansquer et al., 
2008).  
This study further confirmed that the increase serum CREA and CYSC is 
reversible even when FF therapy is continued in the long-term. Recent studies 
have reported the reversibility of CREA levels after discontinuing FF therapy 
(Davis et al., 2011, Park et al., 2017). In the ACCORD study, Mychalekyj et al., 
(2012) demonstrated that FF-associated increase in CREA and CYSC levels was 
reversed 51 days after discontinuation of treatment. However, it has been unclear 
whether the reversibility is complete or partial. The results from this study have 
demonstrated that FF-associated increase in serum CREA and serum CYSC was 
reversible after 12 months of treatment even when treatment was not stopped. 
This study also showed that the increase in serum CREA was only partially 
reversible, while serum CYSC was completely reversible. The data from this study 
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suggests that a decrease in kidney function is the major cause of FF-associated 
increase in serum CREA and CYSC concentrations.  
This study has also shown that FF therapy reduced serum UA levels in patients 
with dyslipidaemia. UA is an endogenous antioxidant which has a beneficial effect 
as an oxygen scavenger (Jung et al., 2018). It is present in normal humans in 
much higher concentrations than vitamin C and is known to cover two-thirds of 
free radical scavenging capacity in plasma (Jung et al., 2018). UA is particularly 
effective in quenching hydroxyl, superoxide, peroxide and peroxynitrite radical and 
is thought to serve a protective physiological role by preventing lipid peroxidation 
(Mahajan et al., 2009). However, hyperuricaemia has been linked with 
hypertension, diabetes and dyslipidaemia, and has become a public health burden 
worldwide, because of its high prevalence and clinical significance. In this study 
FF therapy significantly reduced serum UA level in dyslipidaemic patients by 16% 
(p<0.001, n=13) after three months of FF therapy. The results from this study are 
similar to those of Waldman et al., (2018) who reported a 20.2% (p<0.001, 
n=9795) reduction in serum UA concentration in diabetic patients after six weeks 
of FF therapy. The decrease in serum UA has been associated with the inhibition 
of the URAT1 protein, which is responsible for the transport of UA from the 
kidneys into the blood. Inhibition of URAT1, therefore, leads to an increase in UA 
excretion (Uetake et al., 2010) and a decrease in serum UA levels. However, the 
clinical significance of this decrease in serum UA in patients with dyslipidaemia is 
unclear. 
On the impact of FF on liver function, this study did not support reports that link FF 
therapy with hepatotoxicity, which is often indicated by increased serum 
aminotransferases (Thulin et al., 2008; Kobayashi et al., 2009). Contrary to such 
reports, this study showed a moderate reduction in serum levels ALT and a 
significant decrease in serum AST and GGT at various periods during FF therapy, 
although serum levels of ALB and TBIL did not change significantly. The results 
also showed significant reduction in serum ALP concentration throughout the 
study period. This is consistent with previous reports by Gandhi et al., (2014) who 
showed a similar decrease in liver enzymes in patients with metabolic syndrome 
administered fibrate therapy. The mechanism underlying this decrease in serum 
ALP is not defined. However, changes in hepatic fat deposition and reduction in 
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the rate of release of ALP by the liver, as a result of a reduction in the rate of 
hepatic bile acid secretion are potential mechanisms that have been described 
(Day et al., 1993; Mikhailindis et al., 1998). 
FF and other fibrates have been linked with various forms of myopathy when 
administered as monotherapy or in combination with statins (Wu et al., 2009).  In 
this study, there was no evidence of muscle toxicity as serum levels of CK and 
LDH (enzymes associated with muscle damage) remained comparable with 
baseline values. It is important to note that myopathy associated with FF therapy is 
rare and is often associated with dose/length of treatment and other conditions 
including hypothyroidism (overt or subclinical form), chronic renal failure and 
chronic myelogenous leukaemia (Erdur et al., 2011; Kato et al., 2011; Wang and 
Wang, 2018). While chronic kidney failure is believed to contribute to FF toxicity by 
causing accumulation of the drug, the mechanism by which hypothyroidism 
encourages rhabdomyolysis is not fully understood. Hypothyroidism is also closely 
linked with both dyslipidaemia and kidney dysfunction (Yuan et al., 2015). In this 
study FF administered at 160 mg/day did not have any significant impact on 
thyroid function. This finding suggests that the decrease in kidney function 
observed in the study is not linked to changes in thyroid function. This study did 
not also show any changes in the inflammatory marker, CRP, following FF 
therapy. 
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Figure 6.1 Impact of FF therapy on routine clinical biomarkers.  
Participants were administered FF (160 mg/day). ALB, Albumin; ALT, alanine 
aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; AST, 
aspartate aminotransferase; TBIL, total bilirubin, CRP, C reactive protein; CHOL, total 
cholesterol; TRIG, triglyceride, HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
LDH, lactate dehydrogenase; CK, creatine kinase; CREA, creatinine; CYSC, cystatin C; 
NA, sodium; K, potassium; UA, uric acid; TSH, thyroid stimulating hormone; FT4, free T4; 
FT3, free T3; N, normal; ↓, decreased; ↑, increased biomarker. 
Secondly, it was hypothesised that CYSC, a low molecular weight protein, is a 
better marker than CREA for monitoring kidney function in patients receiving FF 
therapy for dyslipidaemia. Serum CYSC has been touted as a better marker of 
kidney function than CREA, which is routinely used in clinical practice (Hojs et al., 
2008; Bolignano et al., 2010). The use of CREA as a marker of eGFR is reportedly 
marred by several limitations including variations with age, sex, race, diet, muscle 
mass, medication use, catabolic state, tubular secretion and extrarenal excretion 
in severe renal impairment (Thomas et al., 2017). It is also known that the level of 
serum CREA only rises above the normal upper reference range when the GFR 
has be reduced by more than 50%, making it unsuitable as a marker of early 
detection of kidney injury as required when assessing drug toxicity (Perrone et al., 
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1992).  This study has shown that the performance of Gentian CYSC, measured 
by the particle-enhanced turbidimetric immunoassay (PETIA) technique, exceed 
the manufacturer’s specifications with acceptable ranges of precision, linearity and 
assay stability. Unlike other CYSC assays which are based on the particle-
enhanced nephelometric immunoassay (PENIA) technique designed to be used 
on specialist platforms, the Gentian CYSC is designed to be measured on routine 
laboratory platforms as part of the kidney profile.  
Recent studies have reported the superior diagnostic accuracy of serum CYSC-
based equations over other markers and equations in monitoring kidney function 
(Yang et al., 2016). This study showed that CYSC-based equations (i.e. Gentian 
and CKD-EPI CYSC) produced higher estimates of eGFR than the CREA-based 
equations (MDRD and CKD-EPI CREA) and the combined equation (CKD-EPI 
CREA-CYSC). Consequently, a higher number of participants were classified as 
having normal kidney function after FF therapy with the CYSC-based equations 
than with the CREA-based equations. This suggests that either the CREA-based 
equations underestimated the eGFR as suggested in previous reports (Froissart et 
al., 2005; Delanaye and Cohen, 2008) or that the CYSC-based equations 
overestimated the eGFR (Han et al., 2012). Since the GFR was not measured by 
a reference method due to the limitations of its use in clinical practice, it cannot be 
concluded whether the CYSC-based equations preformed better than the CREA-
based equations. Also, there was no significant correlation between the CREA-
based equations and CYSC-based equations. The combined CREA-CYSC-based 
formula showed significant correlation and degree of agreement with both CYSC-
based and CYSC-based equations. Hence, the combined equation emerged as a 
better replacement for the routinely used MDRD equation as suggested in 
previous reports by Inker et al., (2012).  
Furthermore, it was hypothesised that FF is toxic to the kidneys and skeletal 
muscles both of which are involved in the metabolism and excretion of FF, and 
that toxicity to the skeletal muscles and kidney injury accounts for the significant 
increase in serum CREA (Staels et al., 1998; Forsblom et al., 2010). This study 
has shown that within therapeutic concentrations, FF is not toxic to the kidney 
(NRK52E and HEK293) and skeletal muscle (L6) cells, however, at higher 
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concentrations, FF becomes toxic to the cells in a dose- and cell line-dependent 
manner. The results showed that muscle cells were more sensitive to FF than the 
kidney cells. FF toxicity has been reported in recent studies using the human 
HepG2 hepatoma cell line (Jiao and Zhao, 2002) and breast cancer cell lines (Li et 
al., 2014). Consistent with this study, both reports showed that FF-induced toxicity 
to the HepG2 and breast cancer cells was dose-dependent. Li et al., (2014) also 
demonstrated that FF-induced toxicity in breast cancer cell lines was cell line-
dependent.  
As a potential mechanism of FF induced cytotoxicity in the NRK52E, HEK293 and 
L6 cell lines (Figure 6.2), this study showed that FF induced intracellular ROS 
accumulation probably caused an oxidative stress, which resulted in an imbalance 
in the proapoptosis (Bax) and antiapoptosis (Bcl-2) protein ratio in the cells. An 
increase in Bax and/or a decrease in Bcl-2 lead to the activation of caspase 3 and 
modulation of apoptosis (Yang et al., 2002; Zak et al., 2010). Previous studies 
have shown that FF down-regulated Bcl-2 expression and caused apoptosis in 
mantle cell lymphoma cell line (Zak et al., 2010), prostate cancer cell line (Zhao et 
al., 2013) and breast cancer cell line (Li et al., 2014). Oxidative stress also caused 
the modulation of the NFκB (p65) and MAPK (p38 and JNK) signalling pathways 
that culminated in the cell death possibly by apoptosis.  
To conclude, this study has shown that FF therapy impacts differently on routine 
clinical biomarkers. Apart from its effect in reducing high levels of serum TRIG and 
increasing low levels of HDL cholesterol, FF also reduces high levels of serum UA, 
AST, GGT and ALP, particularly in those with higher baseline values. This study 
has also confirmed that FF reduces kidney function as demonstrated by a 
concomitant increase in serum CREA, BUN and CYSC (independent markers of 
kidney function) and decrease in eGFR. This study therefore recommends that 
kidney function is closely monitored in patients administered FF therapy. This 
study has also shown that CYSC-based equations produce higher GFR estimates 
compared with the CREA-based equations. Future studies using a reference 
method to measure the GFR has been recommended in order to determine which 
marker performs better. Finally this study has also shown that FF toxicity is dose- 
and cell line-dependent. The skeletal muscle (L6) cells appear to be more 
sensitive to FF than the kidney (NRK52E and HEK293) cells. The potential 
Fombon, I.S. (2020) 
257 
 
mechanism of FF cytotoxicity involves ROS accumulation and oxidative stress 
leading to cell death via an imbalance in proapoptosis protein (Bax) and 
antiapoptosis protein (Bcl-2), together with activation of the NFκB and MAPK 
signalling pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Molecular mechanism of FF-induced toxicity in muscle and kidney 
cells. 
The overall molecular mechanism of FF cytotoxicity in NRK52E, L6 and HEK293 cells 
involves many steps. Briefly, FF induced intracellular ROS accumulation, which in turn 
created oxidative stress inside the cell. Oxidative stress caused an imbalance in Bax and 
Bcl-2 protein expression leading to activation of the caspase complexes and apoptosis. 
FF cytotoxicity also modulated the NFκB (p65) and MAPK (p38 and JNK) signalling 
pathways leading to cell death (apoptosis). 
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6.1 Limitations and recommendations for future work 
There were some limitations to this study; therefore recommendations have been 
made for future work as follows: 
First, this study was conducted on a small number of participants, mainly patients 
with dyslipidaemia who required FF therapy and whose kidney function was 
relatively normal. Also, the study participants were all Caucasian adults and as 
such do not include any variations that may occur due to ethnicity. As such, these 
results cannot be generalised over a larger scale, but calls for larger prospective 
studies to establish the impact of FF therapy on routine clinical biomarkers.  
Second, serum creatinine concentration was determined by the Jaffé reaction 
method which is less specific and has less precision compared with the enzymatic 
method. However, the calibration of the Beckman Coulter Jaffe creatinine method 
used in this study is traceable to an isotope dilution mass spectrometry (IDMS) 
reference method using the National Institutes of Standards and Technology 
(NIST) Standard Reference Material 967, although traceability does not address 
non-specificity. The Jaffé method is routinely used in the clinics because it is 
cheap and readily available.  
Third, we did not measure GFR by a gold standard method, as this is not feasible 
on a daily basis. This means we were unable to assess the accuracy of serum 
cystatin C- and creatinine-based eGFRs formulas. We recommend further studies 
using a reference method for measuring GFR in order to determine the best GFR 
equation(s) for monitoring kidney function in this cohort, using endogenous 
markers.  
This study has shown that FF cytotoxicity in the kidney and muscle cells was 
associated with intracellular ROS accumulation leading to oxidative stress, which 
in turn caused cell death (apoptosis) via modulation of various signalling pathways 
including regulation of the Bcl-2 family proteins, NFκB and MAPK signalling 
pathways. Although further evidence for this is required, this study provides a solid 
foundation for understanding FF toxicity. The detailed mechanisms should be 
uncovered in future studies including measurement of necrosis in the cells 
exposed to FF. 
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APPENDIX 
Comprehensive List of Participants showing sample provisions 
 
Patient 
No. 
 
Sex 
 
Age 
(Years) 
 
Baseline 
 
Group A 
(3 months) 
 
Group B  
(6 Months) 
 
Group C 
(12 Months) 
 
Comments 
B01 F 63 Yes Yes Yes No   
B02 M 43 Yes Yes Yes No   
B03 M 37 Yes Yes Yes No   
B04 M 58 Yes Yes Yes Yes   
B05 M 52 Yes Yes Yes Yes   
B06 F 50 Yes Yes Yes Yes   
B07 F 38 Yes No No No Drop out  
B08 M 50 Yes Yes No No   
B09 M 70 Yes No No No Drop out  
B10 M 51 Yes Yes Yes No   
B11 M 52 Yes Yes No No   
T01 F 53 Yes Yes No Yes   
T02 F 40 Yes Yes Yes Yes   
T03 M 62 Yes No Yes Yes   
T04 M 47 Yes Yes Yes No   
T05 M 65 Yes Yes No Yes   
T06 M 47 Yes No No No Drop out  
T07 M 34 Yes No No No Drop out  
T08 M 48 Yes No No Yes   
N-number 19 13 10 8 4   
Yes means participant provided samples, No means participant did not provide sample and  
Drop out means participants who provided only the baseline sample and no follow-up sample 
Patient numbers: ‘B’ for participants at BHT and ‘T’ for participants at TST. 
BHT, Burton Hospital’s NHS Foundation Trust, TST, Taunton and Somerset NHS Foundation Trust 
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NRES Committee South West - 
Exeter Whitefriars Level 3 Block B Lewins 
Mead Bristol BS1 2NT  
Telephone: 01173421390 Fax:01173420445 10 December 2014  
Prof. Tim Reynolds Burton 
Hospitals NHS Foundation Trust 
Queen's Hospital Belvedere Rd, 
Burton-on-Trent DE13 0RB  
Dear Prof. Reynolds  
Study title: Role of cystatin C in the evaluation of renal function in patients 
receiving fenofibrate treatment for dyslipidaemia. REC reference: 14/SW/1104 
Protocol number: FAC/CysC/01 IRAS project ID: 150171  
Thank you for your letter of 03 November 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.  
The further information has been considered on behalf of the Committee by the Vice 
Chair, Dr Nicole Dorey and Professor Malcolm Cowburn.  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three months 
from the date of this favourable opinion letter. The expectation is that this information will 
be published for all studies that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, 
please contact the REC Manager, Mrs Kirsten Peck, nrescommittee.southwest-
exeter@nhs.net . Under very limited circumstances (e.g. for student research which has 
received an unfavourable opinion), it may be possible to grant an exemption to the 
publication of the study.  
A Research Ethics Committee established by the Health Research 
Authority  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below.  
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned.  
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Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance should 
be sought from the R&D office on the information it requires to give permission for this 
activity.  
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation.  
Sponsors are not required to notify the Committee of approvals from host organisations  
Registration of Clinical Trials  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant 
is recruited but no later than 6 weeks after recruitment of the first participant.  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process.  
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory.  
If a sponsor wishes to request a deferral for study registration within the required 
timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all 
clinical trials will be registered, however, in exceptional circumstances non registration 
may be permissible with prior agreement from NRES. Guidance on where to register is 
provided on the HRA website.  
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
Ethical review of research sites  
A Research Ethics Committee established by the Health Research 
Authority  
NHS sites  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below).  
Approved documents  
The final list of documents reviewed and approved by the Committee is as follows:  
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Document Version Date Covering letter on headed paper 31 October 2014 Other [e-mail from Ivo Sama] 
28 October 2014 Other [Response to ethics review letter] Other [New PIS ] 2 18 November 2014 Other 
[uPDATED CONSENT FORM - VER 3] 3 10 December 2014 Participant information sheet (PIS) 2 20 
October 2014 REC Application Form [REC_Form_08092014] 08 September 2014 Referee's report or 
other scientific critique report [Early report from University on Project [issues fully addressed]]  
01 01 May 2014  
Research protocol or project proposal [Protocol] 01 29 August 2014 Response to Request for Further 
Information 03 November 2014 Summary CV for Chief Investigator (CI) [Dr Reynolds CV] 04 September 
2014 Summary CV for student [Iwo Fombon CV] 01 29 August 2014  
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
After ethical review  
Reporting requirements  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
A Research Ethics Committee established by the Health Research Authority  
User 
Feedback  
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have 
received and the application procedure. If you wish to make your views known please use 
the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/quality- assurance/  
HRA Training  
We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/  
14/SW/1104 Please quote this number on all correspondence  
With the Committee’s best wishes for the success of this project.  
Yours sincerely  
Mrs Joan Ramsay Vice Chair  
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Email: nrescommittee.southwest-exeter@nhs.net  
Enclosures: “After ethical review – guidance for researchers” [SL-AR2]  
Copy to: Mrs Anne Hogg  
A Research Ethics Committee established by the Health Research 
Authority  
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Flow cytometric analysis of NRK52E cells exposed to various concentrations of fenofibrate for 4 hours and 
stained with Annexin V-FITC/PI. A) Control unstained cells, B) Control cells stained with Annexin V only, C) Control 
cells stained with PI only, D) Control untreated cells, E) Test cells exposed to 250 µM FF, F) Test cells exposed to 500 
µM FF, G) Test cells exposed to 1000 µM FF, H) Control cells exposed to 25 µM H2O2. FF, fenofibrate 
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Flow cytometric analysis of L6 cells exposed to various concentrations of fenofibrate for 4 hours and 
stained with Annexin V-FITC/PI. a) Control unstained cells, b) Control cells stained with Annexin V only, c) 
Control cells stained with PI only, d) Control untreated cells, e) Test cells exposed to 250 µM FF, f) Test cells 
exposed to 500 µM FF, g) Test cells exposed to 1000 µM FF, h) Control cells exposed to 25 µM H2O2. FF, 
fenofibrate 
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Flow cytometric analysis of HEK293 cells exposed to various concentrations of fenofibrate for 4 hours 
and stained with Annexin V-FITC/PI. i) Control unstained cells, ii) Control cells stained with Annexin V only, iii) 
Control cells stained with PI only, iv) Control untreated cells, v) Test cells exposed to 250 µM FF, vi) Test cells 
exposed to 500 µM FF, vii) Test cells exposed to 1000 µM FF, viii) Control cells exposed to 25 µM H2O2. FF, 
fenofibrate 
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Protein expression of SOD in fenofibrate treated NRK52E, L6 and HEK293 cells. Cells were exposed to different concentrations of 
fenofibrate as indicated for 72 hours and SOD protein expression was determined by Western blot analysis. Data represents immunoblot of 
SOD and GAPDH expression for the three cell lines. 
